Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS
Document Type and Number:
WIPO Patent Application WO/2004/029044
Kind Code:
A1
Abstract:
The invention provides a compound of formula (I) where R1, R2, R3, A, n, and p are disclosed herein) or a pharmaceutically acceptable salt thereof (a '2-Pyrimidinylpiperazine Compound'); pharmaceutical compositions comprising an effective amount of a 2-Pyrimidinylpiperazine Compound; and methods for treating or preventing a condition such as pain, urinary incontinence, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a 2-Pyrimidinylpiperazine Compound.

Inventors:
CHEN ZHENGMING (US)
TAFESSE LAYKEA (US)
Application Number:
PCT/US2003/030187
Publication Date:
April 08, 2004
Filing Date:
September 24, 2003
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
EURO CELTIQUE SA (LU)
CHEN ZHENGMING (US)
TAFESSE LAYKEA (US)
International Classes:
A61P25/22; C07D239/42; C07D239/46; C07D401/12; C07D401/14; C07D403/04; (IPC1-7): C07D403/04; C07D239/42; C07D239/46; C07D401/12; C07D401/14; A61K31/506; A61P25/22
Foreign References:
EP0634411A11995-01-18
Other References:
CHEMICAL ABSTRACTS, vol. 110, no. 25, 1989, Columbus, Ohio, US; abstract no. 231663z, page 652; column 1; XP002270351
CHEMICAL ABSTRACTS, vol. 115, no. 11, 1991, Columbus, Ohio, US; abstract no. 105837z, KOMISSAROV,I.: "ANXIOLYTIC ACTIVITY OF 1-(2-PYRIMIDINYL)PIPERAZINE DERIV." page 58; column 2; XP002270352
Attorney, Agent or Firm:
Abrams, Samuel B. (222 East 41st Street New York, NY, US)
Download PDF:
Claims:
What is claimed is:
1. A compound of formula (1) : (I) or a pharmaceutically acceptable salt thereof, wherein: A isC (O),C (S),CH2,CH (CC4 alkyl), orC (CIC4 alkyl) (CC4 alkyl); n is an integer ranging from 0 to 3; each R1 is independently (C1C3)alkyl, O(C1C3) alkyl, halo, C (halo) 3, CH (halo) 2, CH2(halo), NO2, OH, orCN; when A isCH2,CH (CC4 alkyl), orC (CC4 alkyl) (CC4 alkyl), then R2 is phenyl, naphthyl, or (C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups, or, when A isC (O) orC (S) , then R2 is (i) H, (C1C10)alkyl, (C2C10)alkenyl, (C2C10)alkynyl, (C3 C10) cycloalkyl, (CgC14) bicycloalkyl, (C8C14) tricycloalkyl, (C5Clo) cycloalkenyl, (C8 C14) bicycloalkenyl, (C8C14) tricycloalkenyl, (3 to 7membered) heterocycle, or (7 to 10 membered) bicycloheterocycle, each of which, other thanH, is unsubstituted or substituted with one or more R5 groups, or (ii)phenyl,naphthyl, (C14) aryl, or (5 to 10membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is an integer ranging from 0 to 2; each R3 is independently OH, halo, NO2, CN, NH2, (C1C3)alkyl, or CH2OH ; each R4 is independently (C1C6)alkyl, (C2C6)alkenyl, (C2C6)alkynyl, (C3C8) cycloalkyl,(C5C8) cycloalkenyl,phenyl,(C3C5) heterocycle, C (halo) 3, CH (halo) 2, CH2 (halo), CN, OH, halo, N3, NO2, N(R6)2, CH=NR6, NR6OH, COR6, C(O)OR6, OC(O)R6, OC(O)OR6, SR6, S(O)R6, orS (0) 2R6 ; each RS is independentlyCN,OH,halo,N3,NO2,N (R6) a,CH=NR6,NR60H, COR6, C(O) OR6, OC (O) R6, OC (O) OR6,SR6,S (O) R6, orS (O) 2R6 ; and each R6 is independently H, (C1C6)alkyl, (C2C6)alkenyl, (C2C6)alkynyl, (C3C8)cycloalkyl, (C5C8)cycloalkenyl, phenyl, (C3C5) heterocycle, C (halo) 3, CH (halo) 2, orCH2 (halo) ; and each halo is independentlyF,Cl,Br, orI.
2. The compound of claim 1, wherein p is 0 or 1.
3. The compound of claim 1, wherein A isCH2.
4. The compound of claim 1, wherein A isCH (CIC4 alkyl).
5. The compound of claim 1, wherein A isC (ClC4 alkyl) (ClC4 alkyl).
6. The compound of claim 1, wherein A isC (O).
7. The compound of claim 6, wherein R2isH, (CICIO) aUyl, (C2Clo) alkenyl, (C2C10)alkynyl, (C3C10)cycloalkyl, (C8C14)bicycloalkyl, (C8C14)tricycloalkyl, (C5 Cl0) cycloalkenyl, (C8C14)bicycloalkenyl, (C8C14)tricycloalkenyl, (3 to 7 membered) heterocycle, or (7 to 10membered) bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
8. The compound of claim 6, wherein R2 isphenyl,naphthyl,(C, 4) aryl, or(5 to 10membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups.
9. The compound of claim 8, wherein R2 isphenyl.
10. The compound of claim 9, wherein the phenyl is substituted in its 4position with an R4 group.
11. The compound of claim 1, wherein A isC (S).
12. The compound of claim 11, wherein R2 is H, (C1C10)alkyl, (C2C10)alkenyl, (C2C10)alkynyl, (C3C10)cycloalkyl, (C8C14)bicycloalkyl, (C8C14)tricycloalkyl, (C5 Cl0) cycloalkenyl,(C8C, 4) bicycloalkenyl,(C8C, 4) tricycloalkenyl,(3to 7 membered) heterocycle, or (7 to 10membered) bicycloheterocycle, each of which is unsubstituted or substituted with one or more Rs groups.
13. The compound of claim 11, wherein R2 is phenyl, naphthyl, (C14) aryl, or (5 to 10membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups.
14. The compound of claim 13, wherein R2 isphenyl.
15. The compound of claim 14, wherein the phenyl is substituted in its 4position with an R4 group.
16. The compound of claim 1 having the formula (Ia) : (Ia) or a pharmaceutically acceptable salt thereof, wherein R, and R,'are independentlyH, (C,C3) alkyl,O(C,C3) alkyl,halo,C (halo) 3,CH (halo) 2,CH2 (halo),NO2,OH, orCN.
17. The compound of claim 16, wherein R, and RI'are independently (CC3) alkyl,O(CC3) aLkyl, orhalo.
18. The compound of claim 17, wherein A isC (O).
19. The compound of claim 17, wherein A isC (S).
20. The compound of claim 17, wherein A isCH2.
21. The compound of claim 17, wherein A isCH (C1C4 alkyl).
22. The compound of claim 17, wherein A isC (C1C4 alkyl)(C1C4 alkyl).
23. The compound of claim 17, wherein R, isCH3 and R,'isCl.
24. The compound of claim 17, wherein Rl isCH3 and Rl'isOCH3.
25. The compound of claim 16, wherein Rl and Rl'are (ClC3) alkyl.
26. The compound of claim 25, wherein R, and R,'areCH3.
27. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
28. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16 and a pharmaceutically acceptable carrier or excipient.
29. A method for treating pain, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.
30. The method of claim 29, further comprising administering to the animal an effective amount of another therapeutic agent.
31. A method for treating pain, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.
32. The method of claim 31, further comprising administering to the animal an effective amount of another therapeutic agent.
33. A method for treating an addictive disorder, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.
34. The method of claim 33, further comprising administering to the animal an effective amount of another therapeutic agent.
35. A method for treating an addictive disorder, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.
36. The method of claim 35, further comprising administering to the animal an effective amount of another therapeutic agent.
37. A method for treating Parkinson's disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.
38. The method of claim 37, further comprising administering to the animal an effective amount of another therapeutic agent.
39. A method for treating Parkinson's disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.
40. The method of claim 39, further comprising administering to the animal an effective amount of another therapeutic agent.
41. A method for treating anxiety, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.
42. The method of claim 41, further comprising administering to the animal an effective amount of another therapeutic agent.
43. A method for treating anxiety, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.
44. The method of claim 43, further comprising administering to the animal an effective amount of another therapeutic agent.
45. A method for treating schizophrenia, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.
46. The method of claim 45, further comprising administering to the animal an effective amount of another therapeutic agent.
47. A method for treating schizophrenia, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.
48. The method of claim 47, further comprising administering to the animal an effective amount of another therapeutic agent.
49. A method for inhibiting mGluR5receptor function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.
50. The method of claim 49, further comprising contacting the cell with an effective amount of another therapeutic agent.
51. A method for inhibiting mGluR5receptor function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.
52. The method of claim 51, further comprising contacting the cell with an effective amount of another therapeutic agent.
53. A method for preparing a composition, the method comprising admixing a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
54. A kit comprising a container containing the composition of claim 27.
Description:
PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS This application claims the benefit of U. S. Provisional application no. 60/413,193, filed September 24, 2002, and of U. S. Provisional application no. 60/456,042, filed March 19,2003, the disclosure of each of which is incorporated by reference herein in its entirety.

1. FIELD OF THE INVENTION The present invention relates to 2-Pyrimidinylpiperazine Compounds, compositions comprising an effective amount of a 2-Pyrimidinylpiperazine Compound and methods for treating or preventing a condition such as pain, urinary incontinence (IJI), an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression, comprising administering to an animal in need thereof an effective amount of a 2-Pyrimidinylpiperazine Compound.

2. BACKGROUND OF THE INVENTION Pain is the most common symptom for which patients seek medical advice and treatment. Pain can be acute or chronic. While acute pain is usually self-limited, chronic pain persists for 3 months or longer and can lead to significant changes in a patient's personality, lifestyle, functional ability and overall quality of life (K. M. Foley, Pain, in Cecil Textbook of Medicine 100-107 (J. C. Bennett and F. Plum eds. , 20th ed. 1996)).

Moreover, chronic pain can be classified as either nociceptive or neuropathic.

Nociceptive pain includes tissue injury-induced pain and inflammatory pain such as that associated with arthritis. Neuropathic pain is caused by damage to the peripheral or cental nervous system and is maintained by aberrant somatosensory processing. There is a large body of evidence relating activity at both Group I mGluRs (mGluRl and mGluR5) (M. E.

Fundytus, CNSDrugs 15 : 29-58 (2001)) and vanilloid receptors (VR1) (V. Di Marzo et al., Current Opinion in Neurobiology 12: 372-379 (2002) ) to pain processing. Inhibiting mGluRl or mGluR5 reduces pain, as shown by in vivo treatment with antibodies selective for either mGluRl or mGluR5, where neuropathic pain in rats was attenuated (M. E. Fundytus et al., NeuroReport 9: 731-735 (1998) ). It has also been shown that antisense oligonucleotide knockdown of mGluRl alleviates both neuropathic and inflammatory pain (M. E. Fundytus et

al., Brit. J. Pharmacol. 132: 354-367 (2001); M. E. Fundytus et al., Pharmacol., Biochem. & Behavior 73: 401-410 (2002) ). Small molecule antagonists for mGluR5-attenuated pain in in vivo animal models are disclosed in, e. g., K. Walker et al., Neuropharinacology 40: 1-9 (2000) and A. Dogrul et al., NeuroscienceLet. 292: 115-118 (2000)).

Nociceptive pain has been traditionally managed by administering non-opioid analgesics, such as acetylsalicylic acid, choline magnesium trisalicylate, acetaminophen, ibuprofen, fenoprofen, diflusinal, and naproxen; or opioid analgesics, including morphine, hydromorphone, methadone, levorphanol, fentanyl, oxycodone, and oxymorphone. Id. In addition to the above-listed treatments, neuropathic pain, which can be difficult to treat, has also been treated with anti-epileptics (e. g., gabapentin, carbamazepine, valproic acid, topiramate, phenytoin), NMDA antagonists (e. g. , ketamine, dextromethorphan), topical lidocaine (for post-herpetic neuralgia), and tricyclic antidepressants (e. g. , fluoxetine, sertraline and amitriptyline).

UI is uncontrollable urination, generally caused by bladder-detrusor-muscle instability. UI affects people of all ages and levels of physical health, both in health care settings and in the community at large. Physiologic bladder contraction results in large part from acetylcholine-induced stimulation of post-ganglionic muscarinic-receptor sites on bladder smooth muscle. Treatments for UI include the administration of drugs having bladder-relaxant properties, which help to control bladder-detrusor-muscle overactivity. For example, anticholinergics such as propantheline bromide and glycopyrrolate, and combinations of smooth-muscle relaxants such as a combination of racemic oxybutynin and dicyclomine or an anticholinergic, have been used to treat UI (See, e. g., A. J. Wein, Urol.

Clin. N. Am. 22: 557-577 (1995); Levin et al., J. Urol. 128: 396-398 (1982); Cooke et al., S.

Afr. Med. J. 63: 3 (1983); R. K. Mirakhur et al., Anaesthesia 38 : 1195-1204 (1983) ). These drugs are not effective, however, in all patients having uninhibited bladder contractions.

None of the existing commercial drug treatments for UI has achieved complete success in all classes of UI patients, nor has treatment occurred without significant adverse side effects. For example, drowsiness, dry mouth, constipation, blurred vision, headaches, tachycardia, and cardiac arrhythmia, which are related to the anticholinergic activity of traditional anti-UI drugs, can occur frequently and adversely affect patient compliance. Yet despite the prevalence of unwanted anticholinergic effects in many patients, anticholinergic

drugs are currently prescribed for patients having UI. The Mersk Manual af Medical Information 631-634 (R. Berkow ed., 1997).

Certain pharmaceutical agents have been administered for treating addiction. U. S.

Patent No. 5,556, 838 to Mayer et al. discloses the use of nontoxic NMDA-blocking agents co-administered with an addictive substance to prevent the development of tolerance or withdrawal symptoms. U. S. Patent No. 5,574, 052 to Rose et al. discloses co-administration of an addictive substance with an antagonist to partially block the pharmacological effects of the addictive substance. U. S. Patent No. 5, 075, 341 to Mendelson et al. discloses the use of a mixed opiate agonist/antagonist to treat cocaine and opiate addiction. U. S. Patent No.

5,232, 934 to Downs discloses administration of 3-phenoxypyridine to treat addiction. U. S.

Patents No. 5,039, 680 and 5,198, 459 to Imperato et al. disclose using a serotonin antagonist to treat chemical addiction. U. S. Patent No. 5, 556, 837 to Nestler et. al. discloses infusing BDNF or NT-4 growth factors to inhibit or reverse neurological adaptive changes that correlate with behavioral changes in an addicted individual. U. S. Patent. No. 5,762, 925 to Sagan discloses implanting encapsulated adrenal medullary cells into an animal's central nervous system to inhibit the development ofopioid tolerance. U. S. Patent No. 6,204, 284 to Beer et al. discloses racemic ()-l- (3, 4-dichlorophenyl)-3-azabicyclo [3. 1. 0] hexane for use in the prevention or relief of a withdrawal syndrome resulting from addiction to drugs and for the treatment of chemical dependencies. Glutamate release is enhanced during opioid withdrawal (K. Jhamandas et al., J. Neurosience 16: 2758-2766 (1996) ). Recent evidence suggests a role for Group I mGluRs in opioid tolerance and dependence. An interaction between opioids and mGluRs was demonstrated when it was shown that an antagonist at Group I mGluRs significantly attenuated withdrawal symptoms in opioid-dependent rats (M. E. Fundytus et al., Brìt. J. Pharmacol. 113: 1215-1220 (1994) ). More recent results show that antisense oligonucleotide knockdown of mGluRl reduces protein kinase C activity (M. E.

Fundytus et al., Brit. J. Pharmacol. 132: 354-367 (2001) ), which may be associated in the development of opioid tolerance and dependence (see also M. E. Fundytus, CNS Drugs 15: 29-58, (2001) ). Very recently, it has been shown that antisense oligonucleotide knockdown of mGluRl attenuates the development of opioid tolerance (R. N. Sharif et al., Brit. J. Pharmacol. 136: 865-872 (2002) ). Selective antagonists of the mGluR5 receptor have

also been shown to exert anti-dependence activity in vivo (C. Chiamulera et al., Nature Neuroscience 4: 873-874 (2001)).

Without treatment, Parkinson's disease progresses to a rigid akinetic state in which patients are incapable of caring for themselves. Death frequently results from complications of immobility, including aspiration pneumonia or pulmonary embolism. Drugs commonly used for the treatment of Parkinson's disease include carbidopa/levodopa, pergolide, bromocriptine, selegiline, amantadine, and trihexyphenidyl hydrochloride. There remains, however, a need for drugs useful for the treatment of Parkinson's disease and having an improved therapeutic profile.

Currently, benzodiazepines are the most commonly used anti-anxiety agents for generalized anxiety disorder. Benzodiazepines, however, carry the risk of producing impairment of cognition and skilled motor functions, particularly in the elderly, which can result in confusion, delerium, and falls with fractures. Sedatives are also commonly prescribed for treating anxiety. The azapirones, such as buspirone, are also used to treat moderate anxiety. The azapirones, however, are less useful for treating severe anxiety accompanied with panic attacks. Antagonists of the mGluR5 receptor have also been shown to exert anxiolytic and anti-depressant activity in in vivo animal models (E. Tatarczynska et al., Br. J. Pharmacol. 132 (7): 1423-1430 (2001) and P. J. M. Will et al., Trends in Pharmacological Sciences (7) : 331-37 (2001)).

Examples of drugs for treating a seizure and epilepsy include carbamazepine, ethosuximide, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, benzodiazepines, y-vinyl GABA, acetazolamide, and felbamate. Anti-seizure drugs, however, can have side effects such as drowsiness; hyperactivity; hallucinations ; inability to concentrate; central and peripheral nervous system toxicity, such as nystagmus, ataxia, diplopia, and vertigo ; gingival hyperplasia; gastrointestinal disturbances such as nausea, vomiting, epigastric pain, and anorexia; endocrine effects such as inhibition of antidiuretic hormone, hyperglycemia, glycosuria, osteomalacia; and hypersensitivity such as scarlatiniform rash, morbillifonn rash, Stevens-Johnson syndrome, systemic lupus erythematosus, and hepatic necrosis; and hematological reactions such as red-cell aplasia, agranulocytosis, thrombocytopenia, aplastic anemia, and megaloblastic anemia. The Merck Manual of Medical Information 345-350 (R. Berkow ed. , 1997).

Symptoms of strokes vary depending on what part of the brain is affected. Symptoms include loss of or abnormal sensations in an arm or leg or one side of the body, weakness or paralysis of an arm or leg or one side of the body, partial loss of vison or hearing, double vision, dizziness, slurred speech, difficulty in thinking of the appropriate word or saying it, inability to recognize parts of the body, unusual movements, loss of bladder control, imbalance, and falling, and fainting. The symptoms can be permanent and can be associated with coma or stupor. Examples of drugs for treating strokes include anticoagulants such as heparin, drugs that break up clots such as streptokinase or tissue plasminogen activator, and drugs that reduce swelling such as mannitol or corticosteroids. The Merck Manual of Medical Information 352-355 (R. Berkow ed. , 1997).

Pruritus is an unpleasant sensation that prompts scratching. Conventionally, pruritus is treated by phototherapy with ultraviolet B or PWA or with therapeutic agents such as naltrexone, nalmefene, danazol, and tricyclic antidepressants.

Selective antagonists of the metabotropic glutamate receptor 5 ("mGluR5") have been shown to exert analgesic activity in in vivo animal models (K. Walker et al., Neuropharmacology 40: 1-9 (2000) and A. Dogrul et al., Neuroscience Let., 292 (2): 115-118 (2000)).

Selective antagonists of the mGluR5 receptor have also been shown to exert anti- Parkinson activity in vivo (K. J. Ossowska et al., Neuropharmacology 41 (4): 413-20 (2001) and P. J. M. Will et al., Trends in Pharmacological Sciences 22 (7) : 331-37 (2001)).

Selective antagonists of the mGluR5 receptor have also been shown to exert anti- dependence activity in vivo (C. Chiamulera et al., Nature Neuroscience 4 (9): 873-74 (2001)).

International Publication No. WO 99/37304 by Rohne-Poulenc Rorer Pharmaceuticals, Inc. discloses oxoazaheterocyclic compounds useful for inhibiting factorXa.

There remains, however, a clear need in the art for new drugs useful for treating or preventing pain, UI, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression.

Citation of any reference in Section 2 of this application is not to be construed as an admission that such reference is prior art to the present application.

3. SUMMARY OF THE INVENTION The present invention encompasses compounds of formula (I) :

(I) and pharmaceutically acceptable salts thereof, where: A is-C (O)-,-C (S)-,-CH2-,-CH (C1-C4 alkyl)-, or-C (Cl-C4 alkyl) (C-C4 alkyl)-; n is an integer ranging from 0 to 3; each R1 is independently-(C1-C3)alkyl, -O-(C1-C3) alkyl, -halo, -C (halo) 3,-CH (halo) 2, -CH2(halo), -NO2, -OH, or-CN; when A is-CH2-,-CH (CI-C4 alkyl)-, or-C (CI-C4 alkyl) (Cl-C4 alkyl)-, then R2 is- phenyl, -naphthyl, or- (C, 4) aryl, each of which is unsubstituted or substituted with one or more R4 groups, or, when A is-C (O)- or-C (S) -, then R2 is (i) $-H, -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3- C10) cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl, -(C8- Cl4) bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered) heterocycle, or- (7- to 10- membered) bicycloheterocycle, each of which, other than-H, is unsubstituted or substituted with one or more R5 groups, or (ii)-phenyl,-naphthyl,- (C14) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is an integer ranging from 0 to 2; each R3 is independently -OH, -halo, -NO2, -CN, -NH2, -(C1-C3)alkyl, or -CH2OH ; each R4 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl,

-(C3-C) cycloaLkyl,-(C5-C8) cycloalkenyl,-phenyl,-(C3-C5) heterocycle,-C (halo) 3, - CH (halo) 2,-CH2 (halo),-CN,-OH,-halo,-N3,-NO2,-N (R6) z,-CH=NR6,-NR60H,-COR6, -C(O)OR6, -OC(O)R6, -OC(O)OR6, -SR6, -S(O)R6, or -S(O)2R6 ; each Rs is independently-CN,-OH,-halo,-N3,-NOz,-N (Rs) z,-CH=NR6,-NR6OH, -COR6,-C (O) OR6,-OC (O) R6, -OC (O) OR6,-SR6,-S (O) R6, or-S (0) 2R6 ; each R6 is independently-H,-(Cl-C6) aLkyl,-(C2-C6) aLkenyl,-(C2-C6) alkynyl, -(C3-C8) cycloalkyl,-(C5-C8) cycloalkenyl,-phenyl,-(C3-C5) heterocycle,-C (halo) 3, -CH (halo) 2, or-CH2 (halo) ; and each halo is independently-F,-Cl,-Br, or-I.

A compound of formula (I) or a pharmaceutically acceptable salt thereof (a "2-Pyrimidinylpiperazine Compound") is useful for treating or preventing pain, UI, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression (each being a"Condition") in an animal.

The invention also relates to compositions comprising an effective amount of a 2- Pyrimidinylpiperazine Compound and a pharmaceutically acceptable carrier or excipient.

The compositions are useful for treating or preventing a Condition in an animal.

The invention further relates to methods for treating a Condition comprising administering to an animal in need thereof an effective amount of a 2-Pyrimidinylpiperazine Compound.

The invention further relates to methods for preventing a Condition comprising administering to an animal in need thereof an effective amount of a 2-Pyrimidinylpiperazine Compound.

The invention still further relates to methods for inhibiting mGluR5 function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a 2- Pyrimidinylpiperazine Compound.

The invention still further relates to methods for inhibiting mGluRl function in a cell, comprising contacting a cell capable of expressing mGluRl with an effective amount of a 2- Pyrimidinylpiperazine Compound.

The invention still further relates to a method for preparing a composition comprising the step of admixing a 2-Pyrimidinylpiperazine Compound and a pharmaceutically acceptable carrier or excipient.

The invention still further relates to a kit comprising a container containing an effective amount of a 2-Pyrimidinylpiperazine Compound. The kit may further comprise printed instructions for using the 2-Pyrimidinylpiperazine Compound to treat any of the aforementioned Conditions.

The present invention can be understood more fully by reference to the following detailed description and illustrative examples, which are intended to exemplify non-limiting embodiments of the invention.

4. DETAILED DESCRIPTION OF THE INVENTION 4.1 PYRIMIDINYLPIPERAZINE COMPOUNDS OF FORMULA (I) As stated above, the present invention encompasses 2-Pyrimidinylpiperazine Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R1, R2, R3, A, n, and p are defined above.

In the 2-Pyrimidinylpiperazine Compounds, an R, group, when present, can be substituted at the 4-, 5-, or 6-position carbon atom of the pyrimidinyl ring. In one embodiment, n is 1 and Rl is substituted at the 4-position of the pyrimidinyl ring. In another

embodiment, n is 1 and R1 is substituted at the 5-position of the pyrimidinyl ring. In another embodiment, n is 1 and R, is substituted at the 6-position of the pyrimidinyl ring.

In another embodiment p is 0 or 1.

In another embodiment n is 0 and p is 0.

In another embodiment A is-C (O)-.

In another embodiment A is-C (S)-.

In another embodiment A is-CHz.

In another embodiment A is-CH (C1-C4 alkyl)-.

In another embodiment A is-C (Cl-C4 alkyl) (CI-C4 alkyl)-.

In another embodiment, when A is-C (O)-, R2 is -H, -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5- C10) cycloalkenyl,-(Cs-Cl4) bicycloalkenyl,-(C8-CI4) tricycloalkenyl,-(3-to 7- membered) heterocycle, or- (7- to 10-membered) bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.

In another embodiment, when A is-C (O)-, R2 is-phenyl,-naphthyl,-(Cl4) aryl, or-(5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups.

In another embodiment, when A is-C (O)-, R2 is unsubstituted-phenyl.

In another embodiment, when A is-C (O)-, R2 is-phenyl substituted with one or more R4 groups.

In another embodiment, when A is-C (O)-, R2 is-phenyl substituted in its 4-position with an R4 group.

In another embodiment, when A is-C (O)-, R2 is-phenyl substituted in its 4-position with a- (Cl-C6) alkyl group.

In another embodiment, when A is-C (S)-, R2 is -H, -(C1-C10)alkyl, -(C2-C10) alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5- C10)cycloalkenyl, -(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7- membered) heterocycle, or- (7- to 10-membered) bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.

In another embodiment, when A is-C (S)-, R2 is -phenyl, -naphthyl, -(C14) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups.

In another embodiment, when A is-C (S)-, R2 is unsubstituted-phenyl.

In another embodiment, when A is-C (S)-, R2 is-phenyl substituted with one or more R4 groups.

In another embodiment, when A is-C (S)-, R2 is-phenyl substituted in its 4-position with an R4 group.

In another embodiment, when A is-C (S)-, R2 is-phenyl substituted in its 4-position with a -(C1-C6)alkyl group.

In another embodiment, when A is-CH2-, R2is-phenyl,-naphthyl, or- (C, 4) aryl, each of which is unsubstituted or substituted with one or more R4 groups.

In another embodiment, when A is -CH2-, R2 is unsubstituted-phenyl.

In another embodiment, when A is -CH2-, R2 is-phenyl substituted with one or more R4 groups.

In another embodiment, when A is-CH2-, R2 is-phenyl substituted in its 4-position with an R4 group.

In another embodiment, when A is -CH2-, R2 is-phenyl substituted in its 4-position with a- (CI-C6) alkyl group.

In another embodiment, when A is-CH (Cl-C4 alkyl)-, R2 is-phenyl, -naphthyl, or -(Cl4) aryl, each of which is unsubstituted or substituted with one or more R4 groups.

In another embodiment, when A is-CH (Cl-C4 alkyl)-, R2 is unsubstituted -phenyl.

In another embodiment, when A is-CH (Cl-C4 alkyl)-, R2 is-phenyl substituted with one or more R4 groups.

In another embodiment, when A is-CH (Cl-C4alkyl)-, R2is-phenyl substituted in its 4-position with an R4 group.

In another embodiment, when A is-CH ((C1-C4 alkyl)-, R2 is -phenyl substituted in its 4-position with a- (Cl-C6) alkyl group.

In another embodiment, when A is-C (Cl-C4 alkyl) (Cl-C4 alkyl)-, R2 is-phenyl, -naphthyl, or -(C14)aryl, each of which is unsubstituted or substituted with one or more R4 groups.

In another embodiment, when A is-C (C1-C4 alkyl)(C1-C4 alkyl)-, R2 is unsubstituted -phenyl.

In another embodiment, when A is -C(C1-C4 alkyl)(C1-C4 alkyl)-, R2 is -phenyl substituted with one or more R4 groups.

In another embodiment, when A is-C (C1-C4 alkyl)(C1-C4 alkyl)-, R2 is -phenyl substituted in its 4-position with an R4 group.

In another embodiment, when A is-C (C1-C4 alkyl)(C1-C4 alkyl)-, R2 is-phenyl substituted in its 4-position with a- (Cl-C6) alkyl group.

In another embodiment A is-C (O)- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2,-CH2 (halo),-NO2,-OH, or-CN; R2 is (i) -H, -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3- Ciao) cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl, -(C8- C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered) heterocycle, or- (7- to 10- membered) bicycloheterocycle, each of which, other than-H, is unsubstituted or substituted with one or more R5 groups, or (ii)-phenyl,-naphthyl,- (C, 4) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups ; and p is 0.

In another embodiment A is-C (O)- ; n is 1 ; Rt is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is (i) -(C3-C100cycloalkyl or -(3- to 7-membered) heterocycle, each of which is unsubstituted or substituted with one or more R5 groups, or (ii) -phenyl, -naphthyl, -(C14) aryl, or- (5- to 10-membered) heteroaryl, each which is unsubstituted or substituted with one or more R4 groups ; and pis0.

In another embodiment A is-C (O)- ; n is 1 ; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2, -CH2, (halo), -NO2, -OH, or-CN; R2 is (i) -H, -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3- Cio) cycloalkyl,- (C$-C, ) bicycloalkyl,- (C8-CI4) tricycloalkyl,- (C5-Clo) cycloalkenyl,- (C8-

C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered) heterocycle, or- (7- to 10- membered) bicycloheterocycle, each of which, other than-H, is unsubstituted or substituted with one or more Rs groups, or (ii)-phenyl,-naphthyl,- (Cla) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-C (O)- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2, -CH2 (halo),-NO2,-OH, or-CN; R2 is (i) -H, -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3- Cl0) cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl, -(C8- C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered) heterocycle, or- (7- to 10- membered) bicycloheterocycle, each of which, other than-H, is unsubstituted or substituted with one or more R5 groups, or (ii)-phenyl,-naphthyl,- (C14) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; n is 1 ; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is (i)-(C3-Cl0) cycloalkyl or-(3-to 7-membered) heterocycle, each of which is unsubstituted or substituted with one or more R5 groups, or (ii)-phenyl,-naphthyl,- (Cla) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups ; pis 1 ; and R3 is-OH,-halo,-NO2,-CN,-NH2,- (Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-C (O)- ; n is 1; R, is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is (i) -(C3-C10)cycloalkyl or -(3- to 7-membered) heterocycle, each of which is unsubstituted or substituted with one or more Rs groups, or

(ii)-phenyl,-naphthyl,- (C14) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups; p is 1 ; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered) heteroaryl, each which is unsubstituted or substituted with one or more R4 groups; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-C (O)- ; n is 1 ; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, -(C14) aryl, or- (5- to 10-membered) heteroaryl, each which is unsubstituted or substituted with one or more R4 groups; p is 1; and R3 is -OH, -halog, -NO2, -CN, -NH2, -(C1-C3)alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (S)- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2, -CH2 (halo), -NO2, -OH, or-CN; R2 is (i) -H, -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3- Ciao) cycloalkyl,- (C$-C14) bicycloalkyl,- (Cg-C14) tricycloalkyl,- (Cs-Clo) cycloalkenyl,- (Cg- C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered) heterocycle, or- (7- to 10- membered) bicycloheterocycle, each of which, other than-H, is unsubstituted or substituted with one or more R5 groups, or (ii)-phenyl,-naphthyl,- (C14) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups; and p is 0.

In another embodiment A is-C (S)- ; n is 1 ; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is (i)-(C3-Cl0) cycloalkyl or-(3-to 7-membered) heterocycle, each of which is unsubstituted or substituted with one or more Rs groups, or

(ii)-phenyl,-naphthyl,- (C14) aryl, or- (5- to 10-membered) heteroaryl, each which is unsubstituted or substituted with one or more R4 groups; and pis0.

In another embodiment A is-C (S)- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2,-CH2 (halo),-NO2,-OH, or-CN; R2 is (i) -H, -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3- Clo) cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl, -(C8- C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered) heterocycle, or- (7- to 10- membered) bicycloheterocycle, each of which, other than-H, is unsubstituted or substituted with one or more R5 groups, or (ii)-phenyl,-naphthyl,- (C14) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-C (S)- ; n is 1; Ri is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo)i,-CH2 (halo),-NO2,-OH, or-CN ; R2 is (i)-H,- (CnCio) alkyl,- (C2-Clo) alkenyl,- (C2-Clo) alkynyl,- (C3- C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl, -(C8- Ctbicycloalkenyl,- (Cg-CiJtricycloalkenyl,- (3- to 7-membered) heterocycle, or- (7- to 10- membered) bicycloheterocycle, each of which, other than-H, is unsubstituted or substituted with one or more R5 groups, or (ii) -phenyl, -naphthyl, -(C14) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(C-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (S)- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is (i)-(C3-CIO) cycloalkyl or-(3-to 7-membered) heterocycle, each of which is unsubstituted or substituted with one or more R5 groups, or

(ii)-phenyl,-naphthyl,-(Cl4) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-C (S)- ; n is 1; R, is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3, -NO2, -OH, or-CN; R2 is (i)-(C3-Cl0) cycloalkyl or- (3- to 7-membered) heterocycle, each of which is unsubstituted or substituted with one or more R5 groups, or (ii)-phenyl,-naphthyl,- (C, 4) aryl, or- (5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is -OH, -halo, -NO2, -CN, -NH2, -(C1-C3)alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (S)- ; n is 1; RI is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered) heteroaryl, each which is unsubstituted or substituted with one or more R4 groups ; p is 1 ; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) aLkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-C (S)- ; n is 1 ; R, is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3, -NO2, -OH, or-CN; R2 is-phenyl,-naphthyl, -(C14)aryl, or -(5- to 10-membered) heteroaryl, each which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) aLkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-CH2-,-CH (CI-C4 aLkyl)-, or -C(C1-4 alkyl)((C1-C4 alkyl)-; n is 1 ; R, is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2,-CH2 (halo),-NO2,-OH, or-CN; R2 is-phenyl, - naphthyl, or- (C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups; and p is 0.

In another embodiment A is-CH2-,-CH (Cl-C4alkyl)-, or

-C (Cl-C4 alkyl) (Cl-C4 alkyl)-; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring <BR> <BR> <BR> <BR> and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, or- (C, 4) aryl, each which is unsubstituted or substituted with one or more R4 groups; and p is 0.

In another embodiment A is-CH2-,-CH (Cl-C4 alkyl)-, or -C (Cl-C4 alkyl) (Cl-C4 alkyl)-; n is 1; RI is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2,-CH2 (halo),-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, or -(C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups; p is 1; and R3 is -OH, -halo, -NO2, -CN, -NH2, -(C1-C3) alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-CH2-,-CH (Cl-C4 alkyl)-, or -C (Cl-C4 alkyl) (Cl-C4 alkyl)-; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2, -CH2(halo), -NO2, -OH, or-CN; R2 is-phenyl, -naphthyl, or -(C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups; p is 1; and R3 is -OH, -halo, -NO2, -CN, -NH2, -(C1-C3) alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-CH2-,-CH (Cl-C4 alkyl)-, or -C (Cl-C4 alkyl) (Cl-C4 alkyl)-; n is 1; Ri is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, or -(C14)aryl, each of which is unsubstituted or substituted with one or more R4 groups; p is 1; and R3 is-OH, -halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-CH2-,-CH (Cl-C4 alkyl)-, or -C (Cl-C4 alkyl) (CI-C4 alkyl)-; n is 1 ; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, or -(C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups; p is 1; and-R3 is-OH, -halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-CH2-,-CH (Cl-C4 alkyl)-, or -C (CI-C4 alkyl) (Cl-C4 alkyl)-; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, or -(C14) aryl, each

which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is-OH, -halo, -NO2, -CN, -NH2, -(C1-C3)alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-CH2-,-CH (Cl-C4 alkyl)-, or -C (Cl-C4 alkyl) (Cl-C4 alkyl)-; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3, -halo,-C (halo) 3, -NO2, -OH, or-CN; R2 is -phenyl, -naphthyl, or -(C14) aryl, each which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is -OH, -halo, -NO2, -CN, -NH2, -(C1-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-CH2- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2,-CH2 (halo),-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, or -(C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups ; and p is 0.

In another embodiment A is-CH2- ; n is 1; RI is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3, -NO2, -OH, or-CN; R2 is-phenyl,-naphthyl, or -(Cl4) aryl, each which is unsubstituted or substituted with one or more R4 groups ; and p is 0.

In another embodiment A is-CH2- ; n is 1; R, is substituted at the 4-position of the pyrimidinyl ring and is -CH3, -halo, -C (halo) 3,-CH (halo) 2, -CH2(halo), -NO2, -OH, or-CN; R2 is-phenyl, -naphthyl, or -(C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-CH2-; n is 1; R, is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-CH (halo) 2,-CH2 (halo),-NO2,-OH, or-CN; R2 is-phenyl, -naphthyl, or -(C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-CH2- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is-phenyl,-naphthyl, or -(C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is 1 ;

and R3 is-OH,-halo,-NO2,-CN,-NH2,- (Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-CH2- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is -phenyl, -naphthyl, or -(Cl4) aryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is-OH,-halo,-NO2,-CN,-NH2,-(Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-CH2- ; n is 1; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is -phenyl, -naphthyl, or -(Cl4) aryl, each which is unsubstituted or substituted with one or more R4 groups ; p is 1; and R3 is -OH, -halo, -NO2, -CN, -NH2, -(C1-C3)alkyl, or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl ring.

In another embodiment A is-CH2- ; n is 1; RI is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-halo,-C (halo) 3,-NO2,-OH, or-CN; R2 is-phenyl,-naphthyl, or -(Cl4) aryl, each which is unsubstituted or substituted with one or more R4 groups ; p is 1 ; and R3 is-OH,-halo,-NO2,-CN,-NH2,- (Cl-C3) alkyl, or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

4.2 PYRIMIDINYLPIPERAZINE COMPOUNDS OF FORMULA (Ia) In another embodiment, the 2-Pyrimidinylpiperazine Compounds of Formula (I) have the Formula (Ia) :

and pharmaceutically acceptable salts thereof, where: A is-C (O)-,-C (S)-,-CH2-,-CH (Cl-C4 alkyl)-, or-C (Cl-C4 alkyl) (Cl-C4 alkyl)-; RI and R1' are independently -H, -(C1-C3)alkyl, -O-(C1-C3) alkyl, -halo, -C (halo) 3, - CH (halo) 2,-CH2 (halo),-NO2,-OH, or-CN; when A is -CH2-, -CH(C1-C4 alkyl)-, or -C(C1-C4 alkyl)(C1-C4 alkyl)-, then R2 is -phenyl,-naphthyl, or- (C14) aryl, each of which is unsubstituted or substituted with one or more R4 groups, or, when A is-C (O)- or-C (S) -, then R2 is (i) -H, -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10) cycloalkenyl, -(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered) heterocycle, or- (7- to 10-membered) bicycloheterocycle, each of which, other than-H, is unsubstituted or substituted with one or more Rs groups, or (ii)-phenyl,-naphthyl,- (C14)aryl, or -(5- to 10-membered) heteroaryl, each of which is unsubstituted or substituted with one or more R4 groups ; p is an integer ranging from 0 to 2; each R3 is independently-OH,-halo,-NO2,-CN,-NH2,-(C,-C3) alkyl, or-CH2OH ; each R4 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C (halo) 3, - CH (halo) 2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(r6)2, -CH=NR6, -NR6OH, -COR6, -C(O) OR6, -OC (O) R6, -OC (O) OR6,-SR6,-S (O) R6, or-S (0) 2R6 ; each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R6)2, -CH=NR6, -NR6OH, -COR6, -C(O) OR6, -OC (O) R6,-OC (O) OR6,-SR6,-S (O) R6, or-S (O) 2R6 ; and each R6 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C (halo) 3, -CH(halo)2, or -CH2(halo) ; and each halo is independently-F,-Cl,-Br, or-I.

In one embodiment p is 0 or 1.

In another embodiment R1 and Rl'are-H.

In another embodiment Rl and Rl'are-CH3.

In another embodiment R1 is-OCH3 and Rl'is-CH3.

In another embodiment Rl is-halo and Rl'is-CH3.

In another embodiment Rl is-Cl and Rl'is-CH3.

In another embodiment A is-C (O)- ; R, is-CH3,-OCH3 or-halo; R,'is-H or-CH3 ; R2 is-phenyl or-pyridyl, each which is unsubstituted or substituted with one or more R4 groups; and R3 is-H,-CH3 or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; R, is-CH3,-OCH3 or-Cl ; Rl'is-H or-CH3 ; R2 is - phenyl or-pyridyl, each which is unsubstituted or substituted with one or more R4 groups; and R3 is-H,-CH3 or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)-; Rl is-CH3,-OCH3 or-halo; R,'is-H or-CH3 ; R2 is-phenyl or-pyridyl, each which is unsubstituted or substituted with one or more R4 groups selected from-halo and-OCH3 ; and R3 is-H,-CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; Rl is-CH3,-OCH3 or-Cl ; Rl'is-H or-CH3 ; R2 is - phenyl or-pyridyl, each which is unsubstituted or substituted with one or more R4 groups selected from-F and-OCH3 ; and R3 is-H,-CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; R, is-CH3,-OCH3 or-Cl ; Rl'is-H or-CH3 ; R2 is - phenyl which is unsubstituted or substituted with one R4 group para to its point of attachment to (-C = C-A-) and selected from-F and-OCH3 ; and R3 is-H,-CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)-; Rl is-CH3,-OCH3 or-C1 ; Rl'is-H or-CH3 ; R2 is 2-pyridyl which is unsubstituted or substituted with one R4 group at the 5-position of the 2-pyridyl selected from-F and-OCH3 ; and R3 is-H,-CH3 or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; Rl is-CH3,-OCH3 or-Cl ; Rl'is-H or-CH3 ; R2 is 3-pyridyl which is unsubstituted or substituted with one R4 group at the 6-position of the 3-pyridyl selected from-F and-OCH3 ; and R3 is-H,-CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In the 2-Pyrimidinylpiperazine Compounds each R3 group, if present, can be on any carbon of the piperazino ring. In one embodiment, the 2-Pyrimidinylpiperazine Compounds have only one R3 group, and that R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl group. In another embodiment, the 2- Pyrimidinylpiperazine Compound has only one R3 group, and that R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment, two R3 groups are on a single atom of the piperazino ring. In another embodiment, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl group and another R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has two R3 groups, each being attached to a different carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl group. In another embodiment, the 2-Pyrimidinylpiperazine Compound has two R3 groups, each being attached to a different carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In one embodiment, wherein the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, the carbon atom to which an R3 group is attached has the (R) configuration. In another embodiment, wherein the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, the carbon atom to which the R3 group is attached has the (S) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, and at least one of the carbon atoms to which an R3 group is attached has the (R) configuration.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, and at least one of the carbon atoms to which an R3 group is attached has the (S) configuration.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl group, and the carbon to which the R3 group is attached is in the (R) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (R) configuration, and R3is-(CI-C3) alkyl. In another embodiment, the 2-Pyrimidinylpiperazine

Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (R) configuration, and R3is-CH3. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is -CH2OH. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is -CH2CH3.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group, and the carbon to which the R3 group is attached is in the (R) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is -(C1-C3)alkyl. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3is-CH3. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups ; an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is -CH2OH. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3is-CH2CH3.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl group, and the carbon to which the R3 group is attached is in the (S) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen

attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is- (C,-C3) alkyl. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is-CH3. In another embodiment, the 2- Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is -CH2OH. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is -CH2CH3.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group, and the carbon to which the R3 group is attached is in the (S) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is -(C1-C3)alkyl. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (S) configuration, and R3is-CH3. In another embodiment, the 2-Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is -CH2OH. In another embodiment, the 2- Pyrimidinylpiperazine Compound has one or two R3 groups, an R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is -CH2CH3.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl group, and the carbon to which the R3 group is attached is in the

(R) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is- (Cl-C3) alkyl. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is-CH3. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 H20 H. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is -CH2CH3 In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group, and the carbon to which the R3 group is attached is in the (R) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3. group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is- (Cl-C3) alkyl. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is-CH3. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 H20 H. In another embodiment, the 2- Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 H2C H3.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the pyrimidinyl group, and the carbon to which the R3 group is attached is in the (S) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (S) configuration, and R3is-(CI-C3) alkyl. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (S) configuration, and R3is-CH3. In another embodiment, the 2- Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is-CH20H. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the pyrimidinyl group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is -CH2CH3.

In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group, and the carbon to which the R3 group is attached is in the (S) configuration. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is-(C1-C3)alkyl. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (S) configuration, and R3is-CH3. In another embodiment, the 2-Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (S) configuration, and R3 is -CH2OH. In another embodiment, the 2- Pyrimidinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon

atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and R3 is -CH2CH3.

In a preferred embodiment, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group. In another preferred embodiment, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group and the R3 group is a-CH3. In another preferred embodiment, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group and the R3 group is a-CF3.

In another preferred embodiment, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group and the R3 group is a-CH2CH3. In another preferred embodiment, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group and the carbon to which the R3 group is attached is in the (R) configuration. In another preferred embodiment, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and the R3 group is a-CH3. In another preferred embodiment, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and the R3 group is a -CF3. In another preferred embodiment, the R3 group is attached to a carbon atom adjacent to the piperazino nitrogen attached to the A group, the carbon to which the R3 group is attached is in the (R) configuration, and the R3 group is a -CH2CH3.

In another embodiment A is-C (O)- ; n is 2; an Ri is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-OCH3 or-halo ; the other R1 (denoted hereinafter for convenience as"Rl'"to distinguish it from the Ri substituted at the 4-position) is substituted at the 6-position of the pyrimidinyl ring; and R,'is-H or-CH3 ; R2 is -phenyl or-pyridyl, each which is unsubstituted or substituted with one or more R4 groups ; and R3is-H,-CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; n is 2; R1 is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-OCH3 or-Cl ; Rl'is substituted at the 6-position of the pyrimidinyl ring and is-H or-CH3 ; R2 is -phenyl or-pyridyl, each which is unsubstituted or

substituted with one or more R4 groups ; and R3is-H,-CH3 or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; n is 2; RI is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-OCH3 or-halo ; Rl'is substituted at the 6-position of the pyrimidinyl ring and is-H or-CH3 ; R2 is -phenyl or -pyridyl, each which is unsubstituted or substituted with one or more R4 groups selected from-halo and-OCH3 ; and R3is-H,-CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; n is 2; R1 is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-OCH3 or-Cl ; Rl'is substituted at the 6-position of the pyrimidinyl ring and is-H or-CH3 ; R2 is -phenyl or-pyridyl, each which is unsubstituted or substituted with one or more R4 groups selected from-F and-OCH3 ; and R3is-H,-CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; n is 2; Rl is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-OCH3 or-Cl ; Rl'is substituted at the 6-position of the pyrimidinyl ring and is-H or-CH3 ; R2 is -phenyl which is unsubstituted or substituted with one R4 group para to its point of attachment to (-C = C-A-) and selected from-F and -OCH3 ; and R3is-H,-CH3 or-CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; n is 2; R, is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-OCH3 or-Cl ; Rl'is substituted at the 6-position of the pyrimidinyl ring and is-H or -CH3 ; R2 is 2-pyridyl and is unsubstituted or substituted with one R4 group at the 5-position of the 2-pyridyl and selected from-F and-OCH3 ; and R3 is-H, -CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

In another embodiment A is-C (O)- ; n is 2; Ri is substituted at the 4-position of the pyrimidinyl ring and is-CH3,-OCH3 or-Cl ; R,'is substituted at the 6-position of the pyrimidinyl ring and is-H or-CH3 ; R2is 3-pyridyl and is unsubstituted or substituted with one R4 group at the 6-position of the 3-pyridyl and selected from-F and-OCH3 ; and R3 is -H,

-CH3 or -CH2OH and is attached to a carbon atom adjacent to the piperazino nitrogen atom attached to the A group.

Illustrative 2-Pyrimidinylpiperazine Compounds are listed below in Tables 1-4: Table 1 (IIa) (IIb) and pharmaceutically acceptable salts thereof, where: Compound R1 R3 R4 AAA (IIa)-H-H-H AAB (IIa)-H-H-CH3 AAC (IIa) -H -H -n-propyl AAD (IIa) -H -H -n-butyl AAE (IIa)-H-H-t-butyl AAF (IIa) -H -H -iso-butyl AAG (IIa) -H -H -OCH3 AAH (IIa)-H-H-OC2H5 AAI (IIa) -H -H -OC3H7 AAJ (IIa)-H-H-CHF2 AAK (IIa) -H -H -CF3 AAL (IIa) -H -H -CHCl2

Compound R1 R3 R4 AAM (IIa) -H -H -CCl3 AAN (IIa) -H -H -F AAO (IIa)-H-H-Cl AAP (IIa) -H -H -Br AAQ (IIa) -H AAR (IIa) or (IIb) -H -OH -H AAS (IIa) or (IIb) -H -OH -CH3 AAT (IIa) or (IIb) -H -OH -n-propyl AAU (IIa) or (IIb) -H -OH -n-butyl AAV (IIa) or (IIb) -H -OH -t-butyl AAW (IIa) or (IIb) -H -OH -iso-butyl AAX (IIa) or (IIb) -H -OH -OCH3 AAY (IIa) or (IIb) -H -OH -OC2H5 AAZ (IIa) or (IIb) -H -OH -OC3H7 ABA (IIa) or (IIb) -H -OH -CHF2 ABB (IIa) or (IIb) -H -OH -CF3 ABC (IIa) or (IIb) -H -OH -CHCl2 ABD (lIa) or (IIb) -H -OH -CCl3 ABE (na) or (IIb) -H -OH -F ABF (IIa) or (IIb) -H -OH -Cl ABG (IIa) or (IIb) -H -OH -Br ABH (IIa) or (IIb) -H -OH -I ABI (IIa) or (IIb) -H -F -H ABJ (IIa) or (IIb) -H -F -CH3 ABK (IIa) or (Ilb)-H-F-n-propyl ABL (IIa) or (IIb) -H -F -n-butyl ABM (IIa) or (Ilb)-H-F-t-butyl ABN (IIa) or (IIb) -H -F -iso-butyl

Compound R1 R3 R4 ABO (IIa) or (IIb) -H -F -OCH3 ABP (IIa) or (IIb)-H-F-OC2H5 ABQ (Ha) or (IIb) -H -F -OC3H7 ABR (IIa) or (IIb) -H ABS(IIa) or (IIb) -H -F -CF3 ABT(IIa) or (IIb) -H -F -CHCl2 ABU (IIa) or (IIb) -H -F -CCl3 ABV (IIa) or (IIb) -H -F -F ABW (IIa) or (IIb)-H-F-Cl ABX (IIa) or (IIb) -H -F -Br ABY (IIa) or (IIb) -H -F -I ABZ (IIa) or (IIb) -H -Cl -H ACA (IIa) or (IIb) -H -Cl -CH3 ACB (IIa) or (IIb) -H -Cl -n-propyl ACC (IIa) or (IIb) -H -Cl -n-butyl ACD (IIa) or (IIb) -H -Cl -t-butyl ACE (IIa) or (IIb) -H -Cl -iso-butyl ACF (IIa) or (IIb) -H -Cl -OCH3 ACG (IIa) or (IIb) -H -Cl -OC2H5 ACH (IIa) or (IIb) -H -Cl -OC3H7 ACI (IIa) or (IIb) -H -Cl -CHF2 ACJ (IIa) or (IIb) -H -Cl -CF3 ACK (IIa) or (IIb) -H -Cl -CHCl2 ACL (IIa) or (IIb) -H -Cl -CCl3 ACM (IIa) or (IIb) -H -Cl -F ACN(IIa) or (IIb) -H -Cl -Cl ACO(IIa) or (IIb) -H -Cl -Br ACP(IIa) or (IIb) -H -Cl -I

Compound ACQ (IIa) or (IIb) -H -Br -H ACR(IIa) or (IIb) -H -Br -CH3 ACS (IIa) or (IIb) -H -Br -n-propyl Acta) or (IIb) -H -Br -n-butyl ACU (IIa) or (IIb) -H -Br -t-butyl ACV (IIa) or (IIb) -H -Br -iso-butyl ACW (IIa) or (IIb) -H -Br -OCH3 ACX (IIa) or (IIb) -H -Br- OCH2H5 ACY (IIa) or (IIb) -H -Br -OC3H7 ACZ (IIa) or (IIb) -H -Br -CHF2 ADA (IIa) or (IIb) -H -Br -CF3 ADB (Sa) or (IIb) -H -Br -CHCl2 ADC (IIa) or (IIb) -H -Br -CCl3 ADD (IIa) or (IIb)-H-Br-F ADE (lIa) or (IIb) -H -Br -Cl ADF (IIa) or (IIb) -H -Br -Br ADG (IIa) or (IIb)-H-Br-I ADH (na) or (IIb) -H -I -H ADI(IIa) or (IIb) -H -I -CH3 ADJ(IIa) or (IIb) -H -I -n-propyl ADK (IIa) or (IIb) -H -I -n-butyl ADL (IIa) or (IIb)-H-I-t-butyl ADM (IIa) or (IIb) -H -I -iso-butyl ADN (IIa) or (IIb) -H -I -OCH3 ADO (na) or (IIb) -H -I -OC2H5 ADP (IIa) or (IIb) -H -I -OC3H7 ADQ (na) or (IIb) -H -I -CHF2 ADR (IIa) or (Hb)-H-CF3

Compound R1 R3 R4 ADS (Ha) or (IIb) -H -I -CHCl2 ADT (IIa) or (IIb) -H -I -CCl3 ADU (IIa) or (IIb) -H -I -F ADV (IIa) or (IIb) -H -I -Cl ADW (IIa) or (IIb) -H -I -Br ADX (IIa) or (IIb) -H -I -I ADY (IIa) or (IIb) -H -NO2 -H ADZ (IIa) or (IIb) -H -NO2 -CH3 AEA (na) or (IIb) -H -NO2 -n-propyl AEB (IIa) or (IIb) -H -NO2 -n-butyl AEC (IIa) or (IIb) -H -NO2 -t-butyl AED (IIa) or (IIb) -H -NO2 -iso-butyl AEE (IIa) or (IIb) -H -NO2 -OCH3 AEF (IIa) or (IIb) -H -NO2 -OC2H5 AEG (IIa) or (IIb) -H -NO2 -OC3H7 AEH (IIa) or (IIb) -H -NO2 -CHF2 AEI (IIa) or (IIb) -H -NO2 -CF3 AEJ (IIa) or (IIb) -H -NO2 -CHCl2 AEK (IIa) or (IIb) -H -NO2 -CCl3 AEL (IIa) or (IIb) -H -NO2 -F AEM (IIa) or (IIb) -H -NO2 -Cl AEN (IIa) or (IIb) -H -NO2 -Br AEO (IIa) or (IIb) -H -NO2 -I AEP (IIa) or (IIb) -H -CN -H AEQ (IIa) or (IIb) -H -CN -CH3 AER(IIa) or (IIb) -H -CN -n-propyl AES (IIa) or (IIb) -H -CN -n-butyl AET (IIa) or (IIb) -H -CN -t-butyl

Compound R1 R3 R4 AEU (lIa) or (Ilb)-H-CN-iso-butyl AEV (IIa) or (IIb) -H -CN -OCH3 AEW (IIa) or (IIb) -H -CN -OC2H5 AEX (IIa) or (IIb) -H -CN -OC3H7 AEY (IIa) or (IIb) -H -CN -CHF2 AEZ (IIa) or (IIb) -H -CN -CF3 AFA (IIa) or (IIb) -H -CN -CHCl2 AFB (IIa) or (IIb) -H -CN -CCl3 AFC (IIa) or (IIb) -H -CN -F AFD (IIa) or (IIb) -H -CN -Cl AFE (IIa) or (IIb) -H -CN -Br AFF (IIa) or (IIb) -H -CN -I AFG (IIa) or (IIb) -H -NH2 -H AFH (IIa) or (IIb) -H -NH2 -CH3 AFI (IIa) or (IIb) -H -NH2 -n-propyl AFJ (IIa) or (Ilb)-H-NH2-n-butyl AFK (na) or (IIb) -H -NH2 -t-butyl AFL (IIa) or (IIb) -H -NH2 -iso-butyl AFM (IIa) or (IIb) -H -NH2 -OCH3 AFN (IIa) or (IIb) -H -NH2 -OC2H5 AFO(IIa) or (IIb) -H -NH2 -OC3H7 AFP (IIa) or (IIb) -H -NH2 -CHF2 AFQ (IIa) or (IIb) -H -NH2 -CF3 AFR (IIa) or (IIb) -H -NH2 -CHCl2 AFS (IIa) or (IIb) -H -NH2 -CCl3 AFT (IIa) or (IIb) -H -NH2 -F AFU (IIa) or (IIb) -H -NH2 -Cl AFV (IIa) or (IIb) -H -NH2 -Br

Compound R1 R3 R4 AFW (IIa) or (IIb) -H -NH2 -I AFX (na) or (IIb) -H -CH3 -H AFY (IIa) or (Eb)-H-CH3-CH3 AFZ (IIa) or (IIb)-H-CH3-n-propyl AGA (IIa) or (IIb) -H -CH3 -n-butyl AGB (IIa) or (IIb) -H -CH3 -t-butyl AGC (IIa) or (IIb) -H -CH3 -iso-butyl AGD (IIa) or (IIb) -H -CH3 -OCH3 AGE (IIa) or (IIb) -H -CH3 -OC2H5 AGF (IIa) or (IIb) -H -CH3 -OC3H7 AGG (IIa) or (IIb) -H -CH3 -CHF2 AGH (IIa) or (IIb) -H -CH3 -CF3 AGI (IIa) or (IIb) -H -CH3 -CHCl2 AGJ (IIa) or (IIb) -H -CH3 -CCl3 AGK (Ha) or (IIb) -H -CH3 -F AGL (IIa) or (IIb) -H -CH3 -Cl AGM(IIa) or (IIb)-H-CH3-Br AGN (IIa) or (IIb) -H -CH3 -I AGO (IIa) -OH -H -H AGP (lIa)-OH-H-CH3 AGQ (IIa) -OH -H -n-propyl AGR (IIa) -OH -H -n-butyl AGS (IIa) -OH -H -t-butyl AGT (IIa) -OH -H -iso-butyl AGU (IIa) -OH -H -OCH3 AGV (IIa) -OH -H -OC2H5 AGW (IIa) -OH -H -OC3H7 AGX (IIa) -OH -H -CHF2

Compound Ri R3 R4 AGY (IIa) -OH -H -CF3 AGZ (IIa) -OH -H -CHCl2 AHA (IIa) -OH -H -CCl3 AHB (IIa) -OH -H -F AHC (IIa) -OH -H -Cl AHD (IIa) -OH -H -Br AHE (IIa) -OH -H -I AHF (IIa) or (IIb) -OH -OH -H AHG (IIa) or (IIb) -OH -OH -CH3 AHH (IIa) or (IIb) -OH -OH -n-propyl AHI (IIa) or (IIb) -OH -OH -n-butyl AHJ (IIa) or (IIb) -OH -OH -t-butyl AHK (IIa) or (IIb) -OH -OH -iso-butyl AHL (IIa) or (IIb) -OH -OH -OCH3 AHM (IIa) or (IIb) -OH -OH -OC2H5 AHN (IIa) or (IIb) -OH -OH -OC3H7 AHO (IIa) or (IIb) -OH -OH -CHF2 AHP (IIa) or (IIb) -OH -OH -CF3 AHQ (IIa) or (IIb) -OH -OH -CHCl2 AHR (IIa) or (IIb) -OH -OH -CCl3 AHS (IIa) or (IIb) -OH -OH -F AHT (IIa) or (IIb) -OH -OH -Cl AHU (IIa) or (IIb) -OH -OH -Br AHV (IIa) or (IIb) -OH -OH -I AHW (IIa) or (IIb) -OH -F -H AHX (IIa) or (IIb) -OH -F -CH3 AHY (IIa) or (IIb) -OH -F -n-propyl AHZ (IIa) or (IIb) -OH -F -n-butyl

Compound R1 R3 R4 AIA (IIa) or (IIb) -OH -F -t-butyl AIB (IIa) or (IIb) -OH -F -iso-butyl AIC (IIa) or (IIb) -OH -F -OCH3 AID (IIa) or (IIb) -OH -F -OC2H5 AIE (IIa) or (IIb) -OH -F -OC3H7 AIF (IIa) or (IIb) -OH -F -CHF2 AIG (IIa) or (IIb) -OH -F -CF3 AIH (IIa) or (IIb) -OH -F -CHCl2 AII (IIa) or (IIb) -OH -F -CCl3 AIJ (IIa) or (IIb) -OH -F -F AIK (IIa) or (IIb) -OH -F -Cl AIL (IIa) or (IIb) -OH -F -Br AIM (IIa) or (IIb) -OH -F -I AIN (IIa) or (IIb) -OH -Cl -H AIO (IIa) or (IIb) -OH -Cl -CH3 AIP (IIa) or (IIb) -OH -Cl -n-propyl AIQ (IIa) or (IIb) -OH -Cl -n-butyl AIR (IIa) or (IIb) -OH -Cl -t-butyl AIS (IIa) or (IIb) -OH -Cl -iso-butyl AIT (IIa) or (IIb) -OH -Cl -OCH3 AIU (IIa) or (IIb) -OH -Cl -OC2H5 AIV (IIa) or (IIb) -OH -Cl -OC3H7 AIW (IIa) or (IIb) -OH -Cl -CHF2 AIX (IIa) or (IIb) -OH -Cl -CF3 AIY (IIa) or (IIb) -OH -Cl -CHCl2 AIZ (IIa) or (IIb) -OH -Cl -CCl3 AJA (IIa) or (IIb) -OH -Cl -F AJB(IIa) or (IIb) -OH -Cl -Cl

Compound Ri R3 R4 AJC (IIa) or (IIb) -OH -Cl -Br AJD (IIa) or (IIb) -OH -Cl -I AJE (IIa) or (IIb) -OH -Br -H AJF(IIa) or (IIb) -OH -Br -CH3 AJG (IIa) or (IIb) -OH -Br -n-propyl AJH(IIa) or (IIb) -OH -Br -n-butyl AJI (IIa) or (IIb) -OH -Br -t-butyl AJJ (IIa) or (IIb) -OH -Br -iso-butyl AJK (IIa) or (IIb) -OH -Br -OCH3 AJL (IIa) or (IIb) -OH -Br -OC2H5 AJM (IIa) or (IIb) -OH -Br -OC3H7 AJN (IIa) or (IIb) -OH -Br -CHF2 AJO (IIa) or (IIb) -OH -Br -CF3 AJP (IIa) or (IIb) -OH -Br -CHCl2 AJQ (IIa) or (IIb) -OH -Br -CCl3 AJR (IIa) or (IIb) -OH -Br -F AJS (IIa) or (IIb) -OH -Br -Cl AJT (IIa) or (IIb) -OH -Br -Br AJU (IIa) or (IIb)-OH-Br-I AJV (IIa) or (IIb) -OH -I -H AJW (IIa) or (IIb) -OH -I -CH3 AJX (IIa) or (IIb) -OH -I -n-propyl AJY (IIa) or (IIb) -OH -I -n-butyl AJZ (IIa) or (IIb) -OH -I -t-butyl AKA (IIa) or (IIb) -OH -I -iso-butyl AKB (IIa) or (IIb) -OH -I -OCH3 AKC (IIa) or (IIb)-OH-I-OC2H5 AKD (IIa) or (IIb) -OH -I -OC3H7

Compound Ri R3 R4 AKE(IIa) or (IIb) -OH -I -CHF2 AKF (IIa) or (IIb) -OH -I -CF3 AKG (IIa) or (IIb) -OH -I -CHCl2 AKH (IIa) or (IIb) -OH -I -CCl3 AKI (IIa) or (IIb) -OH -I -F AKJ (IIa) or (IIb) -OH -I -Cl AKK(IIa) or (IIb) -OH -I -Br AKL(IIa) or (IIb) -OH -I -I AKL(IIa) or (IIb) -OH -NO2 -H AKN (IIa) or (IIb) -OH -NO2 -CH3 AKO (IIa) or (IIb) -OH -NO2 -n-propyl AKP (IIa) or (IIb) -OH -NO2 -n-butyl AKQ (IIa) or (IIb) -OH -NO2 -t-butyl AKR (IIa) or (IIb) -OH -NO2 -iso-butyl AKS (Ha) or (IIb) -OH -NO2 -OCH3 AKT (IIa) or (IIb) -OH -NO2 -OC2H5 AKU (IIa) or (IIb) -OH -NO2 -OC3H7 AKV (IIa) or (IIb) -OH -NO2 -CHF2 AKW (IIa) or (IIb) -OH -NO2 -CF3 AKX (IIa) or (IIb) -OH -NO2 -CHCl2 AKY (IIa) or (IIb) -OH -NO2 -CCl3 AKZ (IIa) or (IIb) -OH -NO2 ALA (IIa) or (IIb) -OH -NO2 -Cl ALB (IIa) or (IIb) -OH -NO2 -Br ALC (IIa) or (IIb) -OH -NO2 -I ALD (IIa) or (IIb) -OH -CN -H ALE(IIa) or (IIb) -OH -CN -CH3 ALF (IIa) or (IIb) -OH -CN -n-propyl

Compound R1 R3 R4 ALG (IIa) or (IIb)-OH-CN-n-butyl ALH (IIa) or (IIb) -OH -CN -t-butyl ALI (IIa) or (IIb) -OH -CN -iso-butyl ALJ (IIa) or (IIb) -OH -CN -OCH3 ALK (IIa) or (IIb) -OH -CN -OC2H5 ALL (IIa) or (IIb) -OH -CN -OC3H7 ALM (IIa) or (IIb) -OH -CN -CHF2 ALN (IIa) or (IIb) -OH -CN -CF3 ALO (IIa) or (IIb) -OH -CN -CHCl2 ALP (IIa) or (IIb) -OH -CN -CCl3 ALQ (IIa) or (IIb) -OH -CN -F ALR (IIa) or (IIb) -OH -CN -Cl ALS (IIa) or (IIb)-OH-CN-Br ALT (IIa) or (IIb) -OH -CN -I ALU (IIa) or (IIb) -OH -NH2 -H ALV (IIa) or (IIb) -OH -NH2 -CH3 ALW (IIa) or (IIb) -OH -NH2 -n-propyl ALX (IIa) or (IIb) -OH -NH2 -n-butyl ALY (IIa) or (IIb) -OH -NH2 -t-butyl ALZ (IIa) or (IIb) -OH -NH2 -iso-butyl AMA (IIa) or (IIb) -OH -NH2 -OCH3 AMB (IIa) or (IIb) -OH -NH2 -OC2H5 AMC (IIa) or (IIb) -OH -NH2 -OC3H7 AMD (IIa) or (IIb) -OH -NH2 -CHF2 AME (IIa) or (IIb) -OH -NH2 -CF3 AMF (IIa) or (IIb) -OH -NH2 -CHCl2 AMG (IIa) or (IIb) -OH -NH2 -CCl3 AMH (IIa) or (IIb) -OH -NH2 -F

Compound Ri R3 R4 AMI (IIa) or (IIb) -OH -NH2 -Cl AMJ (IIa) or (IIb)-OH-NH2-Br AMK (na) or (IIb) -OH -NH2 -I AML (IIa) or (IIb) -OH -CH3 -H AMM (IIa) or (IIb) -OH -CH3 -CH3 AMN (IIa) or (Ilb)-OH-CH3-n-propyl AMO (IIa) or (IIb) -OH -CH3 -n-butyl AMP (IIa) or (IIb) -OH -CH3 -t-butyl AMQ (IIa) or (IIb) -OH -CH3 -iso-butyl AMR (IIa) or (Ilb)-OH-CH3-OCH3 AMS (IIa) or (IIb) -OH -CH3 -OC2H5 AMT (IIa) or (IIb) -OH -CH3 -OC3H7 AMU (IIa) or (IIb)-OH-CH3-CHF2 AMV (IIa) or (IIb) -OH -CH3 -CF3 AMW (IIa) or (IIb) -OH -CH3 -CHCl2 AMX (IIa) or (IIb) -OH -CH3 -CCl3 AMY (IIa) or (IIb) -OH -CH3 -F AMZ (IIa) or (IIb)-OH-CH3-Cl ANA (IIa) or (IIb) -OH -CH3 -Br ANB (IIa) or (IIb) -OH -CH3 -I ANC (IIa) -F -H -H AND (IIa) -F -H -CH3 ANE (IIa) -F -H -n-propyl ANF (IIa) -F -H -n-butyl ANG (IIa) -F -H -t-butyl ANH (IIa)-F-H-iso-butyl ANI(IIa) -F -H -OCH3 ANJ (IIa) -F -H -OC2H5

Compound R1 R3 R4 ANK (IIa) -F -H -OC3H7 ANL (IIa) -F -H -CHF2 ANM (IIa) -F -H -CF3 ANN (IIa) -F -H -CHCl2 ANO (IIa) -F -H -CCl3 ANP(IIa) -F -H -F ANQ(IIa) -F -H -Cl ANR(IIa) -F -H -Br ANS(IIa) -F -H -I ANT (IIa) or (IIb) -F -OH -H ANU (IIa) or (IIb) -F -OH -CH3 ANV (IIa) or (IIb) -F -OH -n-propyl ANW(IIa) or (IIb) -F -OH -n-butyl ANX(IIa) or (IIb) -F -OH -n-butyl ANY (IIa) or (IIb) -F -OH -iso-butyl ANZ (IIa) or (IIb) -F -OH -OCH3 AOA (IIa) or (IIb) -F -OH -OC2H5 AOB (IIa) or (IIb) -F -OH -OC3H7 AOC (IIa) or (IIb) -F -OH -CHF2 AOD(IIa) or (IIb) -F -OH -CF3 AOE (na) or (IIb) -F -OH -CHCl2 AOF (IIa) or (IIb) -F -OH -CCl3 AOG (IIa) or (IIb) -F -OH -F AOH (IIa) or (IIb) -F -OH -Cl AOI (Ila) or (Ilb)-F-OH-Br AOJ (IIa) or (IIb) -F -OH -I AOK (IIa) or (IIb) -F -F -H AOL (IIa) or (IIb) -F -F -CH3

Compound R1 R3 R4 AOM (IIa) or (IIb) -F -F -n-propyl AON (IIa) or (IIb) -F -F -n-butyl AOO (IIa) or (IIb) -F -F -t-butyl AOP (IIa) or (IIb) -F -F -iso-butyl AOQ(IIa) or (IIb) -F -F -OCH3 AOR (IIa) or (IIb) -F -F -OC2H5 AOS (IIa) or (IIb) -F -F -OC3H7 AOT (IIa) or (IIb) -F -F -CHF2 AOU(IIa) or (IIb) -F -F -CF3 AOV (IIa) or (IIb) -F -F -CHCl2 AOW (IIa) or (IIb) -F -F -CCl3 AOX (IIa) or (Ilb)-F-F-F AOY (IIa) or (IIb) -F -F -Cl AOZ (IIa) or (IIb)-F-F-Br APA (IIa) or (IIb) -F -F -I APB (IIa) or (IIb) -F -Cl -H APC (IIa) or (IIb) -F -Cl -CH3 APD (IIa) or (IIb) -F -Cl -n-propyl APE (IIa) or (IIb)-F-Cl-n-butyl APF (IIa) or (IIb) -F -Cl -t-butyl APG (IIa) or (IIb) -F -Cl -iso-butyl APH (fla) or (IIb) -F -Cl -OCH3 API (IIa) or (IIb) -F -Cl -OC2H5 APJ (IIa) or (IIb) -F -Cl -OC3H7 APK (IIa) or (IIb) -F -Cl -CHF2 APL (lIa) or (IIb) -F -Cl -CF3 APM (IIa) or (IIb) -F -Cl -CHCl2 APN (IIa) or (IIb) -F -Cl -CHCl3

Compound R1 R3 R4 APO (IIa) or (IIb) -F -Cl -F APP(IIa) or (IIb) -F -Cl -Cl APQ (IIa) or (IIb) -F -Cl -Br APR (IIa) or (IIb) -F -Cl -I APS (IIa) or (IIb)-F-Br-H APT (IIa) or (IIb) -F -Br -CH3 APU (IIa) or (IIb) -F -Br -n-propyl APV (IIa) or (IIb) -F -Br -n-butyl APW (IIa) or (IIb) -F -Br -t-butyl APX(IIa) or (IIb) -F -Br -iso-butyl APY (IIa) or (IIb) -F -Br -OCH3 APZ (IIa) or (IIb) -F -Br -OCH2H5 AQA (IIa) or (IIb) -F -Br -OC3H7 AQB (IIa) or (IIb) -F -Br -CHF2 AQC (IIa) or (IIb) -F -Br -CF3 AQD (IIa) or (IIb) -F -Br -CHCl2 AQE (IIa) or (IIb) -F -Br -CCl3 AQF (IIa) or (IIb) -F -Br -F AQG (IIa) or (IIb) -F -Br -Cl AQH (IIa) or (IIb) -F -Br -Br AQI (IIa) or (IIb) -F -Br -I AQJ (IIa) or (IIb) -F -I -H AQK (IIa) or (IIb) -F -I -CH3 AQL (IIa) or (IIb) -F -I -n-propyl AQM(IIa) or (IIb) -F -I -n-butyl AQN (IIa) or (IIb) -F -I -t-butyl AQO (IIa) or (IIb) -F -I -iso-butyl AQP(IIa) or (IIb) -F -I -OCH3

Compound R1 R3 R4 AQQ (IIa) or (IIb) -F -I -OC2H5 AQR (na) or (IIb) -F -I -OC3H7 AQS (IIa) or (IIb) -F -I -CHF2 AQT (IIa) or (IIb) -F -I -CF3 AQU (IIa) or (IIb) -F -I -CHCl2 AQV (IIa) or (IIb) -F -I -CCl3 AQW (IIa) or (IIb) -F -I -F AQX (IIa) or (IIb) -F -I -Cl AQY (IIa) or (IIb) -F -I -Br AQZ (Ha) or (IIb) -F -I -I ARA (IIa) or (IIb) -F -NO2 -H ARB (IIa) or (IIb) -F -NO2 -CH3 ARC C (na) or (IIb) -F -NO2 -n-propyl ARD (IIa) or (IIb) -F -NO2 -n-butyl ARE (IIa) or (IIb) -F -NO2 -t-butyl ARF (IIa) or (IIb) -F -NO2 -iso-butyl ARG (IIa) or (IIb) -F -NO2 -OCH3 ARH (IIa) or (IIb) -F -NO2 -OC2H5 ARI (IIa) or (IIb) -F -NO2 -OC3H7 ARJ (IIa) or (IIb) -F -NO2 -CHF2 ARK (IIa) or (IIb) -F -NO2 -CF3 ARL (IIa) or (IIb) -F -NO2 -CHCl2 ARM (IIa) or (IIb) -F -NO2 -CCl3 ARN (IIa) or (IIb) -F -NO2 -F ARO (IIa) or (IIb) -F -NO2 -Cl ARP (IIa) or (IIb) -F -NO2 -Br ARQ (IIa) or (IIb) -F -NO2 -I ARR (IIa) or (IIb) -F -CN -H

Compound R1 R3 R4 ARS (IIa) or (IIb) -F -CN -CH3 ART (IIa) or (IIb) -F -CN -n-propyl ARU (IIa) or (lIb)-F-CN-n-butyl ARV (IIa) or (IIb) -F -CN -t-butyl ARW (IIa) or (IIb) -F -CN -iso-butyl ARX (IIa) or (IIb) -F -CN -OCH3 ARY (IIa) or (IIb)-F-CN-OC2H5 ARZ (IIa) or (IIb) -F -CN -OC3H7 ASA (IIa) or (IIb) -F -CN -CHF2 ASB (IIa) or (IIb) -F -CN -CF3 ASC (IIa) or (IIb) -F -CN -CHCl2 ASD (IIa) or (IIb)-F-CN-CCl3 ASE (IIa) or (IIb) -F -CN -F ASF (IIa) or (IIb) -F -CN -Cl ASG (na) or (IIb) -F -CN -Br ASH (IIa) or (IIb) -F -CN -I ASI (IIa) or (IIb) -F -NH2 -H ASJ (IIa) or (IIb) -F -NH2 -CH3 ASK (IIa) or (IIb) -F -NH2 -n-propyl ASL (IIa) or (IIb) -F -NH2 -n-butyl ASM (IIa) or (IIb) -F -NH2 -t-butyl ASN (IIa) or (Ilb)-F-NH2-iso-butyl ASO (IIa) or (IIb) -F -NH2 -OCH3 ASP (IIa) or (IIb) -F -NH2 -OC2H5 ASQ (IIa) or (IIb) -F -NH2 -OC3H7 ASR (IIa) or (IIb) -F -NH2 -CHF2 ASS (IIa) or (IIb) -F -NH2 -CF3 AST(IIa) or (IIb) -F -NH2 -CHCl2

Compound R1 R3 R4 ASU (IIa) or (IIb) -F -NH2 -CCl3 ASV(IIa) or (IIb) -F -NH2 -F ASW(IIa) or (IIb) -F -NH2 -Cl ASX(IIa) or (IIb) -F -NH2 -Br ASY(IIa) or (IIb) -F -NH2 -I ASZ (Ha) or (IIb) -F -CH3 -H ATA (IIa) or (IIb) -F -CH3 -CH3 ATB (IIa) or (IIb) -F -CH3 -n-propyl ATC (IIa) or (IIb) -F -CH3 -n-butyl ATD (IIa) or (IIb) -F -CH3 -t-butyl ATE (IIa) or (IIb) -F -CH3 -iso-butyl ATF (IIa) or (IIb) -F -CH3 -OCH3 ATG (IIa) or (IIb) -F -CH3 -OC2H5 ATH (IIa) or (IIb) -F -CH3 -OC3H7 ATI (IIa) or (IIb) -F -CH3 -CHF2 ATJ (IIa) or (IIb) -F -CH3 -CF3 ATK(IIa) or (IIb) -F -CH3 -CHCl2 ATL(IIa) or (IIb) -F -CH3 -CCl3 ATM (IIa) or (IIb) -F -CH3 -F ATN (IIa) or (IIb) -F -CH3 -Cl ATO (IIa) or (IIb) -F -CH3 -Br ATP (IIa) or (IIb) -F -CH3 -I ATQ (IIa)-Cl-H-H ATR (IIa)-Cl-H-CH3 ATS (IIa) -Cl -H -n-propyl ATT (IIa) -Cl -H -n-butyl ATU (IIa) -Cl -H -t-butyl ATV (IIa) -Cl -H -iso-butyl

Compound R, R3 R4 ATW (IIa)-Cl-H-OCH3 ATX(IIa) -Cl -H -OC2H5 ATY (IIa) -Cl -H -OC3H7 ATZ (IIa) -Cl -H -CHF2 AUA (IIa) -Cl -H -CF3 AUB (IIa) -Cl -H -CHCl2 AUC (IIa) -Cl -H -CCl3 AUD (IIa)-Cl-H-F AUE (IIa) -Cl -H -Cl AUF (IIa) -Cl -H -Br AUG (IIa) -Cl -H -I AUH (IIa) or (IIb) -Cl -OH -H AUI (IIa) or (IIb) -Cl -OH -CH3 AUJ (IIa) or (IIb) -Cl -OH -n-pyropyl AUK (Ila) or (IIb) -Cl -OH -n-butyl AUL (IIa) or (IIb) -Cl -OH -t-butyl AUM (IIa) or (IIb) -Cl -OH -iso-butyl AUN (IIa) or (IIb)-Cl-OH-OCH3 AUO (IIa) or (IIb) -Cl -OH -OC2H5 AUP (IIa) or (IIb) -Cl -OH -OC3H7 AUQ (IIa) or (IIb) -Cl -OH -CHF2 AUR (IIa) or (IIb) -Cl -OH -CF3 AUS (IIa) or (IIb) -Cl -OH -CHCl2 AUT (IIa) or (IIb) -Cl -OH -CCl3 AUU (IIa) or (IIb) -Cl -OH -F AUV (IIa) or (IIb) -Cl -OH -Cl AUW (IIa) or (IIb) -Cl -OH -Br AUX (IIa) or (IIb) -Cl -OH -I

Compound Ri R3 R4 AUY (IIa) or (IIb) -Cl -F -H AUZ (Ha) or (IIb) -Cl -F -CH3 AVA (IIa) or (IIb)-Cl-F-n-propyl AVB (IIa) or (IIb)-Cl-F-n-butyl AVC (IIa) or (IIb) -Cl -F -t-butyl AVD (IIa) or (IIb) -Cl -F -iso-butyl AVE (IIa) or (IIb) -Cl -F -OCH3 AVF (IIa) or (IIb) -Cl -F -OC2H5 AVG (IIa) or (IIb) -Cl -F -OC3H7 AVH (IIa) or (IIb) -Cl -F -CHF2 AVI (IIa) or (IIb) -Cl -F -CF3 AVJ (IIa) or (IIb) -Cl -F -CHCl2 AVK (na) or (IIb) -Cl -F -CCl3 AVL (IIa) or (IIb) -Cl -F -F AVM (IIa) or (IIb) -Cl -F -Cl AVN (IIa) or (IIb)-Cl-F-Br AVO (IIa) or (IIb)-Cl-F-I AVP (IIa) or (IIb) -Cl -F -H AVQ (IIa) or (IIb) -Cl -Cl -CH3 AVR (IIa) or (IIb) -Cl -Cl -n-propyl AVS (IIa) or (IIb) -Cl -Cl -n-butyl AVT (IIa) or (IIb) -Cl -Cl -t-butyl AVU (na) or (IIb) -Cl -Cl -iso-butyl AVV (IIa) or (IIb) -Cl -Cl -OCH3 AVW (Ha) or (IIb) -Cl -Cl -OC2H5 AVX (IIa) or (IIb) -Cl -Cl -OC3H7 AVY (IIa) or (IIb) -Cl -Cl -CHF2 AVZ (IIa) or (IIb) -Cl -Cl -CF3

Compound R1 AWA (IIa) or (IIb)-Cl-Cl-CHC12 AWB (IIa) or (IIb) -Cl -Cl -CCl3 AWC (IIa) or (IIb) -Cl -Cl -F AWD (IIa) or (IIb) -Cl -Cl -Cl AWE (IIa) or (IIb) -Cl -Cl -Br AWF (IIa) or (IIb) -Cl -Cl -I AWG (IIa) or (IIb) -Cl -Br -H AWH (IIa) or (IIb) -Cl -Br -CH3 AWI (IIa) or (IIb) -Cl -Br -n-propyl AWJ (IIa) or (IIb) -Cl -Br -n-butyl AWK (IIa) or (IIb)-Cl-Br-t-butyl AWL (IIa) or (IIb) -Cl -Br -iso-butyl AWM (na) or (IIb) -Cl -Br -OCH3 AWN (IIa) or (IIb) -Cl -Br -OC2H5 AWO (IIa) or (IIb) -Cl -Br -OC3H7 AWP (IIa) or (IIb) -Cl -Br -CHF2 AWQ (IIa) or (IIb) -Cl -Br CF3 AWR (IIa) or (IIb) -Cl -Br -CHCl2 AWS (IIa) or (IIb) -Cl -Br -CCl3 AWT (IIa) or (IIb) -Cl -Br -F AWU (IIa) or (IIb) -Cl -Br -Cl AWV (IIa) or (IIb) -Cl -Br -Br AWW (IIa) or (IIb) -Cl -Br -I AWX (IIa) or (IIb) -Cl -I -H AWY (IIa) or (IIb) -Cl -I -CH3 AWZ (IIa) or (IIb) -Cl -I -n-propyl AXA(IIa) or (IIb) -Cl -I -n-butyl AXB(IIa) or (IIb) -Cl -I -t-butyl

Compound R1 R3 R4 AXC(IIa) or (IIb) -Cl -I -iso-butyl AXD (IIa) or (IIb)-Cl-I-OCH3 AXE (IIa) or (IIb) -Cl -I -OC2H5 AXF(IIa) or (IIb) -Cl -I -OC3H7 AXG(IIa) or (IIb) -Cl -I -CHF2 AXH (Ha) or (IIb) -Cl -I -CF3 AXI (IIa) or (IIb) -Cl -I -CHCl2 AXJ (lIa) or (IIb) -Cl -I -CCl3 AXK(IIa) or (IIb) -Cl -I -F AXL (IIa) or (IIb) -Cl -I -Cl AXM (na) or (IIb) -Cl -I -Br AXN(IIa) or (IIb) -Cl -I -I AXO (IIa) or (IIb) -Cl -NO2 -H AXP (na) or (IIb) -Cl -NO2 -CH3 AXQ (na) or (IIb) -Cl -NO2 -n-propyl AXR (IIa) or (IIb) -Cl -NO2 -n-butyl AXS (na) or (IIb) -Cl -NO2 -t-butyl AXT(IIa) or (IIb) -Cl -NO2 -iso-butyl AXU (IIa) or (IIb) -Cl -NO2 -OCH3 AXV (IIa) or (IIb) -Cl -NO2 -OC2H5 AXW (IIa) or (IIb) -Cl -NO2 -OC3H7 AXX(IIa) or (IIb) -Cl -NO2 -C AXY (IIa) or (IIb) -Cl -NO2 -CF3 AXZ (IIa) or (IIb) -Cl -NO2 -CHCl2 AYA (na) or (IIb) -Cl -NO2 -CCl3 AYB (IIa) or (IIb) -Cl -NO2 -F AYC (IIa) or (IIb) -Cl -NO2 -Cl AYD (IIa) or (IIb) -Cl -NO2 -Br

Compound R, R3 R4 AYE (IIa) or (IIb) -Cl -NO2 -I AYF (IIa) or (IIb)-C1-CN-H AYG (IIa) or (IIb) -Cl -CN -CH3 AYH (IIa) or (IIb)-Cl-CN-n-propyl AYI (IIa) or (IIb) -Cl -CN -n-butyl AYI (na) or (IIb) -Cl -CN -t-butyl AYK(IIa) or (IIb) -Cl -CN -iso-butyl AYL (IIa) or (IIb) -Cl -CN -OCH3 AYM (IIa) or (IIb) -Cl -CN -OC2H5 AYN (IIa) or (IIb) -Cl -CN -OC3H7 AYO (IIa) or (IIb) -Cl -CN -CHF2 AYP (IIa) or (IIb) -Cl -CN -CF3 AYQ (IIa) or (IIb) -Cl -CN -CHCl2 AYR (na) or (IIb) -Cl -CN -CCl3 AYS (IIa) or (IIb) -Cl -CN -F AYT (IIa) or (IIb) -Cl -CN -Cl AYU (IIa) or (IIb) -Cl -CN -Br AYV (IIa) or (IIb) -Cl -CN -I AYW (IIa) or (IIb) -Cl -NH2 -H AYX (IIa) or (IIb) -Cl -NH2 -CH3 AYY(IIa) or (IIb) -Cl -NH2 -n-propyl AYZ (IIa) or (IIb) -Cl -NH2 -n-butyl AZA (IIa) or (IIb) -Cl -NH2 -t-butyl AZB (IIa) or (IIb) -Cl -NH2 -iso-butyl AZC (IIa) or (IIb) -Cl -NH2 -OCH3 AZD (IIa) or (IIb) -Cl -NH2 -OC2H5 AZE (IIa) or (IIb) -Cl -NH2 -OC3H7 AZF (Ha) or (IIb) -Cl -NH2 CHF2

Compound Ri R3 R4 AZG (IIa) or (IIb) -Cl -NH2 -CF3 AZH (IIa) or (IIb) -Cl -NH2 -CHCl2 AZI (IIa) or (IIb) -Cl -NH2 -CCl3 AZJ (IIa) or (IIb) -Cl -NH2 -F AZK(IIa) or (IIb) -Cl -NH2 -Cl AZL (IIa) or (IIb) -Cl -NH2 -Br AZM (IIa) or (IIb) -Cl -NH2 -I AZN (IIa) or (IIb)-Cl-CH3-H AZO (IIa) or (IIb) -Cl -CH3 -CH3 AZP (IIa) or (IIb)-Cl-CH3-n-propyl AZQ (IIa) or (IIb) -Cl -CH3 -n-butyl AZR (IIa) or (IIb) -Cl -CH3 -t-butyl AZS(IIa) or (IIb) -Cl -CH3 -iso-butyl AZT (IIa) or (IIb) -Cl -CH3 -OCH3 AZU (IIa) or (IIb) -Cl -CH3 -OC2H5 AZV (IIa) or (IIb) -Cl -CH3 -OC3H7 AZW (IIa) or (IIb) -Cl -CH3 -CHF2 AZX (IIa) or (IIb) -Cl -CH3 -CF3 AZY (IIa) or (IIb) -Cl -CH3 -CHCl2 AZZ (IIa) or (IIb) -Cl -CH3 -CCl3 BAA (IIa) or (IIb) -Cl -CH3 -F BAB (IIa) or (IIb) -Cl -CH3 -Cl BAC (IIa) or (IIb) -Cl -CH3 -Br BAD (IIa) or (IIb) -Cl -CH3 -I BAE (IIa) -CHCl2 -H -H BAF (IIa) -CHCl2 -H -CH3 BAG (IIa) -CHCl2 -H -n-propyl BAH (IIa) -CHCl2 -H -n-butyl

Compound Rt R3 R4 BAI (IIa) -CHCl2 -H -t-butyl BAJ (IIa) -CHCl2 -H -iso-butyl BAK (IIa) -CHCl2 -H -OCH3 BAL (IIa)-CHC12-H-OC2Hs BAM (IIa) -CHCl2 -H -OC3H7 BAN (IIa) -CHCl2 -H -CHF2 BAO (IIa) -CHCl2 -H -CF3 BAP (IIa) -CHCl2 -H -CHCl2 BAQ(IIa) -CHCl2 -H -CCl3 BAR (Ha)-CHC12-H-F ; BAS (IIa)-CHClz-H-Cl BAT (Ita)-CHCIz-H-Br BAU (IIa) -CHCl2 -H -I BAT(IIa) -CHCl2 -H -Br BAU(IIa) -CHCl2 -H -I BAV(IIa) or (IIb) -CHCl2 -OH -H BAW(IIa) or (IIb) -CHCl2 -OH -CH3 BAX(IIa) or (IIb) -CHCl2 -OH -n-propyl BAY (IIa) or (IIb) -CHCl2 -OH -n-butyl BAZ (IIa) or (IIb) -CHCl2 -OH -t-butyl BBA (IIa) or (IIb) -CHCl2 -OH -iso-butyl BBB (IIa) or (IIb) -CHCl2 -OH -OCH3 BBC (na) or (IIb) -CHCl2 -OH -OC2H5 BBD (IIa) or (IIb) -CHCl2 -OH -OC3H7 BBE (IIa) or (IIb) -CHCl2 -OH -CHF2 BBF (IIa) or (IIb) -CHCl2 -OH -CF3 BBG (IIa) or (IIb) -CHCl2 -OH -CHCl2 BBH (IIa) or (IIb) -CHCl2 -OH -CCl3 BBI (IIa) or (IIb) -CHCl2 -OH -F BBJ (IIa) or (IIb) -CHCl2 -OH -Cl

Compound R1 R3 R4 BBK (IIa) or (IIb) -CHCl2 -OH -Br BBL (IIa) or (IIb)-CHCIz-OH-I BBM (IIa) or (Ilb)-CHC12-F-H BBN (IIa) or (IIb) -CHCl2 -F -CH3 BBO (IIa) or (IIb) -CHCl2 -F -n-propyl BBP (IIa) or (IIb) -CHCl2 -F -n-butyl BBQ (IIa) or (IIb) -CHCl2 -F -t-butyl BBR (IIa) or (IIb) -CHCl2 -F -iso-butyl BBS (IIa) or (IIb) -CHCl2 -F -OCH3 BBT (IIa) or (IIb) -CHCl2 -F -OC2H5 BBU (IIa) or (IIb) -CHCl2 -F -OC3H7 BBV (IIa) or (IIb) -CHCl2 -F -CHF2 BBW (IIa) or (IIb) -CHCl2 -F -CF3 BBX(IIa) or (IIb) -CHCl2 -F -CHCl2 BBY (lIa) or (IIb) -CHCl2 -F -CCl3 BBZ (IIa) or (IIb) -CHCl2 -F -F BCA (IIa) or (IIb)-CHClz-F-Cl BCB (IIa) or (IIb) -CHCl2 -F -Br BCC (IIa) or (IIb)-CHC12-F-I BCD (IIa) or (IIb) -CHCl2 -Cl -H BCE (IIa) or (IIb) -CHCl2 -Cl -CH3 BCF (IIa) or (IIb) -CHCl2 -Cl -n-propyl BCG (IIa) or (IIb) -CHCl2 -Cl -n-butyl BCH (IIa) or (IIb) -CHCl2 -Cl -t-butyl BCI (IIa) or (IIb)-CHC12-Cl-iso-butyl BCJ (IIa) or (IIb) -CHCl2 -Cl -OCH3 BCK (IIa) or (IIb) -CHCl2 -Cl -OC2H5 BCL (IIa) or (IIb) -CHCl2 -Cl -OC3H7

Compound R1 R3 R4 BCM (IIa) or (IIb) -CHCl2 -Cl -CHF2 BCN (IIa) or (IIb) -CHCl2 -Cl -CF3 BCO (IIa) or (IIb) -CHCl2 -Cl -CHCl2 BCP(IIa) or (IIb) -CHCl2 -Cl -CCl3 BCQ (B : a) or (IIb) -CHCl2 -Cl -F BCR (IIa) or (IIb) -CHCl2 -Cl -Cl BCS (Ha) or (IIb) -CHCl2 -Cl -Br BCT (Ita) or (IIb) -CHCl2 -Cl -I BCU (IIa) or (IIb) -CHCl2 -Br -H BCV (IIa) or (IIb) -CHCl2 -Br -CH3 BCW (IIa) or (IIb) -CHCl2 -Br -n-propyl BCX (IIa) or (IIb) -CHCl2 -Br -n-butyl BCY (IIa) or (IIb) -CHCl2 -Br -t-butyl BCZ (IIa) or (IIb) -CHCl2 -Br -iso-butyl BDA (IIa) or (IIb) -CHCl2 -Br -OCH3 BDB (na) or (IIb) -CHCl2 -Br -OC2H5 BDC (IIa) or (IIb) -CHCl2 -Br -OC3H7 BDD (IIa) or (IIb) -CHCl2 -Br -CHF2 BDE (IIa) or (IIb) -CHCl2 -Br -CF3 BDF (IIa) or (IIb) -CHCl2 -Br -CHCl2 RDG (IIa) ar (IIb) -CHCl2 -Br -CCl3 BDH (IIa) or (IIb) -CHCl2 -Br -F BDI (IIa) or (IIb) -CHCl2 -Br -Cl BDJ (IIa) or (IIb) -CHCl2 -Br -Br BDK (IIa) or (IIb) -CHCl2 -Br -I BDL (IIa) or (IIb) -CHCl2 -I -H BDM (IIa) or (IIb) -CHCl2 -I -CH3 BDN (na) or (IIb) -CHCl2 -I -n-propyl

Compound R, R3 Ra BDO (IIa) or (IIb)-CHCl2-I-n-butyl BDP (IIa) or (IIb) -CHCl2 -I -t-butyl BDQ (IIa) or (IIb) -CHCl2 -I -iso-butyl BDR (IIa) or (IIb) -CHCl2 -I -OCH3 BDS (IIa) or (IIb) -CHCl2 -I -OC2H5 BDT (IIa) or (IIb) -CHCl2 -I -OC3H7 BDU (IIa) or (IIb) -CHCl2 -I -CHF2 BDV (IIa) or (IIb) -CHCl2 -I -CF3 BDW (IIa) or (IIb) -CHCl2 -I -CHCl2 BDX (IIa) or (IIb) -CHCl2 -I -CCl3 BDY (IIa) or (IIb) -CHCl2 -I -F BDZ (Ha) or (IIb) -CHCl2 -I -Cl BEA (IIa) or (IIb) -CHCl2 -I -Br BEB (IIa) or (IIb) -CHCl2 -I -I BEC (IIa) or (IIb) -CHCl2 -NO2 -H BED (IIa) or (IIb)-CHC12-NO2-CH3 BEE (IIa) or (IIb) -CHCl2 -NO2 -n-propyl BEF (IIa) or (IIb) -CHCl2 -NO2 -n-butyl BEG (IIa) or (IIb) -CHCl2 -NO2 -t-butyl BEH(IIa) or (Ilb)-CHC12-NO2-iso-butyl BEI (IIa) or (IIb) -CHCl2 -NO2 -OCH3 BEJ (Ila) or (IIb) -CHCl2 -NO2 -OC2H5 BEK (IIa) or (IIb) -CHCl2 -NO2 -OC3H7 BEL (IIa) or (IIb) -CHCl2 -NO2 -CHF2 BEM (Ila) or (IIb) -CHCl2 -NO2 -CF3 BEN (IIa) or (IIb) -CHCl2 -NO2 -CHCl2 BEO (IIa) or (IIb) -CHCl2 -NO2 -CCl3 BEP (IIa) or (IIb) -CHCl2 -NO2 -F

Compound R1 R3 R4 BEQ (IIa) or (IIb) -CHCl2 -NO2 -Cl BER (IIa) or (IIb) -CHCl2 -NO2 -Br BES (IIa) or (IIb) -CHCl2 -NO2 -I BET (IIa) or (IIb) -CHCl2 -CN -H BEU (IIa) or (IIb) -CHCl2 -CN -CH3 BEV (IIa) or (IIb) -CHCl2 -CN -n-propyl BEW (IIa) or (IIb) -CHCl2 -CN -n-butyl BEX (IIa) or (IIb)-CHC12-CN-t-butyl BEY (IIa) or (IIb)-CHC12-CN-iso-butyl BEZ (IIa) or (IIb) -CHCl2 -CN -OCH3 BFA (IIa) or (IIb) -CHCl2 -CN -OC2H5 BFB (IIa) or (IIb) -CHCl2 -CN -OC3H7 BFC (IIa) or (IIb) -CHCl2 -CN -CHF2 BFD (IIa) or (IIb) -CHCl2 -CN -CF3 BFE (IIa) or (IIb) -CHCl2 -CN -CHCl2 BFF (IIa) or (IIb) -CHCl2 -CN -CCl3 BFG (IIa) or (IIb) -CHCl2 -CN -F BFH(IIa) or (IIb) -CHCl2 -CN -Cl BFI (IIa) or (IIb) -CHCl2 -CN -Br BFJ (IIa) or (IIb) -CHCl2 -CN -I BFK (IIa) or (IIb) -CHCl2 -NH2 -H BFL (lIa) or (IIb) -CHCl2 -NH2 -CH3 BFM (IIa) or (IIb) -CHCl2 -NH2 -n-propyl BFN (IIa) or (IIb) -CHCl2 -NH2 -n-butyl BFO (IIa) or (IIb) -CHCl2 -NH2 -t-butyl BFP (IIa) or (IIb) -CHCl2 -NH2 -iso-butyl BFQ (IIa) or (IIb) -CHCl2 -NH2 -OCH3 BFR (IIa) or (IIb) -CHCl2 -NH2 -OC2H5

Compound BFS (IIa) or (IIb) -CHCl2 -NH2 -OC3H7 BFT (IIa) or (IIb) -CHCl2 -NH2 -CHF2 BFU (IIa) or (IIb) -CHCl2 -NH2 -CF3 BFV (IIa) or (IIb) -CHCl2 -NH2 -CHCl2 BFW (IIa) or (IIb) -CHCl2 -NH2 -CCl3 BFX (Ila) or (lIb)-CHCl2-NH2-F BFY (IIa) or (IIb) -CHCl2 -NH2 -Cl BFZ (IIa) or (IIb) -CHCl2 -NH2 -Br BGA (IIa) or (IIb) -CHCl2 -NH2 BGB (IIa) or (IIb) -CHCl2 -CH3 -H BGC (IIa) or (IIb) -CHCl2 -CH3 -CH3 BGD (IIa) or (IIb) -CHCl2 -CH3 -n-propyl BGE (IIa) or (IIb) -CHCl2 -CH3 -n-butyl BGF (IIa) or (IIb) -CHCl2 -CH3 -t-butyl BGG (IIa) or (IIb) -CHCl2 -CH3 -iso-butyl BGH (IIa) or (IIb) -CHCl2 -CH3 -OCH3 BGI (Ha) or (IIb) -CHCl2 -CH3 -OC2H5 BGJ(IIa) or (IIb) -CHCl2 -CH3 -OC3H7 BGK (IIa) or (IIb) -CHCl2 -CH3 -CHF2 BGL(IIa) or (IIb) -CHCl2 -CH3 -CF3 BGM (IIa) or (IIb) -CHCl2 -CH3 -CHCl2 BGN (IIa) or (IIb) -CHCl2 -CH3 -CCl3 BGO (IIa) or (IIb) -CHCl2 -CH3 - BGP (IIa) or (IIb) -CHCl2 -CH3 -Cl BGQ (Ila) or (IIb) -CHCl2 -CH3 -Br BGR (IIa) or (IIb) -CHCl2 -CH3 -I BGS (IIa)-CF3-H-H BGT(IIa) -CF3 -H -CH3

Compound Ri R3 R4 BGU (IIa)-CF3-H-n-propyl BGV(IIa) -CF3 -H -n-butyl BGW(IIa) -CF3 -H -t-butyl BGX(IIa) -CF3 -H -iso-butyl BGY(IIa) -CF3 -H -OCH3 BGZ (IIa) -CF3 -H -OC2H5 BHA (IIa) -CF3 -H -OC3H7 BHB(IIa) -CF3 -H -CHF2 BHC (IIa) -CF3 -H -CF3 BHD (IIa) -CF3 -H -CHCl2 BHE (IIa) -CF3 -H -CCl3 BHF (IIa) -CF3 -H -F BHG(IIa) -CF3 -H -Cl BHH (IIa) -CF3 -H -Br BHI (IIa) -CF3 -H -I BHJ (IIa) or (IIb) -CF3 -OH -H BHK (IIa) or (Ilb)-CF3-OH-CH3 BHL (IIa) or (IIb) -CF3 -OH -n-propyl BHM (IIa) or (IIb) -CF3 -OH -n-butyl BHN (IIa) or (IIb) -CF3 -OH -t-butyl BHO (IIa) or (IIb) -CF3 -OH -iso-butyl BHP (IIa) or (IIb) -CF3 -OH -OCH3 BHQ (IIa) or (IIb) -CF3 -OH -OC2H5 BHR (IIa) or (IIb) -CF3 -OH -OC3H7 BHS (IIa) or (IIb) -CF3 -OH -CHF2 BHT (IIa) or (IIb) -CF3 -OH -CF3 BHU (IIa) or (IIb) -CF3 -OH -CHCl2 BHV (IIa) or (IIb) -CF3 -OH -CCl3

Compound R1 R3 R4 BHW (IIa) or (IIb) -CF3 -OH -F BHX (IIa) or (IIb) -CF3 -OH -Cl BHY (IIa) or (IIb) -CF3 -OH -Br BHZ (IIa) or (IIb) -CF3 -OH -I BIA (na) or (IIb) -CF3 -F -H BIB (na) or (IIb) -CF3 -F -CH3 BIC (IIa) or (IIb) -CF3 -F -n-propyl BID (IIa) or (IIb) -CF3 -F -n-butyl BIE (IIa) or (IIb) -CF3 -F -t-butyl BIF (IIa) or (IIb) -CF3 -F -iso-butyl BIG (IIa) or (IIb) -CF3 -F -OCH3 BIH (IIa) or (IIb) -CF3 -F -OC2H5 BII (IIa) or (IIb) -CF3 -F -OC3H7 BIJ (IIa) or (IIb) -CF3 -F -CHF2 BIK (IIa) or (IIb) -CF3 -F -CF3 BIL (IIa) or (IIb) -CF3 -F -CHCl2 BIM(IIa) or (IIb) -CF3 -F -CCl3 BIN (IIa) or (IIb) -CF3 -F -F BIO (IIa) or (IIb) -CF3 -F -Cl BIP (IIa) or (IIb) -CF3 -F -Br BIQ (IIa) or (IIb) -CF3 -F -I BIR(IIa) or (IIb) -CF3 -Cl -H BIS (IIa) or (IIb) -CF3 -Cl -CH3 BIT (IIa) or (IIb) -CF3 -Cl -n-propyl BIU (IIa) or (IIb) -CF3 -Cl -n-butyl BIV (IIa) or (IIb) -CF3 -Cl -t-butyl BIW (IIa) or (IIb) -CF3 -Cl -iso-butyl BIX (IIa) or (IIb) -CF3 -Cl -OCH3

Compound R1 R3 R4 BIY(IIa) or (IIb) -CF3 -Cl -OC2H5 BIZ (IIa) or (IIb) -CF3 -Cl -OC3H7 BJA (IIa) or (IIb) -CF3 -Cl -CHF2 BJB (IIa) or (IIb) -CF3 -Cl -CF3 BJC(IIa) or (IIb) -CF3 -Cl -CHCl2 BJD (IIa) or (IIb) -CF3 -Cl -CCl3 BJE (IIa) or (IIb)-CF3-Cl-F BJF (IIa) or (IIb) -CF3 -Cl -Cl BJG (IIa) or (IIb) -CF3 -Cl -Br BJH (IIa) or (IIb) -CF3 -Cl -I BJI (IIa) or (IIb) -CF3 -Br -H BJJ (IIa) or (IIb) -CF3 -Br -CH3 BJK (lIa) or (IIb) -CF3 -Br -n-propyl BJL (IIa) or (IIb) -CF3 -Br -n-butyl BJM (IIa) or (IIb) -CF3 -Br -t-butyl BJN (IIa) or (IIb) -CF3 -Br -iso-butyl BJO (IIa) or (IIb) -CF3 -Br -OCH3 BJP (IIa) or (IIb) -CF3 -Br -OC2H5 BJQ (IIa) or (IIb) -CF3 -Br -OC3H7 BJR (HA) or (IIb) -CF3 -Br -CHF2 BJS (IIa) or (IIb) -CF3 -Br -CF3 BJT (IIa) or (IIb) -CF3 -Br -CHCl2 BJU (IIa) or (IIb) -CF3 -Br -CCl3 BJV (IIa) or (IIb) -CF3 -Br -F BJW (IIa) or (IIb) -CF3 -Br -Cl BJX (IIa) or (IIb) -CF3 -Br -Br BJY (IIa) or (IIb) -CF3 -Br -I BJZ (IIa) or (IIb) -CF3 -I -H

Compound R1 R3 Ra BKA (IIa) or (IIb) -CF3 -I -CH3 BKB (IIa) or (IIb) -CF3 -I -n-propyl BKC (IIa) or (IIb) -CF3 -I -n-butyl BKD (IIa) or (IIb) -CF3 -I -t-butyl BKE (IIa) or (IIb) -CF3 -I -iso-butyl BKF (IIa) or (IIb) -Cf3 -I -OCH3 BKG (IIa) or (IIb) -CF3 -I -OC2H5 BKH (IIa) or (IIb) -CF3 -I -OC3H7 BKI (IIa) or (IIb) -CF3 -I -CHF2 BKJ (IIa) or (IIb) -CF3 -I -CF3 BKK(IIa) or (IIb) -CF3 -I -CHCl2 BKL(IIa) or (IIb) -CF3 -I -CCl3 BKM (IIa) or (IIb) -CF3 -I -F BKN (IIa) or (IIb) -CF3 -I -Cl BKO (IIa) or (IIb) -CF3 -I -Br BKP (IIa) or (IIb) -CF3 -I -I BKQ (IIa) or (IIb) -CF3 -NO2 -H BKR(IIa) or (IIb) -CF3 -NO2 -CH3 BKS (IIa) or (IIb) -CF3 -NO2 -n-propyl BKT (IIa) or (IIb) -CF3 -NO2 -n-butyl BKU (IIa) or (IIb) -CF3 -NO2 -t-butyl BKV (IIa) or (IIb) -CF3 -NO2 -iso-butyl BKW (IIa) or (IIb) -CF3 -NO2 -OCH3 BKX (IIa) or (IIb) -CF3 -NO2 -OC2H5 BKY (IIa) or (IIb) -CF3 -NO2 -OC3H7 BKZ (IIa) or (IIb) -CF3 -NO2 -CHF2 BLA (IIa) or (IIb) -CF3 -NO2 -CF3 BLB (IIa) or (IIb) -CF3 -NO2 -CHCl2

Compound BLC (I or a) or (IIb) -CF3 -NO2 -CCl3 BLD (na) or (IIb) -CF3 -NO2 -F BLE (IIa) or (IIb) -CF3 -NO2 -Cl BLF (IIa) or (IIb) -CF3 -NO2 -Br BLG (IIa) or (IIb) -CF3 -NO2 -I BLH (IIa) or (IIb) -CF3 -CN -H BLI (IIa) or (IIb) -CF3 -CN -CH3 BLJ (IIa) or (IIb) -CF3 -CN -n-propyl BLK(IIa) or (IIb) -CF3 -CN -n-butyl BLL(IIa) or (IIb) -CF3 -CN -t-butyl BLM (IIa) or (IIb) -CF3 -CN -iso-butyl BLN (IIa) or (IIb) -CF3 -CN -OCH3 BLO (IIa) or (IIb) -CF3 -CN -OC2H5 BLP (IIa) or (IIb) -CF3 -CN -OC3H7 BLQ (IIa) or (IIb) -CF3 -CN -CHF2 BLR (IIa) or (IIb) -CF3 -CN -CF3 BLS (IIa) or (IIb) -CF3 -CN -CHCl2 BLT (IIa) or (IIb) -CF3 -CN -CCl3 BLU (IIa) or (IIb) -CF3 -CN -F BLV (IIa) or (IIb) -CF3 -CN -Cl BLW (na) or (IIb) -CF3 -CN -Br BLX (IIa) or (IIb) -CF3 -CN -I BLY (IIa) or (IIb) -CF3 -NH2 -H BLZ (IIa) or (IIb) -CF3 -NH2 -CH3 BMA (IIa) or (IIb) -CF3 -NH2 -n-propyl BMB (lia) or (IIb) -CF3 -NH2 -n-butyl BMC (IIa) or (IIb) -CF3 -NH2 -t-butyl BMD (IIa) or (IIb) -CF3 -NH2 -iso-butyl

Compound R1 R3 R4 BME (IIa) or (IIb) -CF3 -NH2 -OCH3 BMF(IIa) or (IIb) -CF3 -NH2 -OC2H5 BMG (IIa) or (IIb) -CF3 -NH2 -OC3H7 BMH (na) or (IIb) -CF3 -NH2 -CHF2 BMI (IIa) or (IIb) -CF3 -NH2 -CF3 BMJ (IIa) or (IIb) -CF3 -NH2 -CHCl2 BMK (IIa) or (IIb) -CF3 -NH2 -CCl3 BML (IIa) or (IIb) -CF3 -NH2 -F BMM (IIa) or (IIb) -CF3 -NH2 -Cl BMN (IIa) or (IIb) -CF3 -NH2 -Br BMO (IIa) or (IIb) -CF3 -NH2 -I BMP (IIa) or (IIb) -CF3 -CH3 -H BMQ (IIa) or (IIb) -CF3 -CH3 -CH3 BMR (IIa) or (IIb) -CF3 -CH3 -n-propyl BMS (IIa) or (IIb) -CF3 -CH3 -n-butyl BMT (IIa) or (IIb) -CF3 -CH3 -t-butyl BMU (IIa) or (IIb) -CF3 -CH3 -iso-butyl BMV (IIa) or (IIb) -CF3 -CH3 -OCH3 BMW (IIa) or (IIb) -CF3 -CH3 -OC2H5 BMX (IIa) or (IIb) -CF3 -CH3 -OC3H7 BMY(IIa) or (IIb) -CF3 -CH3 -CHF2 BMZ (IIa) or (IIb) -CF3 -CH3 -CF3 BNA (IIa) or (IIb) -CF3 -CH3 -CHCl2 BNB (IIa) or (IIb) -CF3 -CH3 -CCl3 BNC(IIa) or (IIb) -CF3 -CH3 -F BND(IIa) or (IIb) -CF3 -CH3 -Cl BNE (IIa) or (IIb) -CF3 -CH3 -Br BNF (na) or (IIb) -CF3 -CH3 -I

Compound R1 R3 R4 BNG(IIa) -NO2 -H -H BNH(IIa) -NO2 -H -CH3 BNI (IIa)-NO2-H-n-propyl BNJ (IIa)-NO2-H-n-butyl BNK (IIa) -NO2 -H -t-butyl BNL (IIa)-NO2-H-iso-butyl BNM(IIa) -NO2 -H -OCH3 BNN(IIa) -NO2 -H -OCH5 BNO (IIa) -NO2 -H -OC3H7 BNP (IIa) -NO2 -H -CHF2 BNQ (IIa) -NO2 -H -CF3 BNR (IIa) -NO2 -H -CHCl2 BNS (IIa) -NO2 -H -CCl3 BNT (IIa) -NO2 -H -F -H -Cl BNU (IIa) -NO2 BNV (IIa) -NO2 -H -Br BNW (IIa) -NO2 -H -I BNX (IIa) or (IIb) -NO2 -OH -H BNY (IIa) or (IIb) -NO2 -OH -CH3 BNZ(IIa) or (IIb) -NO2 -OH -n-propyl BOA (na) or (IIb) -NO2 -OH -n-butyl BOB (IIa) or (IIb) -NO2 -OH -t-butyl BOC (IIa) or (IIb) -NO2 -OH -iso-butyl BOD (Ifa) or (IIb) -NO2 -OH -OCH3 BOE (IIa) or (IIb) -NO2 -OH -OC2H5 BOF (Ha) or (IIb) -NO2 -OH -OC3H7 BOG (fla) or (IIb) -NO2 -OH -CHF2 BOH (IIa) or (IIb) -NO2 -OH -CF3

Compound R1 R3 R4 BOI (IIa) or (IIb)-NO2-OH-CHC12 BOJ (IIa) or (IIb) -NO2 -OH -CCl3 BOK (IIa) or (IIb) -NO2 -OH -F BOL (IIa) or (IIb) -NO2 -OH -Cl BOM (IIa) or (IIb)-NO2-OH-Br BON(IIa) or (IIb) -NO2 -OH -I BOO (IIa) or (IIb) -NO2 -F -H BOP (IIa) or (IIb) -NO2 -F -CH3 BOQ (IIa) or (IIb) -NO2 -F -n-propyl BOR(IIa) or (IIb)-NO2-F-n-butyl BOS (IIa) or (IIb) -NO2 -F -t-butyl BOT (IIa) or (IIb) -NO2 -F -iso-butyl BOU (IIa) or (IIb) -NO2 -F -OCH3 BOV (IIa) or (IIb) -NO2 -F -OC2H5 BOW (IIa) or (IIb) -NO2 -F -OC3H7 BOX (IIa) or (IIb) -NO2 -F -CHF2 BOY (IIa) or (IIb) -NO2 -F -CF3 BOZ (IIa) or (IIb) -NO2 -F -CHCl2 BPA (IIa) or (IIb) -NO2 -F -CCl3 BPB (IIa) or (IIb) -NO2 -F -F BPC (IIa) or (IIb) -NO2 -F -Cl BPD (IIa) or (IIb) -NO2 -F -Br BPE (IIa) or (IIb) -NO2 -F -I BPF (IIa) or (IIb) -NO2 -Cl -H BPG (IIa) or (IIb) -NO2 -Cl -CH3 BPH (IIa) or (IIb) -NO2 -Cl -n-propyl BPI (IIa) or (IIb) -NO2 -Cl -n-butyl BPJ (IIa) or (IIb) -NO2 -Cl -t-butyl

Compound Ri R3 R4 BPK (IIa) or (IIb) -NO2 -Cl -iso-butyl BPL (IIa) or (IIb) -NO2 -Cl -OCH3 BPM (IIa) or (IIb) -NO2 -Cl -OCH2H5 BPN (IIa) or (IIb) -NO2 -Cl -CO3H7 BPO (IIa) or (IIb) -NO2 -Cl -CHF2 BPP (IIa) or (IIb) -NO2 -Cl -CF3 BPQ (IIa) or (IIb) -NO2 -Cl -CHCl2 BPR (IIa) or (IIb) -NO2 -Cl -CCl3 BPS (IIa) or (IIb) -NO2 -Cl -F BPT (IIa) or (IIb) -NO2 -Cl -Cl BPU (IIa) or (IIb) -NO2 -Cl -Br BPV (IIa) or (IIb) -NO2 -Cl -I BPW (IIa) or (IIb) -NO2 -Br -H BPX (IIa) or (IIb) -NO2 -Br -CH3 BPY (na) or (IIb) -NO2 -Br -n-propyl BPZ (IIa) or (IIb) -NO2 -Br -n-butyl BQA (IIa) or (IIb) -NO2 -Br -t-butyl BQB (IIa) or (IIb) -NO2 -Br -iso-butyl BQC (IIa) or (IIb) -NO2 -Br -OCH3 BQD (IIa) or (IIb) -NO2 -Br -OC2H5 BQE (na) or (IIb) -NO2 -Br -OC3H7 BQF (IIa) or (IIb) -NO2 -Br -CHF2 BQG (IIa) or (IIb) -NO2 -Br -CF3 BQH (IIa) or (IIb) -NO2 -Br -CHCl2 BQI (IIa) or (IIb) -NO2 -Br -CCl3 BQJ (IIa) or (IIb) -NO2 -Br -F BQK (IIa) or (IIb) -NO2 -Br -Cl BQL (IIa) or (IIb) -NO2 -Br -Br

Compound R1 R3 R4 BQM (IIa) or (IIb) -NO2 -Br -I BQN (na) or (IIb) -NO2 -I -H BQO (IIa) or (IIb) -NO2 -I -CH3 BQP (IIa) or (IIb) -NO2 -I -n-propyl BQQ (IIa) or (IIb) -NO2 -I -n-butyl BQR (IIa) or (IIb) -NO2 -I -t-butyl BQS (IIa) or (IIb) -NO2 -I -iso-butyl BQT (IIa) or (IIb) -NO2 -I -OCH3 BQU (IIa) or (IIb) -NO2 -I -OC2H5 BQV (IIa) or (IIb) -NO2 -I -OC3H7 BQW (IIa) or (IIb) -NO2 -I -CHF2 BQX (IIa) or (IIb) -NO2 -I -CF3 BQY (IIa) or (IIb) -NO2 -I -CHCl2 BQZ (IIa) or (IIb) -NO2 -I -CCl2 BRA (IIa) or (IIb) -NO2 -I -F BRB (IIa) or (IIb) -NO2 -I -Cl BRC (IIa) or (IIb) -NO2 -I -Br BRD (IIa) or (IIb) -NO2 -I -I BRE (IIa) or (IIb) -NO2 -NO2 -H BRF (IIa) or (IIb) -NO2 -NO2 -CH3 BRG (IIa) or (IIb) -NO2 -NO2 -n-propyl BRH (IIa) or (IIb) -NO2 -NO2 -n-butyl BRI (IIa) or (IIb) -NO2 -NO2 -t-butyl BRJ (IIa) or (IIb) -NO2 -NO2 -iso-butyl BRK(IIa) or (IIb) -NO2 -NO2 -OCH3 BRL (IIa) or (IIb) -NO2 -NO2 -CO2H5 BRM (IIa) or (IIb) -NO2 -NO2 -CO3H7 BRN (IIa) or (IIb) -NO2 -NO2 -CHF2

Compound Ri R3 Ra BRO (IIa) or (IIb) -NO2 -NO2 -CF3 BRP (IIa) or (IIb) -NO2 -NO2 -CHCl2 BRQ (na) or (IIb) -NO2 -NO2 -CCl3 BRR (IIa) or (IIb)-NO2-NO2-F BRS (IIa) or (IIb) -NO2 -NO2 -Cl BRT (IIa) or (IIb) -NO2 -NO2 -Br BRU (IIa) or (IIb) -NO2 -NO2 -I BRV (IIa) or (IIb)-NO2-CN-H BRW (IIa) or (IIb) -NO2 -CN -CH3 BRX (IIa) or (IIb) -NO2 -CN -n-propyl BRY (IIa) or (IIb)-NO2-CN-n-butyl BRZ (IIa) or (IIb) -NO2 -CN -t-butyl BSA (IIa) or (IIb) -NO2 -CN -iso-butyl BSB (IIa) or (IIb) -NO2 -CN -OCH3 BSC (IIa) or (IIb) -NO2 -CN -OC2H5 BSD (Ila) or (IIb) -NO2 -CN -OC3H7 BSE (IIa) or (IIb) -NO2 -CN -CHF2 BSF (IIa) or (IIb) -NO2 -CN -CF3 BSG (na) or (IIb) -NO2 -CN -CHCl2 BSH(IIa) or (IIb) -NO2 -CN -CCl3 BSI (IIa) or (IIb) -NO2 -CN -F BSJ (IIa) or (IIb) -NO2 -CN -Cl BSK(IIa) or (IIb) -NO2 -CN -Br BSL (IIa) or (IIb) -NO2 -CN -I BSM(IIa) or (IIb) -NO2 -NH2 -H BSN (Ila) or (IIb) -NO2 -NH2 -CH3 BSO (IIa) or (IIb) -NO2 -NH2 -n-propyl BSP (IIa) or (IIb) -NO2 -NH2 -n-butyl

Compound R1 R3 R4 BSQ (IIa) or (IIb) -NO2 -NH2 -t-butyl BSR (IIa) or (IIb) -NO2 -NH2 -iso-butyl BSS (IIa) or (IIb) -NO2 -NH2 -COH3 BST (Ha) or (IIb) -NO2 -NH2 -OC2H5 BSU (IIa) or (IIb) -NO2 -NH2 -OC3H7 BSV (IIa) or (IIb) -NO2 -NH2 -CHF2 BSW (na) or (IIb) -NO2 -NH2 -CF3 BSX (Ha) or (IIb) -NO2 -NH2 -CHCl2 BSY (IIa) or (IIb) -NO2 -NH2 -CCl3 BSZ (IIa) or (IIb) -NO2 -NH2 -F BTA (IIa) or (IIb) -NO2 -NH2 -Cl BTB (IIa) or (IIb) -NO2 -NH2 -Br BTC (IIa) or (IIb) -NO2 -NH2 -I BTD (IIa) or (IIb) -NO2 -CH3 -H BTE (IIa) or (IIb) -NO2 -CH3 -CH3 BTF(IIa) or (IIb) -NO2 -CH3 -n-propyl BTG (IIa) or (IIb) -NO2 -CH3 -n-butyl BTH (lla) or (IIb) -NO2 -CH3 -t-butyl BTI (IIa) or (IIb) -NO2 -CH3 -iso-butyl BTJ(IIa) or (IIb) -NO2 -CH3 -OCH3 BTK (na) or (IIb) -NO2 -CH3 -OC2H5 BTL (IIa) or (IIb) -NO2 -CH3 -OC3H6 BTM (IIa) or (IIb) -NO2 -CH3 -CHF2 BTN(IIa) or (IIb) -NO2 -CH3 -CF3 : BTO (na) or (IIb) -NO2 -CH3 -CHCl2 BTP (IIa) or (IIb) -NO2 -CH3 -CCl3 BTQ (IIa) or (IIb) -NO2 -CH3 -F BTR (IIa) or (IIb) -NO2 -CH3 -Cl

Compound BTS (IIa) or (IIb) -NO2 -CH3 -Br BTT (IIa) or (IIb) -NO2 -CH3 -I BTU (IIa)-CN BTV (IIa) -CN -H -CH3 BTW (IIa) -CN -H -n-propyl BTX (IIa) -CN -H -n-butyl BTY (IIa) -CN -H -t-butyl BTZ (IIa)-CN-H-iso-butyl BUA (IIa) -CN -H -OCH3 BUB (IIa) -CN -H -OC2H5 BUC (IIa) -CN -H -OC3H7 BUD (IIa) -CN -H -CHF2 BUE (IIa) -CN -H -CF3 BUF (IIa) -CN -H -CHCl2 BUG (IIa) -CN -H -CCl3 BUH (IIa) -CN -H -F BUI (IIa)-CN-H-Cl BUJ(IIa) -CN -H -Br BUK (IIa) -CN -H -I BUL (IIa) or (IIa) -CN -OH -H BUM (Ha) or (IIa) -CN -OH -CH3 BUN (IIa) or (IIa) -CN -OH -n-propyl BUO (IIa) or (IIa) -CN -OH -n-butyl BUP (IIa) or (IIa) -CN -OH -t-butyl BUQ (na) or (IIb) -CN -OH -iso-butyl BUR (na) or (IIb) -CN -OH -OCH3 BUS (IIa) or (IIb) -CN -OH -OC2H5 BUT (IIa) or (IIb) -CN -OH -OC3H7

Compound RI R3 R4 BUU (IIa) or (IIb) -CN -OH -CHF2 BUV (IIa) or (IIb) -CN -OH -CF3 BUW (IIa) or (IIb) -CN -OH -CHCl2 BUX (IIa) or (IIb) -CN -OH -CCl3 BUY (na) or (IIb) -CN -OH -F BUZ (IIa) or (IIb) -CN -OH -Cl BVA (IIa) or (IIb) -CN -OH -Br BVB (IIa) or (IIb)-CN-OH-I BVC (IIa) or (IIb) -CN -F -H BVD (IIa) or (IIb) -CN -F -CH3 BVE (IIa) or (IIb) -CN -F -n-propyl BVF (IIa) or (IIb) -CN -F -n-butyl BVG (IIa) or (IIb) -CN -F -t-butyl BVH (IIa) or (IIb) -CN -F -iso-butyl BVI(IIa) or (IIb) -CN -F -OCH3 BVJ (IIa) or (IIb) -CN -F -OC2H5 BVK (IIa) or (IIb) -CN -F -OC3H7 BVL (IIa) or (IIb) -CN -F -CHF2 BVM (IIa) or (IIb) -CN -F -CF3 BVN (IIa) or (IIb) -CN -F -CHCl2 BVO (IIa) or (IIb) -CN -F -CCl3 BVP (IIa) or (IIb) -CN -F -F BVQ (IIa) or (IIb) -CN -F -Cl BVR (IIa) or (Hb)-CN-F-Br BVS(IIa) or (IIb) -CN -F -I BVT (IIa) or (IIb) CN -Cl -H BVU (IIa) or (IIb) -CN -Cl -CH3 BVV (lIa) or (IIb) -CN -Cl -n-propyl

Compound R1 R3 R4 BVW (IIa) or (IIb) -CN -Cl -n-butyl BVX (IIa) or (IIb) -CN -Cl -t-butyl BVY (IIa) or (IIb) -CN -Cl -iso-butyl BVZ (IIa) or (IIb) -CN -Cl -OCH3 BWA (lIa) or (IIb) -CN -Cl -OC2H5 BWB (IIa) or (IIb) -CN -Cl -OC3H7 BWC (IIa) or (IIb) -CN -Cl -CHF2 BWD (IIa) or (IIb) -CN -Cl -CF3 BWE (IIa) or (IIb) -CN -Cl -CHCl2 BWF (IIa) or (IIb) -CN -Cl -CCl3 BWG (IIa) or (IIb) -CN -cl -F BWH (IIa) or (IIb) -CN -Cl -Cl BWI (na) or (IIb) -CN -Cl -Br BWJ (IIa) or (IIb) -CN -Cl -I BWK (IIa) or (IIb) -CN -Br -H BWL (IIa) or (IIb) -CN -Br -CH3, BWM (IIa) or (IIb) -CN -Br -n-propyl BWN (IIa) or (IIb) -CN -Br -n-butyl BWO (IIa) or (IIb)-CN-Br-t-butyl BWP (IIa) or (IIb)-CN-Br-iso-butyl BWQ(IIa) or (IIb) -CN -Br -OCH3 BWR(IIa) or (IIb) -CN -Br -OC2H5 BWS (IIa) or (IIb) -CN -Br -OC3H7 BWT (IIa) or (IIb) -CN -Br -CHF2 BWU (IIa) or (IIb) -CN -Br -CF3 BWV (IIa) or (IIb) -CN -Br -CHCl2 BWW (IIa) or (IIb) -CN -Br -CCl3 BWX (IIa) or (IIb) -CN -Br -F

Compound Ri BWY (IIa) or (IIb) -CN -Br -Cl BWZ (IIa) or (IIb) -CN -Br -Br BXA (IIa) or (IIb)-CN-Br-I BXB (IIa) or (IIb) -CN -I -H BXC (Ila) or (IIb) -CN -I -CH3 BXD (IIa) or (IIb)-CN-I-n-propyl BXE (IIa) or (IIb) -CN -I -n-butyl BXF (IIa) or (IIb) -CN -I -t-butyl BXG (IIa) or (IIb) -CN -I -iso-butyl BXH (IIa) or (IIb) -CN -I -OCH3 BXI (IIa) or (IIb) -CN -I -OC2H5 BXJ (IIa) or (IIb)-CN-I-OC3H7 BXK (lIa) or (IIb) -CN -I -CHF2 BXL (na) or (IIb) -CN -I -CF3 BXM (IIa) or (IIb) -CN -I -CHCl2 BXN (IIa) or (IIb) -CN -I -CCl3 BXO (IIa) or (IIb) -CN -I -F BXP (IIa) or (IIb) -CN -I -Cl BXQ (IIa) or (IIb) -CN -I -Br BXR (IIa) or (IIb) -CN -I -I BXS (na) or (IIb) -CN -NO2 -H BXT (IIa) or (IIb) -CN -NO2 -CH3 BXU (na) or (IIb) -CN -NO2 -n-propyl BXV (IIa) or (IIb) -CN -NO2 -n-butyl BXW (IIa) or (IIb) -CN -NO2 -t-butyl BXX (IIa) or (IIb) -CN -NO2 -iso-butyl BXY (IIa) or (IIb) -CN -NO2 -OCH3 BXZ (IIa) or (IIb) -CN -NO2 -OC2H5

Compound R1 R3 R5 BYA (IIa) or (IIb) -CN -NO2 -OC3H7 BYB (na) or (IIb) -CN -NO2 -CHF2 BYC (na) or (IIb) -CN -NO2 -CF3 BYD(IIa) or (IIb) -CN -NO2 -CHCl2 BYE (na) or (IIb) -CN -NO2 -CCl3 BYF (IIa) or (IIb) -CN -NO2 -F BYG (IIa) or (IIb) -CN -NO2 -Cl BYH(IIa) or (IIb) -CN -NO2 -Br BYI (IIa) or (IIb) -CN -NO2 -I BYJ(IIa) or (IIb)-CN-CN-H BYK (na) or (IIb) -CN -CN -CH3 BYL(IIa) or (IIb)-CN-CN-n-propyl BYM(IIa) or (IIb)-CN-CN-n-butyl BYN(IIa) or (IIb) -CN -CN -t-butyl BYO(IIa) or (IIb) CN -CN -iso-butyl BYP (IIa) or (IIb) -CN -CN -OCH3 BYQ(IIa) or (IIb) -CN -CN -OC2H5 BYR(IIa) or (IIb) -CN -CN -OC3H7 BYS(IIa) or (IIb) -CN -CN -CHF2 BYT(IIa) or (IIb) -CN -CN -CF3 BYU(IIa) or (IIb) -CN -CN -CHCl2 BYV (na) or (IIb) -CN -CN -CCl3 BYW(IIa) or (IIb) -CN -CN -F BYX(IIa) or (Ilb)-CN-CN-Cl BYY(IIa) or (IIb) -CN -CN -Br BYZ(IIa) or (IIb) -CN -CN -I BZA (IIa) or (IIb) -CN -NH2 BZB (IIa) or (IIb) -CN -NH2 -CH3

Compound Ri R3 R4 BZC (IIa) or (IIb) -CN -NH2 -n-propyl BZD (IIa) or (IIb) -CN -NH2 -n-butyl BZE (Ila) or (IIb) -CN -NH2 -t-butyl BZF (na) or (IIb) -CN -NH2 -iso-butyl BZG (IIa) or (IIb) -CN NH2 -OCH3 BZH (IIa) or (IIb) -CN -NH2 -OC2H5 BZI (IIa) or (IIb) -CN -NH2 -OC3H7 BZJ (IIa) or (IIb) -CN -NH2 -CHF2 BZK (IIa) or (IIb) -CN -NH2 -CF3 BZL (IIa) or (IIb) -CN -NH2 -CHCl2 BZM (IIa) or (IIb) -CN -NH2 -CCl3 BZN (IIa) or (IIb) -CN -NH2 BZO(IIa) or (IIb) -CN -NH2 -Cl BZP (IIa) or (IIb) -CN -NH2 -Br BZQ (IIa) or (IIb) -CN -NH2 -I BZR (IIa) or (IIb) -CN -CH3 -H BZS (IIa) or (IIb) -CN -CH3 -CH3 BZT (IIa) or (IIb) -CN -CH3 -n-propyl BZU (IIa) or (IIb) -CN -CH3 -n-butyl BZV (fla) or (IIb) -CN -CH3 -t-butyl BZW(IIa) or (IIb) -CN -CH3 -iso-butyl BZX (IIa) or (IIb) -CN -CH3 -OCH3 BZY (IIa) or (IIb) -CN -CH3 -OC2H5 BZZ (IIa) or (IIb) -CN -CH3 -OC3H7 CAA (IIa) or (IIb) -CN -CH3 -CHF2 CAB (IIa) or (IIb) -CN -CH3 -CF3 CAC (na) or (IIb) -CN -CH3 -CHCl2 CAD (IIa) or (IIb) -CN -CH3 -CCl3

Compound Rs R3 R4 CAE (IIa) or (IIb) -CN -CH3 -F CAF (IIa) or (IIb)-CN-CH3-Cl CAG (IIa) or (IIb) -CN -CH3 -Br CAH (IIa) or (IIb) -CN -CH3 -I CAI (IIa) -CH3 -H CAJ (IIa) -CH3 -H -C CAK (IIa) -CH3 -H -n-propyl CAL (IIa)-CH3-H-n-butyl CAM (IIa) -CH3 -H -t-butyl CAN (IIa) -CH3 -H -iso-butyl CAO (IIa) -CH3 -H -OCH3 CAP (IIa) -CH3 -H -OC2H5 CAQ (IIa) -CH3 -H -OC3H7 CAR (IIa) -CH3 -H -CHF2 CAS (IIa) -CH3 -H -CF3 CAT (IIa) -CH3 -H -CHCl2 CAU (IIa)-CH3-H-CCl3 CAV (IIa) -CH3 -H -F CAW (IIa) -CH3 -H -Cl CAX (IIa) -CH3 -H -Br CAY (IIa)-CH3-H-I CAZ (IIa) or (IIb) -CH3 -OH -H CBA (IIa) or (IIb) -CH3 -OH -CH3 CBB (IIa) or (IIb) -CH3 -OH -n-propyl CBC(IIa) or (IIb) -CH3 -OH -n-butyl CBD(IIa) or (IIb) -CH3 -OH -t-butyl CBE(IIa) or (IIb) -CH3 -OH -iso-butyl CBF (IIa) or (IIb) -CH3 -OH -OCH3

Compound CBG (IIa) or (IIb) -CH3 -OH -OC2H5 CBH (na) or (IIb) -CH3 -OH -OC3H7 CBI (na) or (IIb) -CH3 -OH -CHF2 CBJ (IIa) or (IIb) -CH3 -OH -CF3 CBK (IIa) or (IIb) -CH3 -OH -CHCl2 CBL (IIa) or (IIb) -CH3 -OH -CCl3 CBM (IIa) or (IIb) -CH3 -OH -F CBN (IIa) or (IIb) -CH3 -OH -Cl CBO (IIa) or (IIb) -CH3 -OH -Br CBP (IIa) or (IIb) -CH3 -OH -I CBQ (na) or (IIb) -CH3 -F -H CBR (IIa) or (Ilb)-CH3-F-CH3 CBS (IIa) or (IIb) -CH3 -F -n-propyl CBT (IIa) or (IIb) -CH3 -F -n-butyl CBU (IIa) or (IIb) -CH3 -F -t-butyl CBV (IIa) or (IIb) -CH3 -F -iso-butyl CBW (IIa) or (IIb) -CH3 -F -OCH3 CBX (IIa) or (IIb) -CH3 -F -OC2H5 CBY (IIa) or (IIb) -CH3 -F -OC3H7 CBZ(IIa) or (IIb) -CH3 -F -CHF2 CCA (IIa) or (IIb) -CH3 -F -CF3 CCB (IIa) or (IIb) -CH3 -F -CHCl2 CCC (na) or (IIb) -CH3 -F -CCl3 CCD (IIa) or (IIb) -CH3 -F -F CCE(IIa) or (IIb) -CH3 -F -Cl CCF (IIa) or (IIb) -CH3 -F -Br CCG (Ha) or (IIb) -CH3 -F -I CCH (IIa) or (IIb) -CH3 -Cl -H

Compound R1 R3 R4 CCI (IIa) or (IIb) -CH3 -Cl -CH3 CCJ (lIa) or (IIb) -CH3 -Cl -n-propyl CCK (lIa) or (IIb) -CH3 -Cl -n-butyl CCL (na) or (IIb) -CH3 -Cl -t-butyl CCM (IIa) or (IIb) -CH3 -Cl -iso-butyl CCN (IIa) or (IIb) -CH3 -Cl -OCH3 CCO (IIa) or (IIb) -CH3 -Cl -OC2H5 CCP (IIa) or (IIb) -CH3 -Cl -OC3H7 CCQ (IIa) or (IIb) -CH3 -Cl -CHF2 CCR (IIa) or (IIb) -CH3 -Cl -CF3 CCS (Da) or (IIb) -CH3 -Cl -CHCl2 CCT (IIa) or (IIb) -CH3 -Cl -CCl3 CCU (IIa) or (IIb) -CH3 -Cl -F CCV (IIa) or (IIb) -CH3 -Cl -Cl CCW (IIa) or (IIb) -CH3 -Cl -Br CCX(IIa) or (IIb) -CH3 -Cl -I CCY (IIa) or (IIb) -CH3 -Br -H CCZ (na) or (IIb) -CH3 -Br -CH3 CDA (IIa) or (IIb) -CH3 -Br -n-propyl CDB (IIa) or (IIb) -CH3 -Br -n-butyl CDC(IIa) or (IIb) -CH3 -Br -t-butyl CDD(IIa) or (IIb) -CH3 -Br -iso-butyl CDE (IIa) or (IIb) -CH3 -Br -OCH3 CDF (IIa) or (IIb) -CH3 -Br -OC2H5 CDG (IIa) or (IIb) -CH3 -Br -OC3H7 CDH(IIa) or (IIb) -CH3 -Br -CHF2 CDI(IIa) or (IIb) -CH3 -Br -CF3 CDJ (IIa) or (IIb) -CH3 -Br -CHCl2

Compound R1 R3 R4 CDK (IIa) or (IIb) -CH3 -Br -CCl3 CDL (IIa) or (IIb)-CH3-Br-F i CDM (IIa) or (IIb) -CH3 -Br -Cl CDN (IIa) or (IIb) -CH3 -Br -Br CDO (IIa) or (IIb) -CH3 -Br -I CDP (IIa) or (IIb) -CH3 -I -H CDQ (IIa) or (IIb) -CH3 -I -CH3 CDR (fla) or (IIb) -CH3 -I -n-propyl CDS (IIa) or (IIb) -CH3 -I -n-butyl CDT (IIa) or (IIb) -CH3 -I -t-butyl CDU (IIa) or (IIb) -CH3 -I -iso-butyl CDV (IIa) or (IIb) -CH3 -I -OCH3 CDW (IIa) or (IIb) -CH3 -I -OC2H5 CDX (IIa) or (IIb) -CH3 -I -OC3H7 CDY (IIa) or (IIb) -CH3 -I -CHF2 CDZ (IIa) or (IIb) -CH3 -I -CF3 CEA (IIa) or (IIb) -CH3 -I -CHCl2 CEB (IIa) or (IIb) -CH3 -I -CCl3 CEC (IIa) or (IIb) -CH3 -I -F CED (IIa) or (IIb) -CH3 -I -Cl CEE (IIa) or (Ilb)-CH3-Br CEF (via) or (IIb) -CH3 -I -I CEG (IIa) or (IIb) -CH3 -NO2 -H CEH (IIa) or (IIb) -CH3 -NO2 -CH3 CEI (IIa) or (IIb) -CH3 -NO2 -n-propyl CEJ (IIa) or (IIb) -CH3 -NO2 -n-butyl CEK (IIa) or (IIb) -CH3 -NO2 -t-butyl CEL (IIa) or (IIb) -CH3 -NO2 -iso-butyl

Compound R1 R3 R4 CEM (IIa) or (IIb) -CH3 -NO2 -OCH3 CEN (IIa) or (IIb) -CH3 -NO2 -OC2H5 CEO (IIa) or (IIb) -CH3 -NO2 -OC3H7 CEP (IIa) or (IIb) -CH3 -NO2 -CHF2 CEQ(IIa) or (IIb) -CH3 -NO2 -CF3 CER(IIa) or (IIb) -CH3 -NO2 -CHCl2 CES (IIa) or (IIb) -CH3 -NO2 -CCl3 CET (IIa) or (IIb) -CH3 -NO2 -F CEU (lIa) or (IIb) -CH3 -NO2 -Cl CEV (IIa) or (IIb) -CH3 -NO2 -Br CEW (Ha) or (IIb) -CH3 -NO2 -I CEX (IIa) or (IIb) -CH3 -CN -H CEY (IIa) or (Ilb)-CH3-CN-CH3 CEZ (IIa) or (IIb) -CH3 -CN -n-propyl CFA (IIa) or (IIb) -CH3 -CN -n-butyl CFB (IIa) or (IIb) -CH3 -CN -t-butyl CFC (na) or (IIb) -CH3 -CN -iso-butyl CFD (IIa) or (IIb) -CH3 -CN -OCH3 CFE (IIa) or (IIb) -CH3 -CN -OC2H5 CFF (IIa) or (IIb) -CH3 -CN -OC3H7 CFG (IIa) or (IIb) -CH3 -CN -CHF2 CFH (IIa) or (IIb) -CH3 -CN -CF3 CFI (IIa) or (IIb) -CH3 -CN -CHCl2 CFJ (IIa) or (IIb) -CH3 -CN -CCl3 CFK (IIa) or (llb)-CH3-CN-F CFL (IIa) or (IIb) -CH3 -CN -Cl CFM (IIa) or (IIb) -CH3 -CN -Br CFN (IIa) or (IIb) -CH3 -CN -I

Compound R, R3 R4 CFO (Sa) or (IIb) -CH3 -NH2 -H CFP (IIa) or (IIb) -CH3 -NH2 -CH3 CFQ (IIa) or (IIb) -CH3 -NH2 -n-propyl CFR (IIa) or (IIb) -CH3 -NH2 -n-butyl CFS (Ha) or (IIb) -CH3 -NH2 -t-butyl CFT (IIa) or (IIb) -CH3 -NH2 -iso-butyl CFU (IIa) or (IIb) -CH3 -NH2 -OCH3 CFV (Ila) or (IIb) -CH3 -NH2 -OC2H5 CFW (IIa) or (IIb) -CH3 -NH2 -OC3H7 CFX (IIa) or (IIb) -CH3 -NH2 -CHF2 CFY (IIa) or (IIb) -CH3 -NH2 -CF3 CFZ (IIa) or (IIb) -CH3 -NH2 -CHCl2 CGA (IIa) or (IIb) -CH3 -NH2 -CCl3 CGB (IIa) or (IIb) -CH3 -NH2 -F CGC (IIa) or (IIb) -CH3 -NH2 -Cl CGD (IIa) or (IIb) -CH3 -NH2 -Br CGE (na) or (IIb) -CH3 -NH2 -I CGF (lIa) or (IIb) -CH3 -CH3 -H CGG (IIa) or (Ilb)-CH3-CH3-CH3 CGH (IIa) or (IIb)-CH3-CH3-n-propyl CGI (IIa) or (IIb) -CH3 -CH3 -n-butyl CGJ (IIa) or (IIb) -CH3 -CH3 -t-butyl CGK (IIa) or (IIb) -CH3 -CH3 -iso-butyl CGL (IIa) or (IIb) -CH3 -CH3 -OCH3 CGM (IIa) or (IIb) -CH3 -CH3 -OC2H5 CGN (IIa) or (IIb) -CH3 -CH3 -OC3H7 CGO(IIa) or (IIb) -CH3 -CH3 -CHF2 CGP (IIa) or (IIb) -CH3 -CH3 -CF3

Compound Ri R3 R4 CGQ (IIa) or (IIb) -CH3 -CH3 -CHCl2 CGR (IIa) or (IIb) -CH3 -CH3 -CCl3 CGS (Ha) or (IIb) -CH3 -CH3 -F CGT (Ha) or (IIb) -CH3 -CH3 -Cl CGUL(IIa) or (IIb) -CH3 -CH3 -Br CGV(IIa) or (IIb) -CH3 -CH3 -I Table 2 and pharmaceutically acceptable salts thereof, where: Compound R1 R3 R4 CGW (IIIa) -H -H -H CGX (IIIa) -H -H -CH3 CGY (IIIa) -H -H -n-propyl CGZ (Ia)-H-H-n-butyl CHA (IIIa) -H -H -t-butyl CHB (IIIa) -H -H -iso-butyl

Compound Ri R3 R4 CHC (IIIa) -H -H -OCH3 CHD (IIIa) -H -H -OC2H5 CHE(IIIa) -H -H -OC3H7 CHF (IIIa) -H -H -CHF2 CHG (IIIa) -H -H -CF3 CHH (IIIa) -H -H -CHCl2 CHI (IIIa) -H -H -CCl3 CHJ(IIIa) -H -H -F CHK (IIIa) -H -H -Cl CHL(IIIa) CHM (IIIa) -H -H -I CHN (DIa) or (mb)-H-OH-H CHO (IIIa) or (IIIb) -H -OH -CH3 CHP (IIIa) or (ffIb)-H-OH-n-propyl CHQ (IIIa) or (IIIb) -H -OH -n-butyl CHR (nia) or (IIIb) -H -OH -t-butyl CHS (IIIa) or (IIIb) -H -OH -iso-butyl CHT (nia) or (IIIb) -H -OH -OCH3 CHU (ma) or (IIIb) -H -OH -OC2H5 CHV(IIIa) or (IIIb) -H -OH -OC3H7 CHV(IIIa) or (IIIb) -H -OH -CHF2 CHX (IIIa) or (IIIb) -H -OH -CF3 CHY (ma) or (IIIb) -H -OH -CHCl2 CHZ (IIIa) or (IIIb) -H -OH -CCl3 CIA (IIIa) or (IIIb) -H -OH -F Cm (ma) or (IIIb) -H -OH -Cl CIC (ma) or (IIIb) -H -OH -Br CID (IIIa) or (IIIb) -H -OH -I

Compound R1 R3 R4 CIE(IIIa) or (IIIb) -H -F -H CIF (nia) or (IIIb) -H -F -CH3 CIG (IIIa) or (IIIb)-H-F-n-propyl CIH (IIIa) or (IIIb) -H -F -n-butyl CII(IIIa) or (IIIb) -H -F -t-butyl CIJ (IIIa) or (IIIb) -H -F -iso-butyl CIK(IIIa) or (IIIb) -H -F -OCH3 CIL (nia) or (IIIb) -H -F -OC2H5 CIM (nia) or (IHb)-H-F-OC3H7 CIN (IIIa) or (IIIb) -H -F -CHF2 CIO (IIIa) or (IIIb) -H -F -CF3 CIP (IIIa) or (IIIb) -H -F -CHCl2 CIQ (IIIa) or (IIIb) -H -F -CCl3 CIR (IIIa) or (IIIb) -H -F -F CIS (IIIa) or (IIIb) -H -F -Cl CIT (IIIa) or (IIIb) -H -F -Br CIU (IIIa) or (IIIb) -H -F -I CIV (IIIa) or (IIIb) -H -Cl -H CIW (IIIa) or (IIIb) -H -Cl -CH3 CIX (IIIa) or (Illb)-H-Cl-n-propyl CrY (IIIa) or (IIIb) -H -Cl -n-butyl CIZ (IIIa) or (Iib)-H-Cl-t-butyl CJA (IIIa) or (HIb)-H-Cl-iso-butyl CJB (IIIa) or (IIIb) -H -Cl -OCH3 CJC (IIIa) or (IIIb) -H -Cl -OC2H5 CJD (ma) or (IIIb) -H -Cl -OC3H7 CJE (IIIa) or (IIIb) -H -Cl -CHF2 CJF (IIIa) or (IlIb)-H-Cl-CF3

Compound Ri R3 R4 CJG (IIIa) or (IIIb) -H -Cl -CHCl2 CJH (DIa) or (IIIb) -H -Cl -CCl3 CJI (IIIa) or (IIIb) -H -Cl -F CJJ (IIIa) or (mb)-H-Cl-Cl CJK (IIIa) or (IIIb) -H -Cl -Br CJL (IIIa) or (IIIb) -H -Cl -I CJM (IIIa) or (IIIb) -H -Br -H CJN (fa) or (IIIb) -H -Br -CH3 CJO (IIIa) or (IIIb) -H -Br -n-propyl CJP (IIIa) or (IIIb) -H -Br -n-butyl CJQ (IIIa) or (IIIb) -H -Br -t-butyl CJR (IIIa) or (IIIb) -H -Br -iso-butyl CJS (nia) or (IIIb) -H -Br -OCH3 CJT (IIIa) or (IIIb) -H -Br -OCH2H5 CJU (nia) or (mb)-H-Br-OC3H7 CJV (IIIa) or (IIIb) -H -Br -CHF2 CJW (IIIa) or (IIIb) -H -Br -CF3 CJX (fa) or (mb)-H-Br-CHC12 CJY (IIIa) or (IIIb) -H -Br -CCl3 CJZ(IIIa) or (HIb)-H-Br-F CKA(IIIa) or (IIIb) -H -Br -Cl CKB (nia) or (IIIb) -H -Br -Br CKC (IIIa) or (IIIb) -H -Br -I CKD (ma) or (IIIb) -H -I -H CKE (IIIa) or (IIIb) -H -I -CH3 CKF (IIIa) or (IIIb) -H -I -n-propyl CKG (IIIa) or (IIIb) -H -I -n-butyl CKH (Ca) or (IIIb) -H -I -t-butyl

Compound R1 R3 R4 CKI (IIIa) or (IIIb) -H -I -iso-butyl CKJ (IIIa) or (IIIb) -H -I -OCH3 CKK (nia) or (IHb)-H-I-OC2H5 CKL (IIIa) or (IIIb) -H -I -OCH7 CKM (nia) or (IIIb) -H -I -CHF2 CKN (ina) or (IIIb) -H -I -CF3 CKO (IIIa) or (IIIb) -H -I -CHCl2 CKP (IIIa) or (IIIb) -H -I -CCl3 CKQ (IIIa) or (IIIb) -H -I -F CKR (nia) or (IIIb) -H -I -Cl CKS (IIIa) or (IIIb) -H -I -Br CKT (IIIa) or (IIIb) -H -I -I CKU (IIIa) or (IIIb) -H -NO2 -H CKV (IIIa) or (IIIb) -H -NO2 -CH3 CKW (nia) or (IIIb) -H -NO2 -n-propyl CKX (IIIa) or (IIIb) -H -NO2 -n-butyl CKY(IIIa) or (IIIb) -H -NO2 -t-butyl CKZ (nia) or (IIIb) -H -NO2 -iso-butyl CLA (ma) or (IIIb) -H -NO2 -OCH3 CLB (IIIa) or (Ib)-H-NO2-OC2H5 CLC(IIIa) or (IIIb) -H -NO2 -OC3H7 CLD (DIa) or (IIIb) -H -NO2 -CHF2 CLE (IIIa) or (IIb)-H-NO2-CF3 CLF (IIIa) or (IIIb) -H -NO2 -CHCl2 CLG (IIIa) or (IIIb) -H -NO2 -CCl3 CLH (IIIa) or (IIIb) -H -NO2 -F CLI (IIIa) or (IIIb) -H -NO2 -Cl CLJ(IIIa) or (IIIb) -H -NO2 -Br

Compound R1 R3 R4 CLK (IIIa) or (IIIb) -H -NO2 -I CLL (nia) or (IIIb) -H -CN -H CLM (IIIa) or (IIIb) -H -CN -CH3 CLN (nia) or (IIIb) -H -CN -n-propyl CLO (IIIa) or (IIIb) -H -CN -n-butyl CLP (ma) or (IIIb) -H -CN -t-butyl CLQ (IIIa) or (IIIb) -H -CN -iso-butyl CLR (IIIa) or (IIb)-H-CN-OCH3 CLS (IIIa) or (IIIb) -H -CN -OC2H5 CLT (nia) or (IIIb) -H -CN -OC3H7 CLU (Ela) or (IIIb) -H -CN -CHF2 CLV (IIIa) or (IIIb) -H -CN -CF3 CLW(IIIa) or (IIIb) -H -CN -CHCl2 CLX (ina) or (IIb)-H-CN-CC13 CLY (IIIa) or (IIIb) -H -CN -F CLZ (IIIa) or (IIIb) -H -CN -Cl CMA (IIIa) or (IIIb) -H -CN -Br CMB (IIIa) or (IIIb) -H -CN -I CMC (DIa) or (IIIb) -H -NH2 -H CMD (IIIa) or (IIIb) -H CME (IIIa) or (IIIb) -H -NH2 -n-propyl CMF (IIIa) or (IIIb) -H -NH2 -n-butyl CMG (IIIa) or (lIb)-H NH2-t-butyl CMH (IIIa) or (IIIb) -H -NH2 -iso-butyl CMI (IIIa) or (IIIb) -H -NH2 -OCH3 CMJ (IIIa) or (IIIb) -H -NH2 -OC2H5 CMK (Dia) or (IIIb) -H -NH2 -OC3H7 CML (nia) or (Ib)-H-NH2-CHF2

Compound R1 R3 R4 CMM (nia) or (IIIb) -H -NH2 -CF3 CMN (IIIa) or (IIIb) -H -NH2 -CHCl2 CMO (IIIa) or (IIIb) -H -NH2 -CCl3 CMP (IIIa) or (IIIb) -H -NH2 -F CMQ (IQa) or (IIIb) -H -NH2 -Cl CMR (nia) or (IIIb) -H -NH2 -Br CMS (IIIa) or (IIIb) -H -NH2 -I CMT (IIIa) or (IIIb) -H -CH3 -H CMU (IIIa) or (IIIb) -H -NH3 -CH3 CMV (IIIa) or (IIIb) -H -CH3 -n-propyl CMW (IIIa) or (IIIb) -H -CH3 -n-butyl CMX (3IIa) or (IIIb) -H -CH3 -t-butyl CMY (IIIa) or (IIIb) -H -CH3 -sio-butyl CMZ (IIIa) or (Ib)-H-CH3-OCH3 CNA (IIIa) or (IIIb) -H -CH3 -OC2H5 CNB (IIIa) or (IIIb) -H -CH3 -OC3H7 CNC (IIIa) or (mb)-H-CH3-CHF2 CND (nia) or (IIIb) -H -CH3 -CF3 CNE (IIIa) or (IIIb) -H -CH3 -CHCl2 CNF (IIIa) or (IIIb) -H -CH3 -CCl3 CNG (IIIa) or (IIIb) -H -CH3 -F CNH (IIIa) or (IIIb) -H -CH3 -Cl CNI (IIIa) or (IIIb) -H -CH3 -Br CNJ (IIIa) or (IIIb) -H -CH3 -I CNK (IIIa) -OH -H -H CNL (IIIa) -OH -H -CH3 CNM (IIIa) -OH -H -n-propyl CNN (IIIa) -OH -H -n-butyl

Compound Ri R3 R4 CNO (IIIa) -OH -H -t-butyl CNP (IIIa) -OH -H -iso-butyl CNQ (Ea)-OH-H-OCH3 CNR (IIIa) -OH -H -OC2H5 CNS (IIIa) -OH -H -OC3H7 CNT (IIIa) -OH -H -CHF2 CNU (IIIa) -OH -H -CF3 CNV (IIIa) -OH -H -CHCl2 CNW (Ha)-OH-H-CC13 CNX (IIIa) -OH -H -F CNY (IIIa) -OH -H -Cl CNZ (IIIa) -OH -H -Br COA (IIIa) -OH -H -I COB (ina) or (IIIb) -OH -OH -H COC (IIIa) or (IIIb) -OH -OH -CH3 COD (nia) or (IIIb) -OH -OH -n-propyl COE (IIIa) or (IIIb) -OH -OH -n-butyl COF (IIIa) or (IIIb) -OH -OH -t-butyl COG(IIIa) or (IIIb) -OH -OH -iso-butyl COH (IIIa) or (IIIb) -OH -OH -OCH3 COI (IIIa) or (IIIb) -OH -OH -OC2H5 COJ (nia) or (IIIb) -OH -OH -OC3H7 COK (nia) or (IIIb) -OH -OH -CHF2 COL (ma) or (IIIb) -OH -OH -CF3 COM (Ea) or (IIIb) -OH -OH -CHCl2 CON (IIIa) or (IIIb) -OH -OH -CCl3 COO (IIIa) or (IIIb) -OH -OH -F COP (IIIa) or (IIIb) -OH -OH -Cl

Compound R1 R3 R4 COQ (IIIa) or (IIIb) -OH -OH -Br COR (nia) or (IIIb) -OH -OH -I COS (IIIa) or (IIIb) -OH -F -H COT (nia) or (IIIb) -OH -F -CH3 COU (IIIa) or (IIIb) -OH -F -n-propyl COV (IIIa) or (IIIb) -OH -F -n-butyl COW (IIIa) or (IIIb) -OH -F -t-butyl COX (Illa) or (IIIb) -OH -F -iso-butyl COY (IIIa) or (IHb)-OH-F-OCH3 COZ (IIIa) or (IIIb) -OH -F -OC2H5 CPA (IIIa) or (IIIb) -OH -F -OC3H7 CPB (nia) or (IIIb) -OH -F -CHF2 CPC (ma) or (mb)-OH-F-CF3 CPD (ma) or (IIIb) -OH -F -CHCl2 CPE (IIIa) or (IIIb) -OH -F -CCl3 CPF(IIIa) or (IIIb) -OH -F -F CPG (IIIa) or (IIIb) -OH -F -Cl CPH (IIIa) or (IIIb) -OH -F -Br CPI (IIIa) or (IIIb) -OH -F -I CPJ (IIIa) or (IIIb) -OH -Cl -H CPK(IIIa) or (IIIb) -OH -Cl -CH3 CPL (IIIa) or (IIb)-OH-Cl-n-propyl CPM (IIIa) or (Ib)-OH-Cl-n-butyl CPN (IIIa) or (IIIb) -OH -Cl -t-butyl CPO (IIIa) or (IIIb) -OH -Cl -iso-butyl CPP (IIIa) or (IIIb) -OH -Cl -OCH3 CPQ (ma) or (IIIb) -OH -Cl -OC2H5 CPR (IIIa) or (IIIb) -OH -Cl -OC3H7

Compound Rl R3 R4 CPS (IIIa) or (IIIb) -OH -Cl -CHF2 CPT (IIIa) or (Eb)-OH-C1-CF3 CPU (DIa) or (IIIb) -OH -Cl -CHCl2 CPV (IIIa) or (IIIb) -OH -Cl -CCl3 CPW(IIIa) or (IIIb) -OH -Cl -F CPX(IIIa) or (IIIb) -OH -Cl -Cl CPY (IIIa) or (IIIb) -OH -Cl -Br CPZ (IIIa) or (IIIb) -OH -Cl -I CQA (IIIa) or (IIIb) -OH -Br -H CQB (nia) or (IIIb) -OH -Br -CH3 CQC (IIIa) or (IIIb) -OH -Br -n-propyl CQD (ma) or (IIIb) -OH -Br -n-butyl CQE (DIa) or (IIIb) -OH -Br -t-butyl CQF (IIIa) or (IIIb) -OH -Br -iso-butyl CQG (IIIa) or (IIIb) -OH -Br -OCH3 CQH (IIIa) or (IIIb) -OH -Br -OC2H5 CQI (Ea) or (IIIb) -OH -Br -OC3H7 CQJ (IIIa) or (IIIb) -OH -Br -CHF2 CQK (IIIa) or (IIIb) -OH -Br -CF3 CQL (IIIa) or (IIIb)-OH-Br-CHCl2 CQM (IIIa) or (IIIb) -OH -Br -CCl3 CQN (IIIa) or (IIIb) -OH -Br -F CQO (DIa) or (IIIb)-OH-Br-Cl CQP (IIIa) or (IIIb) -OH -Br -Br CQQ (ma) or (IIIb) -OH -Br -I CQR (DIa) or (IIIb) -OH -I -H CQS (IIIa) or (IIIb) -OH -I -CH3 CQT (IIIa) or (IIIb)-OH-I-n-propyl

Compound R1 CQU (IIIa) or (IIIb) -OH -I -n-butyl CQV (IIIa) or (IIIb) -OH -I -t-butyl CQW (ma) or (IIIb) -OH -I -iso-butyl CQX (nia) or (IIIb) -OH -I -OCH3 CQY (Illa) or (IIIb) -OH -I -OC2H5 CQZ (nia) or (IIIb) -OH -I -OC3H7 CRA (ma) or (IIIb) -OH -I -CHF2 CRB (nia) or (IIIb) -OH -I -CF3 CRC (IIIa) or (IIIb) -OH -I -CHCl2 CRD (IIIa) or (IIIb) -OH -I -CCl3 CRE (nia) or (DIb)-OH-I-F CRF (IIIa) or (IIIb) -OH -I -Cl CRG (IIIa) or (IIIb) -OH -I -Br CRH (IIIa) or (IIIb) -OH -I -I CRI (IIIa) or (IIIb) -OH -NO2 -H CRJ (IIIa) or (IIIb) -OH -NO2 -CH3 CRK (DIa) or (IIIb) -OH -NO2 -n-propyl CRL (nia) or (lIb)-OH-N02-n-butyl CRM (nia) or (IIIb) -OH -NO2 -t-butyl CRN (lita) or (IIIb) -OH -NO2 -iso-buty CRO (IIIa) or (IIIb) -OH -NO2 -OCH3 CRP (nia) or (IIIb) -OH -NO2 -OC2H5 CRQ (IIIa) or (IIIb) -OH -NO2 -OC3H7 CRR (nia) or (IIIb) -OH -NO2 -CHF2 CRS (IIIa) or (IIIb) -OH -NO2 -CF3 CRT (IIIa) or (IIIb) -OH -NO2 -CHCl2 CRU (IIIa) or (IIIb) -OH -NO2 -CCl3 CRV(IIIa) or (IIIb) -OH -NO2 -F

Compound Ri R3 Ra CRW(IIIa) or (IIIb) -OH -NO2 -Cl CRX(IIIa) or (IIIb) -OH -NO2 -Br CRY(IIIa) or (IIIb) -OH -NO2 -I CRZ(IIIa) or (IIIb) -OH -CN -H CSA(IIIa) or (IIIb) -OH -CN -CH3 CSB(IIIa) or (IIIb) -OH -CN -n-propyl CSC(IIIa) or (IIIb) -OH -CN -n-butyl CSD (Hfa) or (IIIb) -OH -CN -t-butyl CSE (IIIa) or (IIIb) -OH -CN -iso-butyl CSF (nia) or (IIIb) -OH -CN -OCH3 CSG (nia) or (IIIb) -OH -CN -OC2H5 CSH (ma) or (IIIb) -OH -CN -OC3H7 CSI (IIIa) or (IIIb) -OH -CN -CHF2 CSJ (IIIa) or (IIIb)-OH-CN-CF3 CSK (IIIa) or (IIIb) -OH -CN -CHCl2 CSL (IIIa) or (IIIb) -OH -CN -CCl3 CSM (IIIa) or (IIIb) -OH -CN -F CSN (IIIa) or (IIIb) -OH -CN -Cl CSO (IIIa) or (IIIb) -OH -CN -Br CSP (villa) or (IIIb) -OH -CN -I CSQ (IIIa) or (IIIb) -OH -NH2 -H CSR (IIIa) or (IIIb) -OH -NH2 -CH3 CSS (IIIa) or (IIIb) -OH -NH2 -n-propyl CST (IIIa) or (IIIb) -OH -NH2 -n-butyl CSU (ma) or (IIIb) -OH -NH2 -t-butyl CSV (IIIa) or (IIIb) -OH -NH2 -iso-butyl CSW (IIIa) or (IIIb) -OH -NH2 -OCH3 CSX (IIIa) or (IIIb) -OH -NH2 -OC2H5

Compound Rl R3 R4 CSY (IIIa) or (IIIb) -OH -NH2 -OC3H7 CSZ (IIIa) or (IIIb) -OH -NH2 -CHF2 CTA (IIIa) or (IIIb) -OH -NH2 -CF3 CTB(IIIa) or (IIIb) -OH -NH2 -CHCl2 CTC (nia) or (IIIb) -OH -NH2 -CCl3 CTD (IIIa) or (IIIb) -OH -NH2 -F CTE (IIIa) or (IIIb) -OH -NH2 -Cl CTF (IIIa) or (IIIb) -OH -NH2 -Br CTG (IIIa) or (mb)-OH-NH2-I CTH (IIIa) or (IIIb) -OH -CH3 -H CTI (IIIa) or (IIIb) -OH -CH3 -CH3 CTJ (IIIa) or (IIIb) -OH -CH3 -n-propyl CTK (IIIa) or (IIIb) -OH -CH3 -n-butyl CTL (IIIa) or (IIIb) -OH -CH3 -t-butyl CTM (IIIa) or (Hlb)-OH-CH3-iso-butyl CTN (nia) or (IIIb) -OH -CH3 -OCH3 CTO (ma) or (IIIb) -OH -CH3 -OC2H5 CTP (ma) or (IIIb) -OH -CH3 -OC3H7 CTQ (IIIa) or (IIIb) -OH -CH3 -CHF2 CTR (ma) or (IIIb) -OH -CH3 -CF3 CTS (IIIa) or (IIIb) -OH -CH3 -CHCl2 CTT (IIIa) or (IIIb) -OH -CH3 -CCl3 CTU (IIIa) or (mb)-OH-CH3-F CTV (IIIa) or (IIIb) -OH -CH3 -Cl CTW (IIIa) or (IIIb) -OH -CH3 -Br CTX (IIIa) or (IIIb) -OH -CH3 -I CTY (IIIa) CTZ(IIIa) -F -H -CH3

Compound R1 R3 R4 CUA (IIIa) -F -H -n-propyl CUB(IIIa) -F -H -n-butyl CUC(IIIa) -F -H -t-butyl CUD(IIIa) -F -H -iso-butyl CUE (IIIa) -F -H -OCH3 CUF (IIIa) -F -H -OC2H5 CUG (Ia)-F-H-OC3H7 CUH (IIIa) -F -H -CHF2 CUI (IIIa) -F -H -CF3 CUJ(IIIa) -F -H -CHCl2 CUK(IIIa) -F -H -CCl3 CUL(IIIa) -F -H -F CUM(IIIa) -F -H -Cl CUN (HIa)-F-H-Br CUO (IIIa) -F -H -I CUP (IIIa) or (IIIb) -F -OH -H CUQ (IIIa) or (IIIb) -F -OH -CH3 CUR (IIIa) or (IIIb) -F -OH -n-propyl CUS (nia) or (IIIb) -F -OH -n-butyl CUT (IIIa) or (IIIb) -F -OH -t-butyl CUU (IIIa) or (IIIb) -F -OH -iso-butyl CUV (Ia) or (IIIb)-F-OH-OCH3 CUW (IIIa) or (IIIb) -F -OH -OC2H5 CUX (IIIa) or (IIIb) -F -OH -OC3H8 CUY (ma) or (IIIb) -F -OH -CHF2 CUZ (IIIa) or (IIIb) -F -OH -CF3 CVA (IIIa) or (IIIb) -F -OH -CHCl2 CVB (IIIa) or (IIIb) -F -OH -CCl3

Compound R1 R3 R4 CVC(IIIa) or (IIIb) -F -OH -F CVD (IIIa) or (IIIb) -F -OH -Cl CVE(IIIa) or (IIIb) -F -OH -Br CVF(IIIa) or (IIIb) -F -OH -I CVG(IIIa) or (IIIb)-F-F-H CVH(IIIa) or (IIIb) -F -F -CH3 CVI(IIIa) or (IIIb) -F -F -n-propyl CVJ (nia) or (IIIb) -F -F -n-butyl CVK (IIIa) or (IIIb) -F -F -t-butyl CVL (IIIa) or (IIIb) -F -F -iso-butyl CVM (IIIa) or (IIIb) -F -F -OCH3 CVN (IIIa) or (IIIb) -F -F -OC2H5 CVO (IIIa) or (IIIb) -F -F -OC3H7 CVP (IIIa) or (IIIb) -F -F -CHF2 CVQ (IIIa) or (IIIb) -F -F -CF3 CVR (IIIa) or (IIIb) -F -F -CHCl2 CVS (IIIa) or (nib)-F-F-CClg CVT (IIIa) or (nib)-F-F-F CVU (nia) or (b)-F-F-C1 CW (IIIa) or (IIIb) -F -F -Br CVW((IIIa) or (IIIb) -F -F -I CVX (ma) or (IIIb) -F -Cl -H CVY (IIIa) or (IIIb) -F -Cl -CH3 CVZ (IIIa) or (IIIb) -F -Cl -n-propyl CWA (IIIa) or (IIIb) -F -Cl -n-butyl CWB (nia) or (IIIb) -F -Cl -t-bytyl CWC (ma) or (IIIb) -F -Cl -iso-butyl CWD (IIIa) or (IIIb) -F -Cl -OCH3

Compound R1 R3 R4 CWE (IIIa) or (IIIb) -F -Cl -OC3H5 CWF (IIIa) or (IIIb) -F -Cl -OC3H7 CWG (IIIa) or (IIIb) -F -Cl -CHF2 CWH (IIIa) or (IIIb) -F -Cl -CF3 CWI (nia) or (IIIb) -F -Cl -CHCl2 CWJ (IIIa) or (IIIb) -F -Cl -CCl3 CWK (MA) or (IIIb) -F -Cl -F CWL (ffIa) or (IIIb) -F -Cl -Cl CWM (nia) or (IIIb) -F -Cl -Br CWN (ma) or (nib)-F-Cl-I CWO (IIIa) or (IIIb) -F -Br -H CWP (MA) or (IIIb) -F -Br -CH3 CWQ (IIIa) or (IIIb) -F -Br -n-propyl CWR (IIIa) or (IIIb) -F -Br -n-butyl CWS (IIIa) or (IIIb) -F -Br -t-butyl CWT (IIIa) or (IIIb) -F -Br -iso-butyl CWU (nia) or (DIb)-F-Br-OCH3 CWV (IIIa) or (IIIb) -F -Br -OC2H5 CWW (IIIa) or (IIIb) -F -Br -OC3H7 CWX (IIIa) or (IIIb) -F -Br -CHF2 CWY (IIIa) or (IIIb) -F -Br -CF3 CWZ (IIIa) or (IIIb) -F -Br -CHCl2 CXA (IIIa) or (IIIb) -F -Br -CCl3 CXB (IIIa) or (IIIb) -F -Br -F CXC (IIIa) or (Illb)-F-Br-Cl CXD (IIIa) or (IIIb) -F -Br -Br CXE (IIIa) or (IIIb) -F -Br -I CXF (IIIa) or (IIIb) -F -I -H

Compound R, R3 R4 CXG (IIIa) or (IIIb) -F -I -CH3 CXH (IIIa) or (IIIb) -F -I -n-propyl CXI (IIIa) or (IIIb) -F -I -n-butyl CXJ(IIIa) or (IIb)-F-I-t-butyl CXK (IIIa) or (IIIb) -F -I -iso-butyl CXL (IIIa) or (IIIb) -F -I -OCH3 CXM(IIIa) or (IIIb) -F -I -OC2H5 CXN (IIIa) or (IIIb) -F -I -OC3H7 CXO (IIIa) or (IIIb) -F -I -CHF2 CXP (IIIa) or (IIIb)-F-I-CF3 CXQ (IIIa) or (IIIb) -F -I -CHCl2 CXR (IIIa) or (IIIb) -F -I -CCl3 CXS (IIIa) or (nib)-F-I-F CXT (IIIa) or (IIIb) -F -I -Cl CXU (ma) or (IIIb)-F-I-Br CXV (ina) or (mb)-F-I-I CXW (IIIa) or (IIIb) -F -NO2 -H CXX (IIIa) or (IIIb) -F -NO2 -CH3 CXY (IIIa) or (IIIb) -F -NO2 -n-propyl CXZ (IIIa) or (IIIb) -F -NO2 -n-butyl CYA (IIIa) or (IIIb) -F -NO2 -t-butyl CYB (IIIa) or (IIIb) -F -NO2 -iso-butyl CY (ma) or (IIIb) -F -NO2 -OCH3 CYD (IIIa) or (IIIb) -F -NO2 -OC2H5 CYE (nia) or (IIIb) -F -NO2 -OC3H7 CYF (nia) or (IIIb) -F -NO2 -CHF2 CYG (IIIa) or (IIIb) -F -NO2 -CF3 CYH (IIIa) or (IIIb) -F -NO2 -CHCl2

Compound R1 R3 R4 CYI (ma) or (IIIb) -F -NO2 -CCl3 CYJ (IIIa) or (Ib)-F-NO2-F CYK (IIIa) or (IIIb) -F -NO2 -Cl CYL (IIIa) or (IIIb) -F -NO2 -Br CYM (IIIa) or (IIIb) -F -NO2 -I CYN (nia) or (IIIb) -F -CN -H CYO (IIIa) or (IIIb) -F -CN -CH3 CYP (IIIa) or (IIIb)-F-CN-n-propyl CYQ (IIIa) or (IIIb) -F -CN -n-butyl CYR (IIIa) or (IIIb) -F -CN -t-butyl CYS (Illa) or (IIIb)-F-CN-iso-butyl CYT (IIIa) or (IIIb) -F -CN -OCH3 CYU (IIIa) or (IIIb) -F -CN -OC2H5 CYV (IIIa) or (IIIb) -F -CN -OC3H7 CYW (nia) or (IIIb) -F -CN -CHF2 CYX (IIIa) or (IIIb) -F -CN -CF3 CYY (IIIa) or (IIIb) -F -CN -CHCl2 CYZ (IIIa) or (IIIb) -F -CN -CCl3 CZA (IIIa) or (IIIb) -F -CN -F CZB (ma) or (IIIb) -F -CN -Cl CZC (IIIa) or (IIIb) -F -CN -Br CZD (IIIa) or (IIIb) -F -CN -I CZE (IIIa) or (IIIb) -F -NH2 -H CZF (IIIa) or (IIIb) -F -NH2 -CH3 CZG (IIIa) or (IIIb) -F -NH2 -n-propyl CZH (IIIa) or (IIIb) -F -NH2 -n-butyl CZI (ma) or (IIIb) -F -NH2 -t-butyl CZJ (IIIa) or (IIIb) -F -NH2 -iso-butyl

Compound Ri R3 R4 CZK (IIIa) or (IIIb) -F -NH2 -OCH3 CZL (IIIa) or (IIIb) -F -NH2 -OC2H5 CZM (IIIa) or (IIIb) -F -NH2 -OC3H7 CZN (IIIa) or (IIIb) -F -NH2 -CHF2 CZO (IIIa) or (IIIb) -F -NH2 -CF3 CZP (IIIa) or (IIIb) -F -NH2 -CHCl2 CZQ (nia) or (IIIb) -F -NH2 -CCl3 CZR (IIIa) or (IIIb) -F -NH2 -F CZS (IIIa) or (IIIb) -F -NH2 -Cl CZT (IIIa) or (IIIb) -F -NH2 -Br CZU (IIIa) or (IIIb) -F -NH2 -I CZV (IIIa) or (IIIb) -F -CH3 -H CZW (Ea) or (IIIb) -F -CH3 -CH3 CZX (IIIa) or (IIIb) -F -CH3 -n-propyl CZY (ma) or (IIIb) -F -CH3 -n-butyl CZZ (ma) or (IIIb) -F -CH3 -t-butyl DAA(IIIa) or (IIIb) -F -CH3 -iso-butyl DAB(IIIa) or (IIIb) -F -CH3 -OCH3 DAC (IIIa) or (IIIb) -F -CH3 -OC2H5 DAD (nia) or (IIIb) -F -CH3 -OC3H7 DAB (IIIa) or (IIIb) -F -CH3 -CHF2 DAF (IIIa) or (Eb)-F-CH3-CF3 DAG (IIIa) or (IIIb) -F -CH3 -CHCl2 DAH (nia) or (IIIb) -F -CH3 -CCl3 DAI (IIIa) or (IIIb) -F -CH3 -F DAJ (Ea) or (IIIb) -F -CH3 -Cl DAK(IIIa) or (IIIb) -F -CH3 -Br DAL (IIIa) or (IIIb) -F -CH3 -I

Compound R1 R3 R4 DAM(IIIa) -Cl -H -H DAN (IIIa) -Cl -H -CH3 DAO (IIIa)-Cl-H-n-propyl DAP(IIIa) -Cl -H -n-butyl DAO(IIIa) -Cl -H -t-butyl DAQ (IIIa) DAR AR(IIIa) -Cl -H -iso-butyl DAS (IIIa)-Cl-H-OCH3 DAT (IIIa) -Cl -H -OC2H5 DAU (IIIa) -Cl -H -OC3H7 DAV (IIIa) -Cl -H -CHF2 DAW (IIIa) -Cl -H -CF3 DAX(IIIa) -Cl -H -CHCl2 DAY(IIIa) -Cl -H -CCl3 DAZ(IIIa) -Cl -H -F DBA(IIIa) -Cl -H -Cl DBB (IIIa)-C1-H-Br DBC (IIIa) -Cl -H -I DBD (nia) or (IIIb) -Cl -OH -H DBE (nia) or (IIIb)-Cl-OH-CH3 DBF (IIIa) or (IIIb) -Cl -OH -n-propyl DBG (IIIa) or (IIIb) -Cl -OH -n-butyl DBH (IIIa) or (IIIb) -Cl -OH -t-butyl DBI (ina) or (IIIb) -Cl -OH -iso-butyl DBJ (IIIa) or (IIIb)-Cl-OH-OCH3 DBK (ma) or (IIIb) -Cl -OH -OC2H5 DBL (IIIa) or (IIIb) -Cl -OH -OC3H7 DBM (IIIa) or (IIIb) -Cl -OH -CHF2 DBN (IIIa) or (IIIb) -Cl -OH -CF3

Compound R1 DBO (IIIa) or (Ib)-Cl-OH-CHC12 DBP (IIIa) or (IIIb)-Cl-OH-CC13 DBQ (ma) or (IIIb) -Cl -OH -F DBR (ma) or (IIIb) -Cl -OH -Cl DBS (IIIa) or (IIIb) -Cl -OH -Br DBT (IIIa) or (IHb)-Cl-OH-I DBU (IIIa) or (IIIb) -Cl -F -H DBV (IIIa) or (IIIb) -Cl -F -CH3 DBW (ma) or (IIIb) -Cl -F -n-propyl DBX (IIIa) or (IIIb) -Cl -F -n-butyl DBY (IIIa) or (IIIb) -Cl -F -t-butyl DBZ (IIIa) or (IIIb) -Cl -F -iso-butyl DCA (IIIa) or (IIIb) -Cl -F -OCH3 DCB (ma) or (IIIb) -Cl -F -OC2H5 DCC (IIIa) or (IIIb) -Cl -F -OC3H7 DCD (IIIa) or (IIIb) -Cl -F -CHF2 DCE (IIIa) or (IIIb) -Cl -F -CF3 DCF (IIIa) or (IIIb) -Cl -F -CHCl2 DCG (nia) or (IIIb) -Cl -F -CCl3 DCH (IIIa) or (IIIb) -Cl -F -F DCI (IIIa) or (IIIb) -Cl -F -Cl DCJ (IIIa) or (IIIb) -Cl -F -Br DCK (IIIa) or (mb)-Cl-F-I DCL (IIIa) or (IIIb) -Cl -Cl -H DCM (IIIa) or (IIIb) -Cl -Cl -CH3 DCN (nia) or (IIIb) -Cl -Cl -n-propyl DCO (IIIa) or (IIIb) -Cl -Cl -n-butyl DCP (IIIa) or (IIIb) -Cl -Cl -t-butyl

Compound R1 R3 R4 DCQ (nia) or (IIIb) -Cl -Cl -iso-butyl DCR (IIIa) or (IIIb) -Cl -Cl -OCH3 DCS (IIIa) or (IIIb) -Cl -Cl -OC2H5 DCT (IIIa) or (IIIb) -Cl -Cl -OC3H7 DCU (IIIa) or (IIIb) -Cl -Cl -CHF2 DCV (IIIa) or (IIIb) -Cl -Cl -CF3 DCW (ma) or (IIIb) -Cl -Cl -CHCl2 DCX (IIIa) or (IIIb) -Cl -Cl -CCl3 DCY (IIIa) or (inb)-Cl-Cl-F DCZ (IIIa) or (IIIb) -Cl -Cl -Cl DDA (ma) or (IIIb) -Cl -Cl -Br DDB (ma) or (IIIb) -Cl -Cl -I DDC (IIIa) or (IIb)-Cl-Br-H DDD (ma) or (IIIb) -Cl -Br -CH3 DDE (IIIa) or (IIIb) -Cl -Br -n-propyl DDF (IIIa) or (IIIb) -Cl -Br -n-butyl DDG (nia) or (mb)-Cl-Br-t-butyl DDH (IIIa) or (IIIb) -Cl -Br -iso-butyl DDI (IIIa) or (IIIb) -Cl -Br -OCH3 DDJ(IIIa) or (IIIb) -Cl -Br -OC2H5 DDK (IIIa) or (IIIb) -Cl -Br -OC3H7 DDL (IIIa) or (IIIb) -Cl -Br -OCHF2 DDM (IIIa) or (IIIb) -Cl -Br -CF3 DDN (IIIa) or (IIIb) -Cl -Br -CHCl2 DDO(IIIa) or (IIIb) -Cl -Br -CCl3 DDP (ma) or (IIIb) -Cl -Br -F DDQ (IIIa) or (IIIb) -Cl -Br -Cl DDR (IIIa) or (inb)-Cl-Br-Br

Compound R, R3 R4 DDS (IIIa) or (IIIb) -Cl -Br -I DDT (IIIa) or (IIIb) -Cl -I -H DDU (IIIa) or (IIIb)-Cl-I-CH3 DDV (DIa) or (IIIb) -Cl -I -n-propyl DDW (IIIa) or (IIIb) -Cl -I -n-butyl DDX (IIIa) or (IIIb) -Cl -I -t-butyl DDY (IIIa) or (IIb)-Cl-I-iso-butyl DDZ (IIIa) or (IIIb) -Cl -I -OCH3 DEA (IIIa) or (IIIb) -Cl -I -OC2H5 DEB (IIIa) or (IIIb) -Cl -I -OC3H7 DEC (IIIa) or (IIIb) -Cl -I -CHF2 DED (IIIa) or (IIIb) -Cl -I -CF3 DEE (ma) or (IIIb) -Cl -I -CHCl2 DEF(IIIa) or (IIIb) -Cl -I -CCl3 DEG(IIIa) or (IIIb) -Cl -I -F DEH (IIIa) or (IIIb) -Cl -I -Cl DEI (IIIa) or (IIIb) -Cl -I -Br DEJ (IIIa) or (IIIb) -Cl -I -I DEK (IIIa) or (IIIb) -Cl -NO2 -H DEL (IIIA) or (IIIb) -Cl -NO2 -CH3 DEM(IIIa) or (IIIb) -Cl -NO2 -n-propyl DEN (ma) or (IIIb) -Cl -NO2 -n-butyl DEO (IIIa) or (IIIb) -Cl -NO2 -t-butyl DEP (IIIa) or (IIIb) -Cl -NO2 -iso-butyl DEQ(IIIa) or (IIIb) -Cl -NO2 -OCH3 DER (ma) or (IIIb) -Cl -NO2 -OC2H5 DES (IIIa) or (IIIb) -Cl -NO2 -OC3H7 DET (IIIa) or (IIIb) -Cl -NO2 -CHF2

Compound R1 R3 R4 DEU (ma) or (IIIb) -Cl -NO2 -CF3 DEV (IIIa) or (IIIb) -Cl -NO2 -CHCl2 DEW(IIIa) or (IIb)-Cl-NO2-CC13 DEX (IIIa) or (IIIb) -Cl -NO2 -F DEY (IIIa) or (IIIb) -Cl -NO2 -Cl DEZ (IIIa) or (IIIb) -Cl -NO2 -Br DFA (ina) or (IIIb) -Cl -NO2 -I DFB (IIIa) or (m b)-C1-C N-H DFC (IIIa) or (IIb)-Cl-CN-CH3 DFD (IIIa) or (IIIb) -Cl -CN -n-propyl DFE (IIIa) or (IIIb) -Cl -CN -n-butyl DFF (IIIa) or (IHb)-Cl-CN-t-butyl DFG (IIIa) or (IIIb)-Cl-CN-iso-butyl DFH (IIIa) or (IIIb) -Cl -CN -OCH3 DFI (IIIa) or (IIIb) -Cl -CN -OC2H5 DFJ (IIIa) or (IIIb) -Cl -CN -OC3H7 DFK (IIIa) or (IIIb) -Cl -CN -CHF2 DFL (IIIa) or (IIIb) -Cl -CN -CF3 DFM (IIIa) or (IIIb) -Cl -CN -CHCl2 DFN (nia) or (IIIb) -Cl -CN -CCl3 DFO (IIIa) or (IIb)-Cl-CN-F DFP (IIIa) or (IIIb) -Cl -CN -Cl DFQ (ma) or (IIIb) -Cl -CN -Br DFR (ERa) or (lIb)-Cl-CN-I DFS (IIIa) or (IIIb) -Cl -NH2 -H DFT (IIIa) or (IIIb) -Cl -NH2 -CH3 DFU (IIIa) or (IIIb) -Cl -NH2 -n-propyl DFV (IIIa) or (IIIb) -Cl -NH2 -n-butyl

Compound R1 R3 R4 DFW (IIIa) or (IIIb) -Cl -NH2 -t-butyl DFX (nia) or (IIIb) -Cl -NH2 -iso-butyl DFY (ma) or (IIIb) -Cl -NH2 -OCH3 DFZ (ma) or (IIIb) -Cl -NH2 -OC2H5 DGA (IIIa) or (IIIb) -Cl -NH2 -OC3H7 DGB (nia) or (IIIb) -Cl -NH2 -CHF2 DGC (IIIa) or (IIIb) -Cl -NH2 -CF3 DGD (IIIa) or (IIIb) -Cl -NH2 -CHCl2 DGE(IIIa) or (IIIb) -Cl -NH2 -CCl3 DGF(IIIa) or (IIIb) -Cl -NH2 -F DGG (IIIa) or (Ib)-Cl-NH2-Cl DGH (nia) or (IIIb) -Cl -NH2 -Br DGI (IIIa) or (IIIb) -Cl -NH2 -I DGJ (IIIa) or (IIIb) -Cl -CH3 -H DGK (IIIa) or (Ib)-Cl-CH3-CH3 DGL (IIIa) or (IIIb) -Cl -CH3 -n-propyl DGM (IIIa) or (lb)-Cl-CH3-n-butyl DGN (IIIa) or (IIIb) -Cl -CH3 -t-butyl DGO (IIIa) or (IIIb) -Cl -CH3 -iso-butyl DGP (IIIa) or (IIIb) -Cl -CH3 -OCH3 DGQ (IIIa) or (IIIb) -Cl -CH3 -OC2H5 DGR (nia) or (IIIb) -Cl -CH3 -OC3H7 DGS (IIIa) or (IIIb) -Cl -CH3 -CHF2 DGT (IIIa) or (IIIb) -Cl -CH3 -CF3 DGU (IIIa) or (IIIb) -Cl -CH3 -CHCl2 DGV (IIIa) or (IIIb) -Cl -CH3 -CCl3 DGW (IIIa) or (IIIb) -Cl -CH3 -F DGX (IIIa) or (IIIb) -Cl -CH3 -Cl

Compound R1 R3 R4 DGY (nia) or (IIIb) -Cl -CH3 -Br DGZ (IIIa) or (IIIb) -Cl -CH3, -I DHA (IIIa) -CHCl2 -H -H DHB (IIIa) -CHCl2 -H -CH3 DHC (IIIa) -CHCl2 -H -n-propyl DHD (IIIa) -CHCl2 -H -n-butyl DHE (IIIa) -CHCl2 -H -t-butyl DHF (IIIa) -CHCl2 -H -iso-butyl DHG (IIIa) -CHCl2 -H -OCH3 DHH (IIIa) -CHCl2 -H -OC2H5 DHI (IIIa) -CHCl2 -H -OC3H7 DHJ(IIIa) -CHCl2 -H -CHF2 DHK (IIIa) -CHCl2 -H -CF3 DHL(IIIa) -CHCl2 -H -CHCl2 DHM (IIIa) -CHCl2 -H -CCl3 DHN(IIIa) -CHCl2 -H -F DHO(IIIa) -CHCl2 -H -Cl DHP (IIIa) -CHCl2 -H -Br DHQ (HIa)-CHC12-H-I DHR (IIIa) or (IIIb) -CHCl2 -OH -H DHS (nia) or (IIIb) -CHCl2 -OH -CH3 DHT (IIIa) or (IIIb) -CHCl2 -OH -n-propyl DHU (IIIa) or (IIIb) -CHCl2 -OH -n-butyl DHV (Ea) or (IIb)-CHC12-OH-t-butyl DHW (IIIa) or (IIIb) -CHCl2 -OH -iso-butyl DHX (IIIa) or (IIIb) -CHCl2 -OH -OCH3 DHY (ma) or (IIIb) -CHCl2 -OH -OC2H5 DHZ (nia) or (IIIb) -CHCl2 -OH -OC3H7

Compound Ri R3 R4 DIA (IIIa) or (IIIb) -CHCl2 -OH -CHF2 DIB (IIIa) or (IIIb) -CHCl2 -OH -CF3 DIC (IIIa) or (IIIb) -CHCl2 -OH -CHCl2 DID (ma) or (IIIb) -CHCl2 -OH -CCl3 DIE (IIIa) or (IIIb) -CHCl2 -OH -F DIF (IIIa) or (IIIb) -CHCl2 -OH -Cl DIG (IIIa) or (IIIb) -CHCl2 -OH -Br DIR (IIIa) or (IIIb) -CHCl2 -OH -I DII(IIIa) or (mb)-CHC12-F-H DIJ (ma) or (IIIb) -CHCl2 -F -CH3 DIK (IIIa) or (IIIb) -CHCl2 -F -n-propyl DIL (nia) or (IIIb) -CHCl2 -F -n-butyl DIM (ma) or (IIIb) -CHCl2 -F -t-butyl DIN (IIIa) or (IIIb) -CHCl2 -F -iso-butyl DIO (IIIa) or (IIIb) -CHCl2 -F -OCH3 DIP (IIIa) or (IIIb) -CHCl2 -F -OC2H5 DIQ (IIIa) or (IIIb) -CHCl2 -F -OC3H7 DIR (IIIa) or (IIIb) -CHCl2 -F -CHF2 DIS (IIIa) or (IIIb) -CHCl2 -F -CF3 DIT (IIIa) or (IIIb) -CHCl2 -F -CHCl2 DIU (IIIa) or (IIIb) -CHCl2 -F -CCl3 DIV (IIIa) or (IIIb) -CHCl2 -F -F DIW (IIIa) or (IIIb) -CHCl2 -F -Cl DIX (IIIa) or (IIIb) -CHCl2 -F -Br DIY (IIIa) or (IIIb) -CHCl2 -F -I DIZ (IIIa) or (IIIb) -CHCl2 -Cl -H DJA (IIIa) or (IIIb) -CHCl2 -Cl -CH3 DJB (IIIa) or (IIIb)-CHC12-Cl-n-propyl

Compound Ri R3 R4 DJC (IIIa) or (IIIb) -CHCl2 -Cl -n-butyl DJD (IIIa) or (IIIb) -CHCl2 -Cl -t-butyl DJE (nia) or (IIIb) -CHCl2 -Cl -iso-butyl DJF (IIIa) or (IIb)-CHCl2-Cl-OCH3 DJG (IIIa) or (IIIb) -CHCl2 -Cl -OC2H5 DJH (ma) or (IIIb) -CHCl2 -Cl -OC3H7 DJI (IIIa) or (IIIb) -CHCl2 -Cl -CHF2 DJJ (IIIa) or (Ib)-CHCl2-Cl-CF3 DJK (IIIa) or (IIIb) -CHCl2 -Cl -CHCl2 DJL (IIIa) or (IIIb) -CHCl2 -Cl -CCl3 DJM (IIIa) or (IIIb) -CHCl2 -Cl -F DJN (ma) or (IIIb) -CHCl2 -Cl -Cl DJO (IIIa) or (IIIb) -CHCl2 -Cl -Br DJP (IIIa) or (IIIb) -CHCl2 -Cl -I DJQ (IIIa) or (IIIb) -CHCl2 -Br -H DJR(IIIa) or (IIIb) -CHCl2 -Br -CH3 DJS (IIIa) or (IIIb) -CHCl2 -Br -n-propyl DJT (IIIa) or (IIIb) -CHCl2 -Br -n-butyl DJU (IIIa) or (IIIb) -CHCl2 -Br -t-butyl DJV (IIIa) or (IIIb) -CHCl2 -Br -iso-butyl DJW (IIIa) or (IIIb) -CHCl2 -Br -OCH3 DJX (IIIa) or (IIIb) -CHCl2 -Br -OC2H5 DJY (IIIa) or (IIIb) -CHCl2 -Br -OC3H7 DJZ (IIIa) or (IIIb) -CHCl2 -Br -CHF2 DKA (IIIa) or (IIIb) -CHCl2 -Br -CF3 DKB (IIIa) or (IIIb) -CHCl2 -Br -CHCl2 DKC (IIIa) or (IIIb) -CHCl2 -Br -CCl3 DKD (IIIa) or (IIIb) -CHCl2 -Br -F

Compound Ri R3 R4 DKE (nia) or (IIIb) -CHCl2 -Br -Cl DKF (nia) or (IIIb) -CHCl2 -Br -Br DKG (IIIa) or (IIIb) -CHCl2 -Br -I DKH (nia) or (IIIb) -CHCl2 -I -H DKI (IIIa) or (IIIb) -CHCl2 -I -CH3 DKJ (IIIa) or (IIIb) -CHCl2 -I -n-propyl DKK (IIIa) or (IIIb) -CHCl2 -I -n-butyl DKL (IIIa) or (IIIb) -CHCl2 -I -t-butyl DKM (IIIa) or (IIIb) -CHCl2 -I -iso-butyl DKN (IIIa) or (IIIb) -CHCl2 -I -OCH3 DKO (IIIa) or (IIIb) -CHCl2 -I -OC2H5 DKP (IIIa) or (IIIb) -CHCl2 -I -OC3H7 DKQ (IIIa) or (IIIb) -CHCl2 -I -CHF2 DKR (ma) or (IIIb) -CHCl2 -I -CF3 DKS (IIIa) or (IIIb) -CHCl2 -I -CHCl2 DKT (IIIa) or (IIIb) -CHCl2 -I -CCl3 DKU (IIIa) or (IIIb) -CHCl2 -I -F DKV (IIIa) or (IIIb) -CHCl2 -I -Cl DKW (IIIa) or (IIIb) -CHCl2 -I -Br DKX (IIIa) or (IIIb) -CHCl2 -I -I DKY (ma) or (IIIb) -CHCl2 -NO2 -H DKZ (IIIa) or (HIb)-CHClz-NO2-CH3 DLA (nia) or (IIIb) -CHCl2 -NO2 -n-propyl DLB (ma) or (mb)-CHCl2-NO2-n-butyl DLC (ma) or (IIIb) -CHCl2 -NO2 -t-butyl DLD (IIIa) or (IIIb) -CHCl2 -NO2 -iso-butyl DLE (IIIa) or (IIIb) -CHCl2 -NO2 -OCH3 DLF (IIIa) or (IIIb) -CHCl2 -NO2 -OC2H5

Compound R1 R3 R4 DLG (nia) or (IIIb) -CHCl2 -NO2 -OC3H7 DLH (nia) or (IIIb) -CHCl2 -NO2 -CHF2 DLI(IIIa) or (IIIb) -CHCl2 -NO2 -CF3 DLJ (DIa) or (IIIb) -CHCl2 -NO2 -CHCl2 DLK (IIIa) or (IIIb) -CHCl2 -NO2 -CCl3 DLL (E a) or (IIIb) -CHCl2 -NO2 -F DLM (IIIa) or (IIIb) -CHCl2 -NO2 -Cl DLN (IIIa) or (IIIb) -CHCl2 -NO2 -Br DLO (nia) or (IIIb) -CHCl2 -NO2 -I DLP (nia) or (IIIb) -CHCl2 -CN -H DLQ (IIIa) or (IIIb) -CHCl2 -CN -CH3 DLR (DIa) or (IIIb) -CHCl2 -CN -n-propyl DLS (nia) or (IIIb) -CHCl2 -CN -n-butyl DLT (nia) or (IIIb) -CHCl2 -CN -t-butyl DLU (IIIa) or (IIIb) -CHCl2 -CN -iso-butyl DLV (IIIa) or (lb)-CHC12-CN-OCH3 DLW (ina) or (IIIb) -CHCl2 -CN -OC2H5 DLX (nia) or (IIIb) -CHCl2 -CN -OC3H7 DLY (IIIa) or (IIIb) -CHCl2 -CN -CHF2 DLZ(IIIa) or (IIIb) -CHCl2 -CN -CF3 DMA (IIIa) or (IIIb) -CHCl2 -CN -CHCl2 DMB (IIIa) or (IIIb) -CHCl2 -CN -CCl3 DMC (IIIa) or (IIIb) -CHCl2 -CN -F DMD (IIIa) or (IIIb) -CHCl2 -CN -Cl DME (IIIa) or (IIIb) -CHCl2 -CN -Br DMF (ma) or (DIb)-CHCl2-CN-I DMG (nia) or (IIIb) -CHCl2 -NH2 -H DMH (ma) or (IIIb) -CHCl2 -NH2 -CH3

Compound R1 R3 R4 DMI (nia) or (IIIb) -CHCl2 -NH2 -n-propyl DMJ (IIIa) or (IIIb) -CHCl2 -NH2 -n-butyl DMK (ma) or (IIIb) -CHCl2 -NH2 -t-butyl DML (nia) or (IIIb) -CHCl2 -NH2 -iso-butyl DMM (ma) or (IIIb) -CHCl2 -NH2 -OCH3 DMN (IIIa) or (IIIb) -CHCl2 -NH2 -OC2H5 DMO (Illa) or (IIIb) -CHCl2 -NH2 -OC3H7 DMP (IIIa) or (IIIb) -CHCl2 -NH2 -CHF2 DMQ (ma) or (IIIb) -CHCl2 -NH2 -CF3 DMR (IIIa) or (IIIb) -CHCl2 -NH2 -CHCl2 DMS (IIIa) or (IIIb) -CHCl2 -NH2 -CCl3 DMT (IIIa) or (IIIb) -CHCl2 -NH2 -F DMU (IIIa) or (IIIb) -CHCl2 -NH2 -Cl DMV (IIIa) or (IIIb) -CHCl2 -NH2 -Br DMW (IIIa) or (IIIb) -CHCl2 -NH2 -I DMX (IIIa) or (IIIb) -CHCl2 -CH3 -H DMY (IIIa) or (IIIb) -CHCl2 -CH3 -CH3 DMZ (IIIa) or (IIIb) -CHCl2 -CH3 -n-propyl DNA (ma) or (IIIb) -CHCl2 -CH3 -n-butyl DNB (IIIa) or (IIIb) -CHCl2 -CH3 -t-butyl DNC (IIIa) or (Eb)-CHC12-CH3-iso-butyl DND (IIIa) or (IIIb) -CHCl2 -CH3 -OCH3 DNE (IIIa) or (IIIb) -CHCl2 -CH3 -OC2H5 DNF (IIIa) or (IIIb) -CHCl2 -CH3 -OC3H7 DNG(IIIa) or (IIIb) -CHCl2 -CH3 -CHF2 DNH (IIIa) or (IIIb) -CHCl2 -CH3 -CF3 DNI (IIIa) or (IIIb) -CHCl2 -CH3 -CHCl2 DNJ (ma) or (IIIb) -CHCl2 -CH3 -CCl3

Compound Ri R3 R4 DNK (IIIa) or (IIIb) -CHCl2 -CH3 -F DNL (ma) or (IIIb) -CHCl2 -CH3 -Cl DNM (IIIa) or (IIIb) -CHCl2 -CH3 -Br DNN (nia) or (IIIb) -CHCl2 -CH3 -I DNO (IIIa) -CF3 -H -H DNP (IIIa) -CF3 -H -CH3 DNQ (IIIa) -CF3 -H -n-propyl DNR (IIIa) -CF3 -H -n-butyl DNS (IIIa) -CF3 -H -t-butyl DNT (IIIa) -CF3 -H -iso-butyl DNU (IIIa) -CF3 -H -OCH3 DNV (IIIa) -CF3 -H -OC2H5 DNW (IIIa) -CF3 -H -OC3H7 DNX (IIIa) -CF3 -H -CHF2 DNY (IIIa) -CF3 -H -CF3 DNZ (IIIa) -CF3 -H -CHCl2 DOA (IIIa) -CF3 -H -CCl3 DOB (IIIa) -CF3 -H -F DOC (IIIa) -CF3 -H -Cl DOD (Ia)-CF3-H-Br DOE (ma)-CFg-H-I DOF (IIIa) or (IIIb) -CF3 -OH -H DOG (IIIa) or (IIIb) -CF3 -OH -CH3 DOH (IIIa) or (IIIb) -CF3 -OH -n-propyl DOI (Ea) or. (IIIb) -CF3 -OH -n-butyl DOJ (IIIa) or (IIIb) -CF3 -OH -t-butyl DOK (IIIa) or (IIIb) -CF3 -OH -iso-butyl DOL (IIIa) or (IIIb) -CF3 -OH -OCH3

Compound R1 R3 R4 DOM (IIIa) or (IIb)-CF3-OH-OC2Hs DON (IIIa) or (IIIb) -CF3 -OH -OC3H7 DOO (IIIa) or (IIIb) -CF3 -OH -CHF2 DOP (IIIa) or (IIIb) -CF3 -OH -CF3 DOQ (Ea) or (IIIb) -CF3 -OH -CHCl2 DOR (IIIa) or (IIIb) -CF3 -OH -CCl3 DOS (IIIa) or (IIIb) -CF3 -OH -F DOT (IIIa) or (IIIb)-CF3-OH-Cl DOU (IIIa) or (IIIb) -CF3 -OH -Br DOV (IIIa) or (IIIb) -CF3 -OH -I DOW (IIIa) or (IIIb)-CF3-F-H DOX (IIIa) or (IIIb) -CF3 -F -CH3 DOY (ma) or (IIIb) -CF3 -F -n-propyl DOZ (IIIa) or (IIIb) -CF3 -F -n-butyl DPA (IIIa) or (IIIb) -CF3 -F -t-butyl DPB (IIIa) or (IIIb) -CF3 -F -iso-butyl DPC (IIIa) or (IIIb) -CF3 -F -OCH3 DPD (IIIa) or (IIIb) -CF3 -F -OC2H5 DPE (IIIa) or (IIIb) -CF3 -F -OC3H7 DPF (IIIa) or (IIIb) -CF3 -F -CHF2 DPG (IIIa) or (Ib)-CF3-F-CF3 DPH (ma) or (IIIb)-CF3-F-CHCl2 DPI (IIIa) or (IIIb) -CF3 -F -CCl3 DPJ (IIIa) or (IIIb) -CF3 -F -F DPK (IIIa) or (IIIb) -CF3 -F -Cl DPL (IIIa) or (Ib)-CF3-F-Br DPM (IIIa) or (IIIb) -CF3 -F -I DPN (IIIa) or (IIIb) -CF3 -Cl -H

Compound Rl R3 R4 DPO (IIIa) or (IIIb) -CF3 -Cl -CH3 DPP (nia) or (IIIb) -CF3 -Cl -n-propyl DPQ (IIIa) or (IIIb) -CF3 -Cl -n-butyl DPR (IIIa) or (IIIb) -CF3 -Cl -t-butyl DPS (IIIa) or (IIIb) -CF3 -Cl -iso-butyl DPT (IIIa) or (IIIb) -CF3 -Cl -OCH3 DPU (IIIa) or (IIIb) -CF3 -Cl -OC2H5 DPV (Ia) or (IIIb)-CF3-Cl-OC3H7 DPW (IIIa) or (IIIb) -CF3 -Cl -CHF2 DPX (IIIa) or (IIIb) -CF3 -Cl -CF3 DPY (nia) or (IIIb) -CF3 -Cl -CHCl2 DPZ (IIIa) or (IIIb) -CF3 -Cl -CCl3 DQA (IIIa) or (IIIb) -CF3 -Cl -F DQB (ma) or (IIIb) -CF3 -Cl -Cl DQC (IIIa) or (IIIb) -CF3 -Cl -Br DQD (ma) or (IIIb) -CF3 -Cl -I DQE (IIIa) or (IIIb) -CF3 -Br -H DQF (IIIa) or (IIIb) -CF3 -Br -CH3 DQG (IIIa) or (IIIb) -CF3 -Br -n-propyl DQH (IIIa) or (IIIb) -CF3 -Br -n-butyl DQI (ma) or (IIIb) -CF3 -Br -t-butyl DQJ (IIIa) or (inb)-CFg-Br-iso-butyl DQK (IIIa) or (IIIb) -CF3 -Br -OCH3 DQL (IIIa) or (Ellb)-CF3-Br-OC2H5 DQM (IIIa) or (IIIb) -CF3 -Br -OC3H7 DQN (IIIa) or (IIIb) -CF3 -Br -CHF2 DQO (ma) or (IIIb) -CF3 -Br -CF3 DQP (IIIa) or (IIIb) -CF3 -Br -CHCl2

Compound R1 R3 R4 DQQ (IIIa) or (IIIb) -CF3 -Br -CCl3 DQR (IIIa) or (IIIb) -CF3 -Br -F DQS (nia) or (IIIb)-CF3-Br-Cl DQT (IIIa) or (IIIb) -CF3 -Br -Br DQU (IIIa) or (IIIb) -CF3 -Br -I DQV (ma) or (mb)-CF3-I-H DQW (IIIa) or (IIIb) -CF3 -I -CH3 DQX (IIIa) or (IlIb)-CF3-I-n-propyl DQY (IIIa) or (IIIb) -CF3 -I -n-butyl DQZ (IIIa) or (IIIb) -CF3 -I -t-butyl DRA(IIIa) or (IIIb) -CF3 -I iso-butyl DRB (ma) or (IIIb)-CF3-I-OCH3 DRC (IIIa) or (IIIb) -CF3 -I -OC2H5 DRD (ma) or (IIIb)-CF3-I-OC3H7 DRE(IIIa) or (IIIb) -CF3 -I -CHF2 DRF (IIIa) or (IIIb) -CF3 -I -CF3 DRG(IIIa) or (IIIb) -CF3 -I -CHCl2 DRG(IIIa) or (IIIb) -CF3 -I -CCl3 DRI (IIIa) or (IIIb) -CF3 -I -F DRJ (IIIa) or (IIIb) -CF3 -I -Cl DRK (IIIa) or (IIIb) -CF3 -I -Br DRL (IIIa) or (IIIb) -CF3 -I -I DRM (IIIa) or (IIIb) -CF3 -NO2 -H DRN (IIIa) or (IIIb) -CF3 -NO2 -CH3 DRO(IIIa) or (IIIb) -CF3 -ON2 -n-propyl DRP (ma) or (IIIb) -CF3 -NO2 -n-butyl DRQ (ina) or (IIIb) -CF3 -NO2 -t-butyl DRR(IIIa) or (IIIb) -CF3 -NO2 -iso-butyl

Compound R, R3 R4 DRS (nia) or (IIIb) -CF3 -NO2 -OCH3 DRT (nia) or (IIIb) -CF3 -NO2 -OC2H5 DRU (IIIa) or (IIIb) -CF3 -NO2 -OC3H7 DRV (nia) or (IIIb) -CF3 -NO2 -CHF2 DRW (ma) or (IIIb) -CF3 -NO2 -CF3 DRX (IIIa) or (IIIb) -CF3 -NO2 -CHCl2 DRY (IIIa) or (IIIb) -CF3 -NO2 -CCl3 DRZ (nia) or (IIIb) -CF3 -NO2 -F DSA (IIIa) or (IIIb) -CF3 -NO2 -Cl DSB (IIIa) or (IIIb) -CF3 -NO2 -Br DSC (IIIa) or (IIIb) -CF3 -NO2 -I DSD (IIIa) or (IIIb) -CF3 -CN -H DSE (nia) or (IIIb) -CF3 -CN -CH3 DSF (IIIa) or (IIIb) -CF3 -CN -n-propyl DSG (IIIa) or (IIIb) -CF3 -CN -n-butyl DSH (IIIa) or (IIIb) -CF3 -CN -t-butyl DSI (IIIa) or (lb)-CF3-CN-iso-butyl DSJ(IIIa) or (IIIb) -CF3 -CN -OCH3 DSK (IIIa) or (IIIb) -CF3 -CN -OC2H5 DSL (IIIa) or (IIIb) -CF3 -CN -OC3H7 DSM (IIIa) or (IIIb)-CF3-CN-CHF2 DSN (IIIa) or (IIIb) -CF3 -CN -CF3 DSO (nia) or (IIIb) -CF3 -CN -CHCl2 DSP (IIIa) or (IIIb) -CF3 -CN -CCl3 DSQ (IIIa) or (IIIb) -CF3 -CN -F DSR (IIIa) or (IIIb) -CF3 -CN -Cl DSS (IIIa) or (IIIb) -CF3 -CN -Br DST (IIIa) or (IIIb) -CF3 -CN -I

Compound R, R3 R4 DSU (IIIa) or (IIIb) -CF3 -NH2 -H DSV (Ifla) or (IIIb) -CF3 -NH2 -CH3 DSW (IIIa) or (IIIb) -CF3 -NH2 -n-propyl DSX (IIIa) or (IIIb)-CF3-NH2-n-butyl DSY (IIIa) or (IIIb) -CF3 -NH2 -t-butyl DSZ (IIIa) or (Ib)-CF3-NH2-iso-butyl DTA (IIIa) or (IIIb) -CF3 -NH2 -OCH3 DTB (IIIa) or (IIIb) -CF3 -NH2 -OC2H5 DTC (IIIa) or (IIIb) -CF3 -NH2 -OC3H7 DTD (IIIa) or (IIIb) -CF3 -NH2 -CHF2 DTE (nia) or (IIIb) -CF3 -NH2 -CF3 DTF (IIIa) or (IIIb) -CF3 -NH2 -CHCl2 DTG (IIIa) or (IIIb) -CF3 -NH2 -CCl3 DTH (IIIa) or (IIIb) -CF3 -NH2 -F DTI (IIIa) or (IIIb) -CF3 -NH2 -Cl DTJ (ma) or (IIIb)-CF3 NH2-Br DTK (nia) or (IIIb) -CF3 -NH2 -I DTL (IIIa) or (IIIb) -CF3 -CH3 -H DTM (IIIa) or (IIIb) -CF3 -CH3 -CH3 DTN (IIIa) or (IIIb) -CF3 -CH3 -n-propyl DTO (nia) or (IIIb) -CF3 -CH3 -n-butyl DTP (IIIa) or (IIIb) -CF3 -CH3 -t-butyl DTQ (IIIa) or (IIIb) -CF3 -CH3 -iso-butyl DTR (IIIa) or (Ib)-CF3-CH3-OCH3 DTS (IIIa) or (IIIb) -CF3 -CH3 -OC2H5 DTT (IIIa) or (IIIb) -CF3 -CH3 -OC3H7 DTU (IIIa) or (IIIb) -CF3 -CH3 -CHF2 DTV (nia) or (IIIb) -CF3 -CH3 -CF3

Compound R1 R3 R4 DTW (nia) or (IIIb) -CF3 -CH3 -CHCl2 DTX (ma) or (IIIb) -CF3 -CH3 -CCl3 DTY (ma) or (IIIb) -CF3 -CH3 -F DTZ (IIIa) or (IIIb) -CF3 -CH3 -Cl DUA (IIIa) or (IIIb) -CF3 -CH3 -Br DUB (IIIa) or (IIIb) -CF3 -CH3 -I DUC (IIIa) -NO2 -H -H DUD (IIIa) -NO2 -H -CH3 DUE(IIIa) -NO2 -H -n-propyl DUF (IIIa) -NO2 -H -n-butyl DUG (Ia)-NO2-H-t-butyl DUH (IIIa) -NO2 -H -iso-butyl DUI (IIIa) -NO2 -H -OCH3 DUJ (IIIa) -NO2 -H -OC2H5 DUK (IIIa) -NO2 -H -OC3H7 DUL (IIIa) -NO2 -H -CHF2 DUM (IIIa) -NO2 -H -CF3 DUN (IIIa) -NO2 -H -CHCl2 DUO (IIIa) -NO2 -H -CCl3 DUP (IIIa) -NO2 -H -F DUQ (IIIa)-N02-H-Cl DUR (IIIa) -NO2 -H -Br DUS (IIIa) -NO2 -H -I DUT (IIIa) or (IIIb) -NO2 -OH -H DUU (IIIa) or (IIIb) -NO2 -OH -CH3 DUV (IIIa) or (IIIb) -NO2 -OH -n-propyl DUW (IIIa) or (IIIb) -NO2 -OH -n-butyl DUX (IIIa) or (IIIb) -NO2 -OH -t-butyl

Compound Ri R3 R4 DUY (IIIa) or (IIIb) -NO2 -OH -iso-butyl DUZ (IIIa) or (IIIb) -NO2 -OH -OCH3 DVA (IIIa) or (IIIb) -NO2 -OH -OC2H5 DVB (IIIa) or (IIIb) -NO2 -OH -OC3H7 DVC (IIIa) or (IIIb) -NO2 -OH -CHF2 DVD (nia) or (IIIb) -NO2 -OH -CF3 DVE (ma) or (IIIb) -NO2 -OH -CHCl2 DVF (IIIa) or (IIIb) -NO2 -OH -CCl3 DVG (IIIa) or (IIIb) -NO2 -OH -F DVH (IIIb) -NO2 -OH -Cl DVI (ma) or (IIIb) -NO2 -OH -Br DVJ (IIIa) or (IIIb) -NO2 -OH -I DVK (nia) or (IIIb) -NO2 -F -H DVL (IIIa) or (IIIb) -NO2 -F -CH3 DVM (IIIa) or (IIIb) -NO2 -F -n-propyl DVN (Ifla) or (IIIb) -NO2 -F -n-butyl DVO (IIIa) or (IIIb) -NO2 -F -t-butyl DVP (IIIa) or (IIIb) -NO2 -F -iso-butyl DVQ (nia) or (IIIb) -NO2 -F -OCH3 DVR (DIa) or (IIIb)-NO2-F-OC2H5 DVS (IIIa) or (IIIb) -NO2 -F -OC3H7 DVT (IIIa) or (IIIb) -NO2 -F -CHF2 DVU (nia) or (IIIb) -NO2 -F CF3 DVV (IIIa) or (IIIb) -NO2 -F -CHCl2 DVW (IIIa) or (IIIb) -NO2 -F -CCl3 DVX (MA) or (IIIb) -NO2 -F -F DVY (IIIa) or (IIIb)-NOz-F-Cl DVZ (IIIa) or (IIIb) -NO2 -F -Br

Compound R1 R3 R4 DWA (IIIa) or (IIIb) -NO2 -F -I DWB (ma) or (IIIb) -NO2 -Cl -H DWC (IIIa) or (IIIb) -NO2 -Cl -CH3 DWD (IIIa) or (IIIb) -NO2 -Cl -n-propyl DWE (IIIa) or (IIIb) -NO2 -Cl -n-butyl DWF (ma) or (IIIb) -NO2 -Cl -t-butyl DWG (IIIa) or (IIIb) -NO2 -Cl -iso-butyl DWH (IIIa) or (IIIb) -NO2 -Cl -OCH3 DWI (IIIa) or (IIIb) -NO2 -Cl -OC2H5 DWJ (IIIa) or (IIIb) -NO2 -Cl -OC3H7 DWK (IIIa) or (IIIb)-NO2-Cl-CHF2 DWL (IIIa) or (IIIb) -NO2 -Cl -CF3 DWM (IIIa) or (mb)-N02-Cl-CHC12 DWN (IIIa) or (IIIb) -NO2 -Cl -CCl3 DWO (IIIa) or (IIIb) -NO2 -Cl -F DWP (IIIa) or (IIIb) -NO2 -Cl -Cl DWQ (ma) or (IIIb) -NO2 -Cl -Br DWR (IIIa) or (IIIb) -NO2 -Cl -I DWS (IIIa) or (IIIb) -NO2 -Br -H DWT (IIIa) or (IIIb)-NO2-Br-CH3 DWU (IIIa) or (IIIb) -NO2 -Br -n-propyl DWV (ma) or (IIIb) -NO2 -Br -n-butyl DWW (IIIa) or (IIIb)-NO2-Br-t-butyl DWX (IIIa) or (IIIb) -NO2 -Br -iso-butyl DWY (IIIa) or (IIIb)-NO2-Br-OCH3 DWZ (IIIa) or (IIIb) -NO2 -Br -OC2H5 DXA (IIIa) or (IIIb) -NO2 -Br -OC3H7 DXB (nia) or (IIIb) -NO2 -Br -CHF2

Compound R1 R3 R4 DXC (nia) or (IIIb) -NO2 -Br -CF3 DXD (nia) or (IIIb) -NO2 -Br -CHCl2 DXE (IIIa) or (IIIb) -NO2 -Br -CCl3 DXF (nia) or (IIIb) -NO2 -Br -F DXG (ma) or (IIIb) -NO2 -Br -Cl DXH (IIIa) or (IHb)-NO,-Br-Br DXI (IIIa) or (IIIb) -NO2 -Br -I DXJ (IIIa) or (IIIb) -NO2 -I -H DXK (IIIa) or (IIIb) -NO2 -I -CH3 DXL (IIIa) or (IIIb) -NO2 -I -n-propyl DXM (IIIa) or (IIIb) -NO2 -I -n-butyl DXN (ma) or (IIIb) -NO2 -I -t-butyl DXO (ma) or (IIIb) -NO2 -I -iso-butyl DXP (IIIa) or(IIIb) -NO2 -I -OCH3 DXQ (IIIa) or (IIIb) -NO2 -I -OC2H5 DXR (IIIa) or (IIIb) -NO2 -I -OC3H7 DXS (IIIa) or (IIIb) -NO2 -I -CHF2 DXT (IIIa) or (IIIb) -NO2 -I -CF3 DXU (IIIa) or (IIIb) -NO2 -I -CHCl2 DXV (IIIa) or (IIIb) -NO2 -I -CCl2 DXW (IIIa) or (IIIb) -NO2 -I -F DXX (IIIa) or (IIIb) -NO2 -I -Cl DXY (IIIa) or (IIIb) -NO2 -I -Br DXZ (ma) or (IIIb) -NO2 -I -I DYA (IIIa) or (IIIb) -NO2 -NO2 -H DYB (IIIa) or (IIIb) -NO2 -NO2 -CH3 DYC (IIIa) or (IIIb) -NO2 -NO2 -n-propyl DYD (IIIa) or (IIIb) -NO2 -NO2 -n-butyl

Compound R1 R3 R4 DYE (IIIa) or (IIIb) -NO2 -NO2 -t-butyl DYF (ma) or (IIIb) -NO2 -NO2 -iso-butyl DYG (IIIa) or (IIIb) -NO2 -NO2 -OCH3 DYH (IIIa) or (IIIb) -NO2 -NO2 -OC2H5 DYI (nia) or (IIIb) -NO2 -NO2 -OC2H5 DYJ (ma) or (IIIb) -NO2 -NO2 -C DYK (IIIa) or (IIIb) -NO2 -NO2 -CF3 DYL (IIIa) or (IIIb) -NO2 -NO2 -CHCl2 DYM (IIIa) or (IIIb) -NO2 -NO2 -CCl3 DYN (IIIa) or (IIIb) -NO2 -NO2 -F DYO (IIIa) or (IIb)-NO2-NO2-Cl DYP (IIIa) or (IIIb) -NO2 -NO2 -Br DYQ (IIIa) or (IIIb) -NO2 -NO2 DYR (IIIa) or (IIIb) -NO2 -CN -H DYS (ma) or (IIIb) -NO2 -CN -CH3 DYT (ma) or (IIIb) -NO2 -CN -n-propyl DYU (IIIa) or (IIIb) -NO2 -CN -n-butyl DYV (ma) or (IIIb) -NO2 -CN -t-butyl DYW (ma) or (IIIb) -NO2 -CN -iso-butyl DYX (IIIa) or (IIIb) -NO2 -CN -OCH3 DYY (nia) or (IIIb) -NO2 -CN -OC2H5 DYZ (ma) or (IIIb) -NO2 -CN -OC3H7 DZA (IIIa) or (IIIb) -NO2 -CN -CHF2 DZB (IIIa) or (IIIb) -NO2 -CN -CF3 DZC (IIIa) or (IIIb) -NO2 -CN -CHCl2 DZD (Illa) or (IIIb) -NO2 -CN -CCl3 DZE(IIIa) or (IIIb) -NO2 -CN -F DAF(IIIa) or (IIIb) -NO2 -CN -Cl

Compound R1 R3 R4 DZG (IIIa) or (IIIb) -NO2 -CN -Br DZH (IIIa) or (IIIb) -NO2 -CN -I DZI (IIIa) or (IIIb) -NO2 -NH2 -H DZJ (nia) or (IIIb) -NO2 -NH2 -CH3 DZK (nia) or (IIIb) -NO2 -NH2 -n-propyl DZL (nia) or (IIIb) -NO2 -NH2 -n-butyl DZM (IIIa) or (IIIb) -NO2 -NH2 -t-butyl DZN (IIIa) or (IIIb) -NO2 -NH2 -iso-butyl DZO(IIIa) or (IIIb) -NO2 -NH2 -OCH3 DZP (IIIa) or (IIIb) -NO2 -NH2 -OC2H5 DZQ (nia) or (IIIb) -NO2 -NH2 -OC3H7 DZR (nia) or (IIIb) -NO2 -NH2 -CHF2 DZS (ma) or (IIIb) -NO2 -NH2 -CF3 DZT (IIIa) or (IIIb) -NO2 -NH2 -CHCl2 DZU (IIIa) or (IIIb) -NO2 -NH2 -CCl3 DZV (IIIa) or (IIIb) -NO2 -NH2 -F DZW (IIIa) or (IIIb) -NO2 -NH2 -Cl DZX (IIIa) or (IIIb) -NO2 -NH2 -Br DZY (IIIa) or (IIIb) -NO2 -NH2 -I DZZ (IIIa) or (IIIb) -NO2 -CH3 -H EAA (IIIa) or (IIIb) -NO2 -CH3 -CH3 EAB (IIIa) or (IIIb) -NO2 -CH3 -n-propyl EAC (IIIa) or (IIIb) -NO2 -CH3 -n-butyl EAD (IIIa) or (IIIb) -NO2 -CH3 -t-butyl EAE (IIIa) or (IIIb) -NO2 -CH3 -iso-butyl EAF (ma) or (IIIb) -NO2 -CH3 -OCH3 EAG (MA) or (IIIb) -NO2 -CH3 -OC2H5 EAH (IIIa) or (IIIb) -NO2 -CH3 -OC3H7

Compound R1 Ru tu BAI (IIIa) or (IIIb) -NO2 -CH3 -CHF2 EAJ (nia) or (IIIb) -NO2 -CH3 -CF3 EAK (IIIa) or (IIIb) -NO2 -CH3 -CHCl2 EAL (IIIa) or (IIIb) -NO2 -CH3 -CCl3 EAM (IIIa) or (IIIb) -NO2 -CH3 -F EAN (IIIa) or (IIIb)-NO2-CH3-Cl EAO (ma) or (IIIb) -NOs -CH3 -Br EAP(IIIa) or (IIIb) -NO2 -CH3 -I EAQ(IIIa) -CN -H -H EAR (Ea)-CN-CH3 EAS (Ia)-CN-H-n-propyl EAT (IIIa) -CN -H -n-butyl EAU(IIIa) -CN -H -t-butyl EAV(IIIa) -CN -H -iso-butyl EAW (nia)-CN-H-OCHg EAX (IIIa) -CN -H -OC2H5 EAY (IIIa) -CN -H -OC3H7 EAZ (IIIa) -CN -H -CHF2 EBA (IIIa) -CN -H -CF3 EBB(IIIa) -CN -H -CHCl2 EBB(IIIa) -CN -H -CCl3 EBD (IIIa) -CN -H -F EBE (IIIa) -CN -H -Cl EBF (ina)-CN-H-Br EBG(IIIa) -CN -H -I EBH(IIIa) or (IIIb) -CN -OH -H EBI (IIIa) or (IIIb) -CN -OH -CH3 EBJ (IIIa) or (IIIb) -CN -OH -n-propyl

Compound Rl R3 R4 EBK (IIIa) or (IIIb) -CN -OH -n-butyl EBL (IIIa) or (IIIb) -CN -OH -t-butyl EBM (nia) or (IIIb) -CN -OH -iso-butyl EBN (IIIa) or (IIb)-CN-OH-OCH3 EBO (IIIa) or (IIb)-CN-OH-OC2Hs EBP (IIIa) or (IIIb) -CN -OH -OC3H7 EBQ (IIIa) or (IIIb) -CN -OH -CHF2 EBR (IIIa) or (IIIb) -CN -OH -CF3 EBS (IIIa) or (IIIb) -CN -OH -CHCl2 EBT (IIIa) or (IIIb) -CN -OH -CCl3 EBU (IIIa) or (IIIb) -CN -OH -F EBV (IIIa) or (IIIb) -CN -OH -Cl EBW (IIIa) or (IHb)-CN-OH-Br EBX (IIIa) or (IIIb) -CN -OH -I EBY (MA) or (llb)-CN-F-H EBZ (IIIa) or (IIIb) -CN -F -CH3 ECA (DIa) or (IIIb) -CN -F -n-propyl ECB (IIIa) or (IIIb) -CN -F -n-butyl ECC (IIIa) or (IIIb) -CN -F -t-butyl ECD (IIIa) or (IIb)-CN-F-iso-butyl ECE (IIIa) or (m b) -C N-F-O CH3 ECF (IIIa) or (IIb)-CN-F-OC2Hs ECG(IIIa) or (IIIb) -CN -F -OC3H7 ECH(IIIa) or (IIIb) -CN -F -CHF2 ECI(IIIa) or (IIIb) -CN -F -CF3 ECJ(IIIa) or (IIIb) -CN -F -CHCl2 ECK(IIIa) or (IIIb) -CN -F -CCl3 ECI (IIIa) or (IIIb) -CN -F -CF3 ECJ(IIIa) or (IIIb)-CN-F-CHCl2 ECK(IIIa) or (m b)-C N-F-CC13 ECL (IIIa) or (IIIb) -CN -F -F

Compound Ri R3 R4 ECM (IIIa) or (IIIb) -CN -F -Cl ECN (ma) or (HIb)-CN-F-Br ECO (IIIa) or (IIIb) -CN -F -I ECP (nia) or (IIIb) -CN -Cl -H ECQ (nia) or (IIIb) -CN -Cl -CH3 ECR (nia) or (IIIb) -CN -Cl -n-propyl ECS (IIIa) or (IIIb) -CN -Cl -n-butyl ECT (ma) or (IIIb) -CN -Cl -t-butyl ECU (IIIa) or (IIIb) -CN -Cl -iso-butyl ECV (nia) or (IIIb) -CN -Cl -OCH3 ECW (IIIa) or (IIIb) -CN -Cl -OC2H5 ECX (IIIa) or (IIIb) -CN -Cl -OC3H7 ECY (IIIa) or (IIIb) -CN -Cl -CHF2 ECZ (nia) or (IIIb) -CN -Cl -CF3 EDA (IIIa) or (IIIb) -CN -Cl -CHCl2 EDB (IIIa) or (IIIb) -CN -Cl -CCl3 EDC (ma) or (IIIb) -CN -Cl -F EDD (ma) or (IIIb) -CN -Cl -Cl EDE (ma) or (IIIb) -CN -Cl -Br EDF (IIIa) or (HIb)-CN-Cl-I EDG (IIIa) or (IIIb) -CN -Br -H EDH (IIIa) or (IIIb) -CN -Br -CH3 EDI (IIIa) or (IIIb) -CN -Br -n-propyl EDJ (IIIa) or (IIIb) -CN -Br -n-butyl EDK (ma) or (IIIb) -CN -Br -t-butyl EDL (IIIa) or (IIIb) -CN -Br -iso-butyl EDM (IIIa) or (IIIb) -CN -Br -OCH3 EDN (IIIa) or (IIIb) -CN -Br -OC2H5

Compound R1 R3 R4 EDO (IIIa) or (IIIb) -CN -Br -OC3H7 EDP (ma) or (IIIb) -CN -Br -CHF2 EDQ (nia) or (IIIb) -CN -Br -CF3 EDR (IIIa) or (IIIb) -CN -Br -CHCl2 EDS (Ea) or (IIIb) -CN -Br -CCl3 EDT (IIIa) or (IIIb) -CN -Br -F EDU (IIIa) or (IIIb) -CN -Br -Cl EDV (IIIa) or (IIIb) -CN -Br -Br EDW (DIa) or (IIIb) -CN -Br -I EDX (IIIa) or (IIIb)-CN-I-H EDY (IIIa) or (IIIb) -CN -I -CH3 EDZ (IIIa) or (IIIb) -CN -I -n-propyl EEA (IIIa) or (IIIb) -CN -I -n-butyl EEB (IIIa) or (IIIb) -CN -I -t-butyl EEC (IIIa) or (IIIb) -CN -I -iso-butyl EED (IIIa) or (IIIb) -CN -I -OCH3 EEE (IIIa) or (IIIb) -CN -I -OC2H5 EEF (nia) or (IIIb) -CN -I -OC3H7 EEG (IIIa) or (IIIb) -CN -I -CHF2 EEH (nia) or (IIIb) -CN -I -CF3 EEI (ma) or (IIIb) -CN -I -CHCl2 EEJ (IIIa) or (IIIb) -CN -I -CCl3 EEK (ma) or (IIIb) -CN -I -F EEL (nia) or (IIIb) -CN -I -Cl EEM (nia) or (IIIb) -CN -I -Br EEN (IIIa) or (IIIb) -CN -I -I EEO(IIIa) or (IIIb) -CN -NO2 -H EEP(IIIa) or (IIIb) -CN -NO2 -CH3

Compound R2 R3 R4 EEQ (IIIa) or (IIIb) -CN -NO2 -n-propyl EER (IIIa) or (IIIb) -CN -NO2 -n-butyl EES (nia) or (IIIb) -CN -NO2 -t-butyl EET (IIIa) or (IIb)-CN-NO2-iso-butyl EEU (IIIa) or (IIIb) -CN -NO2 -OCH3 EEV (IIIa) or (IIIb) -CN -NO2 -OC2H5 EEW (IIIa) or (IIIb) -CN -NO2 -OC3H7 EEX (IIIa) or (IIIb) -CN -NO2 -CHF2 EEY (IIIa) or (IIIb) -CN -NO2 -CF3 EEZ (nia) or (IIIb) -CN -NO2 -CHCl2 EFA (IIIa) or (IIIb) -CN -NO2 -CCl3 EFB (IIIa) or (IIIb) -CN -NO2 -F EFC (IIIa) or (IIIb) -CN -NO2 -Cl EFD (IIIa) or (IIIb) -CN -NO2 -Br EFE (IIIa) or (IIIb) -CN -NO2 -I EFF (E a) or (IIIb) -CN -CN -H EFG (IIIa) or (IIIb) -CN -CN -CH3 EFH (IIIa) or (lUb)-CN-CN-11-propy, EFI (nia) or (IHb)-CN-CN-n-butyl EFJ (IIIa) or (IIIb) -CN -CN -t-butyl EFK (IIIa) or (IIIb) -CN -CN -iso-butyl EFL (nia) or (IIIb) -CN -CN -OCH3 EFM (IIIa) or (Dib)-CN-CN-OC2H5 EFN (IIIa) or (IIIb) -CN -CN -OC3H7 EFO (nia) or (DIb)-CN-CN-CHF2 EFP(IIIa) or (IIIb) -CN -CN -CF3 EFQ (DIa) or (IIIb) -CN -CN -CHCl2 EFR (IIIa) or (IIIb) -CN -CN -CCl3

Compound EFS (ma) or (IIIb) -CN -CN -F EFT (ma) or (IIIb) -CN -CN -Cl EFU (IIIa) or (IIIb) -CN -CN -Br EFV (IIIa) or (IIIb) -CN -CN -I EFW (IIIa) or (IIIb) -CN -NH2 -H EFX (IIIa) or (IIIb) -CN -NH2 -CH3 EFY (IIIa) or (IIIb) -CN -NH2 -n-propyl EFZ (ma) or (IIb)-CN-NH2-n-butyl EGA (IIIa) or (IIIb) -CN -NH2 -t-butyl EGB (nia) or (IIIb) -CN -NH2 -iso-butyl EGC (IIIa) or (IIIb) -CN -NH2 -OCH3 EGD (ma) or (IIIb) -CN -NH2 -OC2H5 EGE (IIIa) or (IIIb) -CN -NH2 -OC3H7 EGF (IIIa) or (IIIb) -CN -NH2 -CHF2 EGG (IIIa) or (IIIb) -CN -NH2 -CF3 EGH (IIIa) or (DIb)-CN-NH2-CHCl2 EGI (IIIa) or (IIIb) -CN -NH2 -CCl3 EGJ (IIIa) or (IIIb) -CN -NH2 -F EGK (IIIa) or (IIIb) -CN -NH2 -Cl EGL (ma) or (IIIb) -CN -NH2 -Br EGM (IIIa) or (IIIb) -CN -NH2 -I EGN (ma) or (IIIb) -CN -CH3 -H EGO (IIIa) or (IIIb) -CN -CH3 -CH3 EGP (ma) or (IIIb) -CN -CH3 -n-propyl EGQ (IIIa) or (IIIb) -CN -CH3 -n-butyl EGR (nia) or (IIIb) -CN -CH3 -t-butyl EGS (IIIa) or (IIIb) -CN -CH3 -iso-butyl EGT (IIIa) or (IIIb) -CN -CH3 -OCH3

Compound Rl R3 R4 EGU (IIIa) or (IIIb) -CN -CH3 -OC2H5 EGV(IIIa) or (IIIb) -CN -CH3 -OC3H7 EGW (nia) or (IIIb) -CN -CH3 -CHF2 EGX (IIIa) or (IIIb) -CN -CH3 -CF3 EGY (nia) or (IIIb) -CN -CH3 -CHCl2 EGZ (ma) or (Eb)-CN-CH3-CC13 EHA (IIIa) or (IIIb) -CN -CH3 -F EHB (IIIa) or (IIIb) -CN -CH3 -Cl EHC (IIIa) or (IIIb) -CN -CH3 -Br EHD (IIIa) or (Eb)-CN-CH3 EHE (IIIa) -CH3 -H -H EHF (IIIa) -CH3 -H -CH3 EHG (IIIa) -CH3 -H -n-propyl EHH (Ia)-CH3-H-n-butyl EHI (IIIa) -CH3 -H -t-butyl EHJ (DHa)-CH3-H-iso-butyl EHK(IIIa) -CH3 -H -OCH3 EHL(IIIa) -CH3 -H -OC2H5 EHM (IIIa) -CH3 -H -OC3H7 EHN(IIIa) -CH3 -H -CHF2 EHO(IIIa) -CH3 -H -CF3 EHP(IIIa) -CH3 -H -CHCl2 EHQ (IIIa) -CH3 -H -CCl3 EHR (IIIa) -CH3 -H -F EHS (IIIa) -CH3 -H -Cl EHT(IIIa) -CH3 -H -Br EHU(IIIa) -CH3 -H -I EHV (IIIa) or (IIIb) -CH3 -OH -H

Compound R, R3 R4 EHW (IIIa) or (IIIb) -CH3 -OH -CH3 EHX (IIIa) or (IIIb)-CH3-OH-n-propyl EHY (IIIa) or (IIIb) -CH3 -OH -n-butyl EHZ (IIIa) or (IIIb) -CH3 -OH -t-butyl EIA (nia) or (IIIb) -CH3 -OH -iso-butyl EIB (IIIa) or (IIIb) -CH3 -OH -OCH3 EIC (IIIa) or (IIIb) -CH3 -OH -OC2H5 EID (IIIa) or (IIIb) -CH3 -OH -OC3H7 EIE (ma) or (IIIb) -CH3 -OH -CHF2 EIF (ma) or (Mb)-CH3-OH-CF3 EIG (nia) or (IIIb) -CH3 -OH -CHCl2 EIH (IIIa) or (IIIb) -CH3 -OH -CCl3 En (ma) or (IIIb) -CH3 -OH -F EU (IIIa) or (IIIb) -CH3 -OH -Cl EIK (IIIa) or (IIIb) -CH3 -OH -Br EIL (IIIa) or (IIIb) -CH3 -OH -I EIM (IIIa) or (IIIb)-CH3-F-H EIN (IIIa) or (IIIb) -CH3 -F -CH3 EIO (IIIa) or (IIIb) -CH3 -F -n-propyl EIP (IIIa) or (IIIb) -CH3 -F -n-butyl EIQ (nia) or (IIIb) -CH3 -F -t-butyl EIR (IIIa) or (IIIb)-CH3-F-iso-butyl EIS (IIIa) or (IIIb) -CH3 -F -OCH3 EIT (IIIa) or (IIIb) -CH3 -F -OC2H5 EIU (IIIa) or (IIIb) -CH3 -F -OC3H7 EIV (IIIa) or (IIIb) -CH3 -F -CHF2 EIW(IIIa) or (IIIb) -CH3 -F -CF3 EIX (IIIa) or (IIIb) -CH3 -F -CHCl2

Compound R1 R3 R4 EIY (IIIa) or (IIIb) -CH3 -F -CCl3 EIZ (IIIa) or (Iib)-CH3-F-F EJA (nia) or (IIIb) -CH3 -F -Cl EJB (ma) or (IIIb) -CH3 -F -Br EJC (IIIa) or (IIIb) -CH3 -F -I EJD (ma) or (IIIb) -CH3 -Cl -H EJE (nia) or (IIIb) -CH3 -Cl -CH3 EJF (nia) or (IIIb)-CH3-Cl-n-propyl EJG (IIIa) or (IIIb) -CH3 -Cl -n-butyl EJH (IIIa) or (IIIb) -CH3 -Cl -t-butyl EJI (IIIa) or (IIIb) -CH3 -Cl -iso-butyl EJJ (IIIa) or (IIIb) -CH3 -Cl -OCH3 EJK (IIIa) or (IIIb) -CH3 -Cl -OC2H5 EJL (IIIa) or (IIIb) -CH3 -Cl -OC3H7 EJM (IIIa) or (IIIb) -CH3 -Cl -CHF2 EJN (IIIa) or (IIIb) -CH3 -Cl -CF3 EJO (nia) or (IIIb) -CH3 -Cl -CHCl2 EJP (IIIa) or (IIIb) -CH3 -Cl -CCl3 EJQ(IIIa) or (IIIb) -CH3 -Cl -F EJR (IIIa) or (IIIb) -CH3 -Cl -Cl EJS (IIIa) or (IIIb) -CH3 -Cl -Br EJT (DIa) or (IIIb) -CH3 -Cl -I EJU (nia) or (IIIb) -CH3 -Br -H EJV(IIIa) or (IIIb) -CH3 -Br -CH3 EJW (IIIa) or (IIIb) -CH3 -Br -n-propyl EJX(IIIa) or (IIIb) -CH3 -Br -n-butyl EJY (IIIa) or (IIIb) -CH3 -Br -t-butyl EJZ (IIIa) or (IIIb) -CH3 -Br -iso-butyl

Compound Ri R3 R4 EKA (IIIa) or (IIIb) -CH3 -Br -OCH3 EKB (IIIa) or (IIIb) -CH3 -Br -OC2H5 EKC (IIIa) or (IIIb) -CH3 -Br -OC3H7 EKD (IIIa) or (IIIb) -CH3 -Br -CHF2 EKE (IIIa) or (IIIb) -CH3 -Br -CF3 EKF (IIIa) or (IIIb) -CH3 -Br -CHCl2 EKG (nia) or (IIIb) -CH3 -Br -CCl3 EKH (IIIa) or (IIIb) -CH3 -Br -F EKI (IIIa) or (IIIb) -CH3 -Br -Cl EKJ (ma) or (llb)-CH3-Br-Br EKK (IIIa) or (IIIb) -CH3 -Br -I EKL (Ea) or (IIIb) -CH3 -I -H EKM (nia) or (IIIb) -CH3 -I -CH3 EKN (IIIa) or (IIIb) -CH3 -I -n-propyl EKO (nia) or (IIIb) -CH3 -I -n-butyl EKP (IIIa) or (IIIb) -CH3 -I -t-butyl EKQ (IIIa) or (IIIb) -CH3 -I -iso-butyl EKR (IIIa) or (IIIb) -CH3 -I -OCH3 EKS (IIIa) or (Eb)-CH3-I-OC2H5 EKT(IIIa) or (IIIb) -CH3 -I -OC3H7 EKU (IIIa) or (IIIb) -CH3 -I -CHF2 EKV (IIIa) or (IIIb) -CH3 -I -CF3 EKW (IIIa) or (IIIb) -CH3 -I -CHCl2 EKX (IIIa) or (IIIb) -CH3 -I -CCl3 EKY (IIIa) or (IIIb) -CH3 -I -F EKZ (IIIa) or (IIIb) -CH3 -I -Cl ELA (IIIa) or (IIIb) -CH3 -I -Br ELB (IIIa) or (IIIb) -CH3 -I -I

Compound R1 R3 R4 ELC (IIIa) or (IIIb) -CH3 -NO2 -H ELD (IIIa) or (IIIb) -CH3 -NO2 -CH3 ELE (IIIa) or (IIIb)-CH3-NO2-n-propyl ELF (IIIa) or (IIIb) -CH3 -NO2 -n-butyl ELG (nia) or (IIIb) -CH3 -NO2 -t-butyl ELH (nia) or (IIIb)-CH3-NOz-iso-butyl ELI (IIIa) or (IIIb) -CH3 -NO2 -OCH3 ELJ (IIIa) or (IIIb) -CH3 -NO2 -OC2H5 ELK (nia) or (IIIb)-CH3-NO2-OC3H7 ELL (ma) or (IIIb) -CH3 -NO2 -CHF2 ELM (IIIa) or (IIIb) -CH3 -NO2 -CF3 ELN (ma) or (IIIb) -CH3 -NO2 -CHCl2 ELO (IIIa) or (IIIb)-CH3-NO2-CC13 ELP (IIIa) or (IIIb) -CH3 -NO2 -F ELQ (IIIa) or (IIIb) -CH3 -NO2 -Cl ELR (IIIa) or (IIIb)-CH3-NO2-Br ELS (IIIa) or (IIIb) -CH3 -NO2 -I ELT (IIIa) or (IIIb) -CH3 -CN -H ELU (IIIa) or (IIIb) -CH3 -CN -CH3 ELV (IIIa) or (IIIb) -CH3 -CN -n-propyl ELW (IIIa) or (IIIb) -CH3 -CN -n-butyl ELX (IIIa) or (IfIb)-CH3-CN-t-butyl ELY (IIIa) or (IIIb) -CH3 -CN -iso-butyl ELZ (IIIa) or (IIIb) -CH3 -CN -OCH3 EMA (nia) or (IIIb) -CH3 -CN -OC2H5 EMB (IIIa) or (IIIb) -CH3 -CN -OC3H7 EMC (ma) or (IIIb) -CH3 -CN -CHF2 EMD (IIIa) or (IIIb) -CH3 -CN -CF3

Compound Ri 1t3 R4 EME (IIIa) or (IIIb) -CH3 -CN -CHCl2 EMF (ma) or (IIIb) -CH3 -CN -CCl3 EMG (IIIa) or (IIIb) -CH3 -CN -F EMH (IIIa) or (IIIb) -CH3 -CN -Cl EMI (nia) or (Eb)-CH3-CN-Br EMJ (IIIa) or (IIIb) -CH3 -CN -I EMK (nia) or (IIIb) -CH3 -NH2 - EML (ma) or (IIIb) -CH3 -NH2 -CH3 EMM (IIIa) or (IIIb) -CH3 -NH2 -n-propyl EMN (ma) or (IIIb) -CH3 -NH2 -n-butyl EMO (ma) or (IIIb) -CH3 -NH2 -t-butyl EMP (IIIa) or (IIIb) -CH3 -NH2 -iso-butyl EMQ (IIIa) or (IIIb) -CH3 -NH2 -OCH3 EMR (IIIa) or (IIIb) -CH3 -NH2 -OC2H5 EMS (IIIa) or (IIIb) -CH3 -NH2 -OC3H7 EMT (IIIa) or (IIIb) -CH3 -NH2 -CHF2 EMU (IIIa) or (IIIb) -CH3 -NH2 -CF3 EMV (IIIa) or (IIIb) -CH3 -NH2 -CHCl2 EMW (IIIa) or (IIIb) -CH3 -NH2 -CCl3 EMX (IIIa) or (IIIb) -CH3 -NH2 -F EMY (IIIa) or (IIIb) -CH3 -NH2 -Cl EMZ (ma) or (IIIb) -CH3 -NH2 -Br ENA (nia) or (IIIb) -CH3 -NH2 -I ENB (DIa) or (IIIb)-CH3-CH3-H ENC (IIIa) or (IIIb) -CH3 -CH3 -CH3 END (IIIa) or (IIIb) -CH3 -CH3 -n-propyl ENE (nia) or (IIIb) -CH3 -CH3 -n-butyl ENF (IIIa) or (IIIb) -CH3 -CH3 -t-butyl

Compound Rl R3 R4 ENG (nia) or (IIIb) -CH3 -CH3 -iso-butyl ENH (nia) or (IIIb) -CH3 -CH3 -OCH3 ENI (IIIa) or (IIIb) -CH3 -CH3 -OC2H5 ENJ (IIIa) or (IIIb) -CH3 -CH3 -OC3H7 ENK (IIIa) or (IIIb) -CH3 -CH3 -CHF2 ENL(IIIa) or (IIIb) -CH3 -CH3 -CF3 ENM (ma) or (IIb)-CH3-CH3-CHC12 ENN (ma) or (IIIb) -CH3 -CH3 -CCl3 ENO (IIIa) or (IIIb) -CH3 -CH3 -F ENP (ma) or (IIIb) -CH3 -CH3 -Cl ENQ (IIIa) or (IIIb) -CH3 -CH3 Br ENR (IIIa) or (IIIb) -CH3 -CH3 -I Table 3 and pharmaceutically acceptable salts thereof, where: Compound R1 R3 R4 ENS (IVa) -H -H -H

Compound R1 R3 R4 ENT (IVa) -H -H -CH3 ENU (IVa)-H-H-n-propyl ENV (IVa)-H-H-n-butyl ENW(IVa) -H -H -t-butyl ENX(IVa) -H -H -iso-butyl ENY(IVa) -H -H -OCH3 ENZ(IVa) -H -H -OC2H5 EOA (IVa)-H-H-OC3H7 EOB(IVa) -H -H -CHF2 EOC(IVa) -H -H -CF3 EOD (IVa)-H-H-CHC12 EOE (IVa) -H -H -CCl3 EOF (IVa)-H-H-F EOG (IVa) -H -H -Cl EOH (IVa)-H-H-Br EOI (IVa)-H-H-I EOJ (IVa) or (IVb)-H-OH-H EOK (IVa) or (IVb) -H -H -CH3 EOL (IVa) or (IVb) -H -OH -n-propyl EOM (IVa) or (IVb)-H-OH-n-butyl EON (IVa) or (IVb)-H-OH-t-butyl EOO (IVa) or (IVb)-H-OH-iso-butyl EOP (IVa) or (IVb) -H -OH -OCH3 EOQ (IVa) or (IVb) -H -OH -OC2H5 EOR (IVa) or (IVb) -H -OH -OC3H7 EOS (IVa) or (IVb) -H -OH -CHF2 EOT (IVa) or (IVb) -H -OH -CF2 EOU (IVa) or (IVb) -H -OH -CHCl2

Compound R1 EOV (IVa) or (IVb)-H-OH-CC13 EOW (IVa) or (IVb) -H -OH -F EOX(IVa) or (IVb) -H -OH -Cl EOY(IVa) or (IVb) -H -OH -Br EOZ (IVa) or (IVb)-H-OH-I EPA (IVa) or (IVb) -H -F -H EPB (IVa) or (IVb) -H -F -CH3 EPC (IVa) or (IVb)-H-F-n-propyl EPD (IVa) or (IVb)-H-F-n-butyl EPE (IVa) or (IVb)-H-F-t-butyl EPF (IVa) or (IVb)-H-F-iso-butyl EPG (IVa) or (IVb) -H -F -OCH3 EPH (IVa) or (IVb)-H-F-OC2H5 EPI (IVa) or (IVb)-H-F-OC3H7 EPJ (IVa) or (IVb) -H -F -C EPK (IVa) or (IVb)-H-F-CF3 EPL (IVa) or (IVb) -H -F -CHCl2 EPM (IVa) or (IVb) -H -F -CCl3 EPN (IVa) or (IVb)-H-F-F EPO (IVa) or (IVb) -H -F -Cl EPP (IVa) or (IVb) -H -F -Br EPQ (IVa) or (IVb)-H-F-I EPR (IVa) or (IVb) -H -Cl -H EPS (IVa) or (IVb) -H -Cl -CH3 EPT (IVa) or (IVb) -H -Cl -n-propyl EPU (IVa) or (IVb) -H -Cl -n-butyl EPV (IVa) or (IVb) -H -Cl -t-butyl EPW (IVa) or (IVb) -H -Cl -iso-butyl

Compound R1 R3 R4 EPX (IVa) or (IVb)-H-Cl-OCH3 EPY (IVa) or (IVb) -H -Cl -OC2H5 EPZ (IVa) or (IVb) -H -Cl -OC3H7 EQA (IVa) or (IVb) -H -Cl -CHF2 EQB (IVa) or (IVb)-H-Cl-CF3 EQC (IVa) or (IVb)-H-Cl-CHCl2 EQD (IVa) or (IVb) -H -cl -CCl3 EQE (IVa) or (IVb)-H-Cl-F EQF (IVa) or (IVb)-H-Cl-Cl EQG (IVa) or (IVb) -H -Cl -Br EQH(IVa) or (IVb) -H -Cl -I EQI (IVa) or (IVb) -H -Br -H EQJ (IVa) or (IVb) -H -Br -CH3 EQK (IVa) or (IVb) -H -Br -n-propyl EQL (IVa) or (IVb)-H-Br-n-butyl EQM (IVa) or (IVb)-H-Br-t-butyl EQN (IVa) or (IVb)-H-Br-iso-butyl EQO (IVa) or (IVb)-H-Br-OCH3 EQP (IVa) or (IVb) -H -Br -OC2H5 EQQ (IVa) or (IVb) -H -Br -OC3H7 EQR (IVa) or (IVb) -H -Br -CHF2 EQS (IVa) or (IVb)-H-Br-CF3 EQT (IVa) or (IVb) -H -Br -CHCl2 EQU (IVa) or (IVb) -H -Br -CCl3 EQV (IVa) or (IVb)-H-Br-F EQW (IVa) or (IVb)-H-Br-Cl EQX (IVa) or (IVb)-H-Br-Br EQY (IVa) or (IVb) -H -Br -I

Compound Ri R3 R4 EQZ (IVa) or (IVb)-H-I-H ERA (IVa) or (IVb)-H-I-CH3 ERB (IVa) or (IVb)-H-n-propyl ERC (IVa) or (IVb)-H-I-n-butyl ERD (IVa) or (IVb)-H-I-t-butyl ERE (IVa) or (IVb)-H-I-iso-butyl ERF (IVa) or (IVb) -H -I -OCH3 ERG (IVa) or (IVb)-H-I-OC2H5 ERH (IVa) or (IVb) -H -I -OC3H7 ERI (IVa) or (IVb) -H -I -CHF2 ERJ (IVa) or (IVb)-H-I-CF3 ERK (IVa) or (IVb) -H -I -CHCl2 ERL (IVa) or (IVb) -H -I -CCl3 ERM (IVa) or (IVb) -H -I -F ERN (IVa) or (IVb)-H-I-Cl ERO (IVa) or (IVb)-H-I-Br ERP (IVa) or (IVb)-H-I-I ERQ (IVa) or (IVb)-H-NO2-H ERR (IVa) or (IVb)-H-NO2-CH3 ERS (IVa) or (IVb) -H -NO2 -n-propyl ERT (IVa) or (IVb) -H -NO2 -n-butyl ERU (IVa) or (IVb) -H -NO2 -t-butyl ERV (IVa) or (IVb) -H -NO2 -iso-butyl ERW (IVa) or (IVb) -H -NO2 -OCH3 ERX (IVa) or (IVb) -H -NO2 -OC2H5 ERY (IVa) or (IVb) -H -NO2-OC3H7 ERZ (IVa) or (IVb) -H -NO2 -CHF2 ESA(IVa) or (IVb) -H -NO2 -CF3

Compound Ri R3 R4 ESB (IVa) or (IVb) -H -NO2 -CHCl2 ESC (IVa) or (IVb) -H -NO2 -CCl3 ESD (IVa) or (IVb) -H -NO2 -F ESE (IVa) or (IVb) -H -NO2 -Cl ESF (IVa) or (IVb) -H -NO2 -Br ESG (IVa) or (IVb) -H -NO2 -I ESH (IVa) or (IVb)-H-CN-H ESI (IVa) or (IVb)-H-CN-CH3 ESJ (IVa) or (IVb)-H-CN-n-propyl ESK(IVa) or (IVb) -H -CN -n-butyl ESL (IVa) or (IVb)-H-CN-t-butyl ESM (IVa) or (IVb)-H-CN-iso-butyl ESN(IVa) or (IVb) -H -CN -OCH3 ESO (IVa) or (IVb)-H-CN-OC2H5 ESP (IVa) or (IVb) -H -CN -OC3H7 ESQ (IVa) or (IVb) -H -CN -CHF2 ESR (IVa) or (IVb) -H -CN -CF3 ESS (IVa) or (IVb) -H -CN -CHCl2 EST (IVa) or (IVb)-H-CN-CC13 ESU (IVa) or (IVb)-H-CN-F ESV (IVa) or (IVb) -H -CN -Cl ESW (IVa) or (IVb) -H -CN -Br ESX (IVa) or (IVb) -H -CN -I ESY (IVa) or (IVb) -H -NH2 -H ESZ (IVa) or (IVb) -H -NH2 -CH3 ETA(IVa) or (IVb) -H -NH2 -n-propyl ETB (IVa) or (IVb) -H -NH2 -n-butyl ETC (IVa) or (IVb)-H NH2-t-butyl

Compound R1 R3 R4 ETD (IVa) or (IVb)-H-NH2-iso-butyl ETE(IVa) or (IVb)-H-NH2-OCH3 ETF (IVa) or (IVb) -H -NH2 -OC2H5 ETG (IVa) or (IVb) -H -NH2 -OC3H7 ETH (IVa) or (IVb) -H -NH2 -CHF2 ETI (IVa) or (IVb) -H -NH2 -CF3 ETJ (IVa) or (IVb) -H -NH2 -CHCl2 ETK (IVa) or (IVb) -H -NH2 -CCl3 ETL (IVa) or (IVb) -H -NH2 -F ETM (IVa) or (IVb) -H -NH2 -Cl ETN (IVa) or (IVb) -H -NH2 -Br ETO (IVa) or (IVb) -H -NH2 ETP (IVa) or (IVb)-H-CH3-E ETQ (IVa) or (IVb) -H -CH3 -CH3 ETR (IVa) or (IVb) -H -CH3 -n-propyl ETS (IVa) or (IVb) -H -CH3 -n-butyl ETT (IVa) or (IVb) -H -CH3 -t-butyl ETU (IVa) or (IVb) -H -CH3 -iso-butyl ETV (IVa) or (IVb) -H -CH3 -OCH3 ETW (IVa) or (IVb) -H -CH3 -OC2H5 ETX (IVa) or (IVb)-H-CH3-OC3H7 ETY (IVa) or (IVb) -H -CH3 -CHF2 ETZ (IVa) or (IVb) -H -CH3 -CF3 EUA (IVa) or (IVb) -H -CH3 -CHCl2 EUB (IVa) or (IVb) -H -CH3 -CCl3 EUC (IVa) or (IVb) -H -CH3 -F EUD (IVa) or (IVb)-H-CH3-Cl EUE (IVa) or (IVb) -H -CH3 -Br

Compound R1 R3 R4 EUF (IVa) or (IVb) -H -CH3 -I EUG (IVa)-OH-H-H EUH (IVa) -OH -H -CH3 EUI (IVa) -OH -H -n-propyl EUJ (IVa)-OH-H-n-butyl EUK (IVa)-OH-H-t-butyl EUL (IVa)-OH-H-iso-butyl EUM (lVa)-OH-H-OCH3 EUN (IVa) -OH -H -OC2H5 EUO (IVa) -OH -H -OC3H7 EUP (IVa) -OH -H -CHF2 EUQ (IVa) -OH -H -CF3 EUR (IVa) -OH -H -CHCl2 EUS (IVa) -OH -H -CCl3 EUT (IVa)-OH-H-F EUU(IVa) -OH -H -Cl EUV(IVa) -OH -H -Br EUW (IVa)-OH-H-I EUX (IVa) or (IVb) -OH -OH -H EUY (IVa) or (IVb) -OH -OH -CH3 EUZ (IVa) or (IVb) -OH -OH -n-propyl EVA (IVa) or (IVb)-OH-OH-n-butyl EVB (IVa) or (IVb)-OH-OH-t-butyl EVC (IVa) or (IVb)-OH-OH-iso-butyl EVD (IVa) or (IVb) -OH -OH -OCH3 EVE (IVa) or (IVb) -OH -OH -OC2H5 EVF (IVa) or (IVb) -OH -OH -OC3H7 EVG(IVa) or (IVb) -OH -OH -CHF2

Compound R1 R3 R4 EVH (IVa) or (IVb) -OH -OH -CF3 EVI (IVa) or (IVb) -OH -OH -CHCl2 EVJ (IVa) or (IVb)-OH-OH-CCl3 EVK (IVa) or (IVb)-OH-OH-F EVL (IVa) or (IVb) -OH -OH -Cl EVM (IVa) or (IVb)-OH-OH-Br EVN (IVa) or (IVb)-OH-OH-I EVO (IVa) or (IVb)-OH-F-H EVP (IVa) or (IVb)-OH-F-CH3 EVQ (IVa) or (IVa) -OH -F -n-propyl EVR (IVa) or (IVb)-OH-F-n-butyl EVS (IVa) or (IVb)-OH-F-t-butyl EVT (IVa) or (IVb) -OH -F -iso-butyl EVU (IVa) or (IVb) -OH -F -OCH3 EW (IVa) or (IVb) -OH -F -OC2H5 EVW (IVa) or (IVb) -OH -F -OC3H7 EVX (IVa) or (IVb)-OH-F-CHF2 EVY (IVa) or (IVb) -OH -F -CF3 EVZ (IVa) or (IVb) -OH -F -CHCl2 EWA (IVa) or (IVb)-OH-F-CC13 EWB (IVa) or (IVb)-OH-F-F EWC (IVa) or (IVb)-OH-F-Cl EWD (IVa) or (IVb)-OH-F-Br EWE (IVa) or (IVb)-OH-F-I EWF (IVa) or (IVb) -OH -Cl -H EWG(IVa) or (IVb) -OH -Cl -CH3 EWH (IVa) or (IVb)-OH-Cl-n-propyl EWI (IVa) or (IVb)-OH-Cl-n-butyl

Compound RI R3 R4 EWJ (IVa) or (IVb)-OH-Cl-t-butyl EWK (IVa) or (IVb)-OH-Cl-iso-butyl EWL (IVa) or (IVb)-OH-Cl-OCH3 EWM (IVa) or (IVb) -OH -Cl -OC2H5 EWN (IVa) or (IVb)-OH-Cl-OC3H7 EWO (IVa) or (IVb)-OH-Cl-CHF2 EWP (IVa) or (IVb) -OH -Cl -CF3 EWQ (IVa) or (IVb) -OH -Cl -CHCl2 EWR (IVa) or (IVb) -OH -Cl -CCl3 EWS (IVa) or (IVb)-OH-Cl-F EWT (IVa) or (IVb) -OH -Cl -Cl EWU (IVa) or (IVb) -OH -Cl -Br EWV (IVa) or (IVb)-OH-Cl-I EWW (IVa) or (IVb)-OH-Br-H EWX (IVa) or (IVb) -OH -Br -CH3 EWY (IVa) or (IVb) -OH -Br -n-propyl EWZ (IVa) or (IVb)-OH-Br-n-butyl EXA (IVa) or (IVb)-OH-Br-t-butyl EXB (IVa) or (IVb)-OH-Br-iso-butyl EXC (IVa) or (IVb) -OH -Br -OCH3 EXD (IVa) or (IVb) -OH -Br -OC2H5 EXE (IVa) or (IVb) -OH -Br -OC3H7 EXF (IVa) or (IVb) -OH -Br -CHF2 EXG (IVa) or (IVb)-OH-Br-CF3 EXH (IVa) or (IVb)-OH-Br-CHC12 EXI (IVa) or (IVb) -OH -Br -CCl3 EXJ (IVa) or (IVb)-OH-Br-F EXK (IVa) or (IVb)-OH-Br-Cl

Compound R1 R3 R4 EXL (IVa) or (IVb)-OH-Br-Br EXM (IVa) or (IVb)-OH-Br-I EXN (IVa) or (IVb)-OH-I-H EXO (IVa) or (IVb) -OH -I -CH3 EXP (IVa) or (IVb) -OH -I -n-propyl EXQ (IVa) or (IVb)-OH-I-n-butyl EXR (IVa) or (IVb)-OH-I-t-butyl EXS (IVa) or (IVb)-OH-I-iso-butyl EXT (IVa) or (IVb) -OH -I -OCH3 EXU (IVa) or (IVb) -OH -I -OC2H5 EXV (IVa) or (IVb) -OH -I -OC3H7 EXW (IVa) or (IVb)-OH-I-CHF2 EXX (IVa) or (IVb) -OH -I -CF3 EXY (IVa) or (IVb) -OH -I -CHCl2 EXZ (IVa) or (IVb)-OH-I-CCl3 EYA (IVa) or (IVb)-OH-I-F EYB(IVa) or (IVb)-OH-I-Cl EYC (IVa) or (IVb)-OH-I-Br EYD (IVa) or (IVb)-OH-I-I EYE (IVa) or (IVb)-OH-NO2-H EYF (IVa) or (IVb) -OH -NO2 -CH3 EYG (IVa) or (IVb)-OH-NO2-n-propyl EYH (IVa) or (IVb)-OH-NO2-n-butyl EYI (IVa) or (IVb)-OH-NO2-t-butyl EYJ(IVa) or (IVb) -OH -NO2 -iso-butyl EYK(IVa) or (IVb) -OH -NO2 -OCH3 EYL (IVa) or (IVb) -OH -NO2 -OC2H5 EYM(IVa) or (IVb) -OH -NO2 -OC3H7

Compound Ri R3 R4 EYN (IVa) or (IVb)-OH-NO2-CHF2 EYO (IVa) or (IVb)-OH-NO2-CF3 EYP (IVa) or (IVb)-OH-NO2-CHC12 EYQ (IVa) or (IVb) -OH -NO2 -CCl3 EYR (IVa) or (IVb) -OH -NO2 -F EYS (IVa) or (IVb) -OH -NO2 -Cl EYT (IVa) or (IVb) -OH -NO2 -Br EYU (IVa) or (IVb)-OH-NO2-I EYV (IVa) or (IVb)-OH-CN-H EYW (IVa) or (IVb) -OH -CN -CH3 EYX (IVa) or (IVb) -OH -CN -n-propyl EYY (IVa) or (IVb)-OH-CN-n-butyl EYZ (IVa) or (IVb)-OH-CN-t-butyl EZA (IVa) or (IVb)-OH-CN-iso-butyl EZB (IVa) or (IVb) -OH -CN -OCH3 EZC (IVa) or (IVb) -OH -CN -OC2H5 EZD (IVa) or (IVb) -OH -CN -OC3H7 EZE (IVa) or (IVb) -OH -CN -CHF2 EZF (IVa) or (IVb) -OH -CN -CF3 EZG (IVa) or (IVb) -OH -CN -CHCl2 EZH (IVa) or (IVb) -OH -CN -CCl3 EZI (IVa) or (IVb)-OH-CN-F EZJ (IVa) or (IVb) -OH -CN -Cl EZK (IVa) or (IVb)-OH-CN-Br EZL (IVa) or (IVb)-OH-CN-I EZM (IVa) or (IVb) -OH -NH2 -H EZN (IVa) or (IVb) -OH -NH2 -CH3 EZO (IVa) or (IVb)-OH-NH,-n-propyl

Compound R1 R3 R4 EZP (IVa) or (IVb) -OH -NH2 -n-butyl EZQ (IVa) or (IVb) -OH -NH2 -t-butyl EZR(IVa) or (IVb)-OH-NH2-iso-butyl EZS (IVa) or (IVb) -OH -NH2 -COH3 EZT (IVa) or (IVb) -OH -NH2 -CO2H5 EZU (IVa) or (IVb) -OH -NH2 -CO3H7 EZV (IVa) or (IVb) -OH -NH2 -CHF2 EZW (IVa) or (IVb) -OH -NH2 -CF3 EZX (IVa) or (IVb) -OH -NH2 -CHCl2 EZY (IVa) or (IVb) -OH -NH2 -CCl3 EZZ (IVa) or (IVb) -OH -NH2 -F FAA (IVa) or (IVb) -OH -NH2 -Cl FAB (IVa) or (IVb)-OH-NH2-Br FAC (IVa) or (IVb) -OH -NH2 -I FAD (IVa) or (IVb) -OH -CH3 -H FAE (IVa) or (IVb)-OH-CH3-CH3 FAF (IVa) or (IVb)-OH-CH3-n-propyl FAG (IVa) or (IVb) -OH -CH3 -n-butyl FAH (IVa) or (IVb) -OH -CH3 -t-butyl FAI(IVa) or (IVb) -OH -CH3 -iso-butyl FAJ (IVa) or (IVb)-OH-CH3-OCH3 FAK(IVa) or (IVb) -OH -CH3 -OC2H5 FAL (IVa) or (IVb) -OH -CH3 -CO3H7 FAM(IVa) or (IVb) -OH -CH3 -CHF2 FAN (IVa) or (IVb) -OH -CH3 -CF3 FAO (IVa) or (IVb)-OH-CH3-CHCl2 FAP (IVa) or (IVb) -OH -CH3 -CCl3 FAQ (IVa) or (IVb) -OH -CH3 -F

Compound R1 R3 R4 FAR (IVa) or (IVb)-OH-CH3-Cl FAS (IVa) or (IVb)-OH-CH3-Br FAT (IVa) or (IVb) -OH -CH3 -I FAU (IVa)-F-H-H FAV (IVa)-F-H-CH3 FAW (IVa) -F -H -n-propyl FAX (IVa) -F -H -n-butyl FAY (IVa) -F -H -t-butyl FAZ (IVa)-F-H-iso-butyl FBA (IVa) -F -H -OCH3 FBB (IVa)-F-H-OC2H5 FBC (IVa) -F -H -OC3H7 FBD (IVa) -F -H -CHF2 FBE (IVa) -F -H -CF3 FBF (IVa) -F -H -CHCl2 FBG (IVa) -F -H -CCl3 FBH (IVa)-F-H-F FBI (IVa)-F-H-Cl FBJ (IVa)-F-H-Br FBK (IVa)-F-H-I FBL(IVa) or (IVb) -F -OH FBM (IVa) or (IVb) -F -OH -CH3 FBN (IVa) or (IVb) -F -OH -n-propyl FBO (IVa) or (IVb)-F-OH-n-butyl FBP (IVa) or (IVb)-F-OH-t-butyl FBQ (IVa) or (IVb)-F-OH-iso-butyl FBR (IVa) or (IVb) -F -OH -OCH3 FBS (IVa) or (IVb)-F-OH-OC2Hs

Compound R1 R3 R4 FBT (IVa) or (IVb)-F-OH-OC3H7 FBU (IVa) or (IVb)-F-OH-CHF2 FBV (IVa) or (IVb)-F-OH-CF3 FBW (IVa) or (IVb)-F-OH-CHC12 FBX (IVa) or (IVb)-F-OH-CCl3 FBY (IVa) or (IVb) -F -OH -F FBZ (IVa) or (IVb)-F-OH-Cl FCA (IVa) or (IVb)-F-OH-Br FCB (IVa) or (IVb) -F -OH -I FCC (IVa) or (IVb) -F -OH -H FCD (IVa) or (IVb)-F-F-CH3 FCE (IVa) or (IVb)-F-F-n-propyl FCF (IVa) or (IVb)-F-F-n-butyl FCG (IVa) or (IVb)-F-F-t-butyl FCH (IVa) or (IVb)-F-F-iso-butyl FCI (IVa) or (IVb) -F -OH -OCH3 FCJ (IVa) or (IVb)-F-F-OC2H5 FCK (VIa) or (IVb) -F -OH -OC3H7 FCL (IVa) or (IVb) -F -OH -CHF2 FCM (IVa) or (IVb)-F-F-CF3 FCN(IVa) or (IVb) -F -F -CHCl2 FCO (IVa) or (IVb) -F -F -CCl3 FCP (IVa) or (IVb) -F -F -F FCQ (IVa) or (IVb)-F-F-Cl FCR (IVa) or (IVb)-F-F-Br FCS (IVa) or (IVb)-F-F-I FCT (IVa) or (IVb)-F-Cl-H FCU (IVa) or (IVb) -F -F -CH3

Compound FCV (IVa) or (IVb) -F -Cl -n-propyl FCW (IVa) or (IVb)--F-Cl-n-butyl FCX (IVa) or (IVb) -F -Cl -t-butyl FCY (IVa) or (IVb)-F-Cl-iso-butyl FCZ (IVa) or (IVb)-F-Cl-OCH3 FDA (IVa) or (IVb) -F -Cl -OC2H5 FDB (IVa) or (IVb) -F -Cl -OC3H7 FDC (IVa) or (IVb) -F -Cl -CHF2 FDD (IVa) or (IVb)-F-Cl-CF3 FDE (IVa) or (IVb) -F -Cl -CHCl2 FDF (IVa) or (IVb) -F -Cl -CCl3 FDG (IVa) or (IVb) -F -Cl -F FDH(IVa) or (IVb) -F -Cl -Cl FDI (IVa) or (IVb) -F -Cl -Br FDJ (IVa) or (IVb)-F-Cl-I FDK (IVa) or (IVb) -F -Br -H FDL (IVa) or (IVb) -F -Br -CH3 FDM(IVa) or (IVb) -F -Br -n-propyl FDN (IVa) or (IVb) -F -Br -n-butyl FDO(IVa) or (IVb) -F -Br -t-butyl FDP (IVa) or (IVb)-F-Br-iso-butyl FDQ (IVa) or (IVb)-F-Br-OCH3 FDR (IVa) or (IVb)-F-Br-OC2H5 FDS (IVa) or (IVb) -F -Br -OC3H7 FDT (IVa) or (IVb) -F -Br -CHF2 FDU (IVa) or (IVb)-F-Br-CF3 FDV (IVa) or (IVb)-F-Br-CHC12 FDW (IVa) or (IVb) -F -Br -CCl3

Compound Rl R3 R4 FDX (IVa) or (IVb) -F -Br -F FDY (IVa) or (IVb)-F-Br-Cl FDZ (IVa) or (IVb)-F-Br-Br FEA (IVa) or (IVb)-F-Br-I FEB (IVa) or (IVb)-F-I-H FEC (IVa) or (IVb) -F -I -CH3 FED (IVa) or (IVb)-F-I-n-propyl FEE (IVa) or (IVb) -F -I -n-butyl FEF (IVa) or (IVb)-F-I-t-butyl FEG (IVa) or (IVb) -F -I -iso-butyl FEH (IVa) or (IVb) -F -I -OCH3 FEI (IVa) or (IVb) -F -I -OC2H5 FEJ (IVa) or (IVb) -F -I -OC3H7 FEK (IVa) or (IVb) -F -I -CHF2 FEL (IVa) or (IVb) -F -I -CF3 FEM (IVa) or (IVb)-F-I-CHCl2 FEN (IVa) or (IVb) -F -I -CCl3 FEO (IVa) or (IVb)-F-I-F FEP (IVa) or (IVb)-F-I-Cl FEQ (IVa) or (IVb)-F-I-Br FER(IVa) or (IVb)-F-I-I FES (IVa) or (IVb)-F-NO2-H FET (IVa) or (IVb)-F-NO2-CH3 FEU (IVa) or (IVb) -F -NO2 -n-propyl FEV (IVa) or (IVb)-F-N02-n-butyl FEW (IVa) or (IVb) -F -NO2 -t-butyl FEX (IVa) or (IVb) -F -NO2 -iso-butyl FEY (IVa) or (IVb) -F -NO2 -OCH3

Compound Ri R3 R4 FEZ (IVa) or (IVb) -F -NO2 -OC2H5 FFA (IVa) or (IVb) -F -NO2 -OC3H7 FFB (IVa) or (IVb)-F-NO2-CHF2 FFC (IVa) or (IVb)-F-NO2-CF3 FFD (IVa) or (IVb) -F -NO2 -CHCl2 FFE (IVa) or (IVb) -F -NO2 -CCl3 FFF (IVa) or (IVb)-F-NO2-F FFG (IVa) or (IVb)-F-NO2-Cl FFH (IVa) or (IVb) -F -NO2 -Br FFI (IVa) or (IVb) -F -NO2 -I FFJ (IVa) or (IVb)-F-CN-H FFK (IVa) or (IVb) -F -CN -CH3 FFL (IVa) or (IVb)-F-CN-n-propyl FFM (IVa) or (IVb) -F -CN -n-butyl FFN (IVa) or (IVb)-F-CN-t-butyl FFO (IVa) or (IVb)-F-CN-iso-butyl FFP (IVa) or (IVb) -F -CN -OCH3 FFQ (IVa) or (IVb) -F -CN -OC2H5 FFR (IVa) or (IVb) -F -CN -OC3H7 FFS (IVa) or (IVb) -F -CN -CHF2 FFT (IVa) or (IVb) -F -CN -CF3 FFU (IVa) or (IVb) -F -CN -CHCl2 FFV (IVa) or (IVb) -F -CN -CCl3 FFW (IVa) or (IVb) -F -CN -F FFX (IVa) or (IVb)-F-CN-Cl FFY (IVa) or (IVb) -F -CN -Br FFZ(IVa) or (IVb)-F-CN-I FGA (IVa) or (IVb) -F -NH2 -H

Compound R1 R3 R4 FGB (IVa) or (IVb)-F-NH2-CH3 FGC (IVa) or (IVb) -F -NH2 -n-propyl FGD (IVa) or (IVb)-F-NH2-n-butyl FGE (IVa) or (IVb) -F -NH2 -t-butyl FGF (IVa) or (IVb)-F-NH2-iso-butyl FGG (IVa) or (IVb) -F -NH2 -OCH3 FGH (IVa) or (IVb) -F -NH2 -OC2H5 FGI (IVa) or (IVb) -F -NH2 -OC3H7 FG (IVa) or (IVb) -F -NH2 -CHF2 FGK (IVa) or (IVb) -F -NH2 -CF3 FGL (IVa) or (IVb) -F -NH2 -CHCl2 FGM (IVa) or (IVb) -F -NH2 -CCl3 FGN (IVa) or (IVb) -F -NH2 -F FGO (IVa) or (IVb) -F -NH2 -Cl FGP (IVa) or (IVb) -F -NH2 -Br FGQ (IVa) or (IVb) -F -NH2 -I FGR (IVa) or (IVb) -F -CH3 -H FGS (IVa) or (IVb) -F -CH3 -CH3 FGT (IVa) or (IVb)-F-CH3-n-propyl FGU (IVa) or (IVb) -F -CH3 -n-butyl FGV (IVa) or (IVb) -F -CH3 -t-butyl FGW (IVa) or (IVb) -F -CH3 -iso-butyl FGX (IVa) or (IVb)-F-CH3-OCH3 FGY (IVa) or (IVb) -F -CH3 -OC2H5 FGZ (IVa) or (IVb) -F -CH3 -OC3H7 FHA(IVa) or (IVb) -F -CH3 -CHF2 FHB (IVa) or (IVb) -F -CH3 -CF3 FHC (IVa) or (IVb) -F -CH3 -CHCl2

Compound Ri R3 R4 FHD(IVa) or (IVb) -F -CH3 -CCl3 FHE(IVa) or (IVb) -F -CH3 -F FHF(IVa) or (IVb) -F -CH3 -Cl FHG (IVA) or (IVb)-F-CH3-Br FHH (IVa) or (IVb) -F -CH3 -I FHI (IVa) -Cl -H -H FHJ (IVa) -Cl -H -CH3 FHK (IVa) -Cl -H -n-propyl FHL (IVa)-Cl-H-n-butyl FHM (IVa) -Cl -H -t-butyl FHN (IVa)-Cl-H-iso-butyl FHO (IVa) -Cl -H -OCH3 FHP(IVa) -Cl -H -OC2H5 FHQ (IVa) -Cl -H -OC3H7 FHR (IVa) -Cl -H -CHF2 FHS (IVa) -Cl -H -CF3 FHT (IVa) -Cl -H -CHCl2 FHU (IVa)-Cl-H-CCl3 FHV (IVa)-Cl-H-F FHW (IVa) -Cl -H -Cl FHX (IVa) -Cl -H -Br FHY (IVa) -Cl -H -I FHZ (IVa) or (IVb) -Cl -OH -H FIA (IVa) or (IVb) -Cl -OH -CH3 FIB (IVa) or (IVb) -Cl -OH -n-propyl FIC (IVa) or (TVb)-Cl-OH-n-butyl FID (IVa) or (IVb) -Cl -OH -t-butyl FIE (IVa) or (IVb) -Cl -OH -iso-butyl

Compound R1 R3 R4 FIF(IVa) or (IVb) -Cl -OH -OCH3 FIG(IVa) or (IVb) -Cl -OH -OC2H5 FIH (IVa) or (IVb) -Cl -OH -OC3H7 FIL (IVa) or (IVb) -Cl -OH -CHF2 FIJ(IVa) or (IVb) -Cl -OH -CF3 FIK(IVa) or (IVb) -Cl -OH -CHCl2 FIL(IVa) or (IVb) -Cl -OH -CCl3 FIM(IVa) or (IVb) -Cl -OH -F FIN (lVa) or (IVb) -Cl -OH -Cl FIO (IVa) or (rVb)-Cl-OH-Br FIP (IVa) or (IVb) -Cl -OH -I FIQ (IVa) or (IVb) -Cl -F -H FIR (IVa) or (IVb) -Cl -F -CH3 FIS (IVa) or (IVb) -Cl -F -n-propyl FIT (IVa) or (IVb) -Cl -F -n-butyl FIU (IVa) or (IVb) -Cl -F -t-butyl FIV(IVa) or (IVb) -Cl -F -iso-butyl FIW (IVa) or (IVb) -Cl -F -OCH3 FIX (IVa) or (IVb) -Cl -F -OC2H5 FIY (IVa) or (IVb) -Cl -F -OC3H7 FIZ (IVa) or (IVb) -Cl -F -CHF2 FJA (IVa) or (IVb) -Cl -F -CF3 FB(IVa) or (IVb) -Cl -F -CHCl2 FJC (IVa) or (IVb) -Cl -F -CCl3 FJD(IVa) or (IVb) -Cl -F -F FJE(IVa) or (IVb) -Cl -F -Cl FJF (rVa) or (IVb) -Cl -F -Br FJG (IVa) or (IVb) -Cl -F -I

Compound Ri R3 Ra FJH (IVa) or (IVb)-Cl-Cl-H FJI (IVa) or (IVb) -Cl -Cl -CH3 FJJ (IVa) or (IVb) -Cl -Cl -n-propyl FJK (IVa) or (IVb)-Cl-C1-n-butyl FJL (IVa) or (IVb)-Cl-Cl-t-butyl FJM (IVa) or (IVb)-Cl-Cl-iso-butyl FJN (IVa) or (IVb)-Cl-Cl-OCH3 FJO (IVa) or (IVb) -Cl -Cl -OC2H5 FJP (IVa) or (IVb) -Cl -Cl -OC3H7 FJQ (IVa) or (IVb) -Cl -Cl -CHF2 FJR (IVa) or (IVb) -Cl -Cl -CF3 FJS (IVa) or (IVb) -Cl -Cl -CHCl2 FJT (IVa) or (IVb) -Cl -Cl -CCl3 FJU (IVa) or (IVb)-Cl-Cl-F FJV (IVa) or (IVb)-Cl-Cl-Cl FJW (IVa) or (IVb)-Cl-Cl-Br FJX (IVa) or (IVb) -Cl -Cl -I FJY (IVa) or (IVb) -Cl -Br -H FJZ (IVa) or (IVb) -Cl -Br -CH3 FKA (IVa) or (IVb) -Cl -Br -n-propyl FKB (IVa) or (IVb) -Cl -Br -n-butyl FKC(IVa) or (IVb)-Cl-Br-t-butyl FKD(IVa) or (IVb) -Cl -Br -iso-butyl FKE(IVa) or (IVb)-Cl-Br-OCH3 FKF (IVa) or (IVb) -Cl -Br -OC2H5 FKG(IVa) or (IVb) -Cl -Br -OC3H7 FKH (IVa) or (IVb) -Cl -Br -CHF2 FKI (IVa) or (IVb) -Cl -Br -CF3

Compound R1 R3 R4 FKJ (IVa) or (IVb) -Cl -Br -CHCl2 FKK (IVa) or (IVb) -Cl -Br -CCl3 FKL (IVa) or (IVb)-Cl-Br-F FKM (IVa) or (IVb) -Cl -Br -Cl FKN (IVa) or (IVb)-Cl-Br-Br FKO (IVa) or (IVb) -Cl -Br -I FKP (IVa) or (IVb)-Cl-I-H FKQ (IVa) or (IVb) -Cl -I -CH3 FKR (IVa) or (IVb) -Cl -I -n-propyl FKS (IVa) or (IVb)-Cl-I-n-butyl FKT (IVa) or (IVb)-Cl-I-t-butyl FKU (IVa) or (IVb)-Cl-I-iso-butyl FKV (IVa) or (IVb)-Cl-I-OCH3 FKW (IVa) or (IVb)-Cl-I-OC2H5 FKX (IVa) or (IVb) -Cl -I -OC3H7 FKY (IVa) or (IVb)-Cl-I-CHF2 FKZ (IVa) or (IVb) -Cl -I -CF3 FLA (IVa) or (IVb) -Cl -I -CHCl2 FLB (IVa) or (IVb)-Cl-I-CCl3 FLC (IVa) or (IVb) -Cl -I -F FLD (IVa) or (IVb)-Cl-I-Cl FLE (IVa) or (IVb) -Cl -I -Br FLF (IVa) or (IVb)-Cl-I-I FLG (IVa) or (IVb) -Cl -NO2 -H FLH (IVa) or (IVb) -Cl -NO2 -CH3 FLI (IVa) or (IVb)-Cl-NO2-n-propyl FLJ (IVa) or (IVb)-Cl-NO2-n-butyl FLK (IVa) or (IVb) -Cl -NO2 -t-butyl

Compound FLL (IVa) or (IVb) -Cl -NO2 -iso-butyl FLM (IVa) or (IVb)-Cl-NO2-OCH3 FLN (IVa) or (IVb)-Cl-NO2-OC2H5 FLO (IVa) or (IVb)-Cl-NO2-OC3H7 FLP (IVa) or (IVb) -Cl -NO2 -CHF2 FLQ (IVa) or (IVb)-Cl-NO2-CF3 FLR(IVa) or (IVb) -Cl -NO2 -CHCl2 FLS (IVa) or (IVb)--Cl-NO2-CCl3 FLT (IVa) or (IVb) -Cl -NO2 -F FLU (IVa) or (IVb) -Cl -NO2 -Cl FLV (IVa) or (IVb) -Cl -NO2 -Br FLW (IVa) or (IVb) -Cl -NO2 -I FLX (IVa) or (IVb) -Cl -CN -H FLY (IVa) or (IVb) -Cl -CN -CH3 FLZ (IVa) or (IVb) -Cl -CN -n-propyl FMA (IVa) or (IVb)-Cl-CN-n-butyl FMB (IVa) or (IVb) -Cl -CN -t-butyl FMC (IVa) or (IVb) -Cl -CN -iso-butyl FMD (IVa) or (IVb) -Cl -CN -OCH3 FME (IVa) or (IVb) -Cl -CN -OC2H5 FMF (IVa) or (IVb) -Cl -CN -OC3H7 FMG (IVa) or (IVb) -Cl -CN -CHF2 FMH (IVa) or (IVb) -Cl -CN -CF3 FMI (IVa) or (IVb) -Cl -CN -CHCl2 FMJ (IVa) or (IVb) -Cl -CN -CCl3 FMK (IVa) or (IVb)-Cl-CN-F FML (IVa) or (IVb) -Cl -CN -Cl FMM (IVa) or (IVb)-Cl-CN-Br

Compound R1 R3 R4 FMN (IVa) or (IVb)-Cl-CN FMO (IVa) or (IVb)-Cl NHz-H FMP (IVa) or (IVb) -Cl -NH2 -CH3 FMQ (IVa) or (IVb)-Cl-NH2-n-propyl FMR (IVa) or (IVb) -Cl -NH2 -n-butyl FMS (IVa) or (IVb) -Cl -NH2 -t-butyl FMT (IVa) or (IVb) -Cl -NH2 -iso-butyl FMU (IVa) or (IVb)-Cl-NH2-OCH3 FMV (IVa) or (IVb) -Cl -NH2 -OC2H5 FMW (IVa) or (IVb)-Cl-NH2-OC3H7 FMX (IVa) or (IVb) -Cl -NH2 -CHF2 FMY (IVa) or (IVb)-Cl-NH2-CF3 FMZ (IVa) or (IVb) -Cl -NH2 -CHCl2 FNA (IVa) or (IVb) -Cl -NH2 -CCl3 FNB (IVa) or (IVb) -Cl -NH2 -F FNC (IVa) or (IVb) -Cl -NH2 -Cl FND (IVa) or (IVb) -Cl -NH2 -Br FNE (IVa) or (IVb) -Cl -NH2 -I FNF (IVa) or (IVb) -Cl -CH3 -H FNG (IVa) or (IVb) -Cl -CH3 -CH3 FNH(IVa) or (IVb) -Cl -CH3 -n-propyl FNI (IVa) or (IVb) -Cl -CH3 -n-butyl FNJ (IVa) or (IVb) -Cl -CH3 -t-butyl FNK (IVa) or (IVb) -Cl -CH3 -iso-butyl FNL (IVa) or (IVb)-Cl-CH3-OCH3 FNM (IVa) or (IVb) -Cl -CH3 -OC2H5 FNN (IVa) or (IVb) -Cl -CH3 -OC3H7 FNO (IVa) or (IVb) -Cl -CH3 -CHF2

Compound R, R3 R4 FNP (IVa) or (IVb) -Cl -CH3 -CF3 FNQ (IVa) or (IVb) -Cl -CH3 -CHCl2 FNR (IVa) or (IVb)-Cl-CH3-CCl3 FNS (IVa) or (IVb) -Cl -CH3 -F FNT (IVa) or (IVb) -Cl -CH3 -Cl FNU (IVa) or (IVb) -Cl -CH3 -Br FNV (IVa) or (IVb) -Cl -CH3 -I FNW(IVa) -CHCl2 -H -H FNX(IVa) -CHCl2 -H -CH3 FNY (IVa)-CHC12-H-n-propyl FNZ (IVa) -CHCl2 -H -n-butyl FOA (IVa) -CHCl2 -H -t-butyl FOB (IVa) -CHCl2 -H -iso-butyl FOC (IVa) -CHCl2 -H -OCH3 FOD (IVa) -CHCl2 -H -OC2H5 FOE (IVa) -CHCl2 -H -OC3H7 FOF (IVa)-CHC12-H-CHF2 FOG (IVa) -CHCl2 -H -CF3 FOH (IVa) -CHCl2 -H -CHCl2 FOI (IVa)-CHCI2-H-CCl3 FOJ (IVa) -CHCl2 -H -F FOK (IVa)-CHCl2-H-Cl FOL (IVa)-CHC12-H-Br FOM (IVa) -CHCl2 -H -I FON (IVa) or (IVb) -CHCl2 -OH -H FOO (IVa) or (IVb) -CHCl2 -OH -CH3 FOP (IVa) or (IVb) -CHCl2 -OH -n-propyl FOQ (IVa) or (IVb) -CHCl2 -OH -n-butyl

Compound R1 R3 R4 FOR(IVa) or (IVb) -CHCl2 -OH -t-butyl FOS (IVa) or (IVb)-CHCl2-OH-iso-butyl FOT (IVa) or (IVb) -CHCl2 -OH -OCH3 FOU (IVa) or (IVb) -CHCl2 -OH -OC2H5 FOV (IVa) or (IVb) -CHCl2 -OH -OC3H7 FOW (IVa) or (IVb)-CHC12-OH FOX (IVa) or (IVb) -CHCl2 -OH -CF3 FOY (IVa) or (IVb) -CHCl2 -OH -CHCl2 FOZ (IVa) or (IVb) -CHCl2 -OH -CCl3 FPA (IVa) or (IVb) -CHCl2 -OH -F FPB (IVa) or (IVb)-CHCl2-OH-Cl FPC (IVa) or (IVb) -CHCl2 -OH -Br FPD (IVa) or (IVb)-CHC12-OH-I FPE (IVa) or (IVb) -CHCl2 -F -H FPF (IVa) or (IVb)-CHC12-F-CH3 FPG (IVa) or (IVb) -CHCl2 -F -n-propyl FPH (IVa) or (IVb) -CHCl2 -F -n-butyl FPI (IVa) or (IVb) -CHCl2 -F -t-butyl FPJ (IVa) or (IVb) -CHCl2 -F -iso-butyl FPK (IVa) or (IVb) -CHCl2 -F -OCH3 PPL (IVa) or (IVb) -CHCl2 -F -OC2H5 FPM (IVa) or (IVb) -CHCl2 -F -OC3H7 FPN (IVa) or (IVb) -CHCl2 -F -CHF2 FPO (IVa) or (IVb) -CHCl2 -F -CF3 FPP (IVa) or (IVb) -CHCl2 -F -CHCl2 FPQ (rVa) or (IVb)-CHC12-F-CCl3 FPR (IVa) or (IVb) -CHCl2 -F - FPS (IVa) or (IVb) -CHCl2 -F -Cl

Compound R1 R3 R4 FPT (IVa) or (IVb) -CHCl2 -F -Br FPU (IVa) or (IVb)-CHC12-F-I FPV (IVa) or (IVb) -CHCl2 -Cl -H FPW (IVa) or (IVb)-CHC12-Cl-CH3 FPX (IVa) or (IVb)-CHC12-Cl-n-propyl FPY (IVa) or (IVb)-CHC12-Cl-n-butyl FPZ (IVa) or (IVb)-CHC12-Cl-t-butyl FQA (IVa) or (IVb) -CHCl2 -Cl -iso-butyl FQB (IVa) or (IVb) -CHCl2 -Cl -OCH3 FQC (IVa) or (IVb) -CHCl2 -Cl -OC2H5 FQD (IVa) or (IVb) -CHCl2 -Cl -OC3H7 FQE (IVa) or (IVb) -CHCl2 -Cl -CHF2 FQF (IVa) or (IVb) -CHCl2 -Cl -CF3 FQG (IVa) or (IVb) -CHCl2 -Cl -CHCl2 FQH (IVa) or (IVb)-CHC12-Cl-CCl3 FQI (IVa) or (IVb) -CHCl2 -Cl -F FQJ (IVa) or (IVb) -CHCl2 -Cl -Cl FQK (IVa) or (IVb) -CHCl2 -Cl -Br FQL (IVa) or (IVb) -CHCl2 -Cl -I FQM (IVa) or (IVb) -CHCl2 -Br -H FQN(IVa) or (IVb) -CHCl2 -Br -CH3 FQO (IVa) or (IVb) -CHCl2 -Br -n-propyl FQP (IVa) or (IVb)-CHC12-Br-n-butyl FQQ (IVa) or (IVb) -CHCl2 -Br -t-butyl FQR (IVa) or (IVb) -CHCl2 -Br -iso-butyl FQS (IVa) or (IVb)-CHC12-Br-OCH3 FQT (IVa) or (IVb)-CHC12-Br-OC2H5 FQU (IVa) or (IVb) -CHCl2 -Br -OC3H7

Compound R1 R4 FQV (IVa) or (IVb)-CHC12-Br-CHF2 FQW (IVa) or (IVb)-CHC12-Br-CF3 FQX (IVa) or (IVb)-CHCl2-Br-CHC12 FQY (IVa) or (IVb) -CHCl2 -Br -CCl3 FQZ (IVa) or (IVb) -CHCl2 -Br -F FRA (IVa) or (IVb) -CHCl2 -Br -Cl FRB (IVa) or (IVb) -CHCl2 -Br -Br FRC (IVa) or (IVb) -CHCl2 -Br -I FRD (IVa) or (IVb) -CHCl2 -I -H FRE (IVa) or (IVb) -CHCl2 -I -CH3 FRF (IVa) or (IVb) -CHCl2 -I -n-propyl FRG (IVa) or (IVb)-CHC12-I-n-butyl FRH (IVa) or (IVb) -CHCl2 -I -t-butyl FRI (IVa) or (IVb) -CHCl2 -I -iso-butyl FRJ (IVa) or (IVb) -CHCl2 -I -OCH3 FRK (IVa) or (IVb) -CHCl2 -I -OC2H5 FRL (IVa) or (IVb) -CHCl2 -I -OC3H7 FRM (IVa) or (IVb)-CHC12-I-CHF2 FRN (IVa) or (IVb) -CHCl2 -I -CF3 FRO (IVa) or (IVb) -CHCl2 -I -CHCl2 FRP (IVa) or (IVb) -CHCl2 -I -CCl3 FRQ (IVa) or (IVb) -CHCl2 -I -F FRR (IVa) or (IVb) -CHCl2 -I -Cl FRS (IVa) or (IVb)-CHCl2-I-Br FRT (IVa) or (IVb) -CHCl2 -I -I FRU (IVa) or (IVb)-CHC12-NO2-H 'FRV (IVa) or (IVb) -CHCl2 -NO2 -CH3 FRW (IVa) or (IVb)-CHC12-NO2-n-propyl

Compound Ri R3 R4 FRX (IVa) or (IVb) -CHCl2 -NO2 -n-butyl FRY (IVa) or (IVb) -CHCl2 -NO2 -t-butyl FRZ (IVa) or (IVb) -CHCl2 -NO2 -iso-butyl FSA (IVa) or (IVb) -CHCl2 -NO2 -OCH3 FSB (IVa) or (IVb) -CHCl2 -NO2 -OC2H5 FSC (IVa) or (IVb) -CHCl2 -NO2 -OC3H7 FSD (IVa) or (IVb)-CHC12-NO2-CHF2 FSE (IVa) or (IVb) -CHCl2 -NO2 -CF3 FSF (IVa) or (IVb) -CHCl2 -NO2 -CHCl2 FSG (IVa) or (IVb) -CHCl2 -NO2 -CCl FSH(IVa) or (IVb) -CHCl2 -NO2 -F FSI (IVa) or (IVb) -CHCl2 -NO2 -Cl FSJ (IVa) or (IVb) -CHCl2 -NO2 -Br FSK (IVa) or (IVb) -CHCl2 -NO2 -I FSL (IVa) or (IVb) -CHCl2 -CN -H FSM (IVa) or (IVb) -CHCl2 -CN -CH3 FSN (IVa) or (IVb) -CHCl2 -CN -n-propyl FSO (IVa) or (IVb) -CHCl2 -CN -n-butyl FSP (IVa) or (IVb) -CHCl2 -CN -t-butyl FSQ (IVa) or (IVb) -CHCl2 -CN -iso-butyl FSR (IVa} or (IVb) -CHCl2 -CN -OCH3 FSS (IVa) or (IVb) -CHCl2 -CN -OC2H5 FST (IVa) or (IVb) -CHCl2 -CN -OC3H7 FSU (IVa) or (IVb) -CHCl2 -CN -CHF2 FSV (IVa) or (IVb) -CHCl2 -CN -CF3 FSW (IVa) or (IVb) -CHCl2 -CN -CHCl2 FSX (IVa) or (IVb) -CHCl2 -CN -CCl3 FSY (IVa) or (IVb) -CHCl2 -CN -F

Compound R1 R3 R4 FSZ (IVa) or (IVb)-CHCl2-CN-Cl FTA (IVa) or (IVb)-CHCl2-CN-Br FTB (IVa) or (IVb) -CHCl2 -CN -I FTC (IVa) or (IVb)-CHCl2-NH2-H FTD (IVa) or (IVb)-CHCl2-NH2-CH3 FTE (IVa) or (IVb)-CHCl2-NH2-n-propyl FTF (IVa) or (IVb) -CHCl2 -NH2 -n-butyl FTG (IVa) or (IVb) -CHCl2 -NH2 -t-butyl FTH (IVa) or (IVb) -CHCl2 -NH2 -iso-butyl FTI (IVa) or (IVb) -CHCl2 -NH2 -OCH3 FTJ (IVa) or (IVb) -CHCl2 -NH2 -OC2H5 FTK (IVa) or (IVb) -CHCl2 -NH2 -OC3H7 FTL (IVa) or (IVb) -CHCl2 -NH2 -CHF2 FTM (IVa) or (IVb) -CHCl2 -NH2 -CF3 FTN (IVa) or (IVb) -CHCl2 -NH2 -CHCl2 FTO (IVa) or (IVb) -CHCl2 -NH2 -CCl3 FTP (IVa) or (IVb) -CHCl2 -NH2 -F FTQ (IVa) or (IVb) -CHCl2 -NH2 -Cl FTR (IVa) or (IVb) -CHCl2 -NH2 -Br FTS (lVa) or (IVb) -CHCl2 -NH2 -I FTT (IVa) or (IVb) -CHCl2 -CH3 -H FTU (IVa) or (IVb)-CHC12-CH3-CH3 FTV (IVa) or (IVb) -CHCl2 -CH3 -n-propyl FTW (IVa) or (IVb) -CHCl2 -CH3 -n-butyl FTX (IVa) or (IVb) -CHCl2 -CH3 -t-butyl FTY (IVa) or (IVb) -CHCl2 -CH3 -iso-butyl FTZ (IVa) or (IVb) -CHCl2 -CH3 -OCH3 FUA (IVa) or (IVb) -CHCl2 -CH3 -OC2H5

Compound Rl R3. FUB (IVa) or (IVb) -CHCl2 -CH3 -OC3H7 FUC (IVa) or (IVb) -CHCl2 -CH3 -CHF2 FUD (IVa) or (IVb) -CHCl2 -CH3 -CF3 FUE (IVa) or (IVb) -CHCl2 -CH3 -CHCl2 FUF (IVa) or (IVb) -CHCl2 -CH3 -CCl3 FUG (IVa) or (IVb) -CHCl2 -CH3 -F FUH (IVa) or (IVb) -CHCl2 -CH3 -Cl FUI (IVa) or (IVb) -CHCl2 -CH3 -Br FUJ(IVa) or (IVb) -CHCl2 -CH3 -I FUK(IVa) -CF3 -H -H FUL (IVa) -CF3 -H -CH3 FUM (IVa)-CF3-H-n-propyl FUN (IVa)-CF3-H-n-butyl FUO (IVa)-CF3-H-t-butyl FUP (IVa)-CF3-H-iso-butyl FUQ (IVa)-CF3-H-OCH3 FUR (IVa) -CF3 -H -OC2H5 FUS (IVa) -CF3 -H -OC3H7 FUT (IVa) -CF3 -H -CHF2 FUU (IVa) -CF3 -H -CF3 FUV(IVa) -CF3 -H -CHCl2 FUW(IVa) -CF3 -H -CCl3 FUX (IVa) -CF3 -H -F FUY(IVa) -CF3 -H -Cl FUZ(IVa) -CF3 -H -Br FVA (IVa) -CF3 -H -I FVB (IVa) or (IVb) -CF3 -OH -H FVC (IVa) or (IVb) -CF3 -OH -CH3

Compound R1 R3 R4 FVD (IVa) or (IVb)-CF3-OH-n-propyl FVE (IVa) or (IVb)-CF3-OH-n-butyl FVF (IVa) or (IVb)-CF3-OH-t-butyl FVG (IVa) or (IVb)-CF3-OH-iso-butyl FVH (IVa) or (IVb) -CF3 -OH -OCH3 FVI (IVa) or (IVb) -CF3 -OH -OC2H5 FVJ (IVa) or (IVb) -CF3 -OH -OC3H7 FVK (IVa) or (IVb) -CF3 -OH -CHF2 FVL (IVa) or (IVb)-CF3-OH-CF3 FVM (IVa) or (IVb) -CF3 -OH -CHCl2 FVN(IVa) or (IVb) -CF3 -OH -CCl3 FVO(IVa) or (IVb) -CF3 -OH -F FVP (IVa) or (IVb) -CF3 -OH -Cl FVQ(IVa) or (IVb) -CF3 -OH -Br FVR (IVa) or (IVb) -CF3 -OH -I FVS (IVa) or (IVb) -CF3 -F -H FVT (IVa) or (IVb)-CF3-F-CH3 FVU (IVa) or (IVb)-CF3-F-n-propyl FW (IVa) or (IVb)-CF3-F-n-butyl FVW (IVa) or (IVb)-CF3-F-t-butyl FVX (IVa) or (IVb)-CF3-F-iso-butyl FVY (IVa) or (IVb)-CF3-F-OCH3 FVZ (IVa) or (IVb) -CF3 -F -OC2H5 FWA(IVa) or (IVb) -CF3 -F -OC3H7 FWB (IVa) or (IVb) -CF3 -F -CHF2 FWC (IVa) or (IVb) -CF3 -F -CF3 FWD (IVa) or (IVb) -CF3 -F -CHCl2 FWE (IVa) or (IVb) -CF3 -F -CCl3

Compound R1 R3 R4 FWF (IVa) or (IVb) -CF -F -F FWG (IVa) or (IVb) -CF3 -F -Cl FWH (IVa) or (IVb)-CF3-F-Br FWI (IVa) or (IVb)-CF3-F-I FWJ (IVa) or (IVb) -CF3 -Cl -H FWK (IVa) or (IVb)-CF3-Cl-CH3 FWL (IVa) or (IVb)-CF3-Cl-n-propyl FWM (IVa) or (IVb) -CF3 -Cl -n-butyl FWN (IVa) or (IVb) -CF3 -Cl -t-butyl FWO (IVa) or (IVb) -CF3 -Cl -iso-butyl FWP (IVa) or (IVb) -CF3 -Cl -OCH3 FWQ (IVa) or (IVb) -CF3 -Cl -OC2H5 FWR (IVa) or (IVb)-CF3-Cl-OC3H7 FWS (IVa) or (IVb)-CF3-Cl-CHF2 FWT (IVa) or (IVb) -CF3 -Cl -CF3 FWU (IVa) or (IVb) -CF3 -Cl -CHCl2 FWV (IVa) or (IVb) -CF3 -Cl -CCl3 FWW (IVa) or (IVb) -CF3 -Cl -F FWX (IVa) or (IVb) -CF3 -Cl -Cl FWY (IVa) or (IVb)-CF3-Cl-Br FWZ (IVa) or (IVb) -CF3 -Cl -I FXA Va) or (IVb) -CF3 -Br -H FXB (IVa) or (IVb) -CF3 -Br -CH3 FXC (IVa) or (IVb)-CF3-Br-n-propyl FXD (IVa) or (IVb) -CF3 -Br -n-butyl FXE (IVa) or (IVb) -CF3 -Br -t-butyl FXF(IVa) or (IVb) -CF3 -Br -iso-butyl FXG(IVa) or (IVb) -CF3 -Br -OCH3

Compound R1 R3 R4 FXH (IVa) or (IVb) -CF3 -Br -OC2H5 FXI(IVa) or (IVb) -CF3 -Br -OC3H7 FXJ (IVa) or (IVb) -CF3 -Br -CHF2 FXK (IVa) or (IVb) -CF3 -Br -CF3 FXL (IVa) or (IVb) -CF3 -Br -CHCl2 FXM (IVa) or (IVb) -CF3 -Br -CCl3 FXN (IVa) or (IVb) -CF3 -Br -F FXO (IVa) or (IVb) -CF3 -Br -Cl FXP (IVa) or (IVb) -CF3 -Br -Br FXQ (IVa) or (IVb) -CF3 -Br -I FXR (IVa) or (IVb) -CF3 -I -H FXS (IVa) or (IVb)-CF3-I-CH3 FXT (IVa) or (IVb)-CF3-I-n-propyl FXU (IVa) or (IVb)-CF3-I-n-butyl FXV (IVa) or (IVb) -CF3 -I -t-butyl FXW (IVa) or (IVb) -CF3 -I -iso-butyl FXX (IVa) or (IVb) -CF3 -I -OCH3 FXY (IVa) or (IVb) -CF3 -I -OC2H5 FXZ (IVa) or (IVb) -CF3 -I -OC3H7 FYA (IVa) or (IVb) -CF3 -I -CHF2 FYB (IVa) or (IVb)-CF3-CF3 FYC (IVa) or (IVb) -CF3 -I -CHCl2 FYD (IVa) or (IVb) -CF3 -I -CCl3 FYE (lVa) or (IVb) -CF3 -I -F FYF(IVa) or (IVb) -CF3 -I -Cl FYG (IVa) or (IVb) -CF3 -I -Br FYH (IVa) or (IVb) -CF3 -I -I FYI (IVa) or (IVb) -CF3 -NO2 -H

Compound Ri R3 R4 FYJ (IVa) or (IVb) -CF3 -NO2 -CH3 FYK (IVa) or (IVb) -CF3 -NO2 -n-propyl FYL (IVa) or (IVb)-CF3-NO2-n-butyl FYM (IVa) or (IVb) -CF3 -NO2 -t-butyl FYN (IVa) or (IVb) -CF3 -NO2 -iso-butyl FYO (IVa) or (IVb) -CF3 -NO2 -OCH3 FYP (IVa) or (IVb) -CH3 -NO2 -OC2H5 FYQ (IVa) or (IVb) -CF3 -NO2 -OC3H7 FYR (IVa) or (IVb) -CF3 -NO2 -CHF2 FYS (IVa) or (IVb)-CF3-NO2-CF3 FYT (IVa) or (IVb)-CF3-NO2-CHCI2 FYU (IVa) or (IVb) -CF3 -NO2 -CCl3 FYV (IVa) or (IVb) -CF3 -NO2 -F FYW (IVa) or (IVb) -CF3 -NO2 -Cl FYX (IVa) or (IVb) -CF3 -NO2 -Br FYY (IVa) or (IVb) -CF3 -NO2 -I FYZ (IVa) or (IVb)-CF3-CN-H FZA (IVa) or (IVb)-CF3-CN-CH3 FZB (IVa) or (IVb) -CF3 -CN -n-propyl FZC (IVa) or (IVb) -CF3 -CN -n-butyl FZD (IVa) or (IVb)-CF3-CN-t-butyl FZE (IVa) or (IVb)-CF3-CN-iso-butyl FZF (IVa) or (IVb) -CF3 -CN -OCH3 FZG (IVa) or (IVb) -CF3 -CN -OC2H5 FZH (IVa) or (IVb) -CF3 -CN -OC3H7 FZI (IVa) or (IVb)-CF3-CN-CHF2 FZJ (IVa) or (IVb)-CF3-CN-CF3 FZK (IVa) or (IVb)-CF3-CN-CHC12

Compound R1 R3 R4 FZL (IVa) or (IVb)-CF3-CN-CCl3 FZM (IVa) or (IVb) -CF3 -CN -F FZN (IVa) or (IVb) -CF3 -CN -Cl FZO (IVa) or (IVb) -CF3 -CN -Br FZP (IVa) or (IVb) -CF3 -CN -I FZQ (IVa) or (IVb)-CF3-NH2-H FZR (IVa) or (IVb) -CF3 -NH2 -CH3 FZS (IVa) or (IVb)-CF3-NH2-n-propyl FZT (IVa) or (IVb)-CF3-NH2-n-butyl FZU (IVa) or (IVb) -CF3 -NH2 -t-butyl FZV (IVa) or (IVb)-CF3-NH2-iso-butyl FZW (IVa) or (IVb)-CF3-NH2-OCH3 FZX (IVa) or (IVb) -CF3 -NH2 -OC2H5 FZY (IVa) or (IVb) -CF3 -NH2 -OC3H7 FZZ (IVa) or (IVb) -CF3 -NH2 -CHF2 GAA (IVa) or (IVb)-CF3-NH2-CF3 GAB (IVa) or (IVb)-CF3-NH2-CHC12 GAC (IVa) or (IVb) -CF3 -NH2 -CCl3 GAD (IVa) or (IVb) -CF3 -NH2 -F GAE(IVa) or (IVb) -CF3 -NH2 -Cl GAF(IVa) or (IVb) -CF3 -NH2 -Br GAG(IVa) or (IVb) -CF3 -NH2 -I GAH(IVa) or (IVb) -CF3 -CH3 -H GAI(IVa) or (IVb) -CF3 -CH3 -CH3 GAG (IVa) or (IVb) -CF3 -NH2 -I GAH (IVa) or (IVb) -CF3 -CH3 -H GAI (IVa) or (IVb)-CF3-CH3-CH3 GAJ (IVa) or (IVb)-CF3-CH3-n-propyl GAK (IVa) or (IVb) -CF3 -CH3 -n-butyl GAL (IVa) or (IVb) -CF3 -CH3 -t-butyl GAM (IVa) or (IVb) -CF3 -CH3 -iso-butyl

Compound R, R3 R4 GAN (IVa) or (IVb) -CF3 -CH3 -OCH3 GAO (IVa) or (IVb) -CF3 -CH3 -OC2H5 GAP (IVa) or (IVb) -CF3 -CH3 -OC3H7 GAQ (IVa) or (IVb)-CF3-CH3-CHF2 GAR (IVa) or (IVb) -CF3 -CH3 -CF3 GAS (IVa) or (IVb)-CF3-CH3-CHCl2 GAT (IVa) or (IVb) -CF3 -CH3 -CCl3 GAU (IVa) or (IVb) -CF3 -CH3 -F GAV (IVa) or (IVb) -CF3 -CH3 -Cl GAW (IVa) or (IVb)-CF3-CH3-Br GAX (IVa) or (IVb) -CF3 -CH3 -I GAY (IVa)-NO2-H-H GAZ (IVa)-NO2-H-CH3 GBA (IVa)-NO2-H-n-propyl GBB (IVa)-NO2-H-n-butyl GBC (IVa) -NO2 -H -t-butyl GBD (IVa) -NO2 -H -iso-butyl GBE (IVa) -NO2 -H -OCH3 GBF (IVa) -NO2 -H -OC2H5 GBG (IVa) -NO2 -H -OC3H7 GBH (IVa) -NO2 -H -CHF2 GBI (IVa) -NO2 -H -CF3 GBJ (IVa) -NO2 -H -CHCl2 GBK (IVa) -NO2 -H -CCl3 GBL (IVa) -NO2 -H -F GBM (IVa) -NO2 -N -Cl GBN (IVa) -NO2 -H -Br GBO (IVa) -NO2 -H -I

Compound R1 R3 R4 GBP (IVa) or (IVb)-NO2-OH-H GBQ (IVa) or (IVb)-NO2-OH-CH3 GBR (IVa) or (IVb)-NO2-OH-n-propyl GBS (IVa) or (IVb)-N02-OH-n-butyl GBT (IVa) or (IVb) -NO2 -OH -t-butyl GBU (IVa) or (IVb) -NO2 -OH -iso-butyl GBV (IVa) or (IVb) -NO2 -OH -OCH3 GBW (IVa) or (IVb) -NO2 -OH -OC2H5 GBX (IVa) or (IVb) -NO2 -OH -OC3H7 GBY (IVa) or (IVb) -NO2 -OH -CF2 GBZ (IVa) or (IVb)-N02-OH-CF3 GCA (IVa) or (IVb) -NO2 -OH -CHCl2 GCB (IVa) or (IVb) -NO2 -OH -CCl3 GCC (IVa) or (IVb) -NO2 -OH -F GCD (IVa) or (IVb) -NO2 -OH -Cl GCE (IVa) or (IVb) -NO2 -OH -Br GCF (IVa) or (IVb) -NO2 -OH -I GCG (IVa) or (IVb) -NO2 -F -H GCH (IVa) or (IVb) -NO2 -F -CH3 GCI (IVa) or (IVb)-N02-F-n-propyl GCJ (IVa) or (IVb) -NO2 -F -n-butyl GCK (IVa) or (IVb) -NO2 -F -t-butyl GCL (IVa) or (IVb) -NO2 -F -iso-butyl GCM (IVa) or (IVb) -NO2 -F -OCH3 GCN (IVa) or (IVb) -NO2 -F -OC2H5 GCO (IVa) or (IVb) -NO2 -F -OC3H7 GCP (IVa) or (IVb) -NO2 -F -CHF2 GCQ(IVa) or (IVb) -NO2 -F -CF3

Compound GCR (IVa) or (IVb) -NO2 -F -CHCl2 GCS (IVa) or (IVb) -NO2 -F -CCl3 GCT (IVa) or (IVb) -NO2 -F -F GCU (IVa) or (IVb)-N02-F-Cl GCV (IVa) or (IVb) -NO2 -F -Br GCW (IVa) or (IVb) -NO2 -F -I GCX (IVa) or (IVb)-N02-Cl-H GCY (IVa) or (IVb)-N02-Cl-CH3 GCZ (IVa) or (IVb) -NO2 -Cl -n-propyl GDA (IVa) or (IVb) -NO2 -Cl -n-butyl GDB (IVa) or (IVb) -NO2 -Cl -t-butyl GDC (Va) or (IVb) -NO2 -Cl -iso-butyl GDD (IVa) or (IVb) -NO2 -Cl -OCH3 GDE (IVa) or (IVb) -NO2 -Cl -OC2H5 GDF (IVa) or (IVb) -NO2 -Cl -OC3H7 GDG (IVa) or (IVb) -NO2 -Cl -CHF2 GDH (IVa) or (IVb) -NO2 -Cl -CF3 GDI (IVa) or (IVb) -NO2 -Cl -CHCl2 GDJ (IVa) or (IVb) -NO2 -Cl -CCl3 GDK (IVa) or (IVb) -NO2 -Cl -F GDL (IVa) or (IVb) -NO2 -Cl -Cl GDM (IVa) or (IVb) -NO2 -Cl -Br GDN (IVa) or (IVb) -NO2 -Cl -I GDO (IVa) or (IVb) -NO2 -Br -H GDP (IVa) or (IVb) -NO2 -Br -CH3 GDQ (IVa) or (IVb) -NO2 -Br -n-propyl GDR (IVa) or (IVb) -NO2 -Br -n-butyl GDS (IVa) or (IVb) -NO2 -Br -t-butyl

Compound Ru GDT (IVa) or (IVb)-NO2-Br-iso-butyl GDU (IVa) or (lVb)-NO2-Br-OCH3 GDV (IVa) or (IVb)-NO2-Br-OC2H5 GDW (IVa) or (IVb) -NO2 -Br -OC3H7 GDX (IVa) or (IVb) -NO2 -Br -CHF2 GDY (IVa) or (IVb) -NO2 -Br -CF3 GDZ (IVa) or (IVb)-NO2-Br-CHC12 GEA (IVa) or (IVb)-NO2-Br-CC13 GEB (IVa) or (IVb)-NO2-Br-F GEC (IVa) or (IVb) -NO2 -Br -Cl GED (IVa) or (IVb)-NO2-Br-Br GEE (IVa) or (IVb) -NO2 -Br -I GEF (IVa) or (IVb) -NO2 -I -H GEG (IVa) or (IVb) -NO2 -I -CH3 GEH (IVa) or (IVb) -NO2 -I -n-propyl GEI(IVa) or (IVb) -NO2 -I -n-butyl GEJ (IVa) or (IVb) -NO2 -I -t-butyl GEK (IVa) or (IVb) -NO2 -I -iso-butyl GEL (IVa) or (IVb) -NO2 -I -OCH3 GEM (IVa) or (IVb) -NO2 -I -OC2H5 GEN (IVa) or (IVb) -NO2 -I -OC3H7 GEO (IVa) or (IVb) -NO2 -I -CHF2 GEP (IVa) or (IVb)-NO2-I-CF3 GEQ (IVa) or (IVb) -NO2 -I -CHCl2 GER (IVa) or (IVb) -NO2 -I -CCl3 GES (IVa) or (IVb) -NO2 -I -F GET (IVa) or (IVb) -NO2 -I -Cl GEU (IVa) or (IVb) -NO2 -I -Br

Compound R1 R3 R4 GEV (IVa) or (IVb)-NO2-I-I GEW (IVa) or (IVb)-NO2-NO2-H GEX (IVa) or (IVb)-NO2-NO2-CH3 GEY (IVa) or (IVb)-NO2-NO2-n-propyl GEZ (IVa) or (IVb)-NO2-NOz-n-butyl GFA (IVa) or (IVb) -NO2 -NO2 -t-butyl GFB (IVa) or (IVb)-NO2-NO2-iso-butyl GFC (IVa) or (IVb) -NO2 -NO2 -OCH3 GFD (IVa) or (IVb) -NO2 -NO2 -OC2H5 GFE (IVa) or (IVb)-NO2-NOz-OC3H7 GFF (IVa) or (IVb) -NO2 -NO2 -CHF2 GFG (IVa) or (IVb)-NO2-NO2-CF3 GFH (IVa) or (IVb) -NO2 -NO2 -CHCl2 GFI (IVa) or (IVb) -NO2 -NO2 -CCl3 GFJ (IVa) or (IVb) -NO2 -NO2 -F GFK (IVa) or (IVb) -NO2 -NO2 -Cl GFL (IVa) or (IVb) -NO2 -NO2 -Br GFM (IVa) or (IVb) -NO2 -NO2 -I GFN (IVa) or (IVb) -NO2 -CN -H GFO (IVa) or (IVb) -NO2 -CN -CH3 GFP (IVa) or (IVb) -NO2 -CN -n-propyl GFQ (IVa) or (IVb)-N02-CN-n-butyl GFR (IVa) or (IVb) -NO2 -CN -t-butyl GFS (IVa) or (IVb) -NO2 -CN -iso-butyl GFT (IVa) or (IVb) -NO2 -CN -OCH3 GFU (IVa) or (IVb) -NO2 -CN -OC2H5 GFV (IVa) or (IVb) -NO2 -CN -OC3H7 GFW (IVa) or (IVb) -NO2 -CN -CHF2

Compound Ri R3 R4 GFX (IVa) or (IVb)-NO2-CN-CF3 GFY (IVa) or (IVb)-NO2-CN-CHC12 GFZ (IVa) or (IVb)-NO2-CN-CC13 GGA (IVa) or (IVb) -NO2 -CN -F GGB (IVa) or (IVb)-N02-CN-Cl GGC (IVa) or (IVb) -NO2 -CN -Br GGD (IVa) or (IVb)-NO2-CN-I GGE (IVa) or (IVb) -NO2 -NH2 -H GGF (IVa) or (IVb) -NO2 -NH2 -CH3 GGG (IVa) or (IVb) -NO2 -NH2 -n-propyl GGH (IVa) or (IVb) -NO2 -NH2 -n-butyl GGI (IVa) or (IVb) -NO2 -NH2 -t-butyl GGJ(IVa) or (IVb) -NO2 -NH2 -iso-butyl GGK(IVa) or (IVb) -NO2 -NH2 -OCH3 GGL (IVa) or (IVb) -NO2 -NH2 -OC2H5 GGM (IVa) or (IVb) -NO2 -NH2 -OC3H7 GGN (IVa) or (IVb) -NO2 -NH2 -CHF2 GGO(IVa) or (IVb) -NO2 -NH2 -CF3 GGP (IVa) or (IVb) -NO2 -NH2 -CHCl2 GGQ (IVa) or (IVb) -NO2 -NH2 -CCl3 GGR (IVa) or (IVb) -NO2 -NH2 -F GGS (IVa) or (IVb) -NO2 -NH2 -Cl GGT (IVa) or (IVb) -NO2 -NH2 -Br GGU (IVa) or (IVb) -NO2 -NH2 -I GGV (IVa) or (IVb)-NO2-CH3-H GGW (IVa) or (IVb)-NO2-CH3-CH3 GGX (IVa) or (IVb) -NO2 -CH3 -n-propyl GGY (IVa) or (IVb)-NOz-CH3-n-butyl

Compound R, R3 R4 GGZ (IVa) or (IVb) -NO2 -CH3 -t-butyl GHA (IVa) or (IVb) -NO2 -CH3 -iso-butyl GHB (IVa) or (IVb) -NO2 -CH3 -OCH3 GHC (IVa) or (IVb) -NO2 -CH3 -OC2H5 GHD (IVa) or (IVb) -NO2 -CH3 -OC3H7 GHE (IVa) or (IVb) -NO2 -CH3 -CHF2 GHF (IVa) or (IVb) -NO2 -CH3 -CF3 GHG (IVa) or (IVb)-N02-CH3-CHC12 GHH (IVa) or (IVb) -NO2 -CH3 -CCl3 GHI (IVa) or (IVb) -NO2 -CH3 -F GHJ(IVa) or (IVb) -NO2 -CH3 -Cl GHK (IVa) or (IVb) -NO2 -CH3 -Br GHL(IVa) or (IVb) -NO2 -CH3 -I GHM(IVa) -CN -H -H GHN (IVa) -CN -H -CH3 GHO (IVa) -CN -H -n-propyl GHP (IVa) -CN -H -n-butyl GHQ (IVa)-CN-H-t-butyl GHR (IVa)-CN-H-iso-butyl GHS (IVa) -CN -H -OCH3 GHT (IVa)-CN-H-OCH GHT (IVa) -CN -H -OC3H7 GHV (IVa) -CN -H-CHF2 GHW (lVa)-CN-H-CF3 GHX (IVa) -CN -H-CHCl2 GHY (IVa) -CN -H -CCl3 GHZ (IVa)-CN-H-F GIA (IVa)-CN-H-Cl

Compound R1 R3 R4 GIB (IVa)-CN-H-Br GIC (IVa)-CN-H-I GlD (IVa) or (IVb)-CN-OH-H GIE (IVa) or (IVb) -CN -OH -CH3 GIF (IVa) or (IVb)-CN-OH-n-propyl GIG (IVa) or (IVb)-CN-OH-n-butyl GIH (IVa) or (IVb)-CN-OH-t-butyl GII (IVa) or (IVb)-CN-OH-iso-butyl GIJ (IVa) or (IVb) -CN -OH -OCH3 GIK(IVa) or (IVb) -CN -OH -OC2H5 GIL (IVa) or (IVb)-CN-OH-OC3H7 GIM (IVa) or (IVb) -CN -OH -CHF2 GIN (IVa) or (IVb)-CN-OH-CF3 GIO (IVa) or (IVb)-CN-OH-CHC12 GIP (IVa) or (IVb) -CN -OH -CCl3 GIQ (IVa) or (IVb)-CN-OH-F GIR (IVa) or (IVb)-CN-OH-Cl GIS (IVa) or (IVb)-CN-OH-Br GIT (IVa) or (IVb)-CN-OH-I GIU (IVa) or (IVb)-CN-F-H GIV (IVa) or (IVb) -CN -F -CH3 GIW (IVa) or (IVb)-CN-F-n-propyl GIX (IVa) or (IVb)-CN-F-n-butyl GIY (IVa) or (IVb)-CN-F-t-butyl GIZ (IVa) or (IVb)-CN-F-iso-butyl GJA (IVa) or (IVb) -CN -F -OCH3 GJB (IVa) or (IVb) -CN -F -OC2H5 GJC (IVa) or (IVb) -CN -F -OC3H7

Compound R1 R3 R4 GJD(IVa) or (IVb) -CN -F -CHF2 GJE(IVa) or (IVb)-CN-F-CF3 GJF (IVa) or (IVb) -CN -F -CHCl2 GJG (IVa) or (IVb) -CN -F -CCl3 GJH(IVa) or (IVb)-CN-F-F GJI (IVa) or (IVb) -CN -F -Cl GJJ (IVa) or (IVb) -CN -F -Br GJK (IVa) or (IVb) -CN -F -I GJL(IVa) or (IVb) -CN -Cl -H GJM (IVa) or (IVb) -CN -Cl -CH3 GJN (IVa) or (IVb)-GN-Cl-n-propyl GJO (IVa) or (IVb) -CN -Cl -n-butyl GJP (IVa) or (IVb) -CN -Cl -5-tutyl GJQ (IVa) or (IVb) -CN -Cl -iso-butyl GJR(IVa) or (IVb) -CN -Cl -OCH3 GJS (IVa) or (IVb) -CN -Cl -OC2H5 GJT (IVa) or (IVb) -CN -Cl -OC3H7 GJU(IVa) or (IVb)-CN-Cl-CHF2 GJV (IVa) or (IVb) -CN -Cl -CF3 GJW (IVa) or (IVb) -CN -Cl -CHCl2 GJX (IVa) or (IVb)-CN-Cl-CCl3 GJY (IVa) or (IVb)-CN-Cl-F GJZ (IVa) or (IVb) -CN -Cl -Cl GKA(IVa) or (IVb) -CN -Cl -Br GKB (IVa) or (IVb) -CN -Cl -I GKC(IVa) or (IVb)-CN-Br-H GKD (IVa) or (IVb)-CN-Br-CH3 GKE(IVa) or (IVb) -CN -Br -n-propyl

Compound Ri R3 R4 GKF (IVa) or (IVb)-CN-Br-n-butyl GKG (IVa) or (IVb)-CN-Br-t-butyl GKH (IVa) or (IVb)-CN-Br-iso-butyl GKI (IVa) or (IVb)-CN-Br-OCH3 GKJ (IVa) or (IVb) -CN -Br -OC2H5 GKK (IVa) or (IVb) -CN -Br -OC3H7 GKL (IVa) or (IVb) -CN -Br -CHF2 GKM (IVa) or (IVb)-CN-Br-CF3 GKN (IVa) or (IVb) -CN -Br -CHCl2 GKO (IVa) or (IVb)-CN-Br-CC13 GKP (IVa) or (lVb)-CN-Br-F GKQ (IVa) or (IVb) -CN -Br -Cl GKR (IVa) or (IVb)-CN-Br-Br GKS (IVa) or (IVb) -CN -Br -I GKT(IVa) or (IVb) -CN -I -H GKU (IVa) or (IVb)-CN-CH3 GKV (IVa) or (IVb)-CN-I-n-propyl GKW (IVa) or (IVb)-CN-I-n-butyl GKX (IVa) or (IVb)-CN-I-t-butyl GKY (IVa) or (IVb) -CN -I -iso-butyl GKZ (IVa) or (IVb) -CN -I -OCH3 GLA (IVa) or (IVb) -CN -I -OC2H5 GLB (IVa) or (IVb) -CN -I -OC3H7 GLC (IVa) or (IVb) -CN -I -CHF2 GLD (IVa) or (IVb) -CN -I -CF3 GLE (IVa) or (IVb) -CN -I -CHCl2 GLF (IVa) or (IVb) -CN -I -CCl3 GLG (IVa) or (IVb) -CN -I -F

Compound Ri R3 R4 GLH (IVa) or (IVb) -CN -I -Cl GLI (IVa) or (IVb)-CN-I-Br GLJ (IVa) or (IVb) -CN -I -I GLK (IVa) or (IVb) -CN -NO2 -H GLL (IVa) or (IVb)-CN-NO2-CH3 GLM (IVa) or (IVb) -CN -NO2 -n-propyl GLN (IVa) or (IVb) -CN -NO2 -n-butyl GLO (IVa) or (IVb) -CN -NO2 -t-butyl GLP (IVa) or (IVb) -CN -NO2 -iso-butyl GLQ (IVa) or (IVb)-CN-NO2-OCH3 GLR (IVa) or (IVb)-CN-NO2-OC2H5 GLS (IVa) or (IVb) -CN -NO2 -OC3H7 GLT (IVa) or (IVb) -CN -NO2 -CHF2 GLU (IVa) or (IVb) -CN -NO2 -CF3 GLV (IVa) or (IVb)-CN-NO2-CHC12 GLW (IVa) or (IVb) -CN -NO2 -CCl3 GLX (IVa) or (IVb) -CN -NO2 -F GLY(IVa) or (IVb) -CN -NO2 -Cl GLZ (IVa) or (IVb) -CN -NO2 -Br GMA (IVa) or (IVb) -CN -NO2 -I GMB (IVa) or (IVb) -CN -CN -H GMC (IVa) or (IVb) -CN -CN -CH3 GMD (IVa) or (IVb)-CN-CN-n-propyl GME (IVa) or (IVb)-CN-CN-n-butyl GMF (IVa) or (IVb) -CN -CN -t-butyl GMG (IVa) or (lVb)-CN-CN-iso-butyl GMH (IVa) or (IVb) -CN -CN -OCH3 GMI (IVa) or (IVb) -CN -CN -OC2H5

Compound Ri R3 R4 GMJ (IVa) or (IVb) -CN -CN -OC3H7 GMK (IVa) or (IVb) -CN -CN -CHF2 GML (IVa) or (IVb)-CN-CN-CF3 GMM (IVa) or (IVb) -CN -CN -CHCl2 GMN (IVa) or (IVb)-CN-CN-CCl3 GMO (IVa) or (IVb)-CN-CN-F GMP (IVa) or (IVb)-CN-CN-Cl GMQ (TVa) or (IVb) -CN -CN -Br GMR (IVa) or (IVb)-CN-CN-I GMS (IVa) or (IVb) -CN -NH2 -H GMT (IVa) or (IVb)-CN-NE2-CH3 GMU (IVa) or (IVb)-CN-NH2-n-propyl GMV (IVa) or (IVb)-CN-NHz-n-butyl GMW (IVa) or (IVb)-CN-NH2-t-butyl GMX (IVa) or (IVb) -CN -NH2 -iso-butyl GMY (IVa) or (IVb) -CN -NH2 -OCH3 GMZ (IVa) or (IVb) -CN -NH2 -OC2H5 GNA (IVa) or (IVb) -CN -NH2 -OC3H7 GNB (IVa) or (IVb) -CN -NH2 -CHF2 GNC (IVa) or (IVb) -CN -NH2 -CF3 GND (IVa) or (IVb) -CN -NH2 -CHCl2 GNE (IVa) or (IVb) -CN -NH2 -CCl3 GNF (IVa) or (IVb) -CN -NH2 -F GNG (IVa) or (IVb) -CN -NH2 GNH (IVa) or (IVb) -CN -NH2 -Br (GNI(IVa) or (IVb) -CN -NH2 -I GNJ(IVa) or (IVb)-CN-CH3-H GNK(IVa) or (IVb) -CN -CH3 -CH3

Compound RI R3 R4 GNL (IVa) or (IVb)-CN-CH3-n-propyl GNM (IVa) or (IVb)-CN-CH3-n-butyl GNN (IVa) or (IVb) -CN -CH3 -t-butyl GNO (IVa) or (IVb)-CN-CH3-iso-butyl GNP (IVa) or (IVb) -CN -CH3 -OCH3 GNQ (IVa) or (IVb) -CN -CH3 -OC2H5 GNR (IVa) or (IVb) -CN -CH3 -OC3H7 GNS (IVa) or (IVb) -CN -CH3 -CHF2 GNT (IVa) or (IVb) -CN -CH3 -CF3 GNU (IVa) or (IVb) -CN -CH3 -CHCl2 GNV (IVa) or (IVb)-CN-CH3-CCl3 GNW (IVa) or (IVb) -CN -CH3 -F GNX (IVa) or (IVb)-CN-CH3-Cl GNY (IVa) or (IVb) -CN -CH3 -Br GNZ (IVa) or (IVb) -CN -CH3 -I GOA (IVa) -CH3 -H -H GOB (IVa) -CH3 -H -CH3 GOC (IVa) -CH3 -H -n-propyl GOD (IVa) -CH3 -H -n-butyl GOE (IVa)-CH3-H-t-butyl GOF (IVa)-CH3-H-iso-butyl GOG (IVa) -CH3 -H -OCH3 GOH (IVa) -CH3 -H -OC2H5 GOI(IVa) -CH3 -H -OC3H7 GOJ (IVa) -CH3 -H GOK (IVa) -CH3 -H -CF3 GOL (IVa) -CH3 -H -CHCl2 GOM (IVa)-CH3-H-CCl3

Compound R CON(IVa) -CH3 -H -F GOO(IVa) -CH3 -H -Cl - CH3 _g-Br GOP(IVa) -CH3 -H GOQ(IVa) -CH3 -H GOR(IVa) or (IVb) -CH3 -OH -H GOS (IVa) or (IVb)-CX3 OH-CH3 GOS(IVa) or (IVb) -CH3 -OH -CH3 GOT(IVa) or (IVb) -CH3 -OH -n-propyl GOU(IVa) or (IVb) -CH3 -OH -n-butyl GOV (IVa) or (IVb) -CH3 -OH -t-butyl GOW (IVa) or (lVb)-CH3-OH-iso-butyl GOX (IVa) or (IVb)-CH3-OH-OCH3 GOY (IVa) or (IVb) -CH3 -OH -OC2H5 GOZ (IVa) or (IVb) -CH3 -OH -OC3H7 GPA (IVa) or (IVb)-CH3-OH-CHF2 GPB (IVa) or (IVb) -CH3 -OH -CF3 GPC (IVa) or (IVb)-CH3-OH-CHC12 GPD (IVa) or (IVb)-CH3-OH-CCl3 GPE (IVa) or (IVb) -CH3 -OH -F GPF (IVa) or (IVb) -CH3 -OH -Cl GPG (IVa) or (IVb) -CH3 -OH -Br GPH (IVa) or (IVb) -CH3 -OH -I GPI (IVa) or (IVb) -CH3 -F -H GPJ (IVa) or (IVb)-CH3-F-CH3 GPK (IVa) or (IVb) -CH3 -F -n-propyl GPL (IVa) or (IVb) -CH3 -F -n-butyl GPM (IVa) or (IVb)-CH3-F-t-butyl GPN(IVa) or (IVb) -CH3 -F -iso-butyl GPO (IVa) or (IVb) -CH3 -F -OCH3

Compound RI R3 R4 GPP (IVa) or (IVb) -CH3 -F -OC2H5 GPQ (IVa) or (IVb) -CH3 -F -OC3H7 GPR (IVa) or (IVb) -CH3 -F -CHF2 GPS (IVa) or (IVb)-CH3-F-CF3 GPT (IVa) or (IVb) -CH3 -F -CHCl2 GPU (IVa) or (IVb) -CH3 -F -CCl3 GPV (IVa) or (IVb)-CH3-F-F GPW (IVa) or (IVb)-CH3-F-Cl GPX (IVa) or (IVb)-CH3-F-Br GPY (IVa) or (IVb) -CH3 -F -I GPZ (IVa) or (IVb) -CH3 -Cl -H GQA (IVa) or (IVb) -CH3 -Cl -CH3 GQB (IVa) or (IVb) -CH3 -Cl -n-propyl GQC (IVa) or (IVb) -CH3 -Cl -n-butyl GQD (IVa) or (IVb) -CH3 -Cl -t-butyl GQE (IVa) or (IVb) -CH3 -Cl -iso-butyl GQF (IVa) or (IVb) -CH3 -Cl -OCH3 GQG (IVa) or (IVb) -CH3 -Cl -OC2H5 GQH (IVa) or (IVb) -CH3 -Cl -OC3H7 GQI (IVa) or (IVb) -CH3 -Cl -CHF2 GQJ (IVa) or (IVb) -CH3 -Cl -CF3 GQK(IVa) or (IVb) -CH3 -Cl -CHCl2 GQL (IVa) or (IVb) -CH3 -Cl -CCl3 GQM (IVa) or (IVb) -CH3 -Cl -F GQN (IVa) or (IVb) -CH3 -Cl -Cl GQO (IVa) or (IVb) -CH3 -Cl -Br GQP (IVa) or (IVb) -CH3 -Cl -I GQQ (IVa) or (IVb) -CH3 -Br -H

Compound R1 R3 R4 GQR (IVa) or (IVb) -CH3 -Br -CH3 GQS (IVa) or (IVb) -CH3 -Br -n-propyl GQT (IVa) or (IVb) -CH3 -Br -n-butyl GQU (IVa) or (IVb)-CH3-Br-t-butyl GQV (IVa) or (IVb) -CH3 -Br -iso-butyl GQW (IVa) or (IVb) -CH3 -Br -OCH3 GQX (IVa) or (IVb) -CH3 -Br -OC2H5 GQY (IVa) or (IVb) -CH3 -Br -OC3H7 GQZ (IVa) or (IVb) -CH3 -Br -CHF2 GRA (IVa) or (IVb)-CH3-Br-CF3 GRB (IVa) or (IVb) -CH3 -Br -CHCl2 GRC (IVa) or (IVb) -CH3 -Br -CCl3 GRD (IVa) or (IVb)-CH3-Br-F GRE (IVa) or (IVb) -CH3 -Br -Cl GRF (IVa) or (IVb) -CH3 -Br -Br GRG (IVa) or (IVb) -CH3 -Br -I GRH (IVa) or (IVb)-CH3-I-H GRI (IVa) or (IVb) -CH3 -I -CH3 GRJ (IVa) or (IVb) -CH3 -I -n-propyl GRK (IVa) or (IVb)-CH3-I-n-butyl GRL (IVa) or (IVb)-CH3-t-butyl GRM (IVa) or (IVb) -CH3 -I -isobutyl GRN (IVa) or (IVb) -CH3 -I -OCH3, GRO (IVa) or (IVb) -CH3 -I -OC2H5 GRP (IVa) or (IVb) -CH3 -I -OC3H7 GRQ (IVa) or (IVb) -CH3 -I -CHF2 GRR (IVa) or (IVb) -CH3 -I -CF3 GRS (IVa) or (IVb) -CH3 -I -CHCl2

Compound RX _Rs R4 GRT (IVa) or (IVb) -CH3 -I -CCl3 GRU (IVa) or (IVb)-CH3-I-F GRV (IVa) or (IVb)-CH3-I-Cl GRW (IVa) or (IVb)-CH3-I-Br GRX (IVa) or (IVb) -CH3 -I -I GRY (IVa) or (IVb) -CH3 -NO2 -H GRZ (IVa) or (IVb) -CH3 -NO2 -CH3 GSA (IVa) or (IVb) -CH3 -NO2 -n-propyl GSB (IVa) or (IVb) -CH3 -NO2 -n-butyl GSC (IVa) or (IVb) -CH3 -NO2 -t-butyl GSD (IVa) or (IVb) -CH3 -NO2 -iso-butyl GSE (IVa) or (IVb) -CH3 -NO2 -OCH3 GSF (IVa) or (IVb) -CH3 -NO2 -OC2H5 GSG (IVa) or (IVb) -CH3 -NO2 -OC3H7 GSH (IVa) or (IVb) -CH3 -NO2 -CHF2 GSI (IVa) or (IVb) -CH3 -NO2 -CF3 GSJ (IVa) or (IVb) -CH3 -NO2 -CHCl2 GSK (IVa) or (IVb) -CH3 -NO2 -CCl3 GSL (IVa) or (IVb) -CH3 -NO2 -F GSM (IVa) or (IVb) -CH3 -NO2 -Cl GSN (IVa) or (IVb) -CH3 -NO2 -Br GSO(IVa) or (IVb) -CH3 -NO2 -I GSP (IVa) or (IVb)-CH3-CN-H GSQ (IVa) or (IVb) -CH3 -CN -CH3 GSR (IVa) or (IVb)-CH3-CN-n-propyl GSS (IVa) or (IVb) -CH3 -CN -n-butyl GST (IVa) or (IVb)-CH3-CN-t-butyl GSU (IVa) or (IVb) -CH3 -CN -iso-butyl

Compound Ri R3 R4 GSV (IVa) or (IVb)-CH3-CN-OCH3 GSW (IVa) or (IVb) -CH3 -CN -OC2H5 GSX (IVa) or (IVb) -CH3 -CN -OC3H7 GSY (IVa) or (IVb) -CH3 -CN -CHF2 GSZ (IVa) or (IVb) -CH3 -CN -CF3 GTA (IVa) or (IVb) -CH3 -CN -CHCl2 GTB (IVa) or (IVb) -CH3 -CN -CCl3 GTC (IVa) or (IVb) -CH3 -CN -F GTD (IVa) or (IVb)-CH3-CN-Cl- GTE (IVa) or (IVb) -CH3 -CN -Br GTF (IVa) or (IVb) -CH3 -CN -I GTG (IVa) or (IVb) -CH3 -NH2 -H GTH (IVa) or (IVb)-CH3-NH2-CH3 GTI (IVa) or (IVb) -CH3 -NH2 -n-propyl GTJ (IVa) or (IVb)-CH3-NH2-n-butyl GTK (IVa) or (IVb)-CH3-NH2-t-butyl GTL (IVa) or (IVb) -CH3 -NH2 -iso-butyl GTM (IVa) or (IVb) -CH3 -NH2 -OCH3 GTN (IVa) or (IVb) -CH3 -NH2 -OC2H5 GTO (IVa) or (IVb) -CH3 -NH2 -OC3H7 GTP (IVa) or (IVb) -CH3 -NH2 -CHF2 GTQ (IVa) or (IVb)-CH3-NH2-CF3 GTR (IVa) or (IVb) -CH3 -NH2 -CHCl2 GTS (IVa) or (IVb) -CH3 -NH2 -CCl3 GTT (IVa) or (IVb) -CH3 -NH2 -F GTU (IVa) or (IVb) -CH3 -NH2 -Cl GTV (IVa) or (IVb)-CH3-NH2-Br GTW (IVa) or (IVb) -CH3 -NH2 -I

Compound Ri R3 Ra GTX (IVa) or (IVb) -CH3 -CH3 -H GTY (IVa) or (IVb) -CH3 -CH3 -CH3 GTZ (IVa) or (IVb)-CH3-CH3-n-propyl GUA (IVa) or (IVb)-CH3-CH3-n-butyl GUB (IVa) or (IVb)-CH3-CH3-t-butyl GUC (IVa) or (IVb)-CH3-CH3-iso-butyl GUD (IVa) or (IVb) -CH3 -CH3 -OCH3 GUE (IVa) or (IVb) -CH3 -CH3 -OC2H5 GUF (IVa) or (IVb) -CH3 -CH3 -OC3H7 GUG (IVa) or (IVb) -CH3 -CH3 -CHF2 GUH (IVa) or. (IVb) -CH3 -CH3 -CF3 GUI (IVa) or (IVb) -CH3 -CH3 -CHCl2 GUJ (IVa) or (IVb) -CH3 -CH3 -CCl3 GUK (IVa) or (IVb)-CH3-CH3-F GUL (IVa) or (IVb) -CH3 -CH3 -Cl GUM (IVa) or (IVb) -CH3 -CH3 -Br GUN (IVa) or (IVb) -CH3 -CH3 -I Table 4

(Va) (Vb) and pharmaceutically acceptable salts thereof, where: Compound R1' R1 R3 R4 Y Z GUO (Va) or (Vb)-H-CH3-CH3-H-C (H) --C (H)- GUP (Va) or (Vb)-H-CH3-CH3-H-C (H)--N- GUQ (Va) or (Vb)-H-CH3-CH3-H-N--C (H)- GUR (Va) or (Vb)-H-CH3-CH3-F-C (H)--C (H)- GUS (Va) or (Vb)-H-CH3-CH3-F-C (H)--N- GUT (Va) or (Vb)-H-CH3-CH3-F-N--C (H)- GUU (Va) or (Vb)-H-CH3-CH3-OCH3-C (H)--C (H)- GUV (Va) or (Vb)-H-CH3-CH3-OCH3-C (H)--N- GUW (Va) or (Vb)-H-CH3-CH3-OCH3-N--C (H)- GUX (Va) or (Vb) -H -CH3 -CH2OH -H -C(H)- -C(H)- GUY (Va) or (Vb) -H -CH3 -CH2OH -H -C(H)- -N- GUZ (Va) or (Vb) -H -CH3 -CH2OH -H -N- -C(H)- GVA (Va) or (Vb) -H -CH3 -CH2OH -F -C(H)- -C(H)- GVB (Va) or (Vb) -H -CH3 -CH2OH -F -C(H)- -N- GVC (Va) or (Vb) -H -CH3 -CH2OH -F -N- -C(H)- GVD (Va) or (Vb) -H -CH3 -CH2OH -OCH3 -C(H)- -C(H)-

Compound R1' R1 R3 R4 Y Z GVE (Va) or (Vb) -H -CH3 -CH2OH -OCH3 -C(H)- -N- GVF (Va) or (Vb) -H -CH3 -CH2OH -OCH3 -N- -C(H)- GVG (Va)-H-CH3-H-H-C (H)--C (H)- GVH (Va) -H -CH3 -H -H -H -C(H)- -N- GVI (Va) -H -CH3 -H -H -N- -C(H)- GVJ (Va)-H-CH3-H-F-C (H)--C (H)- GVK (Va)-H-CH3-H-F-C (H)--N- GVL (Va) -H -CH3 -H -F -N- -C(H)- GVM (Va)-H-CH3-H-OCH3-C (H)--C (H)- GVN (Va)-H-CH3-H-OCH3-C (H)--N- GVO (Va) -H -CH3 -H -OCH3 -N- -C (H) - GVP (Va) or (Vb)-H-OCH3-CH3-H-C (H)--C (H) - GVQ (Va) or (Vb)-H-OCH3-CH3-H-C (H)--N- GVR (Va) or (Vb)-H-OCH3-CH3-H-N--C (H)- GVS (Va) or (Vb)-H-OCH3-CH3-F-C (H)--C (H)- GVT (Va) or (Vb) -H -OCH3 -CH3 -F -C(H)- -N- GVU (Va) or (Vb)-H-OCH3-CH3-F-N--C (H)- GW (Va) or (Vb)-H-OCH3-CH3-OCH3-C (H)--C (H)- GVW (Va) or (Vb)-H-OCH3-CH3-OCH3-C (H)--N-, GVX (Va) or (Vb) -H -OCH3 -CH3 -OCH3 -N- -C(H)- GVY (Va) or (Vb) -H -OCH3 -CH2OH -H -C(H)- -C(H)- GVZ (Va) or (Vb) -H -OCH3 -CH2OH -H -C(H)- -N- GWA (Va) or (Vb) -H -OCH3 -CH2OH -H -N- -C(H)- GWB (Va) or (Vb) -H -OCH3 -CH2OH -F -C (H) --C (H)- GWC (Va) or (Vb) -H -OCH3 -CH2OH -F -C(H)- -N- GWD (Va) or (Vb) -H -OCH3 -CH2OH -F -N- -C(H)- GWE (Va) or (Vb) -H -OCH3 -CH2OH -OCH3 -C (H) --C (H)- GWF (Va) or (Vb)-H-OCH3-CH20H-OCH3

Compound Rl'Rl R3 R4 Y Z GWG (Va) or (Vb) -H -OCH3 -CH2OH -OCH3 -N- -C (H) - GWH (Va)-H-OCH3-H-H-C (H) --C (H)- GWI (Va)-H-OCH3-H-H-C (H)--N- GWJ (Va)-H-OCH3-H-H-N--C (H) - GWK (Va) -H -OCH3 -H -F -C (H) --C (H)- GWL (Va) -H -OCH3 -H -F -C (H) --N- GWM (Va) -H -OCH3 -H -F -N- -C (H) - GWN (Va) -H -OCH3 -H -OCH3 -C (H) --C (H)- GWO (Va) -H -OCH3 -H -OCH3 -C (H)--N- GWP (Va)-H-OCH3-H-OCH3-N--C (H)- GWQ (Va) or (Vb)-H-Cl-CH3-H-C (H)--C (H) - GWR (Va) or (Vb) -H -Cl -CH3 -H -C(H)- -N- GWS (Va) or (Vb)-H-Cl-CH3-H-N--C (H) - GWT (Va) or (Vb) -H -Cl -CH3 -F -C (H) --C (H)- GWU (Va) or (Vb)-H-Cl-CH3-F-C (H) --N- GWV (Va) or (Vb) -H -Cl -CH3 -F -N- -C (H) - GWW (Va) or (Vb) -H -Cl -CH3 -OCH3 -C (H) --C (H)- GWX (Va) or (Vb) -H -Cl -CH3 -OCH3 -C (H)--N- GWY (Va) or (Vb) -H -Cl -CH3 -OCH3 -N- -C (H) - GWZ (Va) or (Vb) -H -Cl -CH2OH -H -C (H) --C (H)- GXA (Va) or (Vb) -H -Cl -CH2OH -H -C (H) --N- GXB (Va) or (Vb) -H -Cl -CH2OH -H -N- -C (H) - GXC (Va) or (Vb) -H -Cl -CH2OH -F -C (H) --C (H)- GXD (Va) or (Vb)-H-Cl-CH2OH-F-C (H)--N- GXE (Va) or (Vb) -H -Cl -CH2OH -F -N- -C (H) - GXF (Va) or (Vb) -H -Cl -CH2OH -OCH3 -C (H) --C (H)- GXG (Va) or (Vb) -H -Cl -CH2OH -OCH3 -C (H) --N- GXH (Va) or (Vb) -H -Cl -CH2OH -OCH3 -N- -C(H)-

Compound Rl'R1 R3 R4 Y Z GXI (Va) -H -Cl -H -H -C(H)- -C(H)- GXJ (Va)-H-Cl-H-H-C (H)--N- GXK (Va) -H -Cl -H -H -N- -C(H)- GXL (Va) -H -Cl -H -F -C(H)- -C(H)- GXM (Va) -H -Cl -H -F -C(H)- -N- GXN (Va) -H -Cl -H -F -N- -C(H)- GXO (VA) -H -Cl -H -OCH3 -C(H)- -C(H)- GXP (Va) -H -Cl -H -OCH3 -C (H)--N- GXQ (Va) -H -Cl -H -OCH3 -N- -C(H)- GXR (Va) or (Vb) -H -H -CH3 -H -C (H) --C (H)- GXS (Va) or (Vb)-H-H-CH3-H-C (H)--N- GXT (Va) or (Vb)-H-H-CH3-H-N--C (H)- GXU (Va) or (Vb) H-H-CH3-F-C (H) --C (H)- GXV (Va) or (Vb) -H -H -CH3 -F -C(H)- -N- GXW (Va) or (Vb)-H-H-CH3-F-N--C (H)- GXX (Va) or (Vb)-H-H-CH3-OCH3-C (H) --C (H)- GXY (Va) or (Vb)-H-H-CH3-OCH3-C (H)--N- GXZ (Va) or (Vb)-H-H-CH3-OCH3-N--C (H)- GYA (Va) or (Vb)-H-H-CH20H-H-C (H) --C (H)- GYB (Va) or (Vb)-H-H-CH20H-H-C (H)--N- GYC (Va) or (Vb) -H -H -CH2OH -H -N- -C(H)- GYD (Va) or (Vb)-H-H-CH20H-F-C (H)--C (H) - GYE (Va) or (Vb) -H -H -CH2OH -F -C(H)- -N- GYF (Va) or (Vb) -H -H -CH2OH -F -N- -C(H)- GYG (Va) or (Vb) -H -H -CH2OH -OCH3 -C(H)- -C (H) - GYH (Va) or (Vb) -H -H -CH2OH -OCH3 -C(H)- -N- GYI (Va) or (Vb) -H -H -CH2OH -OCH3 -N- -C (H) - GYJ (Va) -H -H -H -H -C (H) --C (H)-

Compound R'1 R1 R3 R4 Y Z GYK (Va)-H-H-H-H-C (H)--N- GYL (Va)-H-H-H-H-N--C (H)- GYM (Va)-H-H-H-F-C (H)--C (H)- GYN (Va)-H-H-H-F-C (H)--N- GYO (Va) -H -H -H -F -N- -C(H)- GYP (Va)-H-H-H-OCH3-C (H) --C (H)- GYQ (Va) -H -H -H -OCH3 -C(H)- -N- GYR (Va)-H-H-H-OCH3-N--C (H)- GYS (Va) or (Vb) -CH3 -CH3 -CH3 -H -C (H) --C (H)- GYT (Va) or (Vb)-CH3-CH3-CH3-H-C (H)--N- GYU (Va) or (Vb)-CH3-CH3-CH3-H-N--C (H)- GYV (Va) or (Vb) -CH3 -CH3 -CH3 -F -C(H)- -C(H)- GYW (Va) or (Vb)-CH3-CH3-CH3-F-C (H)--N- GYX (Va) or (Vb)-CH3-CH3-CH3-F-N--C (H)- GYY (Va) or (Vb) -CH3 -CH3 -CH2OH -H -C(H)- -C(H)- GYZ (Va) or (Vb) -CH3 -CH3 -CH2OH -H -C(H)- -N- GZA (Va) or (Vb) -CH3 -CH3 -CH2OH -H -N- -C(H)- GZB (Va) or (Vb) -CH3 -CH3 -CH2OH -F -C(H)- -C(H)- GZC (Va) or (Vb)-CH3-CH3-CH20H-F-C (H)--N- GZD (Va) or (Vb) -CH3 -CH3 -CH2OH -F -N- -C(H)- GZE (Va)-CH3-CH3-H-H-C (H)--C (H)- GZF (Va) -CH3 -CH3 -H -H -C(H)- -N- GZG (Va) -CH3 -CH3 -H -H -N- -C(H)- GZH (Va) -CH3 -CH3 -H -F -C (H)--C (H)- GZI (Va) -CH3 -CH3 -H -F -C(H)- -N- GZJ (Va) -CH3 -CH3 -H -F -N- -C(H)- GZK (Va) or (Vb) -CH3 -OCH3 -CH3 -H -C(H)- -C(H)- GZL (Va) or (Vb) -CH3 -OCH3 -CH3 -H -C(H)- -N-

Compound R1' R1 R3 R4 Y Z GZM (Va) or (Vb) -CH3 -OCH3 -CH3 -H -N- -C(H)- GZN (Va) or (Vb)-CH3-OCH3-CH3-F-C (H)--C (H)- GZO (Va) or (Vb)-CH3-OCH3-CH3-F-C (H)--N- GZP (Va) or (Vb)-CH3-OCH3-CH3-F-N--C (H)- GZQ (Va) or (Vb) -CH3 -OCH3 -CH3 -OCH3 -C (H)--C (H)- GZR (Va) or (Vb) -CH3 -OCH3 -CH3 -OCH3 -C (H)--N- GZS (Va) or (Vb)-CH3-OCH3-CH3-OCH3-N--C (H)- GZT (Va) or (Vb) -CH3 -OCH3 -CH2OH -H -C(H)- -C(H)- GZU (Va) or (Vb) -CH3 -OCH3 -CH2OH -H -C(H)- -N- GZV (Va) or (Vb) -CH3 -OCH3 -CH2OH -H -N- -C(H)- GZW (Va) or (Vb) -CH3 -OCH3 -CH2OH -F -C(H)- -C(H)- GZX (Va) or (Vb) -CH3 -OCH3 -CH2OH -F -C(H)- -N- GZY (Va) or (Vb) -CH3 -OCH3 -CH2OH -F -N- -C(H)- GZZ (Va) or (Vb) -CH3 -OCH3 -CH2OH -OCH3 -C(H)- -C(H)- HAA (Va) or (Vb) -CH3 -OCH3 -CH2OH -OCH3 -C(H)- -N- HAB (Va) or (Vb) -CH3 -OCH3 -CH2OH -OCH3 -N- -C(H)- HAC (Va) -CH3 -OCH3 -H -H -C(H)- -C(H)- HAD(Va) -CH3 -OCH3 -H -H -C(H)- -N- HAE(Va) -CH3 -OCH3 -H -H -N- -C(H)- HAF(Va) -CH3 -OCH3 -H -F -C(H)- -C(H)- HAG(Va) -CH3 -OCH3 -H -F -C(H)- -N- HAH (Va)-CH3-OCH3-H-F-N--C (H)- HAI(Va) -CH3 -OCH3 -H -OCH3 -C(H)- -C(H)- HAJ (Va) -CH3 -OCH3 -H -OCH3 -C (H)--N- HAK(Va) -CH3 -OCH3 -H -OCH3 -N- -C(H)- HAL (Va) or (Vb)-CH3-Cl-CH3-H-C (H)--C (H)- HAM (Va) or (Vb) -CH3 -Cl -CH3 -H -C(H)- -N- HAN (Va) or (Vb)-CH3-Cl-CH3-H-N--C (H)-

Compourd R'1 R1 R3 R4 Y Z HAO (Va) or (Vb)-CH3-Cl-CH3-F-C (H)--C (H)- HAP (Va) or (Vb)-CH3-Cl-CH3-F-C (H)--N- HAQ (Va) or (Vb)-CH3-Cl-CH3-F-N--C (H)- HAR (Va) or (Vb)-CH3-Cl-CH3-OCH3-C (H) --C (H)- HAS (Va) or (Vb)-CH3-Cl-CH3-OCH3-C (H)--N- HAT (Va) or (Vb)-CH3-Cl-CH3-OCH3-N--C (H) - HAU (Va) or (Vb) -CH3 -Cl -CH2OH -H -C (H) --C (H)- HAV (Va) or (Vb) -CH3 -Cl -CH2OH -H -C(H)- -N- HAW (Va) or (Vb)-CH3-Cl-CH20H-H-N--C (H)- HAX (Va) or (Vb) -CH3 -Cl -CH2OH -F -C (H) --C (H)- HAY (Va) or (Vb) -CH3 -Cl -CH2OH -F -C(H)- -N- HAZ (Va) or (Vb) -CH3 -Cl -CH2OH -F -N- -C(H)- HBA (Va) or (Vb) -CH3 -Cl -CH2OH -OCH3 -C (H) --C (H)- HBB (Va) or (Vb) -CH3 -Cl -CH2OH -OCH3 -C(H)- -N- HBC (Va) or (Vb) -CH3 -Cl -CH2OH -OCH3 -N- -C(H)- HBD (Va)-CH3-Cl-H-H-C (H)--C (H)- HBE (Va) -CH3 -Cl -H -H -C(H)- -N- HBF (Va) -CH3 -Cl -H -H -N- -C(H)- HBG (Va) -CH3 -Cl -H -F -C(H)- -C(H)- HBH (Va) -CH3 -Cl -H -F -C(H)- -N- HBI (Va) -CH3 -Cl -H -F -N- -C(H)- HBJ (Va) -CH3 -Cl -H -OCH3 -C(H)- -C(H)- HBK (Va) -CH3 -Cl -H -OCH3 -C(H)- -N- HBL (Va) -CH3 -Cl -H -OCH3 -N- -C(H)- HBM (Va) or (Vb)-CH3-H-CH3-H-C (H) --C (H)- HBN (Va) or (Vb)-CH3-H-CH3-H-C (H)--N- BO (Va) or (Vb)-CH3-H-CH3-H-N--C (H)- HBP (Va) or (Vb)-CH3-H-CH3-F-C (H)--C

Compound R'1 R1 R3 R4 Y Z HBQ(Va) or (Vb) -CH3 -H -CH3 -F -C(H)- -N- HBR (Va) or (Vb)-CH3-H-CH3-F-N--C (H)- HBS (Va) or (Vb)-CH3-H-CH3-OCH3-C (H) --C (H)- HBT (Va) or (Vb)-CH3-H-CH3-OCH3-C (H)--N- HBU (Va) or (Vb)-CH3-H-CH3-OCH3-N--C (H)- HBV (Va) or (Vb)-CH3-H-CH20H-H-C (H) --C (H)- HBW (Va) or (Vb) -CH3 -H -CH2OH -H -C(H)- -N- HBX (Va) or (Vb) -CH3 -H -CH2OH -H -N- -C(H)- HBY (Va) or (Vb) -CH3 -H -CH2OH -F -C(H)- -C(H)- HBZ (Va) or (Vb) -CH3 -H -CH2OH -F -C(H)- -N- HCA (Va) or (Vb) -CH3 -H -CH2OH -F -N- -C(H)- HCB (Va) or (Vb) -CH3 -H -CH2OH -OCH3 -C(H)- -C(H)- HCC (Va) or (Vb) -CH3 -H -CH2OH -OCH3 -C(H)- -N- HCD (Va) or (Vb) -CH3 -H -CH2OH -OCH3 -N- -C(H)- HCE (Va)-CH3-H-H-H-C (H) --C (H)- HCF (Va)-CH3-H-H-H-C (H)--N- HCG (Va) -CH3 -H -H -H -N- -C(H)- HCH (Va)-CH3-H-H-F-C (H)--C (H)- HCI (Va)-CH3-H-H-F-C (H)--N- HCJ (Va) -CH3 -H -H -F -N- -C (H) - HCK (Va) -CH3 -H -H -OCH3 -C (H)- -C(H)- HCL (Va) -CH3 -H -H -OCH3 -C(H)- -N- HCM (Va) -CH3 -H -H -OCH3 -N- -C(H)-

4. 3 DEFINITIONS As used herein, the terms used above having following meaning: "- (Cl-Clo) alkyl" means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms. Representative saturated straight chain-(Cl-C, 0) alkyls include-methyl,-ethyl,-n-propyl,-n-butyl,-n-pentyl,-n-hexyl, -n-heptyl,-n-octyl,-n-nonyl, and-n-decyl. Representative saturated branched-(Cl-Cl0) alkyls include-isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -2-methylbutyl, -3-methylbutyl, - 2, 2-dimethylbutyl, -2,3-dimethylbutyl,-2-methylpentyl,-3-methylpentyl,-4-methyl pentyl, -2-methylhexyl, -3-methylhexyl, -4-methylhexyl, -5-methylhexyl, -2, 3-dimethylbutyl, - 2, 3-dimethylpentyl, -2,4-dimethylpentyl,-2, 3-dimethylhexyl, -2,4-dimethylhexyl, - 2, 5-dimethylhexyl, -2,2-dimethylpentyl,-2, 2-dimethylhexyl, -3,3-dimethylpentyl, -3, 3-dimethylhexyl, -4,4-dimethylhexyl,-2-ethylpentyl,-3-ethylpentyl,-2-ethylhex yl, <BR> <BR> - 3-ethylhexyl,-4-ethylhexyl,-2-methyl-2-ethylpentyl,-2-methyl -3-ethylpentyl,-2-methyl-4- ethylpentyl,-2-methyl-2-ethylhexyl,-2-methyl-3-ethylhexyl,-2 -methyl-4-ethylhexyl, - 2, 2-diethylpentyl, -3,3-diethylhexyl,-2, 2-diethylhexyl,-3, 3-diethylhexyl and the like.

"- (Cl-C6) alkyl" means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 6 carbon atoms. Representative saturated straight chain- (CI-C6) alkyls include-methyl,-ethyl,-n-propyl,-n-butyl,-n-pentyl, and-n-hexyl. Representative saturated branched- (C,-C6) alkyls include-isopropyl,-sec-butyl,-isobutyl,-tert-butyl,-isopenty l, -2-methylbutyl, -3-methylbutyl, -2, 2-dimethylbutyl, -2,3-dimethylbutyl,-2-methylpentyl, - 3-methylpentyl,-4-methylpentyl and the like.

"-(C1-C4)alkyl" means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 4 carbon atoms. Representative saturated straight chain- (C,-C4) alkyls include-methyl,-ethyl,-n-propyl, and-n-butyl. Representative saturated branched- (Cl- C4) alkyls include-isopropyl,-sec-butyl,-isobutyl, and-tert-butyl.

"-(C1-C3)alkyl" means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 3 carbon atoms. Representative saturated straight chain- (Cl-C3) alkyls include-methyl, -ethyl, and-n-propyl. A representative saturated branched- (Cl-C3) alkyl is -isopropyl.

"- (Ci-C, ) alkenyl" means a straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at least one carbon-carbon double bond.

Representative straight chain and branched (C2-Clo) alkenyls include-vinyl,-allyl,-1-butenyl, <BR> <BR> <BR> <BR> -2-butenyl,-isobutylenyl,-1-pentenyl,-2-pentenyl,-3-methyl-l -butenyl,-2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, -1-hexenyl, -2-hexenyl, -3-hexenyl, -1-heptenyl, -2-heptenyl, - 3-heptenyl,-1-octenyl,-2-octenyl,-3-octenyl,-1-nonenyl,-2-no nenyl,-3-nonenyl, -1-decenyl, -2-decenyl, -3-decenyl and the like.

"- (C2-C6) alkenyl" means a straight chain or branched non-cyclic hydrocarbon having from 2 to 6 carbon atoms and including at least one carbon-carbon double bond.

Representative straight chain and branched (C2-C6) alkenyls include-vinyl,-allyl,-1-butenyl, <BR> <BR> <BR> <BR> <BR> -2-butenyl,-isobutylenyl,-1-pentenyl,-2-pentenyl,-3-methyl-l -butenyl,-2-methyl-2-butenyl, - 2, 3-dimethyl-2-butenyl,-1-hexenyl,-2-hexenyl,-3-hexenyl and the like.

"- (C2-Clo) alkynyl" means a straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at lease one carbon-carbon triple bond.

Representative straight chain and branched-(C2-C10) alkynyls include-acetylenyl,-propynyl, -1-butynyl, -2-butynyl, -1-pentynyl, -2-pentynyl, -3-methyl-1-butynyl, -4-pentynyl, -1-hexynyl, -2-hexynyl, -5-hexynyl, -1-heptynyl, -2-heptynyl, -6-heptynyl, -1-octynyl, -2-octynyl, -7-octynyl, -1-nonynyl, -2-nonynyl, -8-nonynyl, -1-decynyl, -2-decynyl, -9-decynyl and the like.

"-(C2-C6)alkynyl" means a straight chain or branched non-cyclic hydrocarbon having from 2 to 6 carbon atoms and including at lease one carbon-carbon triple bond.

Representative straight chain and branched (C2-C6) alkynyls include-acetylenyl, -propynyl, -1-butynyl, -2-butynyl, -1-pentynyl, -2-pentynyl, -3-methyl-1-butynyl, -4-pentynyl, -1-hexynyl, -2-hexynyl, -5-hexynyl and the like.

"-(C3-CIO) cycloalkyl"means a saturated cyclic hydrocarbon having from 3 to 10 carbon atoms. Representative (C3-CI2cycloalkyls include-cyclopropyl,-cyclobutyl, -cyclopentyl, -cyclohexyl, -cycloheptyl, -cyclooctyl, -cyclononyl, and-cyclodecyl.

"- (C3-C$) cycloalkyl" means a saturated cyclic hydrocarbon having from 3 to 8 carbon atoms. Representative (C3-C8) cycloalkyls include-cyclopropyl,-cyclobutyl,-cyclopentyl, -cyclohexyl, -cycloheptyl, and-cyclooctyl.

"-(Cs-Cl4) bìcycloalkyl"means a bi-cyclic hydrocarbon ring system having from 8 to 14 carbon atoms and at least one saturated cyclic alkyl ring. Representative -(C8-

Cl4) bicycloalkyls include-indanyl, -1, 2,3, 4-tetrahydronaphthyl, -5,6, 7,8-tetrahydronaphthyl, -perhydronaphthyl and the like.

"- (C$-C14) tricycloalkyl" means a tri-cyclic hydrocarbon ring system having from 8 to 14 carbon atoms and at least one saturated cyclic alkyl ring. Representative -(C8- Cl4) tricycloalkyls include-pyrenyl, -1,2, 3, 4-tetrahydroanthracenyl,-perhydroanthracenyl, -aceanthreneyl, -1, 2,3, 4-tetrahydropenanthrenyl,-5, 6,7, 8-tetrahydrophenanthrenyl, -perhydrophenanthrenyl and the like.

"- (CS-Clo) cycloalkenyl" means a cyclic non-aromatic hydrocarbon having at least one carbon-carbon double bond in the cyclic system and from 5 to 10 carbon atoms.

Representative (Cs-Cl0) cycloalkenyls include-cyclopentenyl,-cyclopentadienyl, -cyclohexenyl, -cyclohexadienyl, -cycloheptenyl, -cycloheptadienyl, -cycloheptatrienyl, -cyclooctenyl, -cyclooctadienyl, -cyclooctatrienyl, -cyclooctatetraenyl, -cyclononenyl, -cyclononadienyl, -cyclodecenyl, -cyclodecadienyl and the like.

"-(Cs-C8) cycloalkenyl"means a cyclic non-aromatic hydrocarbon having at least one carbon-carbon double bond in the cyclic system and from 5 to 8 carbon atoms.

Representative (C^-C8) cycloalkenyls include-cyclopentenyl, -cyclopentadienyl, - cyclohexenyl,-cyclohexadienyl,-cycloheptenyl,-cycloheptadien yl,-cycloheptatrienyl, - cyclooctenyl,-cyclooctadienyl,-cyclooctatrienyl,-cyclooctate traenyl and the like.

"- (C8-C14) bicycloalkenyl" means a bi-cyclic hydrocarbon ring system having at least one carbon-carbon double bond in each ring and from 8 to 14 carbon atoms. Representative -(C8-Cl4) bicycloalkenyls include-indenyl,-pentalenyl,-naphthalenyl,-azulenyl,-heptale nyl, -1, 2,7, 8-tetrahydronaphthalenyl and the like.

"-(C8-C14)tricycloalkenyl" means a tri-cyclic hydrocarbon ring system having at least one carbon-carbon double bond in each ring and from 8 to 14 carbon atoms. Representative -(C8-Cl4) tricycloalkenyls include-anthracenyl,-phenanthrenyl,-phenalenyl,-acenaphthale nyl, -as-indacenyl,-s-indacenyl and the like.

"- (5- to 10-membered) heteroaryl" means an aromatic heterocycle ring of 5 to 10 members, including both mono-and bicyclic ring systems, where at least one carbon atom of one or both of the rings is replaced with a heteroatom independently selected from nitrogen, oxygen, and sulfur. In one embodiment one of the- (5- to 10-membered) heteroaryl's rings contain at least one carbon atom. In another embodiment both of the- (5- to 10-

membered) heteroaryl's rings contain at least one carbon atom. Representative (5-to 10- membered) heteroaryls include pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, and quinazolinyl.

"- (3- to 7-membered) heterocycle" or"- (3- to 7-membered) heterocyclo" means a 3-to 7-membered monocyclic heterocyclic ring which is either saturated, unsaturated non-aromatic or aromatic. A 3-or a 4-membered heterocycle can contain up to 3 heteroatoms, a 5- membered heterocycle can contain up to 4 heteroatoms, a 6-membered heterocycle can contain up to 6 heteroatoms, and a 7-membered heterocycle can contain up to 7 heteroatoms.

Each heteroatom is independently selected from nitrogen, which can be quaternized ; oxygen; and sulfur, including sulfoxide and sulfone. The- (3- to 7-membered) heterocycle can be attached via any heteroatom or carbon atom. Representative- (3- to 7-membered) heterocycles include pyridyl, furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl and the like.

"- (3- to 5-membered) heterocycle" or"- (3- to 5-membered) heterocyclo" means a 3-to 5-membered monocyclic heterocyclic ring which is either saturated, unsaturated non-aromatic or aromatic. A 3-or 4-membered heterocycle can contain up to 3 heteroatoms and a 5- membered heterocycle can contain up to 4 heteroatoms. Each heteroatom is independently selected from nitrogen, which can be quaternized ; oxygen; and sulfur, including sulfoxide and sulfone. The- (3- to 5-membered) heterocycle can be attached via any heteroatom or carbon atom. Representative- (3- to 5-membered) heterocycles include furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, triazinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl and the like.

"- (7- to 10-membered) bicycloheterocycle" or"- (7- to 10- membered) bicycloheterocyclo" means a 7-to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated non-aromatic or aromatic. A- (7- to 10-

membered) bicycloheterocycle contains from 1 to 4 heteroatoms independently selected from nitrogen, which can be quaternized ; oxygen; and sulfur, including sulfoxide and sulfone. The (7-to 10-membered) bicycloheterocycle can be attached via any heteroatom or carbon atom.

Representative- (7- to 10-membered) bicycloheterocycles include-quinolinyl,-isoquinolinyl, - chromonyl,-coumarinyl,-indolyl,-indolizinyl,-benzo [b] furanyl,-benzo [b] thiophenyl, <BR> <BR> <BR> <BR> <BR> -indazolyl,-purinyl,-4H-quinolizinyl,-isoquinolyl,-quinolyl, -phthalazinyl,-naphthyridinyl, -carbazolyl,-ß-carbolinyl and the like.

"-(C14)aryl" means a 14-membered aromatic carbocyclic moiety such as anthryl and phenanthryl.

"-CH2 (halo)" means a methyl group wherein one of the hydrogens of the methyl group has been replaced with a halogen. Representative-CH2 (halo) groups include-CH2F,-CH2C1, -CH2Br, and-CH2I.

"-CH (halo) 2"means a methyl group wherein two of the hydrogens of the methyl group have been replaced with a halogen. Representative-CH (halo) 2 groups include-CHF2, -CHC12,-CHBr2, CHBrCl, CHC1I, and-CHI2.

"-C (halo) 3"means a methyl group wherein each of the hydrogens of the methyl group has been replaced with a halogen. Representative-C (halo) 3 groups include-CF3>-CC13, -CBr3, and -CI3.

"-Halogen"or"-Halo"means-F,-Cl,-Br, or-I.

The term"pyrimidinyl ring"means where R, and n are defined above for the 2-Pyrimidinylpiperazine Compounds.

The term"animal,"includes, but is not limited to, a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, guinea pig, and human.

The phrase"pharmaceutically acceptable salt, "as used herein, is any pharmaceutically acceptable salt that can be prepared from a 2-Pyrimidinylpiperazine Compound, including a

salt formed from an acid and a basic functional group, such as a nitrogen group, of one of the 2-Pyrimidinylpiperazine Compounds. Illustrative salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i. e. , 1, 1'-methylene-bis- (2-hydroxy-3-naphthoate) ) salts. The term"pharmaceutically acceptable salt"also refers to a salt prepared from a 2-Pyrimidinylpiperazine Compound having an acidic functional group, such as a carboxylic acid functional group, and a pharmaceutically acceptable inorganic or organic base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-or trialkylamines; dicyclohexylamine ; tributyl amine; pyridine; N-methyl-N-ethylamine ; diethylamine; triethylamine; mono-, bis-or tris- (2-hydroxy-lower alkyl amines), such as mono-, bis-or tris- (2-hydroxyethyl) amine, 2-hydroxy-tert-butylamine or tris- (hydroxymethyl) methylamine, N, N-di-lower alkyl-N- (hydroxy lower alkyl) -amines, such as N, N-dimethyl-N- (2-hydroxyethyl) amine or tri- (2-hydroxyethyl) amine; N-methyl-D-glucamine; and amino acids such as arginine, lysine and the like.

The phrase"effective amount"when used in connection with a 2- Pyrimidinylpiperazine Compound means an amount effective for: (a) treating or preventing a Condition; or (b) inhibiting mGluR5 or mGluRl function in a cell.

The phrase"effective amourit"when used in connection with another therapeutic agent means an amount for providing the therapeutic effect of the other therapeutic agent.

When a first group is"substituted with one or more"second groups, each of one or more of the first group's hydrogen atoms is replaced with a second group.

In one embodiment, a first group is substituted with up to three second groups.

In another embodiment, a first group is substituted with one or two second groups.

In another embodiment, a first group is substituted with only one second group.

The term"UI"means urinary incontinence.

The term"ALS"means amyotrophic lateral sclerosis.

The phrases"treatment of, ""treating"and the like include the amelioration or cessation of a Condition or a symptom thereof.

In one embodiment, treating includes inhibiting, for example, decreasing the overall frequency of episodes of a Condition or a symptom thereof.

The phrases"prevention of,""preventing"and the like include the avoidance of the onset of a Condition or a symptom thereof.

4.4 METHODS FOR MAKING THE 2-PYRIMIDINYLPIPERAZINE COMPOUNDS The 2-Pyrimidinylpiperazine Compounds can be made using conventional organic synthesis and/or by the following illustrative methods.

The 2-Pyrimidinylpiperazine Compounds of Formula (Ib) where A is-C (O)- or-C (S) - can be made by reacting a compound of formula A with a (Cl-Clo) alkyl iodide, or with a (C2- C10) alkenyl iodide or (C2-C10)alkynyl iodide in which the iodine atom is bonded to an sp3 carbon atom, at low temperature, e. g., about 0°C to about-78°C, in the presence of a strong base, e. g., lithium diisopropylamide ("LDA"), optionally in hexamethylphosphoramide ("HMPA"), as shown below in Scheme 1, e. g., for a (Cl-Cl0) alkyl íodide reactant: Scheme 1 f cR,) ri n 1) n N. i N (R3) + (C-Co) alkyll J N LDA/HMPA (R3) p H/ /A I A (c1-c1o) alkyl A Formula ab) A representative procedure for coupling a terminal acetylene and an alkyl iodide is provided in G. M. Strunz et al., Can. J. Chem. 419-432 (1996).

The 2-Pyrimidinylpiperazine Compounds of Formula (Ic) where A is-C (O)- or-C (S) - can be made by reacting a compound of formula A with an aryl iodide, or with a (C2- C10) alkenyl iodide or (C2-C10) alkynyl iodide in which the iodine atom is bonded to an sp2 or sp carbon atom, at room temperature, e. g., about 25°C, in ethyl acetate ("EtOAc") in the presence of Pd (Ph3P) 2 (OAc) 2, CuI and triethylamine ("TEA"), as shown below in Scheme 2, e. g., for an aryl iodide reactant: Scheme 2 I tR1) nN i (R'1) n"' R4 /N (/N R , + N N Pd (Ph3P) 2 (OAc) 2/CuI/ (R3) p J A TEA/Ethyl Acetate A R4- A \/ Formula (Ic) A representative procedure for coupling a terminal acetylene with an aryl iodide is provided in L. A. Hay et al., J. Org. Chem. 5050-5058 (1998).

The compound of formula A where A is-C (O)-, i. e., the compound of formula A', can be made by reacting a compound of formula B with propynoic acid in the presence of 1-hydroxybenzotriazole hydrate ("HOBtH") and 1,3-diisopropylcarbodiimide ("DIC") at room temperature, e. g., about 25°C, as shown below in Scheme 3: Scheme 3 A representative procedure for coupling a carboxylic acid with an amine is provided in F. M. Martin et al., Bioorg Med. Chem. Lett. 2887-2892 (1999).

The compound of formula A'can also be made by reacting a compound of formula B with propynoyl chloride in the presence of a tertiary amine, such as TEA, at a temperature about 100°C, as shown below in Scheme 4: Scheme 4 A representative procedure for coupling an acid chloride with an amine is provided in T. R. Herrin et al., J. Med. Chem. 1216-1223 (1975).

The compound of formula A where A is-C (S)-, i. e. , the compound of formula A" below, can be made by, e. g., reacting a compound of formula A'with Lawesson's reagent at a temperature of about 100°C, as shown below in Scheme 5: Scheme 5

(ruz (R1) - non CN Lawesson's Reagent r l R3) p 100°C R3) p 0 s w0 . S H H A' A" The compound of formula B can be made by reacting a 2-halo-substituted pyrimidine of formula C with an excess of piperazine of formula D in an aprotic organic solvent, e. g., methylene chloride or chloroform, in the presence of a base, e. g., TEA, at a temperature, e. g., of about 50°C, as shown below in Scheme 6: Scheme 6 where X is I, Br, Cl or F.

A representative procedure for reacting a 2-halo-pyrimidine with a piperazine is provided in J. A. Tucker et al., J. Med. Chem. 41 19 : 3727-3735 (1998).

The 2-halo-pyrimidines of formula C and the piperazines of formula D are commercially available or can be made using methods well known to those skilled in the art.

The compound of formula A where A is-CH2-,-CH (Cl-C4 alkyl)-, or-C (CI-C4 alkyl) (Cl-C4 alkyl)-can be made by, e. g., reacting Compound B with a halogenated alkyne compound, as shown below in Scheme 7: Scheme 7 R R \ w (R1) n'- X (R1) n' N\/N H N\/N ) 0- T (R3) p L"N) or (R3) P L,, N) N J or \N H CuBr, acetonitrile R R H Z where R and R'are, independently, H or Cl-C4 alkyl, and X is Cl, Br, or I. Representative procedures for coupling a halogenated alkyne with an amine are provided in H-R Tsou et al., J Med. Chem. 2719-2734 (2001) and R. Geri et al., Gazz. Chim. Ital. 241-248 (1994).

Certain 2-Pyrimidinylpiperazine Compounds can have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. A 2-Pyrimidinylpiperazine Compound can be in the form of an optical isomer or a diastereomer.

Accordingly, the invention encompasses 2-Pyrimidinylpiperazine Compounds and their uses as described herein in the form of their optical isomers, diasteriomers and mixtures thereof, including a racemic mixture. Optical isomers of the 2-Pyrimidinylpiperazine Compounds can be obtained by well known techniques such as chiral chromatography or formation of diastereomeric salts from an optically active acid or base.

In addition, one or more hydrogen, carbon or other atoms of a 2-Pyrimidinylpiperazine Compound can be replaced by an isotope of the hydrogen, carbon or other atoms. Such compounds, which are encompassed by the present invention, are useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.

4.5 THERAPEUTIC USES OF THE 2-PYRIMIDINYLPIPERAZINE COMPOUNDS In accordance with the invention, the 2-Pyrimidinylpiperazine Compounds are administered to an animal in need of treatment or prevention of a Condition.

In one embodiment, an effective amount of a 2-Pyrimidinylpiperazine Compound can be used to treat or prevent any condition treatable or preventable by inhibiting mGluR5.

Examples of conditions that are treatable or preventable by inhibiting mGluR5 include, but are not limited to, pain, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, a pruritic condition, and psychosis.

In another embodiment, an effective amount of a 2-Pyrimidinylpiperazine Compound can be used to treat or prevent any condition treatable or preventable by inhibiting mGluRl.

Examples of conditions that are treatable or preventable by inhibiting mGluRl include, but are not limited to, pain, UI, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, a seizure, stroke, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, and depression.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent acute or chronic pain. Examples of pain treatable or preventable using the 2-Pyrimidinylpiperazine Compounds include, but are not limited to, cancer pain, labor pain, myocardial infarction pain, pancreatic pain, colic pain, post-operative pain, headache pain, muscle pain, arthritic pain, neuropathic pain, and pain associated with a periodontal disease, including gingivitis and periodontitis.

The 2-Pyrimidinylpiperazine Compounds can also be used for treating or preventing pain associated with inflammation or with an inflammatory disease in an animal. Such pain can arise where there is an inflammation of the body tissue which can be a local inflammatory response and/or a systemic inflammation. For example, the 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent pain associated with inflammatory diseases including, but not limited to: organ transplant rejection ; reoxygenation injury resulting from organ transplantation (see Grupp et al., J. Mol. Cell Cardiol. 31: 297-303 (1999) ) including, but not limited to, transplantation of the heart, lung, liver, or kidney; chronic inflammatory diseases of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory lung diseases, such as asthma, adult

respiratory distress syndrome, and chronic obstructive airway disease; inflammatory diseases of the eye, including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis ; chronic inflammatory diseases of the gum, including gingivitis and periodontitis; tuberculosis; leprosy; inflammatory diseases of the kidney, including uremic complications, glomerulonephritis and nephrosis; inflammatory diseases of the skin, including sclerodermatitis, psoriasis and eczema ; inflammatory diseases of the central nervous system, including chronic demyelinating diseases of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimer s disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and viral or autoimmune encephalitis; autoimmune diseases, including Type I and Type II diabetes mellitus; diabetic complications, including, but not limited to, diabetic cataract, glaucoma, retinopathy, nephropathy (such as microaluminuria and progressive diabetic nephropathy), polyneuropathy, mononeuropathies, autonomic neuropathy, gangrene of the feet, atherosclerotic coronary arterial disease, peripheral arterial disease, nonketotic hyperglycemic-hyperosmolar coma, foot ulcers, joint problems, and a skin or mucous membrane complication (such as an infection, a shin spot, a candidal infection or necrobiosis lipoidica diabeticorum) ; immune-complex vasculitis, and systemic lupus erythematosus (SLE); inflammatory diseases of the heart, such as cardiomyopathy, ischemic heart disease hypercholesterolemia, and atherosclerosis; as well as various other diseases that can have significant inflammatory components, including preeclampsia, chronic liver failure, brain and spinal cord trauma, and cancer. The 2-Pyrimidinylpiperazine Compounds can also be used for treating or preventing pain associated with inflammatory disease that can, for example, be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to pro-inflammatory cytokines, e. g., shock associated with pro-inflammatory cytokines. Such shock can be induced, e. g. , by a chemotherapeutic agent that is administered as a treatment for cancer.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent UI.

Examples of UI treatable or preventable using the 2-Pyrimidinylpiperazine Compounds include, but are not limited to, urge incontinence, stress incontinence, overflow incontinence, neurogenic incontinence, and total incontinence.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent an addictive disorder, including but not limited to, an eating disorder, an impulse-control disorder, an alcohol-related disorder, a nicotine-related disorder, an amphetamine-related disorder, a cannabis-related disorder, a cocaine-related disorder, an hallucinogen-related disorder, an inhalant-related disorders, and an opioid-related disorder, all of which are further sub- classified as listed below.

Eating disorders include, but are not limited to, Bulimia Nervosa, Nonpurging Type ; Bulimia Nervosa, Purging Type; Anorexia; and Eating Disorder not otherwise specified (NOS).

Impulse control disorders include, but are not limited to, Intermittent Explosive Disorder, Kleptomania, Pyromania, Pathological Gambling, Trichotillomania, and Impulse Control Disorder not otherwise specified (NOS).

Alcohol-related disorders include, but are not limited to, Alcohol-Induced Psychotic Disorder with delusions, Alcohol Abuse, Alcohol Intoxication, Alcohol Withdrawal, Alcohol Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting Dementia, Alcohol-Induced Persisting Amnestic Disorder, Alcohol Dependence, Alcohol-Induced Psychotic Disorder with hallucinations, Alcohol-Induced Mood Disorder, Alcohol-Induced Anxiety Disorder, Alcohol-Induced Sexual Dysfunction, Alcohol-Induced Sleep Disorder, and Alcohol-Related Disorder not otherwise specified (NOS).

Nicotine-related disorders include, but are not limited to, Nicotine Dependence, Nicotine Withdrawal, and Nicotine-Related Disorder not otherwise specified (NOS).

Amphetamine-related disorders include, but are not limited to, Amphetamine Dependence, Amphetamine Abuse, Amphetamine Intoxication, Amphetamine Withdrawal, Amphetamine Intoxication Delirium, Amphetamine-Induced Psychotic Disorder with delusions, Amphetamine-Induced Psychotic Disorders with hallucinations, Amphetamine-Induced Mood Disorder, Amphetamine-Induced Anxiety Disorder, Amphetamine-Induced Sexual Dysfunction, Amphetamine-Induced Sleep Disorder, and Amphetamine Related Disorder not otherwise specified (NOS).

Cannabis-related disorders include, but are not limited to, Cannabis Dependence, Cannabis Abuse, Cannabis Intoxication, Cannabis Intoxication Delirium, Cannabis-Induced Psychotic Disorder with delusions, Cannabis-Induced Psychotic Disorder with hallucinations,

Cannabis-Induced Anxiety Disorder, and Cannabis Related Disorder not otherwise specified (NOS).

Cocaine-related disorders include, but are not limited to, Cocaine Dependence, Cocaine Abuse, Cocaine Intoxication, Cocaine Withdrawal, Cocaine Intoxication Delirium, Cocaine-Induced Psychotic Disorder with delusions, Cocaine-Induced Psychotic Disorders with hallucinations, Cocaine-Induced Mood Disorder, Cocaine-Induced Anxiety Disorder, Cocaine-Induced Sexual Dysfunction, Cocaine-Induced Sleep Disorder, and Cocaine Related Disorder not otherwise specified (NOS).

Hallucinogen-related disorders include, but are not limited to, Hallucinogen Dependence, Hallucinogen Abuse, Hallucinogen Intoxication, Hallucinogen Withdrawal, Hallucinogen Intoxication Delirium, Hallucinogen-Induced Psychotic Disorder with delusions, Hallucinogen-Induced Psychotic Disorders with hallucinations, Hallucinogen-Induced Mood Disorder, Hallucinogen-Induced Anxiety Disorder, Hallucinogen-Induced Sexual Dysfunction, Hallucinogen-Induced Sleep Disorder, Hallucinogen Persisting Perception Disorder (Flashbacks), and Hallucinogen Related Disorder not otherwise specified (NOS).

Inhalant-related disorders include, but are not limited to, Inhalant Dependence, Inhalant Abuse, Inhalant Intoxication, Inhalant Intoxication Delirium, Inhalant-Induced Psychotic Disorder with delusions, Inhalant-Induced Psychotic Disorder with hallucinations, Inhalant-Induced Anxiety Disorder, and Inhalant Related Disorder not otherwise specified (NOS).

Opioid-related disorders include, but are not limited to, Opioid Dependence, Opioid Abuse, Opioid Intoxication, Opioid Intoxication Delirium, Opioid-Induced Psychotic Disorder with delusions, Opioid-Induced Psychotic Disorder with hallucinations, Opioid-Induced Anxiety Disorder, Opioid Withdrawal, and Opioid Related Disorder not otherwise specified (NOS).

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent Parkinson's disease and parkinsonism and the symptoms associated with Parkinson's disease and parkinsonism, including but not limited to, bradykinesia, muscular rigidity, resting tremor, and impairment of postural balance.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent generalized anxiety or severe anxiety and the symptoms associated with anxiety, including but not limited to, restlessness, tension, tachycardia, dyspnea, depression including chronic"neurotic" depression, panic disorder, agoraphobia and other specific phobias, eating disorders, and personality disorders.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent epilepsy, including but not limited to, partial epilepsy, generalized epilepsy, and the symptoms associated with epilepsy, including but not limited to, simple partial seizures, jacksonian seizures, complex partial (psychomotor) seizures, convulsive seizures (grand mal or tonic- clonic seizures), petit mal (absence) seizures, and status epilepticus.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent a seizure, including but not limited to, infantile spasms, febrile seizures, and epileptic seizures.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent strokes, including but not limited to, ischemic strokes and hemorrhagic strokes.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent a pruritic condition, including but not limited to, pruritus caused by dry skin, scabies, dermatitis, herpetiformis, atopic dermatitis, pruritus vulvae et allai, malaria, insect bites, pediculosis, contact dermatitis, drug reactions, urticaria, urticarial eruptions of pregnancy, psoriasis, lichen planus, lichen simplex chronicus, exfoliative dermatitis, folliculitis, bullous pemphigoid, and fiberglass dermatitis.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent psychosis, including but not limited to, schizophrenia, including paranoid schizophrenia, hebephrenic or disorganized schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, negative or deficit subtype schizophrenia, and non-deficit schizophrenia; a delusional disorder, including erotomanic subtype delusional disorder, grandiose subtype delusional disorder, jealous subtype delusional disorder, persecutory subtype delusional disorder, and somatic subtype delusional disorder; and brief psychosis.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent a cognitive disorder, including but not limited to, delirium and dementia such as multi-infarct dementia, dementia pugilistica, dementia caused by AIDS, and dementia caused by Alzheimer's disease.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent a memory deficiency, including but not limited to, dissociative amnesia and dissociative fugue.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent restricted brain function, including but not limited to, that caused by surgery or an organ transplant, restricted blood supply to the brain, a spinal cord injury, a head injury, hypoxia, cardiac arrest, and hypoglycemia.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent Huntington's chorea.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent ALS.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent retinopathy, including but not limited to, arteriosclerotic retinopathy, diabetic arteriosclerotic retinopathy, hypertensive retinopathy, non-proliferative retinopathy, and proliferative retinopathy.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent a muscle spasm.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent a migraine.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent vomiting, including but not limited to, nausea vomiting, dry vomiting (retching), and regurgitation.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent dyskinesia, including but not limited to, tardive dyskinesia and biliary dyskinesia.

The 2-Pyrimidinylpiperazine Compounds can be used to treat or prevent depression, including but not limited to, major depression and bipolar disorder.

Without wishing to be bound by theory, Applicants believe that the 2- Pyrimidinylpiperazine Compounds are antagonists for mGluR5.

The invention relates to methods for inhibiting mGluR5 function in a cell comprising contacting a cell capable of expressing mGluR5 with an amount of a 2-Pyrimidinylpiperazine Compound effective to inhibit mGluR5 function in the cell. This method can be used in vitro, for example, as an assay to select cells that express mGluR5 and, accordingly, are useful as part of an assay to select compounds useful for treating or preventing pain, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, a pruritic condition, or psychosis. The method is also useful for inhibiting mGluR5 function in a cell in vivo, in an animal, a human in one embodiment, by contacting a cell in an animal with an amount of a 2-

Pyrimidinylpiperazine Compound effective to inhibit mGluR5 function in the cell. In one embodiment, the method is useful for treating or preventing pain in an animal in need thereof.

In another embodiment, the method is useful for treating or preventing an addictive disorder in an animal in need thereof. In another embodiment, the method is useful for treating or preventing Parkinson's disease in an animal in need thereof. In another embodiment, the method is useful for treating or preventing parkinsonism in an animal in need thereof. In another embodiment, the method is useful for treating or preventing anxiety in an animal in need thereof. In another embodiment, the method is useful for treating or preventing a pruritic condition in an animal in need thereof. In another embodiment, the method is useful for treating or preventing psychosis in an animal in need thereof.

Examples of cells capable of expressing mGluR5 are neuronal and glial cells of the central nervous system, particularly the brain, especially in the nucleus accumbens. Methods for assaying cells that express mGluR5 are known in the art.

Without wishing to be bound by theory, Applicants believe that the 2- Pyrimidinylpiperazine Compounds are antagonists for mGluRl.

The invention relates to methods for inhibiting mGluRl function in a cell comprising contacting a cell capable of expressing mGluRl with an amount of a 2-Pyrimidinylpiperazine Compound effective to inhibit mGluRl function in the cell. This method can be used in vitro, for example, as an assay to select cells that express mGluRl and, accordingly, are useful as part of an assay to select compounds useful for treating or preventing a Condition.

The method is also useful for inhibiting mGluRl function in a cell in vivo, in an animal, a human in one embodiment, by contacting a cell, in an animal, with an amount of a 2- Pyrimidinylpiperazine Compound effective to inhibit mGluRl function in the cell. In one embodiment, the method is useful for treating or preventing pain in an animal in need thereof.

In another embodiment, the method is useful for treating or preventing UI in an animal in need thereof. In another embodiment, the method is useful for treating or preventing an addictive disorder in an animal in need thereof. In another embodiment, the method is useful for treating or preventing Parkinson's disease in an animal in need thereof. In another embodiment, the method is useful for treating or preventing parkinsonism in an animal in need thereof. In another embodiment, the method is useful for treating or preventing anxiety in an animal in need thereof. In another embodiment, the method is useful for treating or

preventing epilepsy in an animal in need thereof. In another embodiment, the method is useful for treating or preventing a seizure in an animal in need thereof. In another embodiment, the method is useful for treating or preventing stroke in an animal in need thereof. In another embodiment, the method is useful for treating or preventing a pruritic condition in an animal in need thereof. In another embodiment, the method is useful for treating or preventing psychosis in an animal in need thereof. In another embodiment, the method is useful for treating or preventing a cognitive disorder in an animal in need thereof.

In another embodiment, the method is useful for treating or preventing a memory deficit in an animal in need thereof. In another embodiment, the method is useful for treating or preventing restricted brain function in an animal in need thereof. In another embodiment, the method is useful for treating or preventing Huntington's chorea in an animal in need thereof.

In another embodiment, the method is useful for treating or preventing ALS in an animal in need thereof. In another embodiment, the method is useful for treating or preventing dementia in an animal in need thereof. In another embodiment, the method is useful for treating or preventing retinopathy in an animal in need thereof. In another embodiment, the method is useful for treating or preventing a muscle spasm in an animal in need thereof. In another embodiment, the method is useful for treating or preventing a migraine in an animal in need thereof. In another embodiment, the method is useful for treating or preventing vomiting in an animal in need thereof. In another embodiment, the method is useful for treating or preventing dyskinesia in an animal in need thereof. In another embodiment, the method is useful for treating or preventing depression in an animal in need thereof.

Examples of cells capable of expressing mGluRl include, but are not limited to, cerebellar Purkinje neuron cells, Purkinje cell bodies (punctate), cells of spine (s) of the cerebellum; neurons and neurophil cells of olfactory-bulb glomeruli ; cells of the superficial layer of the cerebral cortex; hippocampus cells; thalamus cells; superior colliculus cells; and spinal trigeminal nucleus cells. Methods for assaying cells that express mGluRl are known in the art.

4.6 THERAPEUTIC/PROPHYLACTIC ADMINISTRATION AND COMPOSITIONS OF THE INVENTION Due to their activity, the 2-Pyrimidinylpiperazine Compounds are advantageously useful in veterinary and human medicine. As described above, the 2-Pyrimidinylpiperazine Compounds are useful for treating or preventing a Condition in an animal in need thereof.

When administered to an animal, the 2-Pyrimidinylpiperazine Compounds are administered as a component of a composition that comprises a pharmaceutically acceptable carrier or excipient. The present compositions, which comprise a 2-Pyrimidinylpiperazine Compound, can be administered orally. The 2-Pyrimidinylpiperazine Compounds of the invention can also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e. g., oral, rectal, and intestinal mucosa, etc.) and can be administered together with another therapeutically active agent. Administration can be systemic or local. Various delivery systems are known, e. g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer the 2-Pyrimidinylpiperazine Compound.

Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the practitioner. In most instances, administration will result in the release of the 2-Pyrimidinylpiperazine Compounds into the bloodstream.

In specific embodiments, it can be desirable to administer the 2-Pyrimidinylpiperazine Compounds locally. This can be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, e. g. , in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository or enema, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

In certain embodiments, it can be desirable to introduce the 2-Pyrimidinylpiperazine \ Compounds into the central nervous system or gastrointestinal tract by any suitable route, including intraventricular, intrathecal, and epidural injection, and enema. Intraventricular

injection can be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

Pulmonary administration can also be employed, e. g. , by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the 2-Pyrimidinylpiperazine Compounds can be formulated as a suppository, with traditional binders and excipients such as triglycerides.

In another embodiment, the 2-Pyrimidinylpiperazine Compounds can be delivered in a vesicle, in particular a liposome (see Langer, Science 249: 1527-1533 (1990) and Treat et al., Liposomes in the Therapy of Infectious Disease and Cancer 317-327 and 353-365 (1989).

In yet another embodiment, the 2-Pyrimidinylpiperazine Compounds can be delivered in a controlled-release system or sustained-release system (see, e. g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled-or sustained-release systems discussed in the review by Langer, Science 249: 1527-1533 (1990) can be used. In one embodiment, a pump can be used (Langer, Science 249: 1527-1533 (1990); Sefton, CRC Crit. Ref. Biomed. Eng 14: 201 (1987); Buchwald et al., Surgery 88: 507 (1980); and Saudek et al., N. Engl. J Med. 321: 574 (1989) ). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release (Langer and Wise eds. , 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds. , 1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem.

23: 61 (1983); Levy et al., Science 228: 190 (1985); During et al., Ann. Neurol. 25: 351 (1989); and Howard et al., J. Neurosurg. 71: 105 (1989) ). In yet another embodiment, a controlled-or sustained-release system can be placed in proximity of a target of the 2-Pyrimidinylpiperazine Compounds, e. g., the spinal column, brain, or gastrointestinal tract, thus requiring only a fraction of the systemic dose.

The present compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration to the animal.

Such pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be saline, gum acacia, gelatin,

starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipients are sterile when administered to an animal. Water, and in one embodiment physiological saline, is a particularly useful excipient when the 2- Pyrimidinylpiperazine Compound is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, particularly for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

The present compositions can take the form of solutions, suspensions, emulsions, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, aerosols, sprays, suspensions, or any other form suitable for use.

In one embodiment, the composition is in the form of a capsule (see e. g. , U. S. Patent No.

5,698, 155). Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro ed., 19th ed. 1995), incorporated herein by reference.

In one embodiment, the 2-Pyrimidinylpiperazine Compounds are formulated in accordance with routine procedures as a composition adapted for oral administration to human beings. Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry ; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compositions. In these latter platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent

composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time-delay material such as glycerol monostearate or glycerol stearate can also be used. Oral, compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are of pharmaceutical grade.

In another embodiment, the 2-Pyrimidinylpiperazine Compounds can be formulated for intravenous administration. Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lidocaine to lessen pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent. Where the 2- Pyrimidinylpiperazine Compounds are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline.

Where the 2-Pyrimidinylpiperazine Compounds are administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.

The 2-Pyrimidinylpiperazine Compounds can be administered by controlled-release or sustained-release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U. S. Patent Nos.: 3,845, 770; 3,916, 899; 3,536, 809; 3, 598, 123; 4,008, 719; 5,674, 533; 5,059, 595; 5, 591, 767; 5, 120, 548 ; 5,073, 543; 5,639, 476; 5,354, 556 ; and 5,733, 566, each of which is incorporated herein by reference. Such dosage forms can be used to provide controlled-or sustained- release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled-or sustained-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. The invention thus encompasses

single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-or sustained-release.

Controlled-or sustained-release pharmaceutical compositions can have a common goal of improving drug therapy over that achieved by their non-controlled or non-sustained counterparts. In one embodiment, a controlled-or sustained-release composition comprises a minimal amount of a 2-Pyrimidinylpiperazine Compound to cure or control the condition in a minimum amount of time. Advantages of controlled-or sustained-release compositions include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled-or sustained-release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels of the 2- Pyrimidinylpiperazine Compound, and can thus reduce the occurrence of adverse side effects.

Controlled-or sustained-release compositions can initially release an amount of a 2- Pyrimidinylpiperazine Compound that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the 2- Pyrimidinylpiperazine Compound to maintain this level of therapeutic or prophylactic effect over an extended period of time. To maintain a constant level of the 2-Pyrimidinylpiperazine Compound in the body, the 2-Pyrimidinylpiperazine Compound can be released from the dosage form at a rate that will replace the amount of 2-Pyrimidinylpiperazine Compound being metabolized and excreted from the body. Controlled-or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.

The amount of the 2-Pyrimidinylpiperazine Compound that is effective in the treatment or prevention of a Condition and can be determined by standard clinical techniques.

In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on the route of administration, and the seriousness of the Condition and can be decided according to the judgment of a practitioner and/or each animal's circumstances. Suitable effective dosage amounts, however, range from about 0.01 mg/kg of body weight to about 2500 mg/kg of body weight, although they are typically about 100 mg/kg of body weight or less. In one embodiment, the effective dosage amount ranges from about 0. 01 mg/kg of body weight to

about 100 mg/kg of body weight of a 2-Pyrimidinylpiperazine Compound, in another embodiment, about 0.02 mg/kg of body weight to about 50 mg/kg of body weight, and in another embodiment, about 0.025 mg/kg of body weight to about 20 mg/kg of body weight.

In one embodiment, an effective dosage amount is administered about every 24 h until the Condition is abated. In another embodiment, an effective dosage amount is administered about every 12 h until the Condition is abated. In another embodiment, an effective dosage amount is administered about every 8 h until the Condition is abated. In another embodiment, an effective dosage amount is administered about every 6 h until the Condition is abated. In another embodiment, an effective dosage amount is administered about every 4 h until the Condition is abated. The effective dosage amounts described herein refer to total amounts administered; that is, if more than one 2-Pyrimidinylpiperazine Compound is administered, the effective dosage amounts correspond to the total amount administered.

Where a cell capable of expressing mGluR5 or mGluRl is contacted with a 2- Pyrimidinylpiperazine Compound in vitro, the amount effective for inhibiting the mGluR5 or mGluRl receptor function in a cell will typically range from about 0. 01, ug/L to about 5 mg/L, in one embodiment, from about 0. 01 llg/L to about 2.5 mg/L, in another embodiment, from about 0. 01 J. gel to about 0.5 mg/L, and in another embodiment, from about 0. 01 g/L to about 0.25 mg/L of a solution or suspension of a pharmaceutically acceptable carrier or excipient. In one embodiment, the volume of solution or suspension comprising the 2- Pyrimidinylpiperazine Compound is from about 0. 01) J. L to about 1 mL. In another embodiment, the volume of solution or suspension is about 200) J. L.

Where a cell capable of expressing VR1, mGluR5, or mGluRl is contacted with a 2- Pyrimidinylpiperazine Compound in vivo, the amount effective for inhibiting the receptor function in a cell will typically range from about 0.01 mg/kg of body weight to about 2500 mg/kg of body weight, although it typically ranges from about 100 mg/kg of body weight or less. In one embodiment, the effective dosage amount ranges from about 0.01 mg/kg of body weight to about 100 mg/kg of body weight of a 2-Pyrimidinylpiperazine Compound, in another embodiment, about 0.020 mg/kg of body weight to about 50 mg/kg-of body weight, and in another embodiment, about 0.025 mg/kg of body weight to about 20 mg/kg of body weight. In one embodiment, an effective dosage amount is administered about every 24 h. In another embodiment, an effective dosage amount is administered about every 12. In another

embodiment, an effective dosage amount is administered about every 8. In another embodiment, an effective dosage amount is administered about every 6 h. In another embodiment, an effective dosage amount is administered about every 4 h.

The 2-Pyrimidinylpiperazine Compounds can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans. Animal model systems can be used to demonstrate safety and efficacy.

The present methods for treating or preventing a Condition in an animal in need thereof can further comprise administering another therapeutic agent to the animal being administered a 2-Pyrimidinylpiperazine Compound. In one embodiment, the other therapeutic agent is administered in an effective amount.

The present methods for inhibiting mGluR5 function in a cell capable of expressing mGluR5 can further comprise contacting the cell with an effective amount of another therapeutic agent.

The present methods for inhibiting mGluRl function in a cell capable of expressing mGluRl can further comprise contacting the cell with an effective amount of another therapeutic agent.

Effective amounts of the other therapeutic agents are known to those skilled in the art.

However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective-amount range. In one embodiment of the invention, where another therapeutic agent is administered to an animal, the effective amount of the 2- Pyrimidinylpiperazine Compound is less than its effective amount would be where the other therapeutic agent is not administered. In this case, without being bound by theory, it is believed that the 2-Pyrimidinylpiperazine Compounds and the other therapeutic agent act synergistically to treat or prevent a Condition.

The other therapeutic agent can be, but is not limited to, an opioid agonist, a non- opioid analgesic, a non-steroidal anti-inflammatory agent, an antimigraine agent, a Cox-lI inhibitor, an antiemetic, a P-adrenergic blocker, an anticonvulsant, an antidepressant, a Ca2+-channel blocker, an anticancer agent, an agent for treating or preventing UI, an agent for treating addictive disorder, an agent for treating Parkinson's disease and parkinsonism, an agent for treating anxiety, an agent for treating epilepsy, an agent for treating a seizure, an agent for treating a stroke, an agent for treating a pruritic condition, an agent for treating

psychosis, an agent for treating Huntington's chorea, an agent for treating ALS, an agent for treating a cognitive disorder, an agent for treating a migraine, an agent for treating vomiting, an agent for treating dyskinesia, or an agent for treating depression, and mixtures thereof.

Examples of useful opioid agonists include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof.

In certain embodiments, the opioid agonist is selected from codeine, hydromorphone, hydrocodone, oxycodone, dihydrocodeine, dihydromorphine, morphine, tramadol, oxymorphone, pharmaceutically acceptable salts thereof, and mixtures thereof.

Examples of useful non-opioid analgesics include non-steroidal anti-inflammatory agents, such as aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, and pharmaceutically acceptable salts thereof, and mixtures thereof. Other suitable non-opioid analgesics include the following, non-limiting, chemical classes of analgesic, antipyretic, non-steroidal anti- inflammatory drugs: salicylic acid derivatives, including aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, and

olsalazin; para-aminophennol derivatives including acetaminophen and phenacetin; indole and indene acetic acids, including indomethacin, sulindac, and etodolac; heteroaryl acetic acids, including tolmetin, diclofenac, and ketorolac; anthranilic acids (fenamates), including mefenamic acid and meclofenamic acid; enolic acids, including oxicams (piroxicam, tenoxicam), and pyrazolidinediones (phenylbutazone, oxyphenthartazone); and alkanones, including nabumetone. For a more detailed description of the NSAIDs, see Paul A. Insel, <BR> <BR> <BR> <BR> <BR> Analgesic-Antipyretic and Anti-inflammatory Agents and Drugs Employed in the Treatment of Gout, in Goodman & Gilman's The Pharmacological Basis of Therapeutics 617-57 (Perry B. Molinhoff and Raymond W. Ruddon eds., 9* ed 1996) and Glen R. Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington : The Science and Practice of Pharmacy VolII1196-1221 (A. R. Gennaro ed. 19th ed. 1995) which are hereby incorporated by reference in their entireties.

Examples of useful Cox-II inhibitors and 5-lipoxygenase inhibitors, as well as combinations thereof, are described in U. S. Patent No. 6,136, 839, which is hereby incorporated by reference in its entirety. Examples of useful Cox-II inhibitors include, but are not limited to, rofecoxib and celecoxib.

Examples of useful antimigraine agents include, but are not limited to, alpiropride, bromocriptine, dihydroergotamine, dolasetron, ergocornine, ergocorninine, ergocryptine, ergonovine, ergot, ergotamine, flumedroxone acetate, fonazine, ketanserin, lisuride, lomerizine, methylergonovine, methysergide, metoprolol, naratriptan, oxetorone, pizotyline, propranolol, risperidone, rizatriptan, sumatriptan, timolol, trazodone, zolmitriptan, and mixtures thereof.

The other therapeutic agent can alternatively be an agent useful for reducing any potential side effects of a 2-Pyrimidinylpiperazine Compounds. For example, the other therapeutic agent can be an antiemetic agent. Examples of useful antiemetic agents include, but are not limited to, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, odansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, and mixtures thereof.

Examples of useful P-adrenergic blockers include, but are not limited to, acebutolol, alprenolol, amosulabol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bufuralol, bunitrolol, bupranolol, butidrine hydrochloride, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol, indenolol, labetalol, levobunolol, mepindolol, metipranolol, metoprolol, moprolol, nadolol, nadoxolol, nebivalol, nifenalol, nipradilol,-oxprenolol, penbutolol, pindolol, practolol, pronethalol, propranolol, sotalol, sulfinalol, talinolol, tertatolol, tilisolol, timolol, toliprolol, and xibenolol.

Examples of useful anticonvulsants include, but are not limited to, acetylpheneturide, albutoin, aloxidone, aminoglutethimide, 4-amino-3-hydroxybutyric acid, atrolactamide, beclamide, buramate, calcium bromide, carbamazepine, cinromide, clomethiazole, clonazepam, decimemide, diethadione, dimethadione, doxenitroin, eterobarb, ethadione, ethosuximide, ethotoin, felbamate, fluoresone, gabapentin, 5-hydroxytryptophan, lamotrigine, magnesium bromide, magnesium sulfate, mephenytoin, mephobarbital, metharbital, methetoin, methsuximide, 5-methyl-5- (3-phenanthryl)-hydantoin, 3-methyl-5-phenylhydantoin, narcobarbital, nimetazepam, nitrazepam, oxcarbazepine, paramethadione, phenacemide, phenetharbital, pheneturide, phenobarbital, phensuximide, phenylmethylbarbituric acid, phenytoin, phethenylate sodium, potassium bromide, pregabaline, primidone, progabide, sodium bromide, solanum, strontium bromide, suclofenide, sulthiame, tetrantoin, tiagabine, topiramate, trimethadione, valproic acid, valpromide, vigabatrin, and zonisamide.

Examples of useful antidepressants include, but are not limited to, binedaline, caroxazone, citalopram, (S)-citalopram, dimethazan, fencamine, indalpine, indeloxazine hydrocholoride, nefopam, nomifensine, oxitriptan, oxypertine, paroxetine, sertraline, thiazesim, trazodone, benmoxine, iproclozide, iproniazid, isocarboxazid, nialamide, octamoxin, phenelzine, cotinine, rolicyprine, rolipram, maprotiline, metralindole, mianserin, mirtazepine, adinazolam, amitriptyline, amitriptylinoxide, amoxapine, butriptyline, clomipramine, demexiptiline, desipramine, dibenzepin, dimetacrine, dothiepin, doxepin, fluacizine, imipramine, imipramine N-oxide, iprindole, lofepramine, melitracen, metapramine, nortriptyline, noxiptilin, opipramol, pizotyline, propizepine, protriptyline, quinupramine, tianeptine, trimipramine, adrafinil, benactyzine, bupropion, butacetin,

dioxadrol, duloxetine, etoperidone, febarbamate, femoxetine, fenpentadiol, fluoxetine, fluvoxamine, hematoporphyrin, hypericin, levophacetoperane, medifoxamine, milnacipran, minaprine, moclobemide, nefazodone, oxaflozane, piberaline, prolintane, pyrisuccideanol, ritanserin, roxindole, rubidium chloride, sulpiride, tandospirone, thozalinone, tofenacin, toloxatone, tranylcypromine, L-tryptophan, venlafaxine, viloxazine, and zimelidine.

Examples of useful Ca2+-channel blockers include, but are not limited to, bepridil, clentiazem, diltiazem, fendiline, gallopamil, mibefradil, prenylamine, semotiadil, terodiline, verapamil, amlodipine, aranidipine, barnidipine, benidipine, cilnidipine, efonidipine, elgodipine, felodipine, isradipine, lacidipine, lercanidipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, cinnarizine, flunarizine, lidoflazine, lomerizine, bencyclane, etafenone, fantofarone, and perhexiline.

Examples of useful anticancer agents include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin, cisplatin, cladribine, crisnatol mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, decitabine, dexormaplatin, dezaguanine, dezaguanine mesylate, diaziquone, docetaxel, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene citrate, dromostanolone propionate, duazomycin, edatrexate, eflornithine hydrochloride, elsamitrucin, enloplatin, enpromate, epipropidine, epirubicin hydrochloride, erbulozole, esorubicin hydrochloride, estramustine, estramustine phosphate sodium, etanidazole, etoposide, etoposide phosphate, etoprine, fadrozole hydrochloride, fazarabine, fenretinide, floxuridine, fludarabine phosphate, fluorouracil, flurocitabine, fosquidone, fostriecin sodium, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, ihnoibsine, interleukin n (including recombinant interleukin II or rIL2), interferon alpha-2a, interferon alpha-2b, interferon alpha-nl, interferon alpha-n3, interferon beta-I a, interferon gamma-I b, iproplatin, irinotecan hydrochloride, lanreotide acetate, letrozole, leuprolide acetate, liarozole hydrochloride,

lometrexol sodium, lomustine, losoxantrone hydrochloride, masoprocol, maytansine, mechlorethamine hydrochloride, megestrol acetate, melengestrol acetate, melphalan, menogaril, mercaptopurine, methotrexate, methotrexate sodium, metoprine, meturedepa, mitindomide, mitocarcin, mitocromin, mitogillin, mitomalcin, mitomycin, mitosper, mitotane, mitoxantrone hydrochloride, mycophenolic acid, nocodazole, nogalamycin, ormaplatin, oxisuran, paclitaxel, pegaspargase, peliomycin, pentamustine, peplomycin sulfate, perfosfamide, pipobroman, piposulfan, piroxantrone hydrochloride, plicamycin, plomestane, porfimer sodium, porfiromycin, prednimustine, procarbazine hydrochloride, puromycin, puromycin hydrochloride, pyrazofurin, riboprine, rogletimide, safingol, safingol hydrochloride, semustine, simtrazene, sparfosate sodium, sparsomycin, spirogermanium hydrochloride, spiromustine, spiroplatin, streptonigrin, streptozotocin, sulofenur, talisomycin, tecogalan sodium, tegafur, teloxantrone hydrochloride, temoporfin, teniposide, teroxirone, testolactone, thiamiprine, thioguanine, thiotepa, tiazofurin, tirapazamine, toremifene citrate, trestolone acetate, triciribine phosphate, trimetrexate, trimetrexate glucuronate, triptorelin, tubulozole hydrochloride, uracil mustard, uredepa, vapreotide, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine. sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine tartrate, vinrosidine sulfate, vinzolidine sulfate, vorozole, zeniplatin, zinostatin, zorubicin hydrochloride.

Examples of other anti-cancer drugs include, but are not limited to, 20-epi-1, 25 dihydroxyvitamin D3 ; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene ; adecypenol; adozelesin; aldesleukin ; ALL-TK antagonists; altretamine ; ambamustine; amidox; amifostine ; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1 ; antiandrogen; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane ; atrimustine ; axinastatin 1 ; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine ; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene ; bisaziridinylspermine ; bisnafide ; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine ; calcipotriol; calphostin C; camptothecin derivatives;

canarypox IL-2 ; capecitabine; carboxamide-amino-triazole ; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine ; cecropin B; cetrorelix; chloroquinoxaline sulfonamide ; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole ; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816 ; crisnatol; cryptophycin 8 ; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam ; cypemycin; cytarabine ocfosfate ; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide ; dexrazoxane ; dexverapamil ; diaziquone; didemnin B ; didox; diethylnorspermine ; dihydro-5-azacytidine; dihydrotaxol, 9- ; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron ; doxifluridine ; droloxifene ; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine ; edrecolomab; eflornithine ; elemene ; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim ; finasteride; flavopiridol; flezelastine ; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex ; formestane ; fostriecin ; fotemustine ; gadolinium texaphyrin; gallium nitrate ; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone ; ihnofosine ; ilomastat; imidazoacridones; imiquimod ; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin ; ipomeanol, 4- ; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron ; jasplakinolide ; kahalalide F; lamellarin-N triacetate ; lanreotide; leinamycin; lenograstim ; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole ; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol ; lonidamine; losoxantrone ; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; metbioninase ; metoclopramide ; MIF inhibitor; mifepristone; miltefosine ; mirimostim ; mismatched double stranded RNA; mitoguazone ; mitolactol; mitomycin analogues; mitonafide; mitotoxin

fibroblast growth factor-saporin; mitoxantrone ; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract ; myriaporone ; N-acetyldinaline; N-substituted benzamides ; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin ; neridronic acid; neutral endopeptidase; nilutamide ; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn ; 06-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; odansetron ; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin ; pamidronic acid; panaxytriol; panomifene ; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole ; perflubron; perfosfamide ; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim ; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium ; porfiromycin ; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor ; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron ; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozyrnes ; RII retinamide ; rogletimide; rohitukine; romurtide; roquinimex ; rubiginone B1 ; ruboxyl; safingol ; saintopin; SarCNU ; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1 ; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin ; sparfosic acid; spicamycinD ; spiromustine; splenopentin; spongistatin 1; squalamine ; stem cell inhibitor; stem-cell division inhibitors; stipiamide ; stromelysin inhibitors; sulfinosine ; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium ; tegafur ; tellurapyrylium; telomerase inhibitors;

temoporfin ; temozolomide; teniposide; tetrachlorodecaoxide ; tetrazomine ; thaliblastine; thiocoraline; thrombopoietin ; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist ; thymotrinan; thyroid stimulating hormone ; tin ethyl etiopurpurin; tirapazamine ; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors ; tretinoin ; triacetyluridine ; triciribine ; trimetrexate ; triptorehn ; tropisetron ; turosteride ; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors ; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol ; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin ; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.

Examples of useful therapeutic agents for treating or preventing UI include, but are not limited to, propantheline, imipramine, hyoscyamine, oxybutynin, and dicyclomine.

Examples of useful therapeutic agents for treating or preventing an addictive disorder include, but are not limited to, methadone, desipramine, amantadine, fluoxetine, buprenorphine, an opiate agonist, 3-phenoxypyridine, levomethadyl acetate hydrochloride, and serotonin antagonists.

Examples of useful therapeutic agents for treating or preventing Parkinson's disease and parkinsonism include, but are not limited to, carbidopa/levodopa, pergolide, bromocriptine, ropinirole, pramipexole, entacapone, tolcapone, selegiline, amantadine, and trihexyphenidyl hydrochloride.

Examples of useful therapeutic agents for treating or preventing anxiety include, but are not limited to, benzodiazepines, such as alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, and triazolam ; non-benzodiazepine agents, such as buspirone, gepirone, ipsapirone, tiospirone, zolpicone, zolpidem, and zaleplon ; tranquilizers, such as barbituates, e. g., amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital, and thiopental; and propanediol carbamates, such as meprobamate and tybamate.

Examples of useful therapeutic agents for treating or preventing epilepsy include, but are not limited to, carbamazepine, ethosuximide, gabapentin, lamotrigine, phenobarbital,

phenytoin, primidone, valproic acid, trimethadione, benzodiazepines, gabapentin, lamotrigine, y-vinyl GABA, acetazolamide, and felbamate.

Examples of useful therapeutic agents for treating or preventing a seizure include, but are not limited to, carbamazepine, ethosuximide, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, benzodiazepines, gabapentin, lamotrigine, y-vinyl GABA, acetazolamide, and felbamate.

Examples of useful therapeutic agents for treating or preventing stroke include, but are not limited to, anticoagulants such as heparin, agents that break up clots such as streptokinase or tissue plasminogen activator, agents that reduce swelling such as mannitol or corticosteroids, and acetylsalicylic acid.

Examples of useful therapeutic agents for treating or preventing a pruritic condition include, but are not limited to, naltrexone ; nalmefene ; danazol; tricyclics such as amitriptyline, imipramine, and doxepin; antidepressants such as those given below; menthol ; camphor; phenol; pramoxine ; capsaicin; tar; steroids; and antihistamines.

Examples of useful therapeutic agents for treating or preventing psychosis include, but are not limited to, phenothiazines such as chlorpromazine hydrochloride, mesoridazine besylate, and thoridazine hydrochloride; thioxanthenes such as chloroprothixene and thiothixene hydrochloride; clozapine; risperidone; olanzapine; quetiapine; quetiapine fumarate; haloperidol; haloperidol decanoate; loxapine succinate; molindone hydrochloride; pimozide; and ziprasidone.

Examples of useful therapeutic agents for treating or preventing Huntington's chorea include, but are not limited to, haloperidol and pimozide.

Examples of useful therapeutic agents for treating or preventing ALS include, but are not limited to, baclofen, neurotrophic factors, riluzole, tizanidine, benzodiazepines such as clonazepan and dantrolene.

Examples of useful therapeutic agents for treating or preventing cognitive disorders include, but are not limited to, agents for treating or preventing dementia such as tacrine; donepezil; ibuprofen; antipsychotic drugs such as thioridazine and haloperidol; and antidepressant drugs such as those given below.

Examples of useful therapeutic agents for treating or preventing a migraine include, but are not limited to, sumatriptan; methysergide ; ergotamine ; caffeine; and beta-blockers such as propranolol, verapamil, and divalproex.

Examples of useful therapeutic agents for treating or preventing vomiting include, but are not limited to, 5-HT3 receptor antagonists such as odansetron, dolasetron, granisetron, and tropisetron ; dopamine receptor antagonists such as prochlorperazine, thiethylperazine, chlorpromazine, metoclopramide, and domperidone; glucocorticoids such as dexamethasone ; and benzodiazepines such as lorazepam and alprazolam.

Examples of useful therapeutic agents for treating or preventing dyskinesia include, but are not limited to, reserpine and tetrabenazine.

Examples of useful therapeutic agents for treating or preventing depression include, but are not limited to, tricyclic antidepressants such as amitryptyline, amoxapine, bupropion, clomipramine, desipramine, doxepin, imipramine, maprotiline, nefazadone, nortriptyline, protriptyline, trazodone, trimipramine, and venlafaxine ; selective serotonin reuptake inhibitors such as citalopram, (S) -citalopram, fluoxetine, fluvoxamine, paroxetine, and setraline ; monoamine oxidase inhibitors such as isocarboxazid, pargyline, phenelzine, and. tranylcypromine ; and psychostimulants such as dextoamphetamine and methylphenidate.

A 2-Pyrimidinylpiperazine Compound and the other therapeutic agent can act additively or, in one embodiment, synergistically. In one embodiment, a 2- Pyrimidinylpiperazine Compound is administered concurrently with another therapeutic agent; for example, a composition comprising an effective amount of a 2- Pyrimidinylpiperazine Compound, an effective amount of another therapeutic agent can be administered. Alternatively, a composition comprising an effective amount of a 2- Pyrimidinylpiperazine Compound and a different composition comprising an effective amount of another therapeutic agent can be concurrently administered. In another embodiment, an effective amount of a 2-Pyrimidinylpiperazine Compound is administered prior or subsequent to administration of an effective amount of another therapeutic agent. In this embodiment, the 2-Pyrimidinylpiperazine Compound is administered while the other therapeutic agent exerts its therapeutic effect, or the other therapeutic agent is administered while the 2-Pyrimidinylpiperazine Compound exerts its therapeutic effect for treating or preventing a Condition.

A composition of the invention is prepared by a method comprising admixing a 2-Pyrimidinylpiperazine Compound or pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or excipient. Admixing can be accomplished using methods well known for admixing a compound (or salt) and a pharmaceutically acceptable carrier or excipient. In one embodiment the composition is prepared such that the 2-Pyrimidinylpiperazine Compound is present in the composition in an effective amount.

4.7 Kits The invention encompasses kits that can simplify the administration of a 2-Pyrimidinylpiperazine Compound to an animal.

A typical kit of the invention comprises a unit dosage form of a 2-Pyrimidinylpiperazine Compound. In one embodiment, the unit dosage form is a container, which can be sterile, containing an effective amount of a 2-Pyrimidinylpiperazine Compound and a pharmaceutically acceptable carrier or excipient. The kit can further comprise a label or printed instructions instructing the use of the 2-Pyrimidinylpiperazine Compound to treat a Condition. The kit can also further comprise a unit dosage form of another therapeutic agent, for example, a second container containing an effective amount of the other therapeutic agent and a pharmaceutically acceptable carrier or excipient. In another embodiment, the kit comprises a container containing an effective amount of a 2-Pyrimidinylpiperazine Compound, an effective amount of another therapeutic agent and a pharmaceutically acceptable carrier or excipient. Examples of other therapeutic agents include, but are not limited to, those listed above.

Kits of the invention can further comprise a device that is useful for administering the unit dosage forms. Examples of such a device include but are not limited to a syringe, a drip bag, a patch, an inhaler, and an enema bag.

The following examples are set forth to assist in understanding the invention and should not be construed as specifically limiting the invention described and claimed herein.

Such variations of the invention, including the substitution of all equivalents now known or later developed, which would be within the purview of those skilled in the art, and changes in formulation or minor changes in experimental design, are to be considered to fall within the scope of the invention incorporated herein.

5. EXAMPLES Examples 1-11 relate to the synthesis of illustrative 2-Pyrimidinylpiperazine Compounds.

5.1 EXAMPLE 1 : SYNTHESIS OF COMPOUND AXA (IIa ! Compound AAA (IIa) was prepared according to the following scheme: nN fit, COOL N HOBt/EDC +--a DMF CNS 9 E 2HC1 0 E F Compound AAA (IIa) A solution of 1- (2-pyrimidinyl) piperazine dihydrochloride ("Compound E, "100 mg, 0.42 mmol), 3-phenyl-2-propynoic acid ("Compound F, "61 mg, 0.42 mmol), 1-hydroxybenzotriazole ("HOBt, "57 mg, 0.42 mmol), and 1- [3- (dimethylamino) propyl] -3- ethylcarboimide hydrochloride ("EDC, "97 mg, 0.54 mmol) in 3 mL dimethylformamide ("DMF") was stirred at room temperature, about 25°C, for 4 hours. After this period, DMF was removed under reduced pressure and the resulting residue was dissolved in ethyl acetate and extracted with brine. The organic layer was dried using Na2SO4 and purified using flash chromatography (normal phase silica gel, 35-60 pm particle size (230-400 mesh) with an ethyl acetate/hexane eluent system) to provide 49 mg of Compound AAA (IIa) as a white solid (40% yield).

The structure of Compound AAA (IIa) was confirmed by'H NMR and mass spectral (MS) analysis. Compound AAA(IIa): 1H NMR (CDC13) 5 8.37 (bd, J = 4.8 Hz, 2H), 7.60 (m, 2H), 7.47 (m, 3H), 6.58 (t, J = 8. 0,4. 8 Hz, 1H), 3.91 (m, 6 H), 3.80 (m, 2H); MS (El) : m/z 315 (M+Na+).

5.2 EXAMPLE 2: SYNTHESIS OF COMPOUND AFX (IIb) Compound AFX (IIb) was prepared according to the following scheme: COOH IN NON NON H N N CHCI3 NN / t N CH3 3 KNß HOBVDIC N CH3 a H J ! DCM. L CI H 3 DCM H 4 H Compound AFX (lob) 2-Chloropyrimidine (1.14 g, 10.0 mmol), 2-methylpiperazine (1.20 g, 12.0 mmol), and triethylamine (1.52 g, 15 mmol) were dissolved in 10 mL of chloroform and the resulting mixture was stirred at room temperature, about 25°C, for 4 hours. The reaction was quenched with water and the resulting mixture was extracted with chloroform. The organic layer was dried, concentrated, and purified using a silica gel column eluted with gradient elution from ethyl acetate to 2/1 ethyl acetate/methanol to provide Compound O as a yellow oil (95% yield).

A solution of Compound O (178 mg, 1. 0 mmol), Compound F (219 mg, 1.5 mmol), HOBt (203mg, 1.5 mmol), and DIC (189 mg. 1. 5 mmol) in 4.5 mL dichloromethane ("DCM") was stirred at room temperature, about 25°C, for 4 hours. After evaporation, the product was purified using a silica gel column eluted with gradient elution from hexane to 1/1 hexane/ethyl acetate to provide 153 mg of Compound AFX (IIb) as a slight yellowish solid (50% yield).

The structure of Compound AFX (IIb) was confirmed by'H NMR and mass spectral (MS) analysis. Compound AFX (IIb) :'H NMR (CDC13) 8 8.35 (d, J = 4.7 Hz, 2H), 7.61 (m, 2H), 7.40 (m, 3H), 6. 55 (dd, J = 4.7, 4.7 Hz, 1H), 4.91 (m, 0. 6H), 4. 78 (m, 2H), 4.63 (dt, J = 1.8, 11. 6 Hz, 0.4H), 4.52 (d, J = 13. 3 Hz, 0.4H), 4.33 (d, J = 13. 3 Hz, 0.6H), 3.59 (m, 0.6H), 3.20 (m, 2.4H), 1.36 (d, J = 6.8 Hz, 1.2H), 1.25 (d, J = 6.8 Hz, 1.8H) ; MS (El) : m/z 329 (M+Na+).

5.3 EXAMPLE 3: SYNTHESIS OF COMPOUND BGS (IIa ! Compound BGS (IIa) was prepared according to the following scheme: G H I Compound BGS (IIa) A solution of 2-chloro-4- (trifluoromethyl) pyrimidine ("Compound G, "400 mg, 2.19 mmol) and piperazine (189 mg, 2.19 mmol) in dimethylsulfoxide ("DMSO,"4 mL) was placed on a shaker at room temperature, about 25°C, for 5 minutes to provide a mixture of the free-base form of Compound H and Compound I. The resulting mixture of Compound H and 5 Compound I was concentrated and separated using flash chromatography as described in Example 1 to provide 200 mg (39% yield) of Compound H.

A solution of Compound H (200 mg, 0.87 mmol), Compound F (138 mg, 0.95 mmol), HOBt (128 mg, 0.95 mmol) and EDC (182 mg, 0.95 mmol) in 3 mL DMF was stirred at room temperature for 4 hours. After this period, DMF was removed under reduced pressure and the resulting residue was dissolved in ethyl acetate and extracted with brine. The organic layer was dried using Na2SO4 and purified using flash chromatography as described in Example 1 to provide 40 mg of Compound BGS (IIa) as a white solid (5% overall yield based on Compound G).

The structure of Compound BGS (IIa) was confirmed by lH NMR and mass spectral (MS) analysis. Compound BGS (IIa) :'H NMR (CDC13) # 8.56 (d, J = 4.8 Hz, 1H), 7.62- 7.58 (m, 2H), 7.50-7. 39 (m, 3H), 6.80 (d, J = 4.8 Hz, 1H), 4.05-4. 01 (m, 2H), 3.99-3. 95 (m, 4H), 3.84-3. 80 (m, 2H); MS (El) : m/z 361 (M+Na+).

5.4 EXAMPLE 4 : SYNTHESIS OF COMPOUND ENS (IVa ! Compound ENS (IVa) was prepared according to the following scheme: J K Compound ENS (IVa) To a solution of 1-(2-pyrimidyl) piperazine ("Compound J, "200 mg, 1.22 mmol) and 3-phenyl-2-propynal ("Compound K, "159 mg, 1.22 mmol) in dichloroethane ("DCE,"10 mL) was added sodium triacetoxyborohydride ("NaB (OAc) 3H," 1. 1 equivalents, 284 mg, 1. 34 mmol). The reaction mixture was placed on a shaker at room temperature, about 25°C, for 2 hours. After this period, the decanted solution was purified using flash chromatography as described in Example 1 to provide 100 mg (30% yield) of a brown oil. The brown oil was

then dissolved in DCM (1 mL) and 1N HCl (6 drops in 0.5 mL diethyl ether) was added to the resulting mixture to provide 100 mg of Compound ENS (IVa), isolated as its hydrochloride as a white solid (30% overall yield).

The structure of Compound ENS (IVa) was confirmed by lE NMR and mass spectral (MS) analysis. Compound ENS (IVa) : 1H NMR (CDCl3) 8 8.33 (d, J = 4.6 Hz, 2H), 7.45- 7.44 (m, 2H), 7.33-7. 30 (m, 3H), 6.65 (t, J = 4.6 Hz, 1H), 3. 95-3. 91 (m, 4H), 3.60 (s, 2H), 2.75-2. 71 (m, 4H); MS (El) : m/z 293 (M+Na+).

5.5 EXAMPLE 5: SYNTHESIS OF COMPOUND GZE (Va) Compound GZE (Va) was prepared according to the following scheme: L M Compound GZE (Va) A solution of Compound F (5 g, 34 mmol) and HOBt (0.1 g. 0.74 mmol) in DMF (50 mL) was cooled to 0°C. Piperazine-1-carboxylic acid tert-butyl ester (6.5 g, 34 mmol) was added as a solid in one portion, followed by the addition of DIC (4. 2 g, 34 mmol) over 10 minutes. The resulting mixture was kept at 0°C for 3 hours, then diluted with DCM (300

mL), twice shaken with 50 mL of water, shaken with NaOH (2N aqueous, 40 mL), and shaken with brine (50 mL). After removing the solvent under reduced pressure, the residue was purified on a silica gel column (3/7 ethyl acetate/hexane) to provide 7.0 g of 4- (3-phenyl- propynoyl)-piperazine-l-carboxylic acid tert-butyl ester ("Compound L") as a white solid (70% yield).

The structure of Compound L was confirmed by'H NMR. Compound L :'H-NMR (CDC13) 7.55-7. 58 (m, 2H), 7.36-7. 45 (m, 3H), 3.81-3. 83 (m, 2H), 3.66-3. 69 (m, 2H), 3.52- 3.55 (m, 2H), 3.45-3. 48 (m, 2H), 1.49 (s, 9H).

A mixture of Compound L (2.0 g) and HC1 (4N in 4 mL 1,4-dioxane) in 1,4-dioxane (10 mL) was shaken at about 25°C for 12 hours. The resulting mixture was diluted with DCM (200 mL) and water (40 mL), then neutralized with NaOH (2N aqueous, 10 mL). The organic layer was separated and the solvent was removed under reduced pressure to provide 1.2 g of 3-phenyl-1-piperazin-1-yl-propynone ("Compound M, "90% yield).

The structure of Compound M was confirmed by'H NMR. Compound M :'H-NMR (CDCl3) 7.55 (dd, J 1. 3,8. 1 Hz, 2H), 7.35-7. 44 (m, 3H), 3.79-3. 84 (m, 2H), 3.68-3. 69 (m, 2H), 2.92-2. 96 (m, 2H), 2.88-2. 89 (m, 2H).

A mixture of Compound M (100 mg, 0.47 mmol), 2-chloro-4,6-dimethyl-pyrimidine (74 mg, 0.47 mmol) and diisopropylethylamine ("DIEA, "0.5 mL) in DMSO (2mL) was heated at 70°C for 18 hours. After cooling to about 25°C, 2 mL of water was added to the reaction mixture. The resulting mixture was shaken at about 25°C for 1 hour. The solid was collected and purified on a silica gel column (1/1 ethyl acetate/hexane) to provide 100 mg of Compound GZE (Va) as a white solid (70% yield).

The structure of Compound GZE (Va) was confirmed by'H NMR and mass spectral (MS) analysis. Compound GZE (Va) :'H-NMR (CDCl3) 7.56-7. 61 (m, 2H), 7.38-7. 47 (m, 3H), 6.35 (s, 1H), 3.95-3. 98 (m, 2H), 3.89-3. 94 (m, 4H), 3.76-3. 79 (m, 2H), 2.32 (s, 6H); MS (El) : m/z 321 (M+H) +.

5.6 EXAMPLE 6 : SYNTHESIS OF COMPOUND (Va) Compound HAC (Va) was prepared according to a scheme similar to Example 5 except that 0.47 mmol of 2-chloro-4-methyl-6-methoxy-pyrimidine was used in place of 2- chloro-4,6-dimethyl-pyrimidine. After the solid free base of Compound HAC (Va) was

collected and purified on a silica gel column (1/1 ethyl acetate/hexane), the free base was dissolved in anhydrous diethyl ether while about 3 equivalents of 1 M HCl in diethyl ether solution was added slowly with stirring. The mixture was sonicated and the top layer was decanted. The remaining solid was washed 3 times with diethyl ether and dried under reduced pressure to provide the hydrochloride salt of Compound HAC (Va).

The structure of Compound HAC (Va) was confirmed by 1H NMR and mass spectral (MS) analysis. Compound HAC (Va) :'H-NMR (DMSO-d6) 7.67 (m, 2H), 7.53 (m, 3H), 6.17 (s, 1H), 3.90 (m, 7H), 3.84 (m, 2H), 3.64 (m, 2H), 2.29 (s, 3H); MS (EI) : m/z 337 (M+H) +.

5.7 EXAMPLE 7 : SYNTHESIS OF COMPOUND HBD (Va ! Compound HBD (Va) was prepared according to a scheme similar to Example 5 except that 0.47 mmol of 2, 6-dichloro-4-methyl-pyrimidine was used in place of 2-chloro- 4,6-dimethyl-pyrimidine. Compound HBD (Va) was obtained as a white solid.

The structure of Compound HBD (Va) was confirmed by'H NMR and mass spectral (MS) analysis. Compound HBD (Va) :'H-NMR (CDCl3) 7.57-7. 59 (m, 2H), 7.38-7. 48 (m, 3H), 6.48 (s, 1H), 3.89-3. 98 (m, 6H), 3.76-3. 79 (m, 2H), 2.35 (s, 3H); MS (EI) : m/z 341 (M+H) +.

5.8 EXAMPLE 8: SYNTHESIS OF COMPOUND GZF (Va) Compound GZF (Va) was prepared according to the following scheme: Compound GZF (Va) A mixture of 2-chloro-4, 6-dimethylpyrimidine (3 g, 21 mmol) and piperazine (9 g, 107 mmol) in 15 mL DMSO was heated in a sealed tube at 100°C for 16 hours. The solvent was removed and the solid product was purified on a silica gel column, eluting with ethyl acetate followed by 1/9 methanol/ethyl acetate, to provide 3.8 g of 1-(4, 6-dimethylpyrimidin- 2-yl) -piperazine ("Compound P, "93% yield).

A mixture of Compound P (3.2 g, 17 mmol), propiolic acid (1. 4 g, 20 mmol), HOBt (300 mg, 2 mmol), and DIC (2.6 mL, 17 mmol) in 40 mL DCM was stirred at about 25°C for 4 hours. The mixture was then shaken with 2N NaOH. The organic layer was separated and dried. After removing the solvent under reduced pressure, the solid product was purified using a silica gel column eluted with gradient elution from 30/70 ethyl acetate/hexane to 70/30 ethyl acetate/hexane to provide 2.2 g of 1- (4- (4, 6-dimethylpyrimidin-2-yl) piperazin-1- yl)-2-propyn-1-one ("Compound Q") as an off-white solid (54% yield).

A mixture of Compound Q (245 mg, 1 mmol), 3-iodo-pyridine (193 mg, 1 mmol), 0.5 mL triethylamine, 30 mg copper) iodide and 50 mg dichloro-bis- (triphenylphospine) palladium (II) in 4 mL ethyl acetate was degassed with argon, and heated at 50°C for 8 hours.

The mixture was purified by column chromatography to provide 110 mg of Compound GZF (Va) as a solid (31 % yield).

The structure of Compound GZF (Va) was confirmed by'H NMR and mass spectral (MS) analysis. Compound GZF (Va) :'H-NMR (CDC13) 8.81 (d, J = 1. 2 Hz, 1H), 8.67 (m, 1H), 7.88 (m, 1H), 7.36 (m, 1H), 6.36 (s, 1H), 3.98 (m, 2H), 3.91 (m, 4H), 3.78 (m, 2H), 2.33 (s, 6H); MS (EI) : m/z 322 (M+H) +.

5.9 EXAMPLE 9: SYNTHESIS OF COMPOUND GZG (Va ! Compound GZG (Va) was prepared according to a scheme similar to Example 8 except that 1 mmol of 2-iodo-pyridine was used in place of 3-iodo-pyridine.

The structure of Compound GZG (Va) was confirmed by'H NMR and mass spectral (MS) analysis. Compound GZG (Va) :'H-NMR (CDC13) 8.67 (m, 1H), 7.74 (m, 1H), 7.63 (m, 1H), 7.37 (m, 1H), 6.34 (s, 1H), 3.96 (br, 4H), 3.93 (m, 2H), 3.77 (m, 2H), 2.31 (s, 6H); MS (EI): m/z 322 (M+H)+.

5.10 EXAMPLE 10 : SYNTHESIS OF COMPOUND GZH(Va) Compound GZH (Va) was prepared according to a scheme similar to Example 8 except that 1 mmol of 1-fluoro-4-iodo-benzene was used in place of 3-iodo-pyridine.

The structure of Compound GZH (Va) was confirmed by'H NMR and mass spectral (MS) analysis. Compound GZH (Va) : 1H-NMR (CDCl3) 7.58 (m, 2H), 7.10 (m, 2H), 6.36 (s, 1H), 3.96 (m, 2H), 3.91 (m, 4H), 3.78 (m, 2fit), 2.32 (s, 6H) ; MS (El) : m/z 339 (M+H) +.

5.11 EXAMPLE 11: SYNTHESIS OF COMPOUND GZI(Va) Compound GZI (Va) was prepared according to a scheme similar to Example 8 except that 1 mmol of 2-fluoro-5-iodo-pyridine was used in place of 3-iodo-pyridine.

The structure of Compound GZI (Va) was confirmed by'H NMR and mass spectral (MS) analysis. Compound GZI (Va) :'H-NMR (CDCl3) 8.45 (d, J = 2.4 Hz, 1H), 7.99 (ddd, J = 2. 4,7. 3 and 8.4 Hz, 0.5H), 7.96 (ddd, J = 2. 4,7. 0 and 8.8 Hz, 0.5H), 7.02 (dd, J = 0. 7,3. 1

Hz, 0. 5H), 6.99 (dd, J = 0.6, 2.8 Hz, 0. 5H), 6.36 (s, 1H), 3.95-4. 00 (m, 2H), 3.85-3. 94 (m, 4H), 3.75-3. 78 (m, 2H), 2.33 (s, 6H); MS (El) : m/z 340 (M+H) +.

5.12 EXAMPLE 12: BINDING OF AN ILLUSTRATIVE 2-PYRIMIDINYLPIPERAZINE COMPOUND TO MGLUR5 The following assay demonstrates that Compound AAA (IIa), an illustrative 2-Pyrimidinylpiperazine Compound, binds to mGluR5.

Cell cultures: Primary glial cultures were prepared from cortices of Sprague-Dawley 18 days old embryos. The cortices were dissected and then dissociated by trituration. The resulting cell homogenate was plated onto poly-D-lysine precoated T175 flasks (BIOCOAT, commercially available from Becton Dickinson and Company Inc. of Franklin Lakes, NJ) in Dulbecco's Modified Eagle's Medium ("DMEM, "pH 7.4), buffered with 25 mM HEPES, and supplemented with 15% fetal calf serum ("FCS, "commercially available from Hyclone Laboratories Inc. of Omaha, NE), and incubated at 37°C and 5% CO2. After 24 hours, FCS supplementation was reduced to 10%. On day six, oligodendrocytes and microglia were removed by strongly tapping the sides of the flasks. One day following this purification step, secondary astrocytes cultures were established by subplating onto 96 poly-D-lysine precoated T175 flasks (BIOCOAT) at a density of 65,000 cells/well in DMEM and 10% FCS. After 24 hours, the astrocytes were washed with serum free medium and then cultured in DMEM, without glutamate, supplemented with 0.5% FCS, 20 mM HEPES, 10 ng/mL epidermal growth factor ("EGF"), 1 mM sodium pyruvate, and 1X penicillin/streptomycin at pH 7.5 for 3 to 5 days at 37°C and 5% C02. The procedure allows the expression of the mGluR5 receptor by astrocytes, as demonstrated by S. Miller et al., J. Neuroscience 15 (9): 6103-6109 (1995).

Assay Protocol: After 3-5 days incubation with EGF, the astrocytes were washed with 127 mM NaCl, 5 mM KC1, 2 mM MgCt, 700 mM NaH2P04, 2 mM CaCI2, 5 mM NaHCO3, 8 mM HEPES, 10 mM Glucose at pH 7.4 ("Assay Buffer") and loaded with the dye Fluo-4 (commercially available from Molecular Probes Inc. of Eugene, OR) using 0.1 mL of Assay Buffer containing Fluo-4 (3 mM final). After 90 minutes of dye loading, the cells were then washed twice with 0.2 mL Assay Buffer and resuspended in 0.1 mL of Assay Buffer. The plates containing the astrocytes were then transferred to a Fluorometric hnaging Plate reader

(commercially available from Molecular Devices Corporation of Sunnyvale, CA) for the assessment of calcium mobilization flux in the presence of glutamate and in the presence or absence of antagonist. After monitoring fluorescence for 15 seconds to establish a baseline, DMSO solutions containing various concentrations of the 2-Pyrimidinylpiperazine Compounds diluted in Assay Buffer (0.05 mL of 4X dilutions for competition curves) were added to the cell plate and fluorescence was monitored for 2 minutes. 0.05 mL of a 4X glutamate solution (agonist) was then added to each well to provide a final glutamate concentration in each well of 10 mM. Plate fluorescence was then monitored for an additional 60 seconds after agonist addition. The final DMSO concentration in the assay was 1.0%. In each experiment, fluorescence was monitored as a function of time and the data analyzed using Microsoft Excel and GraphPad Prism. Dose-response curves were fit using a non-linear regression to determine ICso value.. Compound AAA (IIa) showed an ICso value of 554. 8 i 136.8 nM (mean of 5 experiments). In each experiment each data point was determined two times.

5.13 EXAMPLE 13: BINDING OF AN ILLUSTRATIVE 2-PYRIMIDINYLPIPERAZINE COMPOUND TO MGLUR5 Alternatively, the following assay can be used to demonstrate that a 2-Pyrimidinylpiperazine Compound binds to and modulates the activity of mGluR5.

40,000 CHO-rat mGluR5 cells/well are plated into 96 well plate (Costar 3409, Black, clear bottom, 96 well, tissue culture treated) for an overnight incubation in Dulbecco's Modified Eagle's Medium (DMEM, pH 7.4) and supplemented with glutamin, 10% FBS, 1% Pen/Strep, and 500ug/mL Geneticin. CHO-rat mGluR5 cells are washed and treated with Optimem medium and incubated for 1-4 hours prior to loading cells. Cell plates are then washed with loading buffer (127 mM NaCl, 5 mM KCl, 2 mM MgCl2, 700 lem Na H2PO4, 2 mM CaCl2, 5 mM NaHC03, 8 mM Hepes, and 10 mM glucose, pH 7.4) and then incubated with 3 tM Fluo 4 (commercially available from Molecular probes Inc. of Eugene, OR) in 0.1 mI, of loading buffer. After 90 minutes of dye loading, the cells are then washed twice with 0.2 mL loading buffer and resuspended in 0.1 mL loading buffer.

The plates containing the CHO-rat mGluR5 cells are then transferred to a Fluorometric Imaging Plate Reader (FLIPR) (commercially available from Molecular Devices

Corporation of Sunnyvale, CA) for the assessment of calcium mobilization flux in the presence of glutamate and in the presence or absence of test compounds. After monitoring fluorescence for 15 seconds to establish a baseline, DMSO solutions containing various concentrations of the test compound diluted in loading buffer (0.05 mL of 4X dilutions for the competition curves) are added to the cell plate and fluorescence is monitored for 2 minutes.

0.05 mL of 4X glutamate solution (agonist) is then added to each well to provide a final glutamate concentration in each well of 10 uM. Plate fluorescence is then monitored for an additional 60 seconds after agonist addition. The final DMSO concentration in the assay is 1.0%. In each experiment, fluorescence is monitored as a function of time and the data analyzed using Microsoft Excel and GraphPad Prism. Dose-response curves are fit using a non-linear regression to determine the IC50 value. In each experiment, each data point is determined two times.

5.14 EXAMPLE 14: IN Vivo ASSAYS FOR PREVENTION OR TREATMENT OF PAIN Test Animals: Each experiment uses rats weighing between 200-260 g at the start of the experiment. The rats are group-housed and have free access to food and water at all times, except prior to oral administration of a 2-Pyrimidinylpiperazine Compound when food is removed for 16 hours before dosing. A control group acts as a comparison to rats treated with a 2-Pyrimidinylpiperazine Compound. The control group is administered the carrier for the 2-Pyrimidinylpiperazine Compound. The volume of carrier administered to the control group is the same as the volume of carrier and 2-Pyrimidinylpiperazine Compound administered to the test group.

Acute Pain: To assess the actions of the 2-Pyrimidinylpiperazine Compounds for the treatment or prevention of acute pain the rat tail flick test can be used. Rats are gently restrained by hand and the tail exposed to a focused beam of radiant heat at a point 5 cm from the tip using a tail flick unit (Model 7360, commercially available from Ugo Basile of Italy).

Tail flick latencies are defined as the interval between the onset of the thermal stimulus and the flick of the tail. Animals not responding within 20 seconds are removed from the tail flick unit and assigned a withdrawal latency of 20 seconds. Tail flick latencies are measured immediately before (pre-treatment) and 1,3, and 5 hours following administration of a

2-Pyrimidinylpiperazine Compound. Data are expressed as tail flick latency (s) and the percentage of the maximal possible effect (% MPE), i. e. , 20 seconds, is calculated as follows: [ (post administration latency) - (pre-administration latency)] % MPE = X 100 (20 s pre-administration latency) The rat tail flick test is described in F. E. D'Amour et al.,"A Method for Determining Loss of Pain Sensation,"J. Pharmacol. Exp. Ther. 72: 74-79 (1941).

Acute pain can also be assessed by measuring the animal's response to noxious mechanical stimuli by determining the paw withdrawal threshold ("PWT"), as described below.

Inflammatory Pain: To assess the actions of the 2-Pyrimidinylpiperazine Compounds for the treatment or prevention of inflammatory pain the Freund's complete adjuvant ("FCA") model of inflammatory pain is used. FCA-induced inflammation of the rat hind paw is associated with the development of persistent inflammatory mechanical hyperalgesia and provides reliable prediction of the anti-hyperalgesic action of clinically useful analgesic drugs (L. Bartho et al.,"Involvement of Capsaicin-sensitive Neurones in Hyperalgesia and Enhanced Opioid Antinociception in Inflammation,"Nauny-Schmiedeberg's Archives of PharmacoL 342: 666-670 (1990)). The left hind paw of each animal is administered a 50 cl intraplantar injection of 50% FCA. 24 hour post injection, the animal is assessed for response to noxious mechanical stimuli by determining the PWT, as described below. Rats are then administered a single injection of 1,3, 10 or 30 mg/Kg of either a 2-Pyrimidinylpiperazine Compound ; 30 mg/Kg of a control selected from Celebrex, indomethacin or naproxen ; or carrier. Responses to noxious mechanical stimuli are then determined 1,3, 5, and 24 hours post administration. Percentage reversal of hyperalgesia for each animal is defined as:

[ (post administration PWT)- (pre-administration PWT)] % Reversal = X 100 [ (Baseline PWT) - (pre-administration PWT)] Neuropathic Pain: To assess the actions of the 2-Pyrimidinylpiperazine Compounds for the treatment or prevention of neuropathic pain either the Seltzer model or the Chung model can be used.

In the Seltzer model, the partial sciatic nerve ligation model of neuropathic pain is used to produce neuropathic hyperalgesia in rats (Z. Seltzer et al.,"A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury,"Pain 43 : 205-218 (1990) ). Partial ligation of the left sciatic nerve is performed under isoflurane/O2 inhalation anaesthesia. Following induction of anesthesia, the left thigh of the rat is shaved and the sciatic nerve exposed at high thigh level through a small incision and is carefully cleared of surrounding connective tissues at a site near the trocanther just distal to the point at which the posterior biceps semitendinosus nerve branches off of the common sciatic nerve.

A 7-0 silk suture is inserted into the nerve with a 3/8 curved, reversed-cutting mini-needle and tightly ligated so that the dorsal 1/3 to 1/2 of the nerve thickness is held within the ligature.

The wound is closed with a single muscle suture (4-0 nylon (Vicryl) ) and a Vetbond surgical glue. Following surgery, the wound area is dusted with antibiotic powder. Sham-treated rats undergo an identical surgical procedure except that the sciatic nerve is not manipulated.

Following surgery, animals are weighed and placed on a warm pad until they recover from anesthesia. Animals are then returned to their home cages until behavioral testing begins.

The animal is assessed for response to noxious mechanical stimuli by determining PWT, as described below, prior to surgery (baseline), then immediately prior to and 1, 3, and 5 hours after drug administration for the left rear paw of the animal. Percentage reversal of neuropathic hyperalgesia is defined as:

[ (post administration PWT) - (pre-administration PWT)] % Reversal = X 100 [ (Baseline PWT) - (pre-administration PWT)] In the Chung model, the spinal nerve ligation model of neuropathic pain is used to produce mechanical hyperalgesia, thermal hyperalgesia and tactile allodynia in rats. Surgery is performed under isoflurane/O2 inhalation anaesthesia. Following induction of anaesthesia a 3 cm incision is made and the left paraspinal muscles are separated from the spinous process at the L4-S2 levels. The L6 transverse process is carefully removed with a pair of small rongeurs to identify visually the L4-L6 spinal nerves. The left L5 (or Ls and L6) spinal nerve (s) is isolated and tightly ligated with silk thread. A complete hemostasis is confirmed and the wound is sutured using non-absorbable sutures, such as nylon sutures or stainless steel staples. Sham-treated rats undergo an identical surgical procedure except that the spinal nerve (s) is not manipulated. Following surgery animals are weighed, administered a subcutaneous (s. c. ) injection of saline or ringers lactate, the wound area is dusted with antibiotic powder and they are kept on a warm pad until they recover from the anesthesia.

Animals are then returned to their home cages until behavioral testing begins. The animals are assessed for response to noxious mechanical stimuli by determining PWT, as described below, prior to surgery (baseline), then immediately prior to and 1,3, and 5 hours after being administered a 2-Pyrimidinylpiperazine Compound for the left rear paw of the animal. The animal can also be assessed for response to noxious thermal stimuli or for tactile allodynia, as described below. The Chung model for neuropathic pain is described in S. H. Kim,"An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat,"Pain 50 (3): 355-363 (1992).

Response to Mechanical Stimuli as an Assessment of Mechanical Hvperalgesia : The paw pressure assay can be used to assess mechanical hyperalgesia. For this assay, hind paw withdrawal thresholds (PWT) to a noxious mechanical stimulus are determined using an analgesymeter (Model 7200, commercially available from Ugo Basile of Italy) as described in C. Stein,"Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds,"Pharmacol. Biochem. and Behavior 31: 451-455 (1988). The maximum weight that can be applied to the hind paw

is set at 250 g and the end point is taken as complete withdrawal of the paw. PWT is determined once for each rat at each time point and only the affected (ipsilateral) paw is tested.

Response to Thermal Stimuli as an Assessment of Thermal Hyperalgesia : The plantar test can be used to assess thermal hyperalgesia. For this test, hind paw withdrawal latencies to a noxious thermal stimulus are determined using a plantar test apparatus (commercially available from Ugo Basile of Italy) following the technique described by K. Hargreaves et al., "A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia,"Pain 32 (1) : 77-88 (1988). The maximum exposure time is set at 32 seconds to avoid tissue damage and any directed paw withdrawal from the heat source is taken as the end point. Three latencies are determined at each time point and averaged. Only the affected (ipsilateral) paw is tested.

Assessment of Tactile Allodynia : To assess tactile allodynia, rats are placed in clear, plexiglass compartments with a wire mesh floor and allowed to habituate for a period of at least 15 minutes. After habituation, a series of von Frey monofilaments are presented to the plantar surface of the left (operated) foot of each rat. The series of von Frey monofilaments consists of six monofilaments of increasing diameter, with the smallest diameter fiber presented first. Five trials are conducted with each filament with each trial separated by approximately 2 minutes. Each presentation lasts for a period of 4-8 seconds or until a nociceptive withdrawal behavior is observed. Flinching, paw withdrawal or licking of the paw are considered nociceptive behavioral responses.

5.15 EXAMPLE 15 : IN VIVO ASSAYS FOR PREVENTION OR TREATMENT OF ANXIETY The elevated plus maze test or the shock-probe burying test can be used to assess the anxiolytic activity of 2-Pyrimidinylpiperazine Compounds in rats or mice.

The Elevated Plus Maze Test: The elevated plus maze consists of a platform with 4 arms, two open and two closed (50 x 10 x 50 cm enclosed with an open roof). Rats (or mice) are placed in the center of the platform, at the crossroad of the 4 arms, facing one of the closed arms. Time spent in the open arms vs the closed arms and number of open arm entries during the testing period are recorded. This test is conducted prior to drug administration and

again after drug administration. Test results are expressed as the mean time spent in open arms and the mean number of entries into open arms. Known anxiolytic drugs increase both the time spent in open arms and number of open arm entries. The elevated plus maze test is described in D. Treit, "Animal Models for the Study of Anti-anxiety Agents: A Review," Neuroscience & Biobehavioral Reviews 9 (2): 203-222 (1985).

The Shock-Probe Burying Test: For the shock-probe burying test the testing apparatus consists of a plexiglass box measuring 40 x 30 x 40 cm, evenly covered with approximately 5 cm of bedding material (odor absorbent kitty litter) with a small hole in one end through which a shock probe (6.5 cm long and 0.5 cm in diameter) is inserted. The plexiglass shock probe is helically wrapped with two copper wires through which an electric current is administered. The current is set at 2 mA. Rats are habituated to the testing apparatus for 30 min on 4 consecutive days without the shock probe in the box. On test day, rats are placed in one corner of the test chamber following drug administration. The probe is not electrified until the rat touches it with its snout or fore paws, at which point the rat receives a brief 2 mA shock. The 15 min testing period begins once the rat receives its first shock and the probe remains electrified for the remainder of the testing period. The shock elicits burying behavior by the rat. Following the first shock, the duration of time the rat spends spraying bedding material toward or over the probe with its snout or fore paws (burying behavior) is measured as well as the number of contact-induced shocks the rat receives from the probe. Known anxiolytic drugs reduce the amount of burying behavior. In addition, an index of the rat's reactivity to each shock is scored on a 4 point scale. The total time spent immobile during the 15 min testing period is used as an index of general activity.

The shock-probe burying test is described in D. Treit, 1985, supra.

5.16 EXAMPLE 16: IN Vivo ASSAYS FOR PREVENTION OR TREATMENT OF AN ADDICTIVE DISORDER The conditioned place preference test or drug self-administration test can be used to assess the ability of 2-Pyrimidinylpiperazine Compounds to attenuate the rewarding properties of known drugs of abuse.

The Conditioned Place Preference Test: The apparatus for the conditioned place preference test consists of two large compartments (45 x 45 x 30 cm) made of wood with a plexiglass front wall. These two large compartments are distinctly different. Doors at the back of each large compartment lead to a smaller box (36 x 18 x 20 cm) box made of wood, painted grey, with a ceiling of wire mesh. The two large compartments differ in terms of shading (white vs black), level of illumination (the plexiglass door of the white compartment is covered with aluminum foil except for a window of 7 x 7 cm), texture (the white compartment has a 3 cm thick floor board (40 x 40 cm) with nine equally spaced 5 cm diameter holes and the black has a wire mesh floor), and olfactory cues (saline in the white compartment and 1 mL of 10% acetic acid in the black compartment). On habituation and testing days, the doors to the small box remain open, giving the rat free access to both large compartments.

The first session that a rat is placed in the apparatus is a habituation session and entrances to the smaller grey compartment remain open giving the rat free access to both large compartments. During habituation, rats generally show no preference for either compartment.

Following habituation, rats are given 6 conditioning sessions. Rats are divided into 4 groups: carrier pre-treatment + carrier (control group), 2-Pyrimidinylpiperazine Compound pre- treatment + carrier, carrier pre-treatment + morphine, 2-Pyrimidinylpiperazine Compound pre-treatment + morphine. During each conditioning session the rat is injected with one of the drug combinations and confined to one compartment for 30 min. On the following day, the rat receives a carrier + carrier treatment and is confined to the other large compartment.

Each rat receives three conditioning sessions consisting of 3 drug combination-compartment and 3 carrier-compartment pairings. The order of injections and the drug/compartment pairings are counterbalanced within groups. On the test day, rats are injected prior to testing (30 min to 1 hour) with either morphine or carrier and the rat is placed in the apparatus, the doors to the grey compartment remain open and the rat is allowed to explore the entire apparatus for 20 min. The time spent in each compartment is recorded. Known drugs of abuse increase the time spent in the drug-paired compartment during the testing session. If the 2-Pyrimidinylpiperazine Compound blocks the acquisition of morphine conditioned place preference (reward), there will be no difference in time spent in each side in rats pre-treated with a 2-Pyrimidinylpiperazine Compound and the group will not be different from the group

of rats that was given carrier + carrier in both compartments. Data will be analyzed as time spent in each compartment (drug combination-paired vs carrier-paired). Generally, the experiment is repeated with a minimum of 3 doses of a 2-Pyrimidinylpiperazine Compound.

The Drug Self-Administration Test: The apparatus for the drug self-administration test is a standard commercially available operant conditioning chamber. Before drug trials begin rats are trained to press a lever for a food reward. After stable lever pressing behavior is acquired, rats are tested for acquisition of lever pressing for drug reward. Rats are implanted with chronically indwelling jugular catheters for i. v. administration of compounds and are allowed to recover for 7 days before training begins. Experimental sessions are conducted daily for 5 days in 3 hour sessions. Rats are trained to self-administer a known drug of abuse, such as morphine. Rats are then presented with two levers, an"active"lever and an"inactive"lever. Pressing of the active lever results in drug infusion on a fixed ratio 1 (FR1) schedule (i. e. , one lever press gives an infusion) followed by a 20 second time out period (signaled by illumination of a light above the levers). Pressing of the inactive lever results in infusion of excipient. Training continues until the total number of morphine infusions stabilizes to within 10% per session. Trained rats are then used to evaluate the effect of 2-Pyrimidinylpiperazine Compounds pre-treatment on drug self-administration. On test day, rats are pre-treated with a 2-Pyrimidinylpiperazine Compound or excipient and then are allowed to self-administer drug as usual. If the 2-Pyrimidinylpiperazine Compound blocks the rewarding effects of morphine, rats pre-treated with the 2-Pyrimidinylpiperazine Compound will show a lower rate of responding compared to their previous rate of responding and compared to excipient pre-treated rats. Data is analyzed as the change in number of drug infusions per testing session (number of infusions during test session- number of infusions during training session).

5.17 EXAMPLE 17: FUNCTIONAL ASSAY FOR CHARACTERIZING MGLUR1 ANTAGONISTIC PROPERTIES Functional assays for the characterization of mGluR 1 antagonistic properties are well known in the art. For example, the following procedure can be used.

A CHO-rat mGluRl cell line is generated using cDNA encoding rat mGluRl receptor (M. Masu and S. Nakanishi, Nature 349: 760-765 (1991) ). The cDNA encoding rat mGluRl receptor can be obtained from, e. g., Prof. S. Nakanishi (Kyoto, Japan).

40,000 CHO-rat mGluRl cells/well are plated into a COSTAR 3409, black, clear bottom, 96 well, tissue culture treated plate (commercially available from Fisher Scientific of Chicago, IL) and are incubated in Dulbecco's Modified Eagle's Medium (DMEM, pH 7.4) supplemented with glutamin, 10% FBS, 1% Pen/Strep, and 500 J, g/mL Geneticin for about 12 h. The CHO-rat mGluRl cells are then washed and treated with OPTIMEM medium (commercially available from Invitrogen, Carlsbad, CA) and incubated for a time period ranging from 1 to 4 hours prior to loading the cells with the dye FLUO-4 (commercially available from Molecular Probes Inc., Eugene, OR). After incubation, the cell plates are washed with loading buffer (127 mM NaCl, 5 mM KC1, 2 mM MgCl2, 700 VM, NaH2po4, 2 mM CaCl2, 5 mMNaHC03, 8 mM HEPES, and 10 mM glucose, pH 7.4) and incubated with 3 , ut FLUO-4 in 0.1 mL loading buffer for 90 min. The cells are then washed twice with 0. 2 mL loading buffer, resuspended in 0.1 mL of loading buffer, and transferred to a FLIPR for measurement of calcium mobilization flux in the presence of glutamate and in the presence or absence of a 2-Pyrimidinylpiperazine Compound.

To measure calcium mobilization flux, fluoresence is monitored for about 15 s to establish a baseline and DMSO solutions containing various concentrations of a 2-Pyrimidinylpiperazine Compound ranging from about 50 uM to about 0.8 nM diluted in loading buffer (0.05 mL of a 4X dilution) are added to the cell plate and fluoresence is monitored for about 2 min. 0.05 mL of a 4X glutamate solution (agonist) is then added to each well to provide a final glutamate concentration in each well of 10 je. M and fluoresence is monitored for about one additional min. The final DMSO concentration in the assay is 1%.

In each experiment fluoresence is monitored as a function of time and the data is analyzed using a non-linear regression to determine the ICSO value. In each experiment each data point is determined twice.

The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention.

Indeed, various modifications of the invention in addition to those shown and described

herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.

A number of references have been cited, the entire disclosures of which are incorporated herein by reference.